<SEC-DOCUMENT>0001013762-16-001577.txt : 20160512
<SEC-HEADER>0001013762-16-001577.hdr.sgml : 20160512
<ACCEPTANCE-DATETIME>20160512160630
ACCESSION NUMBER:		0001013762-16-001577
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		56
CONFORMED PERIOD OF REPORT:	20160331
FILED AS OF DATE:		20160512
DATE AS OF CHANGE:		20160512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DelMar Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001498382
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				990360497
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-54801
		FILM NUMBER:		161643737

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720-999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(604) 629-5989

	MAIL ADDRESS:	
		STREET 1:		SUITE 720-999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Berry Only Inc.
		DATE OF NAME CHANGE:	20100805
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q0316_delmarpharma.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Form 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Mark One)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&thorn; </FONT></TD>
    <TD STYLE="width: 94%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt"><FONT STYLE="font-size: 10pt">For the quarterly period ended March 31, 2016</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">o</FONT></TD>
    <TD STYLE="width: 94%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt"><FONT STYLE="font-size: 10pt">For the transition period from __________________ to __________________________</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Commission file number: 000-54801</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">DelMar Pharmaceuticals, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Exact name of registrant as specified in its charter)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; width: 50%; font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Nevada</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 49%; font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">99-0360497</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation or organization)</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; width: 50%; border-bottom: Black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Suite 720-999 West Broadway</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Vancouver, British Columbia, Canada</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P></TD>
    <TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 49%; vertical-align: bottom; padding-bottom: 1.5pt; border-bottom: Black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">V5Z 1K5</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">(zip code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><U>(604) 629-5989</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Registrant's telephone number, including area code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>N/A</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Former name, former address and former fiscal year, if changed since last report)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Yes <FONT STYLE="font-family: Wingdings">&thorn;
</FONT>No <FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such shorter
period that the registrant was required to submit and post such files).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Yes <FONT STYLE="font-family: Wingdings">&thorn;
</FONT>No <FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2
of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Large accelerated filer <FONT STYLE="font-family: Wingdings">o</FONT></FONT></TD>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 48%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Accelerated filer <FONT STYLE="font-family: Wingdings">o</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Non-accelerated filer <FONT STYLE="font-family: Wingdings">o</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Do not check if smaller reporting company)</P></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Smaller reporting company <FONT STYLE="font-family: Wingdings">&thorn;</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Yes <FONT STYLE="font-family: Wingdings">o </FONT>No
<FONT STYLE="font-family: Wingdings">&thorn;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicated the number of shares outstanding
of each of the issuer's classes of common stock, as of the latest practicable date, 40,253,056&nbsp;shares of common stock, par
value $0.001, are issued and outstanding as of May 12, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; text-align: center; border-bottom: Black 1.5pt solid">Page No.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; text-align: center"><B>PART I. - FINANCIAL
    INFORMATION</B></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">Item 1.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><A HREF="#finan">Financial Statements.</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; text-align: center">2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">Item 2.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><A HREF="#Management">Management's Discussion and Analysis of Financial Condition and Results of Operations.</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; text-align: center; vertical-align: bottom">23</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">Item 3.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><A HREF="#Quantitative">Quantitative and Qualitative Disclosures About Market Risk.</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; text-align: center">49</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">Item 4</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><A HREF="#Controls">Controls and Procedures.</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; text-align: center">49</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; text-align: center"><B>PART II - OTHER
    INFORMATION</B></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">Item 1.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><A HREF="#item1">Legal Proceedings.</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; text-align: center">50</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">Item 1A.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><A HREF="#item1a">Risk Factors.</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; text-align: center">50</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">Item 2.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><A HREF="#item2">Unregistered Sales of Equity Securities and Use of Proceeds.</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; text-align: center">50</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">Item 3.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><A HREF="#item3">Defaults Upon Senior Securities.</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; text-align: center">50</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">Item 4.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><A HREF="#item4">Mine Safety Disclosures.</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; text-align: center">50</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">Item 5.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><A HREF="#item5">Other Information.</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; text-align: center">50</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">Item 6.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><A HREF="#item6">Exhibits</A>.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; text-align: center">50</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART 1. - FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><A NAME="finan"></A>Item 1. Financial Statements. </B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">DelMar
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated
Condensed Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the nine months ended March 31, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(expressed
in US dollars unless otherwise noted)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>DelMar Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated
Condensed Interim Balance Sheets</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(expressed
in US dollars unless otherwise noted)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Note</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">March
    31, <BR>2016 <BR>$</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">June
    30, <BR>2015 <BR>$</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Assets</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    Restated</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current
    assets</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">937,355</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,754,433</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Taxes
    and other receivables</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,142</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25,831</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid
    expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">85,292</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">245,038</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    costs</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">60,647</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">550,119</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,115,436</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,575,421</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Intangible
    assets - net</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">39,875</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,155,311</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,575,421</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Liabilities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current
    liabilities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts
    payable and accrued liabilities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">646,948</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">762,265</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Related
    party payables</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">5</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">29,018</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">90,820</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">675,966</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">853,085</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock
    option liability</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">149,698</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">179,445</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Derivative
    liability</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,017,250</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,364,381</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,842,914</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,396,911</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stockholders&rsquo;
    accumulated deficit</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preferred
    stock</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Authorized</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,000,000 shares,
    $0.001 par value</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issued
    and outstanding</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif">278,530 Series
    A shares at March 31, 2016 (June 30, 2015 &ndash; 278,530)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">4</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">278,530</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">278,530</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1 special voting
    share at March 31, 2016 (June 30, 2015 &ndash; 1)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    stock</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Authorized</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">200,000,000
    shares, $0.001 par value</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">44,309,098 issued
    at March 31, 2016 (June 30, 2015 &ndash; 39,455,931)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">44,309</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">39,456</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional
    paid-in capital</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21,805,867</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17,363,208</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,190,553</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">89,432</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(24,028,040</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(18,613,294</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated
    other comprehensive income</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21,178</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21,178</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(687,603</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(821,490</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,155,311</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,575,421</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Nature
of operations and liquidity risk</B> (note 1)</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Restatement
of previously issued financial statements</B> (note 2)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated condensed interim financial statements.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>DelMar Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated
Condensed Interim Statement of Loss and Comprehensive Loss</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">(Unaudited)</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">(expressed
in US dollars unless otherwise noted)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Note</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Three
    months <BR>ended <BR>March 31, <BR>2016 <BR>$</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Three
    months <BR>ended <BR>March 31, <BR>2015 <BR>$</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nine
    months ended <BR>March 31, <BR>2016 <BR>$</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nine
    months ended <BR>March 31, <BR>2015 <BR>$</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(as
    restated)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(as
    restated)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
    and development</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">790,323</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">641,839</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,183,355</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,925,635</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
    and administrative</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">630,226</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">500,753</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,994,923</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,601,982</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,420,549</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,142,592</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,178,278</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,527,617</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    (income) loss</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
    in fair value of derivative liability</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(276,584</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">781,152</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">943,050</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">451,794</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
    in fair value of derivative liability due to change in warrant terms</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">270,965</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(23,658</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss
    on exchange of warrants</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">156,219</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">249,062</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Foreign
    exchange (gain) loss</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(10,523</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,826</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">16,257</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">16,512</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    expense</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,091</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    income</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(41</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(70</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(71</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(331</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(280,148</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">944,127</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,230,201</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">695,470</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    and comprehensive loss for the period</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,140,401</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,086,719</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,408,479</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,223,087</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; text-indent: -22.5pt; padding-left: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Basic
    loss per share</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.03</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.05</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.12</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.11</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -22.5pt; padding-left: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Basic
    weighted average number of shares</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">44,309,098</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38,976,827</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">43,587,549</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">37,732,995</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated condensed interim financial statements.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>DelMar Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated
Condensed Interim Statement of Cash Flows</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;(expressed
in US dollars unless otherwise noted)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nine
    months ended March 31,</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></P>
                                                                  <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></P>
                                                                  <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">As Restated</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    flows from operating activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss for the period</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,408,479</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4,223,087</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Items
    not affecting cash</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amortization</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,430</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued
    interest</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,091</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
    in fair value of derivative liability</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">943,050</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">451,794</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
    in fair value of derivative liability due to change in warrant terms</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">270,965</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(23,658</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss
    on exchange of warrants</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">249,062</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares
    issued for services</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">80,400</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
    issued for services</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">400,389</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.3in; padding-left: 0.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock
    option expense</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">138,711</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">323,358</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,568,534</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,220,440</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes in non-cash working capital</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Taxes
    and other receivables</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,311</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(39,472</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid
    expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">159,746</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(14,375</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts
    payable and accrued liabilities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(115,317</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">241,269</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.3in; padding-left: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Related
    party payables</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(61,802</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(11,457</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(23,684</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">175,965</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,592,218</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,044,475</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    flows from investing activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Intangible
    assets</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(16,762</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">(16,762</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    flows from financing activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    proceeds from issuance of shares and warrants</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,453,633</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Series
    A preferred stock dividend</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,267</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4,178</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    proceeds from the exercise of warrants</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">405,183</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,404,177</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    costs</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(60,647</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(108,637</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,791,902</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,291,362</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Decrease
    in cash and cash equivalents</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(817,078</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,753,113</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents - beginning of period</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,754,433</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,759,711</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents - end of period</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">937,355</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,006,598</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Supplementary information</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance
    of preferred shares for the settlement of the loan payable to Valent (note 4)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">278,530</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reclassification of derivative liability
    upon the exercise or exchange of Investor Warrants (note 6)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">247,440</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,120,257</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reclassification of derivative liability
    upon the amendment of warrants (note 6)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,343,300</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">975,278</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reclassification of stock option liability
    upon the forfeiture of stock options</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">29,747</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38,038</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred costs recognized as equity
    issue costs</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">550,119</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in; text-indent: -20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated condensed interim financial statements.</FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>DelMar Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
to Consolidated Condensed Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>March
31, 2016</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(expressed
in US dollars unless otherwise noted)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nature
                                         of operations and liquidity risk</FONT></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>





<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Nature
of operations</B></FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 13pt 21.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">DelMar
Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) is a clinical stage drug development company with a focus on the treatment of
cancer.&nbsp;&nbsp;&nbsp;We are conducting clinical trials in the United States with our product candidate, VAL-083, as a potential
new treatment for glioblastoma multiforme (&ldquo;GBM&rdquo;), the most common and aggressive form of brain cancer.&nbsp;&nbsp;We
have also acquired certain exclusive commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment
of chronic myelogenous leukemia (&ldquo;CML&rdquo;) and lung cancer.&nbsp;&nbsp;In order to accelerate our development timelines
and reduce technical risk, we leverage existing clinical and commercial data from a wide range of sources.&nbsp;&nbsp;We plan
to seek marketing partnerships in China in order to potentially generate future royalty revenue.</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company is a Nevada corporation formed on June 24, 2009 under the name Berry Only Inc. On January 25, 2013 (the &ldquo;Closing
Date&rdquo;), the Company entered into and closed an exchange agreement (the &ldquo;Exchange Agreement&rdquo;), with Del Mar Pharmaceuticals
(BC) Ltd. (&ldquo;DelMar (BC)&rdquo;), 0959454 B.C. Ltd. (&ldquo;Callco&rdquo;), and 0959456 B.C. Ltd. (&ldquo;Exchangeco&rdquo;)
and the security holders of DelMar (BC). Upon the closing of the Exchange Agreement, DelMar (BC) became a wholly-owned subsidiary
of the Company (the &ldquo;Reverse Acquisition&rdquo;). As a result of the shareholders of DelMar (BC) having a controlling interest
in the Company subsequent to the Reverse Acquisition, for accounting purposes the transaction is a capital transaction with DelMar
(BC) being the accounting acquirer even though the legal acquirer is the Company.</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">DelMar
Pharmaceuticals, Inc. is the parent company of DelMar (BC), a British Columbia, Canada corporation, and Callco and Exchangeco
which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition.</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 13pt 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">The
address of the Company&rsquo;s administrative offices is Suite 720 - 999 West Broadway, Vancouver, British Columbia, V5Z 1K5 and
the Company&rsquo;s clinical operations are located at 3485 Edison Way, Suite R, Menlo Park, California, 94025.</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">References
to the Company refer to the Company and its wholly-owned subsidiaries, DelMar (BC), Callco and Exchangeco.</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>DelMar Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
to Consolidated Condensed Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>March
31, 2016</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(expressed
in US dollars unless otherwise noted)</FONT></P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Liquidity
risk</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the nine-month period ended March 31, 2016, the Company reported a loss of $5,408,479 and an accumulated deficit of $24,028,040
at that date. As at March 31, 2016, the Company had cash and cash equivalents on hand of $937,355. The Company does not have the
prospect of achieving revenues in the near future and the Company will require additional funding to maintain its research and
development projects and for general operations. There is a great degree of uncertainty with respect to the expenses the Company
will incur in executing its business plan. In addition, the Company has not begun to commercialize or generate revenues from its
product candidate.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consequently,
management is pursuing various financing alternatives to fund the Company&rsquo;s operations so it can continue as a going
concern (note 9) in the medium to longer term. Subsequent to March 31, 2016, the Company completed a convertible preferred
share private placement for gross proceeds of $6.1 million. We believe, based on our current estimates, that we will be able to fund
our operations beyond the next twelve months.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 21.55pt">There is no assurance that our cost estimates
will prove to be accurate or that unforeseen events, problems or delays will not occur that would require us to seek additional
debt and/or equity funding. The ability of the Company to meet its obligations and continue the research and development of its
product candidate is dependent on its ability to continue to raise adequate financing. There can be no assurance that such financing
will be available to the Company in the amount required at any time or for any period or, if available, that it can be obtained
on terms satisfactory to the Company. The Company may tailor its drug candidate development program based on the amount of funding
the Company raises.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt/13pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Restatement
                                         of previously issued financial statements</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 21.55pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; background-color: white">In
our 2015 Annual Report on Form 10-K/A, we restated our previously issued consolidated financial statements and the related disclosures
for the fiscal years ended June 30, 2015 and June 30, 2014 and for each of the quarters ended March 31, 2013, June 30, 2013, September
30, 2013, December 31, 2013, March 31, 2014, September 30, 2014, December 31, 2014, and March 31, 2015 (the &quot;Restated Periods&quot;).</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">The
restatement is the result of our corrections for the effect of financial statement errors attributable to the incorrect accounting
for certain warrants issued for placement agent services issued on March 6, 2013 (the &ldquo;2013 Placement Agent Warrants&rdquo;).
The 2013 Placement Agent Warrants were improperly accounted for as equity instruments at the time they were issued. During the
preparation of our financial statements for the first quarter of fiscal 2016, we discovered that the 2013 Placement Agent Warrants
represented a derivative liability and should not have been recognized as equity. The exercise price of the 2013 Placement Agent
Warrants is subject to adjustment in certain circumstances. The public equity financing that we completed in August 2015 resulted
in the exercise price of the 2013 Placement Agent Warrants being reduced. Accordingly, we have classified the 2013 Placement Agent
Warrants as a derivative liability on the Consolidated Balance Sheets at June 30, 2015 and June 30, 2014 as well as recognized
the gain/loss from the revaluation of the derivative liability in the Consolidated Statement of Operations and Comprehensive Loss
of the years ended June 30, 2015 and June 30, 2014. We have also reflected the cumulative impact of the fair value adjustments
from March 6, 2013 to June 30, 2014 in the accumulated deficit.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 21.55pt"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>DelMar Pharmaceuticals, Inc.</B></FONT>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
to Consolidated Condensed Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>March
31, 2016</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(expressed
in US dollars unless otherwise noted)</FONT></P>






<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="background-color: white">The aggregate
impacts of correcting the errors relating to the 2013 Placement Agent Warrants, as of, and for the three and nine months ended
March 31, 2015 were as follows:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended March
    31, 2015</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    previously reported <BR>$</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Restatement
    adjustment <BR>$</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    restated <BR>$</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
    in fair value of derivative liability</FONT></TD><TD STYLE="width: 1%; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">343,569</FONT></TD><TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">437,583</FONT></TD><TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">781,152</FONT></TD><TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss
    for the period</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,649,136</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">437,583</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,086,719</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Basic
    and diluted loss per share</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.04</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.01</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.05</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE><BR STYLE="clear: both">

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended March 31, 2015</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    previously reported <BR>$</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Restatement
    adjustment <BR>$</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    restated <BR>$</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
    in fair value of derivative liability</FONT></TD><TD STYLE="width: 1%; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">276,963</FONT></TD><TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">174,831</FONT></TD><TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">451,794</FONT></TD><TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss
    for the period</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,048,256</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">174,831</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,223,087</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Basic
    and diluted loss per share</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.11</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.00</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.11</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: right; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
                                         At March 31, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">As previously reported</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">$&nbsp;</FONT></P></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Restatement adjustment</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">$&nbsp;</FONT></P></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">As restated</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">$&nbsp;</FONT></P></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Derivative
    liability</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,487,137</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,956,471</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,443,608</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional
    paid-in capital</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17,455,279</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(136,800</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17,318,479</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,138,426</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,048,994</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">89,432</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(22,715,848</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,229,323</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">(18,486,525</FONT></TD><TD STYLE="font-weight: normal; text-align: left">)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
</TABLE><P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
assessed the impact of these errors on our previously issued financial statements and concluded that the combined impact of these
errors was material to our financial statements. Consequently, we have restated the prior period financial statements identified
above. All amounts in our consolidated financial statements in this Quarterly Report on Form 10-Q affected by the restatement
adjustments reflect such amounts as restated.</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Significant
                                         accounting policies</FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Basis
of presentation</B></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
consolidated condensed interim financial statements of the Company have been prepared in accordance with United States Generally
Accepted Accounting Principles (&ldquo;U.S. GAAP&rdquo;) and are presented in United States dollars. The Company&rsquo;s functional
currency is the United States dollar.</FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>DelMar Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
to Consolidated Condensed Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>March
31, 2016</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(expressed
in US dollars unless otherwise noted)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
accompanying consolidated condensed interim financial statements include the accounts of the Company and its wholly-owned subsidiaries,
DelMar BC, Callco, and Exchangeco. All intercompany balances and transactions have been eliminated.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
principal accounting policies applied in the preparation of these financial statements are set out below and have been consistently
applied to all periods presented.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Unaudited
interim financial data</B></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
accompanying unaudited March 31, 2016 consolidated condensed interim balance sheet, the consolidated condensed interim statements
of loss and comprehensive loss for the three and nine months ended March 31, 2016 and 2015, and consolidated condensed cash flows
for the nine months ended March 31, 2016 and 2015, and the related interim information contained within the notes to the consolidated
condensed interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange
Commission for interim financial information. Accordingly, they do not include all of the information and the notes required by
U.S. GAAP for complete financial statements. These consolidated condensed interim financial statements should be read in conjunction
with the audited financial statements of the Company as at June 30, 2015 filed in our amended Form 10-K/A filed with the Securities
and Exchange Commission on November 16, 2015. In the opinion of management, the unaudited consolidated condensed interim financial
statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the
Company&rsquo;s financial position at March 31, 2016 and results of its operations for the three and nine months ended March 31,
2016 and 2015, and its cash flows for the nine months ended March 31, 2016 and 2015. The results for three and nine months ended
March 31, 2016 are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2016 or for any
other future annual or interim period.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Use
of estimates</B></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
preparation of consolidated condensed interim financial statements in conformity with U.S. GAAP requires management to make estimates
and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent
liabilities as at the end or during the reporting period. Actual results could significantly differ from those estimates. Significant
areas requiring management to make estimates include the derivative liability and the valuation of equity instruments issued for
services. There have been no changes to the methodology used in determining these estimates from the period ended June 30, 2015.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><B>Intangible assets</B></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><I>Website development costs</I></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Website
development costs are stated at cost less accumulated amortization. The Company capitalizes website development costs associated
with graphics design and development of the website application and infrastructure. Costs related to planning, content input,
and website operations are expensed as incurred. The Company amortizes website development costs on a straight-line basis over
three years. The website costs consist of $16,762 in cash costs and $29,543 in non-cash consideration in the form of the issuance
of warrants. The Company recognized $3,858 and $6,430 respectively, in amortization during the three and nine months ended March
31, 2016. There was no amortization in either the three or nine months ended March 31, 2015.</FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>DelMar Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
to Consolidated Condensed Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>March
31, 2016</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(expressed
in US dollars unless otherwise noted)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Loss
per share</B></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss
per share is calculated based on the weighted average number of common shares outstanding. For the three and nine month periods
ended March 31, 2016 and 2015 diluted loss per share does not differ from basic loss per share since the effect of the Company&rsquo;s
warrants and stock options are anti-dilutive. At March 31, 2016, potential common shares of 18,388,945 (March 31, 2015 &ndash;
13,472,870) relating to warrants and 3,465,000 (March 31, 2015 &ndash; 3,595,000) relating to stock options were excluded from
the calculation of net loss per common share because their inclusion would be anti-dilutive.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Recent
accounting pronouncements</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) or other
standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe
that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position
or results of operations upon adoption.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Accounting
Standards Update (&ldquo;ASU&rdquo;) 2014-15 - Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern</I></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
objective of the guidance is to require management to explicitly assess an entity's ability to continue as a going concern, and
to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management
will assess if there is substantial doubt about an entity's ability to continue as a going concern within one year after the issuance
date of an entity&rsquo;s financial statements. The new standard defines substantial doubt and provides examples of indicators
thereof. The definition of substantial doubt incorporates a likelihood threshold of &quot;probable&quot; similar to the current
use of that term in U.S. GAAP for loss contingencies. The new standard will be effective for all entities in the first annual
period ending after March 15, 2016 (March 31, 2016 for calendar year-end entities). Earlier application is permitted. The Company
is currently assessing this standard for its impact on future reporting periods.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">4</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Valent
                                         Technologies, LLC</FONT></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">On
September 30, 2014, the Company entered into an exchange agreement (the &ldquo;Valent Exchange Agreement&rdquo;) with Valent Technologies,
LLC (&ldquo;Valent&rdquo;), an entity owned by the Company&rsquo;s Chief Scientific Officer and director, and DelMar (BC). Pursuant
to the Valent Exchange Agreement, Valent exchanged its loan payable in the outstanding amount of $278,530 (including aggregate
accrued interest to March 31, 2015 of $28,530), issued to Valent by DelMar (BC), for 278,530 shares of the Company&rsquo;s Series
A Preferred Stock. The shares of Series A Preferred Stock have a stated value of $1.00 per share (the &ldquo;Stated Value&rdquo;)
and are not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of
3% of the Stated Value per year, payable quarterly in arrears.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">&nbsp;</FONT><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B></B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font: 12pt Times New Roman, Times, Serif"><B>DelMar Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
to Consolidated Condensed Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>March
31, 2016</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(expressed
in US dollars unless otherwise noted)</FONT></P>


<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0pt 21.55pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0pt 21.55pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the three and nine months ended March 31, 2016, the Company recorded $2,089 and $6,267 respectively related to the dividend payable
to Valent. The dividends have been recorded as a direct increase in accumulated deficit. For the nine months ended March 31, 2015
the Company accrued $2,091 in interest expense on the loan payable to the date of the conversion on September 30, 2014 and $4,178
related to the dividend for the period from October 1, 2014 to March 31, 2015.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt/13pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">5</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Related
                                         party transactions</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>During
the nine months ended March 31, 2016</I></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to consulting agreements with the Company&rsquo;s officers, the Company recognized a total of $360,000 (2015 - $385,000) in compensation
expense for the nine months ended March 31, 2016.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">At
March 31, 2016 there is an aggregate amount of $29,018 (June 30, 2015 - $90,820) owed to the Company&rsquo;s officers and directors
for fees and expenses. The Company pays related party payables incurred for fees and expenses under normal commercial terms.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company paid $127,583 in directors&rsquo; fees (2015 - $77,667) during the nine months ended March 31, 2016.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company recorded $6,267 in dividends related to the Series A Preferred Stock issued to Valent (note 4).</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>During
the nine months ended March 31, 2015</I></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective
September 30, 2014, the Company entered into and closed an agreement with Valent to exchange its loan with Valent for 278,530
shares of preferred stock of the Company (note 4).</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company accrued $2,091 in interest expense on the loan payable to Valent to the date of the conversion on September 30, 2014 and
$4,178 related to the dividend on the Series A Preferred Stock for the period from October 1, 2014 to March 31, 2015 (note 4).</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Derivative
                                         liability</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 13pt 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company has issued common stock purchase warrants. Based on the terms of certain of these warrants the Company determined that
the warrants were a derivative liability which is recognized at fair value at the date of the transaction and re-measured at fair
value each reporting period with the changes in fair value recorded in the consolidated condensed statement of loss and comprehensive
loss.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Investor
Warrants</I></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
connection with the Reverse Acquisition (note 1), during the quarter ended March 31, 2013 the Company issued units consisting
of one share of common stock and one five-year warrant (the &ldquo;Investor Warrants&rdquo;) to purchase one share of common stock
at an exercise price of $0.80. The exercise price of the Investor Warrants is subject to adjustment in the event that the Company
issues common stock at a price lower than the exercise price, subject to certain exceptions. As a result of the financing completed
by the Company during the three months ended September 30, 2015 (note 7) the exercise price of the Investor Warrants was reduced
from $0.80 to $0.786. As a result of the price being reduced, the Company has recognized a loss of $8,098 on the revaluation of
the warrants.</FONT></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>DelMar Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
to Consolidated Condensed Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>March
31, 2016</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(expressed
in US dollars unless otherwise noted)</FONT></P>


<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Investor
Warrant exercises</U></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
the nine months ended March 31, 2016, 515,500 Investor Warrants were exercised at an exercise
price of $0.786 per share. The Company received proceeds of $405,183 from these exercises. The warrants that have been exercised
were revalued at their exercise date and then the reclassification to equity was recorded resulting in $247,440 of the derivative
liability being reclassified to equity.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
the nine months ended March 31, 2015 the Company concluded a tender offer whereby the holders of the Investor Warrants had the
opportunity to exercise their warrants at an exercise price of $0.65. Under the tender offer, a total of 762,227 warrants were
exercised for net proceeds of $470,676 after payment by the Company of a 5% warrant agent fee of $24,772. In addition, during
the nine months ended March 31, 2015, 1,223,847 warrants were exercised at an exercise price
of $0.65 per warrant. The Company received proceeds of $795,501 from these exercises.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
a result of all of the Investor Warrant exercises during the nine months ended March 31, 2015, the Company received net proceeds
of $1,266,177 from the exercise of 1,986,074 warrants. The Investor Warrants that have been exercised were revalued at their exercise
date and then the reclassification to equity was recorded resulting in $391,422 of the derivative liability being reclassified
to equity.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Investor
Warrant exchanges</U></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
December 31, 2014, the Company issued 414,889 shares of common stock in exchange for 1,244,666 Investor Warrants. The Investor
Warrants that have been exchanged were revalued at their exchange date and then a reclassification to equity was recorded. The
reclassification to equity upon the exchange was $305,112. The Company recognized a loss of $92,843 at the time of the exchange.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
January 8, 2015, the Company filed a tender offer statement with the Securities and Exchange Commission, and on January 23, 2015,
the Company filed an amendment thereto. The tender offer provided the holders of the Investor Warrants with the opportunity to
receive one&nbsp;share of common stock for every three Investor Warrants tendered. On February 9, 2015 the Company&rsquo;s tender
offer expired. A total of 1,591,875 Investor Warrants were exchanged for 530,625 shares of common stock. The Investor Warrants
that have been exchanged were revalued at their exchange date and then a reclassification to equity was recorded. The reclassification
to equity upon the exchange was $423,723. The Company recognized a loss of $156,219 at the time of the exchange.</FONT></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>DelMar Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
to Consolidated Condensed Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>March
31, 2016</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(expressed
in US dollars unless otherwise noted)</FONT></P>


<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Investor
Warrant amendments</U></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 21.55pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
March 29, 2016, the Company entered into amendments (the &ldquo;Investor Warrant Amendments&rdquo;) with the holders of certain
Investor Warrants. Pursuant to the Investor Warrant Amendments, 250,000 Investor Warrants were amended to extend the expiration
date to March 31, 2019 and remove the provision requiring an adjustment of the exercise price in the event the Company sells common
stock at a purchase price lower than the current warrant exercise price. As a result of the Investor Warrant Amendments, the Company
has recognized a loss of $7,000 and has reclassified $65,750 from the derivative liability to equity resulting in an increase
to equity of $58,750. The Investor Warrants were revalued to the date of the amendment and were then reclassified to equity.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>2013
Placement Agent Warrants</I></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Also
in connection with the Reverse Acquisition (note 1), on March 6, 2013 the Company issued 5,250,000 warrants (the &ldquo;2013 Placement
Agent Warrants&rdquo;) that are exercisable at $0.80 per share until March 6, 2018 but can be exercised on a cashless basis. The
exercise price of the 2013 Placement Agent Warrants is subject to adjustment in the event that the Company sells common stock
at a price lower than the exercise price, subject to certain exceptions. As a result of the financing completed by the Company
during the quarter ended September 30, 2015 (note 7) the exercise price of the 2013 Placement Agent Warrants was reduced from
$0.80 to $0.786. As a result of the price being reduced, the Company has recognized a loss of $13,467.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 21.55pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
December 30, 2015, the Company entered into amendments (the &ldquo;2013 Placement Agent Warrant Amendments&rdquo;) with the holders
of the 2013 Placement Agent Warrants. Pursuant to the 2013 Placement Agent Warrant Amendments, 5,050,000 2013 Placement Agent
Warrants were amended to extend the expiration date to June 30, 2019 and remove the provision requiring an adjustment of the exercise
price in the event the Company sells common stock at a purchase price lower than the current warrant exercise price. As a result
of the 2013 Placement Agent Warrant Amendments, the Company has recognized a loss of $242,400 and has reclassified $2,277,550
from the derivative liability to equity resulting in an increase to equity of $2,035,150. The 2013 Placement Agent Warrants were
revalued to the date of the amendment and were then reclassified to equity.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Dividend
Warrants</I></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
connection with the Reverse Acquisition (note 1), effective January 24, 2013, the Company effected a warrant dividend (the &ldquo;Warrant
Dividend&rdquo;) pursuant to which the Company issued one five-year warrant to purchase one share of common stock at an exercise
price of $1.25 for each outstanding share of common stock (the &ldquo;Dividend Warrants&rdquo;). Pursuant to the Warrant Dividend,
the Company issued an aggregate of 3,250,007 Dividend Warrants.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
October 31, 2014, the Company and all of its Dividend Warrant holders entered into amendments to the Dividend Warrants such that
the Company&rsquo;s redemption rights and certain provisions of the Dividend Warrant agreements relating to potential cash settlement
of the Dividend Warrants were removed. The Dividend Warrants were revalued to the date of the amendment on October 31, 2014 which
resulted in a reclassification to equity of $975,278.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>2015
Agent Warrants</I></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
part of the Company&rsquo;s financing completed during the quarter ended September 30, 2015 (note 7), the Company
issued 93,908 warrants to certain placement agents (&ldquo;2015 Agent Warrants&rdquo;). The 2015 Agent Warrants are
exercisable at a per share price equal to $0.75 during the five-year period commencing six months from the effective date of
the Public Offering, which period shall not extend further than five years from the effective date of the Public Offering.
Therefore, all 2015 Agent Warrants expire on July 15, 2020.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>DelMar Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
to Consolidated Condensed Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>March
31, 2016</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(expressed
in US dollars unless otherwise noted)</FONT></P>


<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Warrants
issued for services</I></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
a prior period, the Company issued 300,000 warrants for services. The warrants were issued on September 12, 2013 and are exercisable
on a cashless basis at an exercise price of $1.76 for five years.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company&rsquo;s derivative liability is summarized as follows:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">March
    31, <BR>2016 <BR>$</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">June
    30, <BR>2015 <BR>$</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(as
    restated)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Opening
    balance</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,364,381</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,111,007</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance
    of 2015 Agent Warrants</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">29,594</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change in
    fair value of warrants</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">943,050</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(627,433</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change in
    fair value due to change in warrant terms</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">270,965</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(23,658</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reclassification
    to equity upon amendment of warrants</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,343,300</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(975,278</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reclassification
    to equity upon exchange of warrants</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(728,835</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reclassification
    to equity upon exercise of warrants</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(247,440</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(391,422</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Closing
    balance</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,017,250</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,364,381</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE><BR STYLE="clear: both">

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stockholders&rsquo;
                                         equity</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Preferred
stock</B></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Authorized</I></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,000,000
preferred shares, $0.001 par value</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Issued
and outstanding</I></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9;&#9;Special
voting shares &ndash; at March 31, 2016 &ndash; 1 (June 30, 2015 &ndash; 1)</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9;&#9;Series
A shares &ndash; at March 31, 2016 &ndash; 278,530 (June 30, 2015 &ndash; 278,530)</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective
September 30, 2014 pursuant to the Company&rsquo;s Valent Exchange Agreement (note 4), the Company filed the Series A Certificate
of Designation with the Secretary of State of Nevada. Pursuant to the Series A Certificate of Designation, the Company designated
278,530 shares of preferred stock as Series A Preferred Stock. The shares of Series A Preferred Stock have a stated value of $1.00
per share (the &ldquo;Stated Value&rdquo;) and are not convertible into common stock. The holder of the Series A Preferred Stock
is entitled to dividends at the rate of 3% of the Stated Value per year, payable quarterly in arrears. Upon any liquidation of
the Company, the holder of the Series A Preferred Stock will be entitled to be paid, out of any assets of the Company available
for distribution to stockholders, the Stated Value of the shares of Series A Preferred Stock held by such holder, plus any accrued
but unpaid dividends thereon, prior to any payments being made with respect to the common stock.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>DelMar Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
to Consolidated Condensed Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>March
31, 2016</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(expressed
in US dollars unless otherwise noted)</FONT></P>



<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Common
stock</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Authorized</I></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">200,000,000
common shares, $0.001 par value</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Issued
and outstanding</I></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">March
31, 2016 &ndash; 44,309,098 (June 30, 2015 &ndash; 39,455,931)</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
issued and outstanding common shares at March 31, 2016 include 4,056,042 shares of common stock on an as-exchanged basis with
respect to the shares of Exchangeco that can be exchanged for shares of common stock of the Company.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid"><P STYLE="font: bold 10pt/10.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares
                                         of common stock</FONT></P> <P STYLE="font: bold 10pt/10.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">outstanding</FONT></P></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
                                         stock</FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional
                                         paid-in capital</FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right; padding-bottom: 1.5pt; border-bottom: Black 1.5pt solid"><P STYLE="font: bold 10pt/10.5pt Times New Roman, Times, Serif; margin: 0 0.1in 0 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P><P STYLE="font: bold 10pt/10.5pt Times New Roman, Times, Serif; margin: 0 0.1in 0 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P><P STYLE="font: bold 10pt/10.5pt Times New Roman, Times, Serif; margin: 0 0.1in 0 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P><P STYLE="font: bold 10pt/10.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants</FONT></P></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; font-weight: bold; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">June
    30, 2015 &ndash; as previously reported</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">39,455,931</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">39,456</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17,500,008</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,138,426</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Restatement
    adjustments</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(136,800</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,048,994</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">June 30,
    2015 &ndash; as restated</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">39,455,931</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">39,456</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17,363,208</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">89,432</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance
    of shares and warrants &ndash; net of issue costs (i)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,277,667</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,278</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,198,453</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">671,189</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reclassification
    of warrants (ii)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,343,300</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercise
    of warrants for cash (iii)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">515,500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">515</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">652,108</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
    issued for services (iv)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">429,932</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares issued
    for services (v)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">60,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">60</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">80,340</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock-based
    compensation</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">138,711</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reclassification
    of stock option liability</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">29,747</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding: 0 0 4pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">March
    31, 2016</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">44,309,098</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">44,309</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21,805,867</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,190,553</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE><BR STYLE="clear: both">

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)
On July 15, 2015 the Company&rsquo;s Registration Statement on Form S-1 relating to a public offering by the Company
of common stock and common stock purchase warrants (the &ldquo;Public Offering&rdquo;) was declared effective by
the Securities and Exchange Commission. Pursuant to the Offering, the Company issued 4,277,667 shares of common stock
at $0.60 per share and 4,277,667 warrants (the &ldquo;2015 Public Offering Warrants&rdquo;) to purchase shares of common
stock at $0.001 per warrant for total gross proceeds of $2,566,660. The 2015 Public Offering Warrants are exercisable at
$0.75 per share for a period of five years until they expire on July 31, 2020.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in">The Company engaged certain placement
agents for the sale of a portion of the shares and 2015 Public Offering Warrants. Under the Company&rsquo;s
engagement agreements with these placement agents, the Company agreed to pay up to a 7% cash commission and issue warrants to
purchase shares of common stock (the &ldquo;2015 Agent Warrants&rdquo;) up to the number of shares of our common stock equal
to 5% of the aggregate number of shares sold in the Offering by such placement agents. Pursuant to the placement agent
agreements the Company paid a total cash commission of $80,575 and issued 93,908 2015 Agent Warrants (note 6). The 2015 Agent
Warrants are exercisable at a per share price equal to $0.75 during the five-year period commencing six months from the
effective date of the Public Offering, which period shall not extend further than five years from the effective date of the
2015 Public Offering. Therefore, all 2015 Agent Warrants expire on July 15, 2020.</P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition to the cash commission of $80,575 the Company also incurred additional cash issue and closing costs of $582,511 (including
costs deferred at June 30, 2015 of $550,119) resulting in net cash proceeds of $1,903,514. The 2015 Agent Warrants have been recognized
as non-cash issue costs of $29,594.</FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>DelMar Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
to Consolidated Condensed Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>March
31, 2016</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(expressed
in US dollars unless otherwise noted)</FONT></P>


<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)
Upon the amendment of the Investor Warrants and the 2013 Placement Agent Warrants, the Company reclassified the related derivative
liability to equity (note 6).</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)
During the  nine months ended March 31, 2016, 515,500 Investor Warrants were exercised for proceeds of $405,183 (note
6).</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in">(iv) During the nine months ended March 31,
2016, the Company issued 1,060,000 warrants for services. All warrants have an exercise price of $0.75. Of these warrants,
60,000 expire on July 31, 2020, 500,000 expire March 1, 2020, and 500,000 expire February 1, 2021.</P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(v)
During the nine months ended March 31, 2016, the Company issued 60,000 shares of common stock for services.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Stock
Options</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table sets forth the stock options outstanding:&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Number
                                         of</B></FONT></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>stock</B></FONT></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>options</B></FONT></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>outstanding</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Weighted</B></FONT></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>average</B></FONT></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>exercise</B></FONT></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>price</B></FONT></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>$</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 70%; font-weight: bold; text-align: left; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>June
                                         30, 2015</B></FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,595,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.94</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Granted</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">390,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.01</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Forfeited</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(470,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.08</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding: 0; text-align: left; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cancelled</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(50,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.05</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding: 0; font-weight: bold; text-align: left; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>March
                                         31, 2016</B></FONT></TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,465,000</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.92</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>DelMar Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
to Consolidated Condensed Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>March
31, 2016</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(expressed
in US dollars unless otherwise noted)</FONT></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table summarizes stock options currently outstanding and exercisable at March 31, 2016:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted average exercise
    price <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number <BR>outstanding at <BR>March 31, <BR>2016</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR>average <BR>remaining <BR>contractual <BR>life <BR>(years)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number <BR>exercisable <BR>at <BR>March 31, <BR>2016</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted average <BR>exercise <BR>price <BR>$</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">0.39</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">775,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">5.88</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">775,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">0.39</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.74</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">180,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.84</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">180,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.74</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.80</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.94</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">180,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.94</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.92</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,770,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.37</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,696,796</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.05</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.12</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.77</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.12</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.54</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.54</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.30</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">120,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7.17</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">120,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.30</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0.92</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,465,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,116,129</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0.91</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Included
in the number of stock options outstanding are 775,000 stock options granted at an exercise price of CDN $0.50. The exercise prices
shown in the above table have been converted to $0.39 using the period ending closing exchange rate.</FONT></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>DelMar Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
to Consolidated Condensed Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>March
31, 2016</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(expressed
in US dollars unless otherwise noted)</FONT></P>



<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Certain
stock options have been granted to non-employees and will be revalued at each reporting date until they have fully vested. The
stock options have been re-valued using a Black-Scholes pricing model using the following assumptions:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right; padding: 0 0 1.5pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid"><P STYLE="font: bold 10pt/11.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">March
                                         31,</FONT></P> <P STYLE="font: bold 10pt/11.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></P></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dividend
    rate</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Volatility</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9;84.8%
                                         to 118</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Risk-free
    rate</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Term - years</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9;0.5
                                         to 3.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE><BR STYLE="clear: both">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in">The Company has recognized the following amounts
as stock option expense for the periods noted:&nbsp; &nbsp;&nbsp;</P>



<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 18pt; font-weight: bold; text-align: right; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Three
                                         months ended</FONT></P>
                                                                                                   <P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">March 31,</FONT></P>

</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nine
                                         months ended</FONT></P>
                                                                                                   <P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>
                                                                 <P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">March
                                         31,</FONT></P>

</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 18pt; font-weight: bold; text-align: right; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></P>
                                                                 <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></P>
                                                                 <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016
    <BR>$</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></P>
                                                                 <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
    and development</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,165</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">26,853</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">36,395</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">39,909</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
    and administrative</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,678</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">35,995</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">102,316</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">102,262</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-indent: -0.3in; padding-left: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">23,843</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">62,848</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">138,711</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">142,171</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE><BR STYLE="clear: both"><P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in">All of the total stock option expense of $138,711
for the nine months ended March 31, 2016 has been recognized as additional paid in capital. Of the stock option expense of $142,171
for the nine months ended March 31, 2015 $142,447 has been recognized as additional paid in capital and $276 has been recognized
as a reduction of the stock option liability. The aggregate intrinsic value of stock options outstanding at March 31, 2016 was
$396,538 (March 31, 2015 - $345,131) and the aggregate intrinsic value of stock options exercisable at March 31, 2016 was $396,538
(March 31, 2015 - $333,139). As of March 31, 2016 there was $93,016 in unrecognized compensation expense that will be recognized
over the next three years. No stock options granted under the plan have been exercised to March 31, 2016. Upon the exercise of
stock options new shares will be issued.</P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in">A summary of status of the Company&rsquo;s unvested
stock options under the plan is presented below:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 18pt; font-weight: bold; text-align: right; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 18pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid"><P STYLE="font: bold 10pt/11.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
                                         of</FONT></P> <P STYLE="font: bold 10pt/11.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Options</FONT></P></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid"><P STYLE="font: bold 10pt/11.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted</FONT></P> <P STYLE="font: bold 10pt/11.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">average</FONT></P> <P STYLE="font: bold 10pt/11.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">exercise</FONT></P> <P STYLE="font: bold 10pt/11.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">price</FONT></P> <P STYLE="font: bold 10pt/11.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></P></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid"><P STYLE="font: bold 10pt/11.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted</FONT></P> <P STYLE="font: bold 10pt/11.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">average</FONT></P> <P STYLE="font: bold 10pt/11.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">grant
                                         date</FONT></P> <P STYLE="font: bold 10pt/11.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">fair
                                         value</FONT></P> <P STYLE="font: bold 10pt/11.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></P></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 57%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Unvested
    at June 30, 2015</B></FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">722,361</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.95</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.41</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Granted</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">390,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.01</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.73</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Vested</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(481,634</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.91</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.64</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Forfeited</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(260,370</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.92</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.24</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cancelled</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(21,486</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.05</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.57</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: bottom; padding-left: -40pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Unvested
    at March 31, 2016</B></FONT></TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">348,871</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.02</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: right; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.55</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE><BR STYLE="clear: both">

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>DelMar Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
to Consolidated Condensed Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>March
31, 2016</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(expressed
in US dollars unless otherwise noted)</FONT></P>


<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in">Certain of the Company&rsquo;s warrants have
been recognized as a derivative liability (note 6). The following table&nbsp;summarizes all of the Company&rsquo;s outstanding
warrants as of March 31, 2016:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-indent: 0; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Description</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Number</B></FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; font-weight: bold; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance
    &ndash; June 30, 2015</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13,472,870</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015 Public
    Offering     Warrants (i)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,277,667</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015 Agent     Warrants (ii)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">93,908</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
    issued for services (iii)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,060,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
    exercised for cash (iv)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(515,500</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding: 0 0 4pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance
    - March 31, 2016</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18,388,945</FONT></TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE><BR STYLE="clear: both">

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 13pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">i)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Issued
                                         as part of the Company&rsquo;s financing completed in August 2015. Warrants are exercisable
                                         at $0.75 until July 31, 2020.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 13pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ii)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Issued
                                         as part of the Company&rsquo;s financing completed in August 2015. The 2015 Agent Warrants
                                         are exercisable at a price of $0.75 during the period commencing January 15, 2016 until
                                         their expiry on July 15, 2020.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 13pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">iii)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         have an exercise price of $0.75. Of the total, 60,000 vest in tranches of 20,000 warrants
                                         each on November 30, 2015, March 31, 2016, and January 31, 2016 and are exercisable commencing
                                         January 1, 2016 until they expire on July 31, 2020. In addition, 500,000 of the warrants
                                         vest in tranches of 150,000 on March 1, 2015, and 50,000 on each of March 31, 2016, January
                                         31, 2016, February 29, 2016, March 31, 2016, April 30, 2016, May 31, 2016, and June 30,
                                         2016 until they expire on March 1, 2020. Also, 500,000 of the warrants vest in tranches
                                         of 83,333 on each of February 29, 2016, March 31, 2016, April 30, 2016, May 31, 2016,
                                         June 30, 2016 and July 31, 2016 until they expire on February 1, 2021.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 13pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">iv)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">515,500
                                         Investor Warrants were exercised for cash at $0.786 per share for proceeds of $405,183.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt/13pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 13pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Financial
                                         instruments</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company has financial instruments that are measured at fair value. To determine the fair value, we use the fair value hierarchy
for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs
by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use
to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are
inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of
inputs that may be used to measure fair value are as follows:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
                                         one&nbsp;- inputs utilize quoted prices (unadjusted) in active markets for identical
                                         assets or liabilities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
                                         two&nbsp;- inputs are inputs other than quoted prices included in Level 1 that are observable
                                         for the asset or liability, either directly or indirectly such as interest rates, foreign
                                         exchange rates, and yield curves that are observable at commonly quoted intervals;&nbsp;and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
                                         three&nbsp;- unobservable inputs developed using estimates and assumptions, which are
                                         developed by the reporting entity and reflect those assumptions that a market participant
                                         would use.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>DelMar Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
to Consolidated Condensed Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>March
31, 2016</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(expressed
in US dollars unless otherwise noted)</FONT></P>


<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Assets
and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes
in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value
hierarchy.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company&rsquo;s financial instruments consist of cash and cash equivalents, other receivables, accounts payable, related party
payables and derivative liability. The carrying values of cash and cash equivalents, other receivables, accounts payable and related
party payables approximate their fair values due to the immediate or short-term maturity of these financial instruments.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Derivative
liability</U></FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company accounts for certain warrants under the authoritative guidance on accounting for derivative financial instruments indexed
to, and potentially settled in, a company&rsquo;s own stock, on the understanding that in compliance with applicable securities
laws, the warrants require the issuance of securities upon exercise and do not sufficiently preclude an implied right to net cash
settlement. The Company classifies these warrants on its balance sheet as a derivative liability which is fair valued at each
reporting period subsequent to the initial issuance. The Company has used a simulated probability valuation model to value the
warrants. Determining the appropriate fair-value model and calculating the fair value of warrants requires considerable judgment.
Any change in the estimates (specifically probabilities) used may cause the value to be higher or lower than that reported. The
estimated volatility of the Company&rsquo;s common stock at the date of issuance, and at each subsequent reporting period, is
based on the historical volatility of similar life sciences companies. The risk-free interest rate is based on rates published
by the government for bonds with a maturity similar to the expected remaining life of the warrants at the valuation date. The
expected life of the warrants is assumed to be equivalent to their remaining contractual term.</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 13pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">a)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Fair
                                         value of derivative liability</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
derivative is not traded in an active market and the fair value is determined using valuation techniques. The Company uses judgment
to select a variety of methods to make assumptions that are based on specific management plans and market conditions at the end
of each reporting period. The Company uses a fair value estimate to determine the fair value of the derivative liability. The
carrying value of the derivative liability would be higher or lower as management estimates around specific probabilities change.
The estimates may be significantly different from those recorded in the consolidated financial statements because of the use of
judgment and the inherent uncertainty in estimating the fair value of these instruments that are not quoted in an active market.
All changes in the fair value are recorded in the consolidated statement of operations and comprehensive loss each reporting period.
This is considered to be a Level 2 financial instrument.</FONT></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 20pt"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>DelMar Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
to Consolidated Condensed Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>March
31, 2016</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(expressed
in US dollars unless otherwise noted)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company has the following liabilities under the fair value hierarchy:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 18pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">March
    31, 2016</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 18pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 64%; font-weight: bold; text-align: left; padding-left: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Liability</FONT></TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
                                         1</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
                                         2</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
                                         3</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.3in; padding-left: 0.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Derivative
    liability</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,017,250</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE><BR STYLE="clear: both">

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 18pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">June
    30, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 18pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(as
    restated)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 18pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 64%; font-weight: bold; text-align: left; padding-left: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Liability</FONT></TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
                                         1</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
                                         2</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
                                         3</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.3in; padding-left: 0.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Derivative
    liability</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,364,381</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE><BR STYLE="clear: both">

<P STYLE="font: bold 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">9</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subsequent
                                         events</FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-align: justify"><B>Series B Preferred Share
Issuance</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-align: justify"><B></B>On April 29, 2016, May 4, 2016, and May 12, 2016 the Company entered into Securities Purchase Agreements (the &ldquo;Purchase
Agreements&rdquo;), pursuant to which it issued an aggregate of 764,363 shares of Series B Preferred Stock at a purchase price
of at $8.00 per share for total gross proceeds of $6.1 million. Each share of Series B Preferred Stock is convertible into ten
shares of common stock equating to a conversion price of $0.80 (the &ldquo;Conversion Price&rdquo;) and will automatically convert
to common stock at the earlier of 24 hours following regulatory approval of VAL-083 with a minimum closing bid price of $2 or
five years from the final closing dates. The holders of the Series B Preferred Stocks are entitled to an annual cumulative, in
arrears dividend at the rate of 9% payable quarterly. The 9% dividend shall accrue quarterly commencing on the date of issue and
be payable quarterly on June 30, September 30, December 31, and March 31&nbsp;of each year commencing on June 30, 2016. Dividends
shall be payable solely by delivery of shares of common stock (the &ldquo;PIK Shares&rdquo;), in an amount for each holder equal
to the aggregate dividend payable to such holder with respect to the shares of Series B Preferred Stock held by such holder divided
by the Conversion Price. The Series B Preferred Shares do not contain any repricing features.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 2pt 0 2pt 21.55pt">In addition, the Company and the holders entered
into a royalty agreement, pursuant to which the Company will pay the holders of the Series B preferred shares, in aggregate, a
low, single-digit royalty based on their pro rata ownership of the Series B preferred shares on products sold directly by the
Company or sold pursuant to a licensing or partnering arrangement (the &ldquo;Royalty Agreement&rdquo;).</P>

<P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 2pt 0 2pt 21.55pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-align: left">Upon conversion of a holder&rsquo;s shares to
common stock, such holder shall no longer receive ongoing royalty payments under the Royalty Agreement but will be entitled to
receive any residual royalty payments that have vested. Rights to the royalties shall vest during the first three years following
the applicable closing date, in equal thirds to holders of the Series B Preferred Stock on each of the three vesting dates, upon
which vesting dates such royalty amounts shall become &ldquo;Vested Royalties&rdquo;.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>DelMar Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
to Consolidated Condensed Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>March
31, 2016</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/16pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(expressed
in US dollars unless otherwise noted)</FONT></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-align: left">The Company engaged certain placement agents
for the sale of a portion of the Series B Preferred Stock. Under the Company&rsquo;s engagement agreements with these placement
agents, the Company agreed to pay up to an 8% cash commission and issue warrants to purchase shares of common stock (the &ldquo;2016
Agent Warrants&rdquo;) up to the number of shares of our common stock equal to 8% of the aggregate number of shares underlying
the Series B Preferred Stock sold in the offering by such placement agents. Pursuant to the placement agent agreements the Company
paid a total cash commission of approximately $283,000 and issued 356,050 2016 Agent Warrants. The 2016 Agent Warrants are exercisable
at a per share price equal to $1.00 during the five-year period commencing six months from May 12, 2016 which period shall not
extend further than five years from the closing dates. Therefore, all 2016 Agent Warrants expire on May 12, 2021.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: left">In addition to the cash commission the Company
also incurred additional cash issue and closing costs of approximately $340,000 (including costs deferred at March 31, 2016 of
$60,647) resulting in net cash proceeds of approximately $5.5 million.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-align: justify"><B>Investor Warrant Amendments</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-align: justify">Subsequent to March 31,
2016, the Company amended an additional 1,970,238 Investor Warrants (note 6). As a result of the amendments, the Company has reclassified
a portion of its derivative liability to equity resulting in an increase in equity of approximately $500,000.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-align: justify"><B>Stock Options</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt; text-align: justify">Subsequent to March 31,
2016, 320,000 stock options were granted and 270,000 stock options were forfeited.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 21.55pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in">&nbsp;</P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt 0pt"><B>Item 2.</B><FONT STYLE="letter-spacing: 27pt">&nbsp;</FONT><B><A NAME="Management"></A>Management's
Discussion and Analysis of Financial Condition and Results of Operations.</B></P>



<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">This Management&rsquo;s Discussion and
Analysis (&ldquo;MD&amp;A&rdquo;) contains &ldquo;forward-looking statements&rdquo;, which represent our projections, estimates,
expectations or beliefs concerning, among other things, financial items that relate to management&rsquo;s future plans or objectives
or to our future economic and financial performance. In some cases, you can identify these statements by terminology such as &ldquo;may&rdquo;,
&ldquo;should&rdquo;, &ldquo;plans&rdquo;, &ldquo;believe&rdquo;, &ldquo;will&rdquo;, &ldquo;anticipate&rdquo;, &ldquo;estimate&rdquo;,
&ldquo;expect&rdquo; &ldquo;project&rdquo;, or &ldquo;intend&rdquo;, including their opposites or similar phrases or expressions.
You should be aware that these statements are projections or estimates as to future events and are subject to a number of factors
that may tend to influence the accuracy of the statements. These forward-looking statements should not be regarded as a representation
by the Company or any other person that the events or plans of the Company will be achieved. You should not unduly rely on these
forward-looking statements, which speak only as of the date of this report. Except as may be required under applicable securities
laws, we undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the
date of this report or to reflect the occurrence of unanticipated events.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">You should review the factors and risks
we describe under &ldquo;Risk Factors&rdquo; in our report on Form 10-K/A for the year ended June 30, 2015 and in the Company&rsquo;s
other filings with the Securities and Exchange Commission, available at www.sec.gov. Actual results may differ materially from
any forward-looking statement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">DelMar Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;)
is a clinical stage drug development company with a focus on the treatment of cancer. We are conducting clinical trials in the
United States with our product candidate, VAL-083, as a potential new treatment for glioblastoma multiforme (&ldquo;GBM&rdquo;),
the most common and aggressive form of brain cancer. We have also acquired certain exclusive commercial rights to VAL-083 in China
where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (&ldquo;CML&rdquo;) and lung cancer. In
order to accelerate our development timelines and reduce technical risk, we leverage existing clinical and commercial data from
a wide range of sources. We plan to seek marketing partnerships in China and elsewhere in order to supplement our own commercialization
efforts and potentially generate future royalty revenue.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Recent Highlights</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 2%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&#9679;</FONT></TD>
    <TD STYLE="width: 92%; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">We
    closed a private placement for gross proceeds of $6.1 million.&nbsp;&nbsp;These proceeds have provided sufficient net equity
    to meet the listing requirements of a national exchange.&nbsp;&nbsp;We plan to file an application to list our shares on a
    national exchange as soon as practicable.&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">The United States Food and Drug Administration (&ldquo;FDA&rdquo;) granted an orphan drug designation to VAL-083 for the treatment of ovarian cancer and medulloblastoma.&nbsp;&nbsp;In addition, we have previously been granted an orphan drug designation for VAL-083 in glioma in the USA and Europe.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At the American Association for Cancer
        Research (&ldquo;AACR&rdquo;) annual meeting, we reported:</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
<UL STYLE="margin-top: 0in; list-style-type: circle; font-family: Times New Roman, Times, Serif">

        <LI STYLE="font: 10pt/normal Times New Roman, Times, Serif; text-align: justify; margin: 0 0.25in 6pt 0">A well-tolerated VAL-083
        dosing regimen of 40 mg/m<SUP>2</SUP>/daily every 3 days in a 21-day cycle has been selected for advancement into a Phase III refractory
        GBM study;</LI>
        <LI STYLE="font: 10pt/normal Times New Roman, Times, Serif; text-align: justify; margin: 0 0.25in 6pt 0">The Phase III study design
        and initiation shall be determined in consultation with the FDA during a meeting planned for the first half of 2016;</LI>
        <LI STYLE="font: 10pt/normal Times New Roman, Times, Serif; text-align: justify; margin: 0 0.25in 6pt 0">The majority of GBM patients
        enrolled in DelMar&rsquo;s Phase I/II clinical trial have tumors exhibiting features correlated with resistance to currently available
        therapies, aggressive disease and poor patient outcomes<B>,</B> and<B>;</B></LI>
        <LI STYLE="font: 10pt/normal Times New Roman, Times, Serif; text-align: justify; margin: 0 0.25in 6pt 0">This clinical trial is
        ongoing with expected median survival of eight to nine months following bevacizumab failure. Results to date support the potential
        of VAL-083 to offer a clinically meaningful survival benefit and a promising new treatment option for GBM patients who have failed,
        or are unlikely to respond to, currently available chemotherapeutic regimens.</LI>
</UL STYLE="font-family: Times New Roman, Times, Serif"></TD></TR>
</TABLE>


<P STYLE="margin: 0">


<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 2%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&#9679;</FONT></TD>
    <TD STYLE="width: 92%; padding-right: 0.5in; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">We presented data demonstrating that VAL-083 induces apoptosis independent of p53 status, and appears to have a distinct mode of action from other chemotherapies widely used in the treatment of cancer.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-align: justify; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">We announced a collaboration with the University of Texas MD Anderson Cancer Center (&ldquo;MD Anderson&rdquo;) to accelerate the clinical development of VAL-083 for the treatment of GBM.&nbsp;&nbsp;As part of the collaboration, MD Anderson will initiate a new Phase II clinical study with VAL-083 in patients with GBM at first recurrence/progression, prior to Avastin&reg; exposure;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">At the AACR &ndash; Advances in Pediatric Research: From Mechanisms and Models to Treatment and Survivorship Conference, we presented data indicating that VAL-083 offers potential therapeutic alternatives in difficult-to-treat pediatric brain tumors. In March 2016 the FDA Office of Orphan Products Development (&ldquo;OOPD&rdquo;) granted orphan drug designation for VAL-083 in the treatment of medulloblastoma;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">At the AACR &ndash; Advances in Ovarian Cancer Research: Exploiting Vulnerabilities Conference, we presented data supporting the effectiveness of VAL-083 against cisplatin-resistant ovarian cancers and raised the potential for VAL-083 as a treatment for ovarian cancers as a single-agent against platinum-resistant tumors or in combination with platinum-based chemotherapeutic regimens. In April 2016 the FDA OOPD also granted orphan drug designation for VAL-083 in the treatment of ovarian cancer;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">We continued to strengthen our intellectual property portfolio. DelMar now holds six issued US patents and four issued international patents. In addition, we have filed eleven patent applications across eight patent families.</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>VAL-083</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our product candidate, VAL-083, represents
a &ldquo;first-in-class&rdquo; small molecule chemotherapeutic which means that the molecular structure of VAL-083 is not an analogue
or derivative of other small molecule chemotherapeutics approved for the treatment of cancer. VAL-083 was originally discovered
in the 1960&rsquo;s and has been assessed in 42 Phase I and Phase II clinical trials sponsored by the National Cancer Institute
(&ldquo;NCI&rdquo;) in the United States as a treatment against various cancers including lung, brain, cervical, ovarian tumors
and leukemia. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types. VAL-083
is approved as a cancer chemotherapeutic in China for the treatment of CML and lung cancer. VAL-083 has not been approved for any
indications outside of China.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon obtaining regulatory approval,
we intend to commercialize VAL-083 for the treatment of orphan and other cancer indications where patients have failed other therapies
or have limited medical options. Orphan diseases are defined in the United States under the Rare Disease Act of 2002 as &ldquo;any
disease or condition that affects fewer than 200,000 persons in the United States&rdquo;. The Orphan Drug Act of 1983 is a federal
law that provides financial and other incentives including a seven-year period of market exclusivity in the United States to encourage
the development of new treatments for orphan diseases. In February 2012, we announced that VAL-083 has been granted protection
under the Orphan Drug Act by the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) for the treatment of glioma, including GBM.
In January 2013, the European Medicines Agency (&ldquo;EMA&rdquo;) also granted orphan drug protection to VAL-083 for the treatment
of glioma. In Europe, the period of market exclusivity is for a ten-year period. &nbsp;In 2016, the FDA also granted Orphan Drug
protection to VAL-083 for the treatment of medulloblastoma and ovarian cancer.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We research the mechanism of action
of potential product candidates to determine the clinical indications best suited for therapy and seek to rapidly advance into
human clinical trials and toward commercialization. The mechanism of action of VAL-083 is understood to be a bi-functional alkylating
agent. Alkylating agents are a commonly used class of chemotherapy drugs. They work by binding to DNA and interfering with normal
processes within the cancer cell, which prevents the cell from making the proteins needed to grow and survive. After exposure to
alkylating agents, the cancer cell becomes dysfunctional and dies. There are a number of alkylating agents on the market that are
used by physicians to treat different types of cancer.</P>



<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on published research and our
own data, the cytotoxic functional groups and the mechanism of action of VAL-083 are understood to be functionally different from
alkylating agents commonly used in the treatment of cancer. VAL-083 has previously demonstrated activity in cell-lines that are
resistant to other types of chemotherapy. No evidence of cross-resistance has been reported in published clinical studies. Therefore,
we believe that VAL-083 may be effective in treating tumors that have failed or become resistant to other chemotherapies.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have presented new research at peer-reviewed
scientific meetings demonstrating that VAL-083 is active in patient-derived tumor cell lines and cancer stem cells that are resistant
to other chemotherapies.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">VAL-083 readily crosses the blood brain
barrier where it maintains a long half-life in comparison to the plasma. Published pre-clinical and clinical research demonstrates
that VAL-083 is selective for brain tumor tissue.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The main dose-limiting toxicity (&ldquo;DLT&rdquo;)
related to the administration of VAL-083 in previous NCI-sponsored clinical studies was myelosuppression. Myelosuppression is the
decrease in cells responsible for providing immunity, carrying oxygen, and those responsible for normal blood clotting. Myelosuppression
is a common side effect of chemotherapy. There is no evidence of lung, liver or kidney toxicity even with prolonged treatment by
VAL-083. Commercial data from the Chinese market where the drug has been approved for more than 15 years supports the safety findings
of the NCI studies.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Modern medicine allows for better management
of myelosuppressive side effects. We believe this offers the potential opportunity to improve upon the drug&rsquo;s already established
efficacy profile by substantially increasing the dose of VAL-083 that can be safely administered to GBM patients.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Background on GBM</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Worldwide, there are an estimated 240,000
new cases of brain and central nervous system (&ldquo;CNS&rdquo;) tumors each year. Gliomas are a type of CNS tumor that arises
from glial cells in the brain or spine. Glial cells are the cells surrounding nerves. Their primary function is to provide support
and protection for neurons in the CNS.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">GBM, also known as Grade IV astrocytoma,
is the most common and the most lethal form of glioma. According to the World Health Organization, GBM occurs with an incidence
of 3.17 per 100,000 person-years. Approximately 15,000 new cases of GBM were expected to be diagnosed in the United States during
2015. &nbsp;</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">GBM progresses quickly and patients
deteriorate rapidly. Common symptoms include headaches, seizures, nausea, weakness, paralysis and personality or cognitive changes
such as loss of speech or difficulty in thinking clearly.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The majority of GBM patients do not
survive for more than two years following diagnosis, and the median survival in newly diagnosed patients with best available treatments
is 14.6 months.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Standard treatment following diagnosis
includes surgical resection to remove as much of the tumor as possible (&ldquo;debulking&rdquo;) followed by radiotherapy with
concomitant and adjuvant chemotherapy with Temodar&reg; (temozolomide, &ldquo;TMZ&rdquo;). Nearly all patients diagnosed with GBM
will relapse following first-line treatment, with a 1-year survival rate of approximately 25% following failure of front-line therapy,
with average 5-year survival rate less than 3%.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Avastin&reg; (bevacizumab, an anti-VEGF
antibody) is approved as a single agent for patients with recurrent GBM following prior therapy as an alternative to corticosteroids
to relieve disease symptoms in the US, Canada, Australia and Japan. Avastin&reg; carries a &ldquo;black-box warning&rdquo; related
to severe, sometimes fatal, side effects related to gastrointestinal perforations, wound healing complications and hemorrhage.
There are no data demonstrating an improvement in disease-related symptoms or increased survival in refractory GBM with Avastin&reg;.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">TMZ and the nitrosoureas, including
carmustine, lomustine, and nimustine, are alkylating agents that readily cross the blood-brain-barrier (&ldquo;BBB&rdquo;) and
are used in the treatment of CNS cancers, including GBM. Alkylating agents are among the oldest type of cancer chemotherapies in
use today. Alkylating agents bind to DNA to cause damage to cancer cells. Their anti-tumor mechanism is via alkylation of DNA resulting
in base-pair mismatch or strand-mediated cross links between base pairs. The DNA damage caused by alkylating agents mimics naturally
occurring errors, resulting in apoptosis and tumor cell death.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The primary anti-cancer mechanism of
TMZ and the nitrosoureas is to attack the tumor&rsquo;s DNA via alkylation of the O6-position of the DNA base residue, guanine.
TMZ treatment causes DNA damage mainly by methylation at the O6-position of guanine resulting in guanine-thymine base pair mismatches
during replication. Nitrosoureas mediate their cytotoxic effect by ethylation at the O6-position of guanine which produces a cross-link
to cytosine residues resulting in double-strand DNA breaks during mitosis.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A majority of GBM patients&rsquo; tumors
are resistant to TMZ or nitrosourea therapy due to high expression of a naturally occurring enzyme called O6-DNA methylguanine
methyl-transferase (&ldquo;MGMT&rdquo;) enzyme which repairs O6-guanine lesions. MGMT repair in turn inhibits the activity of TMZ
and nitrosoureas and allows a patients&rsquo; GBM tumor to continue to grow in spite of treatment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Consistent with the importance of its
repair activity, high expression of MGMT is strongly correlated with poor patient outcomes. Several clinical studies have established
that MGMT is an important prognostic indicator of response to TMZ and patient survival.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Probability of GBM Patient Survival
Correlated to Expression of MGMT Enzyme</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unmethylated promoter = High MGMT
Expression and Significantly Shorter Survival)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 216px; width: 352px"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>VAL-083 in GBM</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">VAL-083 is an alkylating agent which
readily crosses the BBB. Its primary cytotoxic mechanism, epoxide derived DNA cross-links at the N7 position of guanine, is distinct
from TMZ or the nitrosoureas.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research demonstrates that VAL-083&rsquo;s
unique cytotoxic mechanism forms DNA cross-links at the N7 position of guanine and retains cytotoxic activity independent of MGMT
expression <I>in vitro</I>. We have presented new research at peer-reviewed scientific meetings demonstrating that VAL-083 is active
in patient-derived tumor cell lines and cancer stem cells that are resistant to other chemotherapies. Of particular importance
is resistance to Temodar&reg; due to activity of the repair enzyme known as MGMT, which results in chemoresistance in many GBM
patients. At AACR in 2012, we presented data demonstrating that VAL-083 is active independent of MGMT resistance in laboratory
studies. VAL-083 has more potent activity against brain tumor cells in comparison to TMZ and overcome resistance associated with
MGMT suggesting the potential to surpass the current standard-of-care in the treatment of GBM.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0.5in"><B>A Summary of Our Data
Demonstrating that VAL-083&rsquo;s Anti-Tumor Mechanism is Distinct from, and can Overcome, MGMT-Related Chemoresistance in the
Treatment of GBM</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; color: red"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 321px; width: 632px">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">VAL-083 has been assessed in multiple
historical NCI-sponsored clinical studies as chemotherapy in the treatment of newly diagnosed and recurrent brain tumors and other
cancers. In general, tumor regression in brain cancer was achieved following therapy in greater than 40% of patients treated and
stabilization was achieved in an additional 20% to 30%. In published clinical studies VAL-083 has previously been shown to have
a statistically significant impact on median survival in high grade glioma brain tumors when combined with radiation versus radiation
alone with results similar or superior to other chemotherapies approved for use in GBM.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>A Summary of Published Data adapted
from Separate Sources Comparing the Efficacy of VAL-083 </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>and Other Therapies in the Treatment
of GBM</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center; line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparative Therapy</b></font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Median Survival Benefit</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chemotherapy</b></font></td>
    <td style="width: 1%; line-height: 107%">&nbsp;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Radiation (XRT)</b></font></td>
    <td style="width: 1%; line-height: 107%">&nbsp;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Radiation + Chemotherapy</b></font></td>
    <td style="width: 1%; line-height: 107%">&nbsp;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>vs. XRT alone</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Temodar</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1 months</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58 weeks </font><br>
<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14.6 months)</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5 months</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VAL-083</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.8 months</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67 weeks </font><br>
<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16.8 months)</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.0 months</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lomustine</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: center; line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52 weeks</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: center; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carmustine</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: center; line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40-50 weeks</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: center; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Semustine</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: center; line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35 weeks</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: center; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avastin</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.a.</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: center; line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: center; line-height: 107%">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Additional support for the differentiated
profile of VAL-083 and TMZ comes from the results of studies with GBM cancer stem cells (&ldquo;CSCs&rdquo;). GBM CSCs display
strong resistance to TMZ, even where MGMT expression is low. However, our data demonstrates that GBM CSCs are susceptible to VAL-083
independent of MGMT expression.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on historical data and our own
research, we believe that VAL-083 has the potential to offer physicians and patients a new paradigm in the treatment of GBM that
will address significant unmet medical needs. In addition, the profile of VAL-083 offers the potential of additive or synergistic
benefit as a future combination therapy with existing chemotherapeutic agents or novel vaccines or immunotherapy approaches currently
under investigation.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Interim Phase I/II Results in Refractory
GBM</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We filed an investigational new drug
(&ldquo;IND&rdquo;) application with the FDA and initiated human clinical trials with VAL-083 as a potential treatment for refractory
GBM in 2011. Details of the study are available at http://www.clinicaltrials.gov/ct2/show/NCT01478178?term=VAL-083&amp;rank=1)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our clinical trial is a Phase I/II,
open-label, single arm dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics and anti-cancer activity
of VAL-083 in patients with refractory GBM. To be eligible for our clinical trial, patients must have been previously treated for
GBM with surgery and/or radiation, if appropriate, and must have failed both bevacizumab (Avastin&reg;) and temozolomide (Temodar&reg;),
unless either or both are contra-indicated. Response to treatment with VAL-083 is measured prior to each treatment cycle.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The overall goal of our Phase I/II clinical
trial is to determine a modernized dosing regimen for advancement into a registration-directed clinical trial. The Phase I portion
of the study involved dose escalation cohorts until a maximum tolerated dose (&ldquo;MTD&rdquo;) was established in the context
of modern care. A further 14 patient Phase II expansion was then enrolled at the MTD to gather further safety data at our chosen
therapeutic dose and to further explore the outcomes in this patient population.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">To date, 48 GBM patients have been enrolled
in our Phase I/II clinical trial at five centers: the Mayo Clinic in Rochester, Minnesota (&ldquo;Mayo&rdquo;), the Brain Tumor
Center at University of California, San Francisco (&ldquo;UCSF&rdquo;), the Sarah Cannon Cancer Research Center (&ldquo;SCRI&rdquo;)
in Nashville, Tennessee, Denver, Colorado, and the SCRI affiliate site at the Florida Cancer Specialist Research Institute in Sarasota,
Florida.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have presented interim data from
our Phase I/II clinical trial at peer-reviewed scientific meetings including most recently at the annual meetings of AACR in April
2016 and SNO in November 2015. We anticipate presenting additional data at upcoming scientific meetings during 2016.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In summary, at doses tested to date,
our interim clinical data is as follows.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><I><U>Pharmacokinetics</U></I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pharmacokinetic (&ldquo;PK&rdquo;) analyses
showed dose-dependent linear systemic exposure with a short (1-2h) plasma terminal half-life; average Cmax at 40 mg/m2/day was
781 ng/mL (5.3&micro;M). The observed PK profile is comparable to published literature. Prior NCI-sponsored studies demonstrated
that VAL-083 readily crosses the blood brain barrier and has a long (&gt;20 hour) half-life in the central nervous system (&ldquo;CNS&rdquo;).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe that this PK profile is optimal
for the treatment of brain tumors: A long CNS half-life is expected to maximize exposure of the drug in the brain increasing the
likelihood of successful treatment outcomes, while a short plasma half-life is desirable to minimize systemic side effects.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on observed and previously published
pharmacokinetics, DelMar believes that therapeutic doses equal to, or above, 20 mg/m2 daily on days 1, 2 and 3 of a 21-day cycle
should deliver sufficient levels of VAL-083 to brain tumors to achieve a therapeutic benefit.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><I><U>Safety and Tolerability</U></I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">In the Phase I dose escalation
regimen, no serious adverse events (&ldquo;SAE&rdquo;) related to Val-083 were encountered at doses up to 40 mg/m<SUP>2</SUP>/day.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Increasing frequency of, and higher
grade, hematologic toxicities were observed at doses above 40 mg/m<SUP>2</SUP>/day. Consistent with the published literature, the
observed dose limiting toxicity for VAL-083 is primarily thrombocytopenia (low platelets). Observed platelet nadir occurred at
approximately day 18, and recovery was rapid and spontaneous following treatment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Based on Phase I observations,
fourteen additional patients were enrolled in a Phase II expansion cohort at 40mg/m<SUP>2</SUP>, which was established at the MTD.
The purpose of the Phase II expansion cohort was to gather further safety data at our chosen therapeutic dose and to further explore
the outcomes in this patient population.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Consistent with Phase I, the dose
of VAL-083 of 40 mg/m<SUP>2</SUP> on days 1, 2 and 3 of a 21-day cycle was generally well tolerated in Phase II. At this dose,
one subject previously treated with CCNU, a nitrosourea agent, reported severe (Grade 4) thrombocytopenia. As a result of this
observation, the protocol inclusion criterion for platelet count was increased from 100,000/&mu;L to 150,000/&mu;L for patients
receiving prior nitrosoureas within 12 weeks preceding enrollment. No other dose limiting toxicities were observed in Phase II.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Based on these data, we believe
that the 40mg dose is the optimal dose to advance into registration-directed Phase III clinical trials as it maximizes the amount
of drug that can be delivered to the tumor while minimizing untoward toxicity.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><I><U>Doses Achieved</U></I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We confirmed that we achieved doses
of VAL-083 that are substantially higher than were utilized in the original published NCI-sponsored clinical trials. A summary
in comparison to the NCI&rsquo;s historical regimen is as follows:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Dosing Regimen</b></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&amp; Study</b></P></td>
    <TD STYLE="line-height: 107%">&nbsp;</td>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Single Dose</b></font></td>
    <TD STYLE="line-height: 107%">&nbsp;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Acute Regimen</b></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(single cycle)</b></P></td>
    <TD STYLE="line-height: 107%">&nbsp;</td>
    <TD STYLE="border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Comparative Cumulative Dose</b></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(@ 35 days)</b></P></td>
    <TD STYLE="line-height: 107%">&nbsp;</td>
    <TD STYLE="border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Dose Intensity</b></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(dose per week)</b></P></td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="width: 22%; line-height: 107%">&nbsp;</td>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</td>
    <TD STYLE="width: 12%; line-height: 107%">&nbsp;</td>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</td>
    <TD STYLE="width: 12%; line-height: 107%">&nbsp;</td>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</td>
    <TD STYLE="width: 12%; line-height: 107%">&nbsp;</td>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</td>
    <TD STYLE="width: 12%; line-height: 107%">&nbsp;</td>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</td>
    <TD STYLE="width: 12%; line-height: 107%">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">NCI GBM</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">historical regimen</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><i>(Eagan etal)</i></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">daily x 5 q 5wks</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(cycle = 35 days)</P></td>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</td>
    <TD STYLE="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25 mg/m<sup>2</sup></font></td>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</td>
    <TD STYLE="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x5 days =</font></td>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</td>
    <TD STYLE="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125 mg/m<sup>2</sup></font></td>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</td>
    <TD STYLE="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125 mg/m<sup>2</sup></font></td>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</td>
    <TD STYLE="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25mg/m<sup>2</sup>/wk</font></td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</td>
    <TD STYLE="line-height: 107%">&nbsp;</td>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</td>
    <TD STYLE="line-height: 107%">&nbsp;</td>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</td>
    <TD STYLE="line-height: 107%">&nbsp;</td>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</td>
    <TD STYLE="line-height: 107%">&nbsp;</td>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</td>
    <TD STYLE="line-height: 107%">&nbsp;</td>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">DelMar VAL-083</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">optimized regimen</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">daily x 3 q 3wks</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(cycle = 21 days)</P></td>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</td>
    <TD STYLE="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40 mg/m<sup>2</sup></font></td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x3 days&nbsp;=</font></td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120 mg/m<sup>2</sup></font></td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">240 mg/m<sup> 2</sup></font></td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40mg/m<sup>2</sup>/wk</font></td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td colspan="11" style="padding-top: 6pt; text-align: justify; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Daily x 5 q 5wks refers to a dosing regimen of once per day for five consecutive days every five weeks (35-day cycle); while daily x 3 q 3wks refers to a dosing regimen of once per day for three consecutive days every three weeks (21-day cycle)</i>.</font></td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our optimized dosing regimen increases
the amount of VAL-083 delivered to the CNS by 60% over historical regimens without increased toxicity. Thus, the DelMar regimen
achieves both a higher maximum concentration and higher overall exposure, which we believe may increase the likelihood of successful
treatment outcomes in glioblastoma and other brain tumors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><I><U>Tumor Response and Outcomes</U></I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">GBM patients in our Phase I/II
clinical trial were not re-resected prior to treatment with VAL-083 and therefore had a growing recurrent GBM tumor at the time
of enrollment. Patients were monitored for tumor response by MRI.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Consistent with un-resected refractory
GBM, median progression free survival (&ldquo;PFS&rdquo;) was short at 1.2 months (range: 0.2 &ndash; 20.1 months). Five GBM patients
treated with VAL-083 were reported to have stable disease as their best response following treatment; the remainder reported progressive
disease.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Disease progression is typical
in a refractory GBM population with non-resected tumors. However, we believe that that slowed progression may provide meaningful
clinical benefit in this patient population through prolonged overall survival and improved quality of life.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Ad-hoc subgroup analysis of the
Phase I dose-escalation data indicated a dose response trend. Increased survival was observed following initiation of treatment
in a high dose (30 and 40mg/m<SUP>2</SUP>) sub-group vs. a low dose (&le;5mg/m<SUP>2</SUP>) sub-group.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Observed Survival Based on Sub-Group
Analysis</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><IMG SRC="image_003.jpg" ALT="" STYLE="height: 170px; width: 267px"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">According to published literature, GBM
patients failing bevacizumab have a poor prognosis with expected survival of under five months. To date, more than half of patients
receiving an assumed therapeutic dose of VAL-083 (&ge;20mg/m<SUP>2</SUP>) have survived more than six months following bevacizumab
failure; more than 40% have survived for nine months or are currently alive, and more than 20% have survived for twelve months
or are currently alive with median survival expected to be determined at between eight and nine months following bevacizumab failure.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; width: 33%; text-align: center; vertical-align: bottom"><B>Reference</B></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; width: 32%; text-align: center; vertical-align: bottom"><B>Post
    Bevacizumab Salvage Therapy</B></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; width: 33%; text-align: center; vertical-align: bottom"><B>Median
    Survival from Bevacizumab Failure</B></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">Rahman (2014)</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">nitrosourea</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; text-align: center">4.3 months</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">Mikkelson (2011)</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">TMZ + irinotecan</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; text-align: center">4.5 months</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">Lu (2011)</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">dasatinib</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; text-align: center">2.6 months</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">Reardon (2011)</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">etoposide</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; text-align: center">4.7 months</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">Reardon (2011)</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">TMZ</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; text-align: center">2.9 months</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">Iwomoto (2009)</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">various</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%; text-align: center">5.1 months</TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 27%; text-align: center"><B><I>VAL-083 interim survival @ Therapeutic Dose</I></B></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 16%; text-align: center; vertical-align: bottom; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0"><I>6 months</I></P>


</TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 16%; text-align: center; vertical-align: bottom; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0"><I>9 months&#9;</I></P>


</TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 16%; text-align: center; vertical-align: bottom; border-bottom: Black 1.5pt solid"><I>12 months</I></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: center"><B><I>After Avastin<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">&reg;<B><I>
Failure (AACR2016)</I></B></FONT></I></B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">52%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">43%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22%</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="5" STYLE="text-align: center">Expected Median OS:&nbsp;&nbsp;8 &ndash; 9 months</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">While recognizing that our data are
representative of a relatively small, non-controlled Phase I/II clinical trial, we believe these outcomes support the potential
of VAL-083 to offer meaningful clinical benefit to GBM patients who have failed bevacizumab, compared to currently available therapy.
The study is ongoing and analysis of patient outcomes is continuing. We anticipate presenting additional data at scientific meetings
during 2016.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><I><U>MGMT &amp; IDH1</U></I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">High expression of DNA repair protein
<FONT STYLE="background-color: white">O<SUP>6</SUP>-methylguanin-DNA-methyltransferase</FONT> (&ldquo;MGMT&rdquo;) and wild-type
form of the enzyme<FONT STYLE="background-color: white">&nbsp;isocitrate dehydrogenase (&ldquo;</FONT>IDH1&rdquo;) have been correlated
with poor outcomes in GBM.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The methylation status of the MGMT promoter
was characterized by PCR and/or ELISA for nineteen GBM patients enrolled in DelMar&rsquo;s trial: IDH1 status was reported in eleven
patients; both MGMT and IDH1 status were reported in four patients. Of patients tested, 84% exhibited high MGMT and 90% were wild-type
IDH1. All patients whose samples were tested for both markers were MGMT unmethylated by PCR and wild-type IDH1, a genotype that
is correlated with particularly poor prognosis.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">MGMT and IDH-1 have been previously
shown to be diagnostic markers that correlate with resistance to currently available therapies (e.g. temozolomide) and GBM patient
outcomes. Measurement of these biomarkers has become routine in clinical practice. While the science behind their importance in
the disease pathway and their ultimate predictive value are still being explored, we believe we will ultimately be able to use
these markers in a prognostic fashion to select the patients most likely to respond to treatment as we expand the clinical development
of VAL-083.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For example, we have previously demonstrated
that VAL-083&rsquo;s anti-tumor mechanism is active independent from the MGMT status <I>in vitro.</I> We can therefore utilize
the measurement of MGMT to identify newly diagnosed GBM patients which are least likely to respond to temozolomide. We believe
that employing this strategy will allow us to focus our development and commercialization efforts on GBM patients with the greatest
unmet medical need.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Additional Planned Clinical Trials
in GBM</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Registration-directed Phase III
Trial in Refractory GBM</U></I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have requested a guidance meeting
with the FDA and plan to meet with them during the first half of 2016 to discuss our proposed clinical trial design. The dose chosen,
size, design and timing of initiation of the registration-directed clinical trial will depend on review of the data from the Phase
II expansion phase of our current study and discussions with the FDA and our clinical advisors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on historical development of other
products in GBM, we believe that we may be able to obtain FDA approval to commercialize VAL-083 to treat patients who have failed
other therapies from an open-label registration-directed Phase II/III clinical trial, which will save significant costs of a large
randomized Phase III clinical trial. We also believe that the FDA may grant Breakthrough Therapy, Fast Track, Accelerated Approval
and/or Priority Review status to VAL-083, which will enable us to begin filing for commercial approval during the clinical trial
process. Breakthrough Therapy, Fast Track, Accelerated Approval and Priority Review are expedited drug development designations
established by the FDA that are intended to make therapeutically important drugs available at an earlier time.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Data from our planned registration-directed
Phase II/III trial will form the basis of our application for FDA approval. Our overall goal remains to complete registration-directed
clinical trial with VAL-083 and to seek FDA approval as a new therapy for refractory glioblastoma in the timeliest manner possible.
Based on our current financial resources, initiation of the registration-directed trial will require additional funding to support
the expanded clinical operations necessary to conduct and manage the study.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Subject to guidance from the FDA and
availability of funding, we believe it is possible that we will initiate registration-directed Phase II/III studies within the
next 6 - 9 months. We will provide a formal update, including any adjustment to our projected timelines based on our discussions
with the FDA and our clinical advisors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Phase II Trial in Newly Diagnosed
GBM</U></I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on our data supporting a unique
cytotoxic mechanism for VAL-083, we believe that VAL-083 may be a potentially superior alternative to currently approved chemotherapies
used in the treatment of newly diagnosed GBM patients whose tumors express features, such as high expression of MGMT, that make
them unlikely to respond to currently available chemotherapy such as temozolomide.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We plan to conduct a single arm open-label
Phase II study in newly diagnosed GBM patients whose tumors exhibit high-expression of MGMT. In this study, VAL-083 will be combined
with radiotherapy as a potential replacement for temozolomide in patients with high expression of MGMT. The main goal of the trial
will be to confirm the safety of DelMar&rsquo;s optimized dosing regimen in combination with radiotherapy and to investigate outcomes
of the combination therapy in GBM patients with high expression of MGMT. The trial will be conducted at Sun Yat Sen University
in Guangzhou China in collaboration with our partner in China, Guangxi Wuzhou Pharmaceutical Group Co. Ltd. (Guangxi Wuzhou Pharma),
who will provide funding for the trial. Sun Yat Sen University has completed scientific review of our protocol and is preparing
a final ethics review submission. Subject to finalization of contractual obligations between Guangxi Wuzhou Pharma and Sun Yat
Sen University, and ethics committee approval, we expect to begin this study in the first half of calendar 2016.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Phase II Study in First Recurrence
of GBM in Collaboration with University of Texas MD Anderson Cancer Center</U></I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2016, we entered into a collaboration
with MD Anderson to accelerate the clinical development of VAL-083 for the treatment of GBM. As part of the collaboration, MD Anderson
will initiate a randomized Phase II clinical study with VAL-083 in patients with GBM at first recurrence/progression, prior to
Avastin&reg; (bevacizumab) exposure.&nbsp; MGMT promoter methylation status will be used as a validated biomarker for enrollment
and tumors must exhibit an unmethylated MGMT promoter for patients to be eligible for the trial and patients eligible for the study
will have recurrent GBM characterized by a high expression of MGMT.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The primary endpoint of this trial will
be overall survival at nine months in comparison to historical data. Subject to Institutional Review Board (&ldquo;IRB&rdquo;)
approval, this study is expected to begin in the first half of 2016.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Other Indications for VAL-083</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Central Nervous System Metastases
of Solid Tumors</U></I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2013, we announced a plan to
split our ongoing Phase I/II clinical trial protocol into two separate studies: one focusing solely on refractory GBM and the other
focusing on secondary brain cancers caused by other tumors that have spread to the brain. The successful management of systemic
tumors by modern targeted therapies has led to increased incidence of mortality due to central nervous system metastases of lung
cancer and other solid tumors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Bases on historical clinical activity
and our own research, we believe that VAL-083 may be suitable for the treatment of patients with CNS metastases who currently have
limited treatment options. Subject to the availability of financial and operating resources, we plan to develop a separate protocol
for the continued exploration of VAL-083 in patients with secondary brain cancer caused by a solid tumor spreading to the brain.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>VAL-083 in Lung Cancer</U></I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Lung cancer is a leading cause of cancer-related
mortality around the world and effective treatment for lung cancer remains a significant global unmet need despite advances in
therapy. In general, prognosis for lung cancer patients remains poor, with a 5-year survival rate of less than 14% among males
and less than 18% among females in most countries. Globally, the market for lung cancer treatment may exceed $7 billion by 2019
according to a report published by Transparency Market research.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Non-small cell lung cancer (&ldquo;NSCLC&rdquo;)
is the most common type of lung cancer. There are three common forms of NSCLC: adenocarcinomas are often found in an outer area
of the lung; squamous cell carcinomas are usually found in the center of the lung next to an air tube (bronchus); and large cell
carcinomas, which can occur in any part of the lung and tend to grow and spread faster than adenocarcinoma. NSCLC accounts for
85% of all lung cancer cases in the United States and approximately 90% of lung cancer cases diagnosed in China.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Smoking is the most important risk factor
in the development of lung cancer. According to the World Cancer Report (2008), 21% of cancer deaths are related to smoking, especially
lung cancer. Additionally, high levels of air pollution have been implicated as significant causes of lung cancer. Incidence of
lung cancer in the United States is approximately 59 per 100,000 with the majority (52:100,000) being NSCLC.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">According to The Nationwide Nutrition
and Health Survey (2002), China has the world&rsquo;s largest smoking population, with a smoking rate of 24.0% on average (50.2%
for men and 2.8% for women), and a total number of 350 million smokers. The World Health Organization reports that the incidence
of lung cancer in China is 34 per 100,000 population. However, some estimates are much higher exceeding 120 per 100,000 population
for males aged 55-60 in urban areas.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">According to a survey conducted by the
Chinese Ministry of Health and the Ministry of Science and Technology, smoking, poor diet, water pollution and environmental problems
have caused the nation's cancer death rate to rise 80 percent in the past 30 years and cancer   now accounts for 25 percent
of all urban deaths and 21 percent of all rural deaths. Based on these trends, the World Health Organization projects that the
incidence of lung cancer in China is expected to exceed one million (1,000,000) new cases per year by 2025.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The activity of VAL-083 against solid
tumors, including lung cancer, has been established in both pre-clinical and human clinical trials conducted by the NCI. VAL-083
has been approved by the CFDA for the treatment of lung cancer. However, sales of VAL-083 in China have been limited by a lack
of modern data, poor distribution, and preference for targeted therapies such as tyrosine kinase inhibitors (&ldquo;TKIs&rdquo;)
in the modern era.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The current standard of care for newly
diagnosed NSCLC is platinum-based combination therapy or TKI therapy for patients whose cancer exhibits epidermal growth factor
receptor (&ldquo;EGFR&rdquo;) mutations. Patients exhibiting EGFR mutations have shown an initial response rate to TKIs which exceeds
the response rate for conventional chemotherapy. However, TKI resistance has emerged as an important unmet medical need.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe VAL-083&rsquo;s unique bi-functional
alkylating mechanism of action could make it a valuable drug of choice in NSCLC patients who are or become resistant to TKI therapy.
In addition, VAL-083 readily crosses the blood brain barrier suggesting that it may be possible for VAL-083 to treat patients whose
lung cancer has spread to the brain.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on these beliefs, we have acquired
certain commercial rights to VAL-083 in China where it is approved for the treatment of lung cancer. We have begun to establish
a strong scientific and clinical rationale to support the development of VAL-083 as a potential treatment for NSCLC.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We plan to work with leading oncologists
to develop new clinical and non-clinical data which will demonstrate the clinical utility of VAL-083 in NSCLC patients who are
resistant to TKIs. We believe this strategy will result in sales growth for VAL-083 in China and generate future revenue for the
Company through sales and marketing partnerships as well as position VAL-083 for global development in lung cancer.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2014 at AACR we announced results
of a pre-clinical study designed to evaluate the activity of VAL-083 in in vivo models of drug-resistant NSCLC in comparison to
cisplatin. In an established murine xenograft model of NSCLC, the activity of VAL-083 was compared to standard platinum-based therapy
with cisplatin against human NSCLC cell lines A549 (TKI-sensitive) and H1975 (TKI-resistant). In the study, VAL-083 demonstrated
superior efficacy and safety in the treatment of TKI-susceptible (A549) tumors and in TKI-resistant (H1975) tumors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment
                                         of TKI-sensitive (A549) NSCLC with 3 mg/kg of VAL-083 resulted in tumor growth delay
                                         of 26 days compared to untreated controls. Cisplatin (5 mg/kg) resulted in tumor growth
                                         delay of just four days. In addition, mean tumor volume on day 68 was significantly reduced
                                         in animals treated with 3 mg/kg VAL-083 (p=0.001) compared to untreated controls.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment
                                         of TKI-resistant (H1975) NSCLC with 4 mg/kg of VAL-083 resulted in a statistically significant
                                         reduction in tumor volume (p=0.01) versus untreated control after 27 days. In the same
                                         model, treatment with 5 mg/kg of cisplatin failed to achieve statistically significant
                                         reduction in tumor volume (p=0.23) versus untreated control after 27 days. Longer-term
                                         safety assessments are ongoing in this model.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0.5in 6pt 0; text-align: justify">In April 2016, we presented
new non-clinical data at the AACR annual meeting. We reported that VAL-083:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">induces apoptosis independent
of p53 status, and appears to have a distinct mode of action from platinum-based chemotherapies widely used in the treatment of
NSCLC and ovarian cancer;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">demonstrated an ability to
circumvent cisplatin-resistance in all ovarian cell lines tested;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">was active against NSCLC
tumors harboring T790M, p53 and/or KRAS mutations, known to confer resistance to currently available therapies; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">demonstrated super-additivity
or synergy in combination with platinum-based chemotherapy.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">These data demonstrated that VAL-083&rsquo;s mechanism is
distinct from platinum-based chemotherapy, the current standard of care for NSCLC. VAL-083 retains its high level of anti-cancer
activity in p53 mutated NSCLC cell lines compared to cisplatin or oxaliplatin.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The p53 gene plays a central role in
the protection of the human body from cancer and is responsible for initiating the process of programmed cell death, or apoptosis,
which directs a cell to commit suicide if it becomes damaged or cancerous. The p53 pathway is also integral to the activity of
many chemotherapy drugs. p53 is frequently mutated in NSCLC and p53 mutations are highly correlated with resistance to chemotherapy
and poor patient outcomes in NSCLC.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2015 at the AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer Therapeutics we presented data on the benefit of&nbsp;VAL-083 in combination
with platinum-based chemotherapy regimens in the treatment of NSCLC. The results of the study presented provide support for VAL-083
as a viable treatment option for NSCLC patients who fail to respond to standard-of-care platinum-based therapy or TKI therapy,
and also support potential therapeutic benefits of a VAL-083 along with platinum combination regimens in newly diagnosed patients.
We demonstrated that the combination of VAL-083 with either cisplatin or oxaliplatin demonstrated a superadditive (synergistic)
effect against NSCLC cell lines, including those resistant to TKI therapy in vitro.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2014, we presented non-clinical
data at the AACR New Horizon&rsquo;s in Cancer Research Meeting. These data also support superior activity of VAL-083 compared
to standard platinum-based treatment in both TKI-sensitive and TKI-resistant tumor models. Further, our data demonstrate that VAL-083
may have a synergistic effect in combination with cisplatin. These data suggest the potential of VAL-083 to be used in combination
with platinum-based chemotherapy and to address modern unmet medical needs in the treatment of TKI-resistant NSCLC, especially
where platinum-based therapy has already failed or is predicted to give sub-optimal outcomes.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">These results may have immediate implications
in the treatment of NSCLC in China, where VAL-083 is approved for as a chemotherapy for the treatment of lung cancer. The data
also support exploring future clinical development of VAL-083 as a lung cancer therapy in the rest of the world thereby providing
DelMar with a potential opportunity to expand our clinical development focus beyond glioblastoma.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As a next step in the investigation
of VAL-083 as a potential treatment for NSCLC, we have developed a protocol for a post-market clinical study to be conducted by
a leading cancer clinician in the context of the current approval in China.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We plan to conduct this trial in collaboration
with Guangxi Wuzhou Pharmaceutical Group Co. Ltd. (Guangxi Wuzhou Pharma). Under the terms of our collaboration agreement with
Guangxi Wuzhou Pharma, we are responsible for establishing protocols for and conducting clinical trials and Guangxi Wuzhou Pharma
is responsible for the costs associated with clinical trials conducted in China. Our goal is to initiate this clinical trial as
soon as practicable. with the aim to develop new data to support product growth in China and to establish clinical proof of concept
to expand our drug development efforts with VAL-083.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Conducting this clinical trial in China
under our collaboration agreement with Guangxi Wuzhou Pharma will allow us to enhance the potential value of VAL-083 without significantly
increasing our own planned cash expenditures. We also believe that these new data will support the potential to establish global
partnerships and collaborations with larger pharmaceutical companies who have the resources and commercial infrastructure to effectively
develop and commercialize VAL-083 as a treatment for NSCLC on a world-wide basis.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I><U>VAL-083 in Pediatric Brain Cancers</U></I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2015 at AACR&rsquo;s&nbsp;-
Advances in Pediatric Research: From Mechanisms and Models to Treatment and Survivorship we presented data indicating that VAL-083
offers potential therapeutic alternatives in the treatment of pediatric brain tumors. In March 2016 the FDA Office of Orphan Products
Development (OOPD) granted orphan drug designation for VAL-083 in the treatment of medulloblastoma.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I><U>VAL-083 in Ovarian Cancers</U></I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2015 at the AACR&rsquo;s
Advances in Ovarian Cancer Research: Exploiting Vulnerabilities Conference, the Company presented data from its collaboration with
researchers at MD Anderson Cancer Center. The data demonstrate the effectiveness of VAL-083 against cisplatin-resistant ovarian
cancers and raise the potential for VAL-083 as a treatment for ovarian cancers as a single-agent against platinum-resistant tumors
or in combination with platinum-based chemotherapeutic regimens. In April 2016 the FDA OOPD also granted orphan drug designation
for VAL-083 in the treatment of ovarian cancer.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I><U>VAL-083 in Leukemia and Hematologic Cancers</U></I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The NCI studied VAL-083 extensively
in laboratory and animal models of hematological malignancies (blood cancers). VAL-083 has been approved for the treatment of chronic
myeloid leukemia, or CML, in China.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">CML, also known as chronic myeloid leukemia
is a cancer of the white blood cells. The incidence of CML in the United States is approximately two per 100,000 of population.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe that our pre-clinical research
and data from NCI-sponsored studies and commercial evidence from the Chinese market support that there exists a substantive clinical
benefit of VAL-083 in CML. We also believe that the unique mechanism of action of VAL-083, in combination with newly developed
data positions the drug as a valuable therapy for patients who have failed other treatments, including TKIs. This represents a
significant clinical and commercial opportunity for large subsets of patient populations in the existing-approved China market
as well as for global development in CML.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on these beliefs, we have acquired
certain commercial rights to VAL-083 in China, where it is approved for the treatment of CML and lung cancer. We have also developed
new non-clinical data demonstrating that VAL-083 is active against TKI-resistant CML.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Additional Indications</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In historical studies sponsored by the
NCI in the United States, VAL-083 exhibited clinical activity against a range of tumor types including central nervous system tumors,
solid tumors and hematologic malignancies. We have established new non-clinical data supporting the activity of VAL-083 in different
types of cancer that are resistant to modern targeted therapies and we believe that the unique cytotoxic mechanism of VAL-083 may
provide benefit to patients in a range of indications. We intend to continue to research these opportunities, and if appropriate,
expand our clinical development efforts to include additional indications.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Guangxi Wuzhou Pharmaceutical Company</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to a memorandum of understanding
and collaboration agreement, dated October 25, 2012, we have established a strategic collaboration with Guangxi Wuzhou Pharmaceutical
Company (&ldquo;Guangxi Wuzhou Pharmaceuticals&rdquo;), a subsidiary of publicly traded Guangxi Wuzhou Zhongheng Group Co., Ltd.
(SHG: 600252) (the &ldquo;Guangxi Agreement&rdquo;). VAL-083 is approved for the treatment of chronic myelogenous leukemia (&ldquo;CML&rdquo;)
and lung cancer in China and Guangxi Wuzhou Pharmaceuticals is the only manufacturer licensed by the CFDA to produce the product
for the China market. Through the Guangxi Agreement, we have obtained drug product for our VAL-083 clinical trials in the United
States and we have also secured certain commercial rights in China.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Guangxi Agreement, we
granted to Guangxi Wuzhou Pharmaceuticals a royalty-free license to certain of our intellectual property, as it relates to quality
control and drug production methods for VAL-083, and we agreed that Guangxi Wuzhou Pharmaceuticals will be our exclusive supplier
of VAL-083 for clinical trials and commercial sales, subject to Guangxi Wuzhou Pharmaceuticals obtaining and maintaining cGMP certification
by the FDA, EMA or other applicable regulatory agencies, and Guangxi Wuzhou Pharmaceuticals being able to meet volumes ordered
by us. The Company and Guangxi Wuzhou Pharmaceuticals will work together to ensure the product specifications meet global standards
in order to accelerate international development and regulatory approval. Guangxi Wuzhou Pharmaceuticals will be our exclusive
supplier of VAL-083 for clinical development and commercial sales, subject to its meeting and maintaining required regulatory certification.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">This Guangxi Agreement also provides
us with certain exclusive commercial rights related to drug supply. Specifically, the Guangxi Agreement establishes an exclusive
supply relationship between us and Guangxi Wuzhou Pharmaceuticals for the Chinese market and all markets outside China. Guangxi
Wuzhou Pharmaceuticals agreed that it may not sell VAL-083 for markets outside of China to any other purchaser other than us. In
addition, Guangxi Wuzhou Pharmaceuticals granted us a pre-emptive right in China (subject to our acceptance of proposed sales volume
and prices) to purchase VAL-083 produced by Guangxi Wuzhou Pharmaceuticals.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our collaboration with Guangxi
Wuzhou Pharmaceuticals positions us with the potential to generate revenue through product sales or royalties for
VAL-083&rsquo;s approved indications in China while we seek global approval in new indications.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our strategy in China is to work in
collaboration with Guangxi Wuzhou Pharmaceuticals and globally recognized clinical investigators to develop new clinical and non-clinical
data in collaboration with leading cancer researchers. We believe these data, if favorable, will allow the repositioning and sales
growth of VAL-083 in the China market under its approved indications and provide us with clinical proof-of-concept to support global
development of VAL-083 for the treatment of hematologic cancers and lung cancer.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We and Guangxi Wuzhou Pharmaceuticals
have formed a clinical advisory board to oversee clinical studies. Under the terms of the Guangxi Agreement, Guangxi Wuzhou Pharmaceuticals
will provide funding support for clinical trials conducted in China and we are responsible for development and commercialization.
We anticipate establishing sales channels in China through a third-party marketing partner in collaboration with Guangxi Wuzhou
Pharmaceuticals in order to obtain sales or royalty revenue from that market.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The term of the Guangxi Agreement (except
as it relates to the exclusive rights in the China market) is indefinite, subject to termination upon written agreement of all
parties, or if either party breaches any material term and fails to remedy such breach within 30 days of receipt of notice of the
breach, or if any action to be taken thereunder is not agreed to by both parties, provided that such matter is referred to the
chief executive officer of both parties, and they are unable to resolve such matter within 90 days. No payments have been made
to date under the Guangxi Agreement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
protection of intellectual property rights in China (where VAL-083 is manufactured pursuant to the Guangxi Agreement with the
only manufacturer presently licensed by the CFDA to produce the product for the China market, and where VAL-083 is approved for
the treatment of CML and lung cancer) is relatively weak compared to the United States, which may negatively affect our ability
to generate revenue from VAL-083.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Corporate History</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a Nevada corporation formed on
June 24, 2009 under the name Berry Only, Inc. Prior to a reverse acquisition undertaken on January 25, 2013 (see note 1 to the
consolidated condensed financial statements) Berry did not have any significant assets or operations. The Company is the parent
company of Del Mar Pharmaceuticals (BC) Ltd. (&ldquo;DelMar (BC)&rdquo;), a British Columbia, Canada corporation incorporated on
April 6, 2010, that is focused on the development of drugs for the treatment of cancer. The Company is also the parent company
to 0959454 B.C. Ltd., a British Columbia corporation (&ldquo;Callco&rdquo;), and 0959456 B.C. Ltd., a British Columbia corporation
(&ldquo;Exchangeco&rdquo;). Callco and Exchangeco were formed to facilitate the reverse acquisition.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the reverse acquisition,
the Company acquired (either directly or indirectly (through Exchangeco)) all of the issued and outstanding shares of DelMar (BC)
on January 25, 2013. As a result of the shareholders of DelMar (BC) owning a controlling interest in the Company subsequent to
the reverse acquisition, for accounting purposes the transaction is a capital transaction with DelMar (BC) being the accounting
acquirer even though the legal acquirer is Berry. Therefore, the historic financial statements of DelMar (BC) are presented as
the comparative balances for the periods prior to the reverse acquisition.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">References to the Company, &ldquo;we&rdquo;,
&ldquo;us&rdquo;, and &ldquo;our&rdquo; refer to the Company and its wholly-owned subsidiaries, DelMar (BC), Callco and Exchangeco.
References to &ldquo;Berry&rdquo; relate to the Company prior to the reverse acquisition.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;&nbsp;</B></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Outstanding
Securities</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B></B>&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of May 12,
2016, we have 40,253,056 shares of common stock issued and outstanding, 4,056,042 shares of common stock issuable upon exchange
of the Exchangeable Shares of Exchangeco (which entitle the holder to require Exchangeco to redeem (or, at the option of the Company
or Callco, to have the Company or Callco purchase) the Exchangeable Shares, and upon such redemption or purchase to receive an
equal number of shares of common stock of the Company) (the Exchangeable Shares are recognized on an as-exchanged for common stock
basis for financial statement purposes), outstanding warrants to purchase 18,744,995 shares of common stock, 764,363 shares of
outstanding Series B Preferred Stock convertible into 7,643,630 shares of common stock, and outstanding options to purchase 3,515,000
shares of common stock. All Exchangeable Shares, warrants, and options are convertible or exercisable into one share of common
stock. Each share of Series B Preferred Stock is convertible into ten shares of common stock.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Related Parties</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company acquired its VAL-083 prototype
drug, patents and technology rights from Valent Technologies, LLC, (&ldquo;Valent&rdquo;), an entity owned by Dr. Dennis Brown,
the Company&rsquo;s Chief Scientific Officer. As a result, Valent is a related party to the Company.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following related party transactions
and balances have been recorded by the Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>During the nine months ended March
31, 2016</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to consulting agreements with
the Company&rsquo;s officers the Company recognized a total of $360,000 (2015 - $385,000) in compensation expense for the nine
months ended March 31, 2016.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company paid $127,583 (2015 - $77,667)
in directors&rsquo; fees during the nine months ended March 31, 2016.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2016 there is an aggregate
amount of $29,018 (June 30, 2015 - $90,820) owed to the Company&rsquo;s officers and directors for fees and expenses. The Company
pays related party payables incurred for fees and expenses under normal commercial terms.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded $6,627 in dividends
related to the Series A Preferred Stock issued to Valent.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>During the nine months ended March
31, 2015</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt">Effective September 30, 2014, the Company entered into
and closed an agreement with Valent to exchange its loan with Valent for 278,530 shares of preferred stock of the Company.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">The Company accrued $2,091 in interest expense on the
loan payable to Valent to the date of the conversion on September 30, 2014 and $4,178 related to the dividend on the Series A Preferred
Stock for the period from October 1, 2014 to March 31, 2015.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Derivative Liability</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued common stock
purchase warrants. Based on the terms of certain of these warrants the Company determined that the warrants were a derivative liability
which is recognized at fair value at the date of the transaction and re-measured at fair value each reporting period with the changes
in fair value recorded in the consolidated condensed statement of loss and comprehensive loss.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Investor Warrants</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the reverse acquisition
during the quarter ended March 31, 2013 the Company issued units consisting of one share of common stock and one five-year warrant
(the &ldquo;Investor Warrants&rdquo;) to purchase one share of common stock at an exercise price of $0.80. The exercise price of
the Investor Warrants is subject to adjustment in the event that the Company issues common stock at a price lower than the exercise
price, subject to certain exceptions. As a result of the financing completed by the Company during the three months ended September
30, 2015 the exercise price of the Investor Warrants was reduced from $0.80 to $0.786. As a result of the price being reduced,
the Company has recognized a loss of $8,098.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><U>Investor Warrant exercises</U></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">During the nine months ended March 31, 2016, 515,500 Investor
Warrants were exercised  at an exercise price of $0.786 per share. The Company received proceeds
of $405,183 from these exercises. The warrants that have been exercised were revalued at their exercise date and then the reclassification
to equity was recorded resulting in $247,440 of the derivative liability being reclassified to equity.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">During the nine months ended March 31, 2015 the Company concluded
a tender offer whereby the holders of the Investor Warrants had the opportunity to exercise their warrants at an exercise price
of $0.65. Under the tender offer, a total of 762,227 warrants were exercised for net proceeds of $470,676 after payment by the
Company of a 5% warrant agent fee of $24,772. In addition, during the nine months ended March 31, 2015, 1,223,847 warrants were
exercised  at an exercise price of $0.65 per share warrant. The Company received proceeds of $795,501
from these exercises.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">As a result of all of the Investor Warrant exercises during
the nine months ended March 31, 2015, the Company received net proceeds of $1,266,177 from the exercise of 1,986,074 warrants.
The Investor Warrants that have been exercised were revalued at their exercise date and then the reclassification to equity was
recorded resulting in $391,422 of the derivative liability being reclassified to equity.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><U>Investor Warrant exchanges</U></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On December 31, 2014, the Company issued 414,889 shares of
common stock in exchange for 1,244,666 Investor Warrants. The Investor Warrants that have been exchanged were revalued at their
exchange date and then a reclassification to equity was recorded. The reclassification to equity upon the exchange was $305,112.
The Company recognized a loss of $92,843 at the time of the exchange.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On January 8, 2015, the Company filed a tender offer statement
with the Securities and Exchange Commission, and on January 23, 2015, the Company filed an amendment thereto. The tender offer
provided the holders of the Investor Warrants with the opportunity to receive one&nbsp;share of common stock for every three Investor
Warrants tendered. On February 9, 2015 the Company&rsquo;s tender offer expired. A total of 1,591,875 Investor Warrants were exchanged
for 530,625 shares of common stock. The Investor Warrants that have been exchanged were revalued at their exchange date and then
a reclassification to equity was recorded. The reclassification to equity upon the exchange was $423,723. The Company recognized
a loss of $156,219 at the time of the exchange.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0 0 13pt"><U>Investor Warrant amendments</U></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">On March 29, 2016, the Company entered
into amendments (the &ldquo;Investor Warrant Amendments&rdquo;) with the holders of certain Investor Warrants. Pursuant to the
Investor Warrant Amendments, 250,000 Investor Warrants were amended to extend the expiration date to March 31, 2019 and remove
the provision requiring an adjustment of the exercise price in the event the Company sells common stock at a purchase price lower
than the current warrant exercise price. As a result of the Investor Warrant Amendments, the Company has recognized a loss of $7,000
and has reclassified $65,750 from the derivative liability to equity resulting in an increase to equity of $58,750. The Investor
Warrants were revalued to the date of the amendment and were then reclassified to equity.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>2013 Placement Agent Warrants</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 6, 2013 the Company
issued 5,250,000 warrants (the &ldquo;2013 Placement Agent Warrants&rdquo;) that are exercisable at $0.80 per share until
March 6, 2018 but can be exercised on a cashless basis. The exercise price of the 2013 Placement Agent Warrants is subject to
adjustment in the event that the Company sells common stock at a price lower than the exercise price, subject to certain
exceptions. As a result of the financing completed by the Company during the quarter ended September 30, 2015 the exercise
price of the 2013 Placement Agent Warrants was reduced from $0.80 to $0.786. As a result of the exercise price being reduced,
the Company has recognized a loss of $13,467.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">On December 30, 2015, the Company
entered into amendments (the &ldquo;2013 Placement Agent Warrant Amendments&rdquo;) with the holders of the 2013 Placement Agent
Warrants. Pursuant to the 2013 Placement Agent Warrant Amendments, 5,050,000 2013 Placement Agent Warrants were amended to extend
the expiration date to June 30, 2019 and remove the provision requiring an adjustment of the exercise price in the event the Company
sells common stock at a purchase price lower than the exercise price. As a result of the 2013 Placement Agent Warrant Amendments,
the Company has recognized a loss of $242,400 and has reclassified $2,277,550 from the derivative liability to equity resulting
in an increase in equity of $2,035,150. The 2013 Placement Agent Warrants were revalued to the date of the amendment and were then
reclassified to equity.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>Dividend Warrants</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In connection with the reverse acquisition, effective January
24, 2013, the Company effected a warrant dividend (the &ldquo;Warrant Dividend&rdquo;) pursuant to which the Company issued one
five-year warrant to purchase one share of common stock at an exercise price of $1.25 for each outstanding share of common stock
(the &ldquo;Dividend Warrants&rdquo;). Pursuant to the Warrant Dividend, the Company issued an aggregate of 3,250,007 Dividend
Warrants.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On October 31, 2014, the Company and all of its Dividend
Warrant holders entered into amendments to the Dividend Warrants such that the Company&rsquo;s redemption rights and certain provisions
of the Dividend Warrant agreements relating to potential cash settlement of the Dividend Warrants were removed. The Dividend Warrants
were revalued to the date of the amendment on October 31, 2014 which resulted in a reclassification to equity of $975,278.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>2015 Agent Warrants</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of the
Company&rsquo;s financing completed during the quarter ended September 30, 2015 (the &ldquo;Public Offering&rdquo;), the
Company issued 93,908 warrants to certain placement agents (&ldquo;2015 Agent Warrants&rdquo;). The 2015 Agent Warrants are
exercisable at a per share price equal to $0.75 during the five-year period commencing six months from the effective date of
the Public Offering, which period shall not extend further than five years from the effective date of the Public Offering.
Therefore, all Agent Warrants expire on July 15, 2020.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Warrants issued for services</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued 300,000 warrants
for services. The warrants were issued on September 12, 2013 and are exercisable on a cashless basis at an exercise price of $1.76
for five years.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&rsquo;s derivative liability
is summarized as follows:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March&nbsp;31,</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2016</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>June 30,</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2015</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(as&nbsp;restated)</b></font></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; text-align: justify">Opening balance</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,364,381</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5,111,007</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Issuance of 2015 Agent Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,594</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Change in fair value of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">943,050</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(627,433</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Change in fair value due to change in warrant terms</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">270,965</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,658</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Reclassification to equity upon amendment of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,343,300</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(975,278</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Reclassification to equity upon exchange of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(728,835</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Reclassification to equity upon exercise of warrants</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(247,440</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(391,422</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 4pt">Closing balance</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,017,250</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,364,381</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Selected Quarterly Information</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The financial information reported herein
has been prepared in accordance with accounting principles generally accepted in the United States. The Company&rsquo;s functional
currency at March 31, 2016 is the USD. The following tables represent selected financial information for the Company for the periods
presented.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Selected Balance Sheet Data</I>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2016</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>June 30,</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2015</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(as&nbsp;restated)</b></font></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">937,355</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,754,433</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Working capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">439,470</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,722,336</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,155,311</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,575,421</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Derivative liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,017,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,364,381</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total stockholders&rsquo; deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(687,603</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(821,490</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>Selected Statement of Operations Data </I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>For the three months ended:</B> &nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">March&nbsp;31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">March&nbsp;31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">2015</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(as restated)</b></font></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">790,323</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">641,839</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">630,226</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,753</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Change in fair value of derivative liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(276,584</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">781,152</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Change in fair value of derivative liability due to change in warrant terms</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Loss on exchange of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156,219</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Foreign exchange (gain) loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,523</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,826</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Interest income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(41</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(70</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Net loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,140,401</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,086,719</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Basic weighted average number of shares outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,309,098</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,976,827</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Basic loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.03</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.05</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>For the nine months ended:</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">March&nbsp;31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">March&nbsp;31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">2015</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(as restated)</b></font></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,183,355</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,925,635</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,994,923</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,601,982</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Change in fair value of derivative liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">943,050</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">451,794</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Change in fair value of derivative liability due to change in warrant terms</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">270,965</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,658</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Loss on exchange of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">249,062</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Foreign exchange loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,257</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,512</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,091</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Interest income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(71</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(331</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Net loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,408,479</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,223,087</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Basic weighted average number of shares outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,587,549</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,732,995</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Basic loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.12</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.11</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Expenses net of share-based payments</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table discloses research
and development, and general and administrative expenses net of share-based payment expenses.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>For the three months ended:</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2016</b></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></P></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2015</b></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></P></td>
    <td style="line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td colspan="2" style="text-align: right; line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td colspan="2" style="text-align: right; line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 78%; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development </font></td>
    <td style="width: 1%; line-height: 107%">&nbsp;</td>
    <td style="width: 1%; line-height: 107%">&nbsp;</td>
    <td style="width: 8%; text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">790,323</font></td>
    <td style="width: 1%; line-height: 107%">&nbsp;</td>
    <td style="width: 1%; line-height: 107%">&nbsp;</td>
    <td style="width: 1%; line-height: 107%">&nbsp;</td>
    <td style="width: 8%; text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">641,839</font></td>
    <td style="width: 1%; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payments included in research and development </font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(129,466</font></td>
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26,853)</font></td>
    <td style="padding-bottom: 1.5pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development net of share-based compensation </font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">660,857</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">614,986</font></td>
    <td style="line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: right; line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: right; line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative </font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">630,226</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">500,753</font></td>
    <td style="line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payments included in general and administrative </font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(113,196</font></td>
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(35,995</font></td>
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative net of share-based compensation </font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">517,030</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">464,758</font></td>
    <td style="line-height: 107%">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>For the nine months ended:</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2016</b></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></P></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2015</b></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></P></td>
    <td style="line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td colspan="2" style="text-align: right; line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td colspan="2" style="text-align: right; line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 78%; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development </font></td>
    <td style="width: 1%; line-height: 107%">&nbsp;</td>
    <td style="width: 1%; line-height: 107%">&nbsp;</td>
    <td style="width: 8%; text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,183,355</font></td>
    <td style="width: 1%; line-height: 107%">&nbsp;</td>
    <td style="width: 1%; line-height: 107%">&nbsp;</td>
    <td style="width: 1%; line-height: 107%">&nbsp;</td>
    <td style="width: 8%; text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,925,635</font></td>
    <td style="width: 1%; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payments included in research and development </font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(178,107</font></td>
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(39,909</font></td>
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development net of share-based compensation </font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,005,248</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,885,726</font></td>
    <td style="line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: right; line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: right; line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative </font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,994,923</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,601,982</font></td>
    <td style="line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payments included in general and administrative </font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(441,393</font></td>
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(283,449</font></td>
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative net of share-based compensation </font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,553,530</font></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; line-height: 107%">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,318,533</font></td>
    <td style="line-height: 107%">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Comparison of the three months ended
March 31, 2016 and March 31, 2015</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2016</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2015</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Change</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change<BR> %</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(as restated)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">790,323</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">641,839</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">148,484</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">23</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">630,226</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,753</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">129,473</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Change in fair value of derivative liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(276,584</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">781,152</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,057,736</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(135</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Change in fair value of derivative liability due to change in warrant terms</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss on exchange of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156,219</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(156,219</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(100</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Foreign exchange (gain) loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,523</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,826</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,349</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(254</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Interest income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(41</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(70</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">29</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(41</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,140,401</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,086,719</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(946,318</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I></I></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I></I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>Research and Development</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses increased
to $790,323 for the three months ended March 31, 2016 from $641,839 for the three months ended March 31, 2015. Non-cash expenses
included in research and development for the three months ended March 31, 2016 totaled $129,466 compared to $26,853 for the three
months ended March 31 2015. In relation to research and development expenses during the three months ended March 31, 2016 the Company
incurred stock option expense and a portion of the warrants issued for services while during the three months ended March 31, 2015
the Company recognized non-cash expenses relating to stock option expense only. Excluding the impact of non-cash expenses, research
and development expenses increased to $660,857 for the three months ended March 31, 2016 from $614,986 for the three months ended
March 31, 2015.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Overall, research and development costs,
excluding the effect of non-cash expenses, were consistent for the three month periods ended March 31, 2016 and March 31, 2015.
Clinical development costs have increased slightly in the current period due to data management and FDA meeting preparation costs,
and clinical set-up expenses that were not incurred in the prior period. Clinical set-up expenses have been realized as the Company
has begun preparation for its Phase III registration-directed study. Data management costs related to data collection and analysis
for the dose escalation and 14-patient expansion studies. Offsetting these items during the three months ended March 31, 2016 were
lower costs for drug manufacturing than in the three months ended March 31, 2015. Preclinical research expenses have decreased
in the current quarter as a result of the Company recognizing higher grant proceeds in the current quarter compared to the prior
quarter.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>General and Administrative</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expenses
were $630,226 for the three months ended March 31, 2016 compared to $500,753 for the three months ended March 31, 2015. The increase
was partially attributable to an increase in non-cash expenses. Non-cash expenses increased to $113,196 for the three months ended
March 31, 2016 from $35,995 for the three months ended March 31, 2015. In relation to general and administrative expenses during
the three months ended March 31, 2016, the Company incurred non-cash expenses related to warrants issued for services and stock
option expense while during the three months ended March 31, 2015 the Company incurred non-cash expenses relating to stock options
only.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Excluding the impact of non-cash expenses,
general and administrative expenses increased to $517,030 for the three months ended March 31, 2016 from $464,758 for the three
months ended March 31, 2015. The principal reason for the increase was due to higher costs for press releases and other related
activities such as the Company&rsquo;s social media outlets which were started in the fall of 2015</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Change in fair value of derivative
liability</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on the terms of certain warrants
issued by the Company, the Company determined that the warrants were a derivative liability which is recognized at fair value at
the date of the transaction and re-measured at fair value every reporting period with gains or losses on the changes in fair value
recorded in the consolidated condensed interim statement of loss and comprehensive loss. The balances recognized during the three
months ended March 31, 2016 and 2015 were primarily due to changes in the Company&rsquo;s common stock price between the date the
warrants were last valued on December 31, 2015 and 2014 respectively and March 31, 2016 and 2015 respectively which are the valuation
dates used during the quarters ended March 31.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized a gain of $276,584
from the change in fair value of the derivative liability for the three months ended March 31, 2016. In addition, the Company recognized
a loss of $7,000 which resulted from the amendment of certain Investor Warrants. For the three months ended March 31, 2015 the
Company recognized a loss of $781,152 due to the change in fair value of the derivative liability. In addition, during the quarter
ended March 31, 2015, the Company exchanged certain Investor Warrants for shares of common stock resulting in the recognition of
a loss of $156,219 on the exchange.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Changes in the Company&rsquo;s common
stock price can result in significant volatility in the Company&rsquo;s reported net loss due to its impact on the fair value of
the derivative liability. As a result of revaluation gains and losses, the Company expects that its reported net income or loss
will continue to fluctuate widely.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Foreign Exchange Gain</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&rsquo;s functional currency
at March 31, 2016 is the USD but the Company incurs a portion of its expenses in CDN. The foreign exchange gains and losses are
reported in other (income) loss in the Consolidated Condensed Interim Statement of Loss and Comprehensive Loss.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized a foreign exchange
gain of $10,523 for the quarter ended March 31, 2016 compared to a loss of $6,826 for the quarter ended March 31, 2015. The change
was due to changes in the exchange rate between the CDN and the USD and to varying levels of CDN cash and accounts payable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>Preferred Share Dividend</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to a loan agreement dated February
3, 2011, the Company received a loan from Valent in the amount of $250,000 for the purchase of the prototype drug product. The
loan was payable on demand, unsecured and bore interest at 3% per year. Effective September 30, 2014 the loan balance, including
accumulated interest to September 30, 2014, was exchanged for 278,530 shares of the Company&rsquo;s Series A Preferred Stock. The
Series A Preferred Stock pays an annual dividend of 3%.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">For the three-months ended March 31, 2016 and 2015, the Company
recorded $2,089 related to the dividend payable to Valent. The dividend has been recorded as a direct increase in accumulated deficit
and was paid subsequent to quarter end.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Comparison of the nine months ended
March 31, 2016 and March 31, 2015</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2016</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2015</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Change</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change<BR> %</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(as restated)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,183,355</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,925,635</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">257,720</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">13</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,994,923</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,601,982</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">392,941</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Change in fair value of derivative liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">943,050</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">451,794</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">491,256</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">109</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Change in fair value of derivative liability due to change in warrant terms</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">270,965</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,658</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">294,623</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,245</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss on exchange of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">249,062</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(249,062</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(100</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Foreign exchange loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,257</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,512</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(255</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,091</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,091</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(100</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Interest income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(71</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(331</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">260</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(78</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,408,479</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,223,087</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,185,392</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>Research and Development</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses increased
to $2,183,355 for the nine months ended March 31, 2016 from $1,925,635 for the nine months ended March 31, 2015. The increase was
largely attributable to an increase in clinical development, travel, and non-cash expenses partially offset by decreases in pre-clinical
research and intellectual property costs. Non-cash expenses included in research and development for the nine months ended March
31, 2016 were $178,107 compared to $39,909 in the nine months ended March 31, 2015. In the current period, the Company recognized
non-cash expenses related to stock option expense and warrants issued for services. In the prior period, the Company recognized
stock option expense only.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Excluding the impact of non-cash expenses,
research and development expenses increased to $2,005,248 from $1,885,726 during the nine months ended March 31, 2016 compared
to the nine months ended March 31, 2015. Clinical development costs increased in the current period compared to the prior period
partially due to higher monitoring costs as the Company continued the 14-patient expansion portion of its phase I/II study. During
the three months ended September 30, 2015 we announced full enrollment of the 14-patient expansion portion of our study. In addition,
we have enrolled patients at five clinics which involves increased monitoring and data costs. In the prior period, we were enrolling
single cohorts of three patients at a time which resulted in lower direct clinical, monitoring, and data management costs. Clinical
development costs have also increased due to data management and FDA meeting preparation costs, as well as clinical set-up expenses
that were not incurred in the prior period. Data management costs were incurred related to data collection and analysis for the
dose escalation and 14-patient expansion studies. Clinical set-up expenses have been incurred as the Company begins preparation
for its Phase III registration-directed study.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Travel costs increased during the nine
months ended March 31, 2016 compared to the nine months ended March 31, 2015 as the Company attended several conferences in the
current period in support of the release of data in new indications including pediatric brain tumors and ovarian cancer. The reduction
in pre-clinical costs in the current period compared to the prior period is partially due to timing and partially due to grant
funding. During the nine months ended March 31, 2015, several studies were on-going at the B.C. Cancer Agency, MD Anderson, and
the University of British Columbia. During the nine months ended March 31, 2016, studies were on-going at the University of British
Columbia but the balance of the pre-clinical study plan was still being finalized. Also, the Company made more claims under its
grant funding with the Government of Canada in the current nine months than in the prior nine months. Intellectual property costs
have decreased in the nine months ended March 31, 2016 compared to the nine months ended March 31, 2015 as the Company filed more
new patent applications in the prior period which resulted in higher expenses.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>General and Administrative</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative
expenses were $1,994,923 for the nine months ended March 31, 2016 compared to $1,601,982 for the nine months ended March 31,
2015. The increase was partially attributable to an increase in non-cash expenses to $441,393 in the nine months ended March
31, 2016 from $283,449 for the nine months ended March 31, 2015. In relation to general and administrative expenses during
the nine months ended March 31, 2016 the Company incurred non-cash expenses related to stock options, and shares and warrants
issued for services while during the nine months ended March 31, 2015 the Company incurred non-cash expenses relating to
stock options and for shares issued for services.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Excluding the impact of non-cash expenses,
general and administrative expenses increased to $1,553,530 during the nine months ended March 31, 2016 from $1,318,553 for the
nine months ended March 31, 2015. The principal reasons for the increase were higher professional fees, travel, and facilities
costs. Professional fees increased during the nine months ended March 31, 2016 compared to the nine months ended March 31, 2015
due to higher fees related to partnering and business development activities as well as investor relations, and directors&rsquo;
fees. The Company&rsquo;s Board of Directors has expanded by two seats as the Company has strengthened its corporate governance.
Travel costs increased during the nine months ended March 31, 2016 compared to the nine months ended March 31, 2015 due to travel
related to the Company&rsquo;s financing completed during the quarter ended September 30, 2015 as well as follow up with investors
subsequent to the closing of the financing. Facilities costs increased in the period compared to the prior period largely due an
increase in promotion costs as the Company launched its social media channels.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Change in fair value of derivative
liability</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on the terms of certain warrants
issued by the Company, the Company determined that the warrants were a derivative liability which is recognized at fair value at
the date of the transaction and re-measured at fair value every reporting period with gains or losses on the changes in fair value
recorded in the consolidated condensed interim statement of loss and comprehensive loss. The balances recognized during the nine
months ended March 31, 2016 and 2015 were primarily due to changes in the Company&rsquo;s common stock price between the date the
warrants were last valued on June 30, 2015 and 2014 respectively and March 31, 2016 and 2015 respectively which are the valuation
dates used during the nine months ended March 31.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized a loss of $943,050
from the change in fair value of the derivative liability for the nine months ended March 31, 2016. In addition, the Company also
recognized a total loss of $270,965 which resulted from the change in fair value of the 2013 Placement Agent Warrants and the Investor
Warrants upon their respective amendments. For the nine months ended March 31, 2015 the Company recognized a loss of $451,794 due
to the change in fair value of the derivative liability. In addition, as result of amending Investor Warrants and Dividend Warrants
during the period ended March 31, 2015, the Company also recognized a gain of $23,658. Also, during the nine months ended March
31, 2015, the Company exchanged certain Investor Warrants for shares of common stock resulting in the recognition of a loss of
$249,062 on the exchange.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Changes in the Company&rsquo;s common
stock price can result in significant volatility in the Company&rsquo;s reported net loss due to its impact on the fair value of
the derivative liability. As a result of revaluation gains and losses, the Company expects that its reported net income or loss
will continue to fluctuate significantly.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Foreign Exchange Gain</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&rsquo;s functional currency
at March 31, 2016 is the USD but the Company incurs a portion of its expenses in CDN. The foreign exchange gains and losses are
reported in other (income) loss in the Consolidated Condensed Interim Statement of Loss and Comprehensive Loss.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized a foreign exchange
loss of $16,257 for the nine months ended March 31, 2016 compared to a loss of $16,512 for the nine months ended March 31, 2015.
The change was due to changes in the exchange rate between the CDN and the USD and to varying levels of CDN accounts payable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>Preferred Share Dividend and Interest Expense</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">For the nine months ended March 31, 2016 the Company recorded
$6,267 related to the dividend payable to Valent. The dividend has been recorded as a direct increase in accumulated deficit and
was paid subsequent to quarter end.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">For the nine months ended March 31, 2015, the Company recognized
$4,178 related to the dividend payable to Valent and $2,091 related to interest from June 30, 2014 to September 30, 2014 when the
loan was converted to preferred shares. The dividend has been recorded as a direct increase in accumulated deficit and the $2,091
has been recognized as interest expense.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Nine months ended March 31, 2016
compared to the nine months ended March 31, 2015</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2016</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2015</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Change</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Change</b></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>%</b></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%; text-align: justify">Cash flows from operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(3,592,218</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(3,044,475</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(547,743</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">18</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Cash flows from investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,762</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,762</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(100</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Cash flows from financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,791,902</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,291,362</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,500,540</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">116</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>Operating Activities</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in operating activities
increased to $3,592,218 for the nine months ended March 31, 2016 from $3,044,475 for the nine months ended March 31, 2015. During
the nine months ended March 31, 2016 and 2015 the Company reported net losses of $5,408,479 and $4,223,087 respectively. The loss
from the revaluation of the derivative liability was $943,050 for the nine months ended March 31, 2016 compared to a loss of $451,794
for the nine months ended March 31, 2015. Excluding the impact of changes in the fair value of the derivative liability, non-cash
items relating to amortization, loss due to changes in warrant terms, warrants and shares issued for services, and stock option
expense totaled $896,895 for the nine months ended March 31, 2016. Non-cash items relating to the accrued interest, gain due to
changes in warrant terms, loss on exchange of warrants, and share-based compensation totaled $550,853 for the nine months ended
March 31, 2015. The most significant changes in non-cash working capital for the nine months ended March 31, 2016 were cash used
in a reduction of accounts payable and accrued liabilities of $115,317, cash used in a reduction of related party payables of $61,802,
and cash flow from a decrease in prepaid expenses of $159,746. In the nine months ended March 31, 2015 the most significant item
was cash from an increase in accounts payable and accrued liabilities of $241,269.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Investing Activities</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended March 31,
2016 the Company incurred $16,762 in cash costs for the development of its web site. There were no investing activities during
the nine months ended March 31, 2015.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Financing Activities</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended March 31,
2016 the Company received $405,183 from the exercise of warrants and $2,453,633 in net proceeds from the completion of a public
offering by the Company of common stock and common stock purchase warrants. Including deferred costs recorded by the Company at
June 30, 2015, the total net cash proceeds of the offering was $1,903,514.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company received net proceeds of
$1,404,177 from the exercise of warrants during the nine months ended March 31, 2015.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the Company recorded $6,267
and $4,178 related to the dividend payable to Valent during the nine months ended March 31, 2016 and 2015 respectively.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Operating Capital and Capital Expenditure
Requirements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><U>Liquidity Risk</U></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">(See note 1 to the Consolidated Condensed Interim Financial
Statements)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">For the nine-month period ended March 31, 2016, the Company
reported a loss of $5,408,479 and an accumulated deficit of $24,028,040 at that date. As at March 31, 2016, the Company had cash
and cash equivalents on hand of $937,355. The Company does not have the prospect of achieving revenues in the near future and the
Company will require additional funding to maintain its research and development projects and for general operations. There is
a great degree of uncertainty with respect to the expenses the Company will incur in executing its business plan. In addition,
the Company has not begun to commercialize or generate revenues from its product candidate.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Consequently, management is pursuing various financing
alternatives to fund the Company&rsquo;s operations so it can continue as a going concern in the medium to longer term.
Subsequent to March 31, 2016, the Company completed a convertible preferred share private placement for gross proceeds of
$6.1 million. We believe, based on our current estimates, that we will be able to fund our operations beyond the next twelve
months.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">There is no assurance that our cost estimates will prove
to be accurate or that unforeseen events, problems or delays will not occur that would require us to seek additional debt and/or
equity funding. The ability of the Company to meet its obligations and continue the research and development of its product candidate
is dependent on its ability to continue to raise adequate financing. There can be no assurance that such financing will be available
to the Company in the amount required at any time or for any period or, if available, that it can be obtained on terms satisfactory
to the Company. The Company may tailor its drug candidate program based on the amount of funding the Company raises.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our future funding requirements will
depend on many factors, including but not limited to:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the rate of progress and cost of our clinical trials, preclinical studies and other discovery and research and development activities;</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs associated with establishing manufacturing and commercialization capabilities;</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of acquiring or investing in businesses, product candidates and technologies;</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs and timing of seeking and obtaining FDA and other regulatory approvals;</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effect of competing technological and market developments; and</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the economic and other terms and timing of any collaboration, licensing or other arrangements into which we may enter.</font></td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Until we can generate a sufficient amount
of product revenue to finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through
public or private equity offerings, debt financings or strategic collaborations. Although we are not reliant on institutional credit
finance and therefore not subject to debt covenant compliance requirements or potential withdrawal of credit by banks, the current
economic climate has also affected the availability of funds and activity in equity markets. We do not know whether additional
funding will be available on acceptable terms, or at all. If we are not able to secure additional funding when needed, we may have
to delay, reduce the scope of or eliminate one or more of our clinical trials or research and development programs or make changes
to our operating plan. In addition, we may have to seek a partner for one or more of our product candidate programs at an earlier
stage of development, which would lower the economic value of those programs to us.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Critical Accounting Policies </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements,
in conformity with generally accepted accounting principles in the United States, requires companies to establish accounting policies
and to make estimates that affect both the amount and timing of the recording of assets, liabilities, revenues and expenses. Some
of these estimates require judgments about matters that are inherently uncertain and therefore actual results may differ from those
estimates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 114pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A detailed presentation of all of the
Company&rsquo;s significant accountings policies and the estimates derived therefrom is included in Note 4 to the Company&rsquo;s
consolidated financial statements for the year ended June 30, 2015 contained in our Form 10-K/A filed with the SEC on November
16, 2015. While all of the significant accounting policies are important to the Company&rsquo;s consolidated financial statements,
the following accounting policies and the estimates derived therefrom have been identified as being critical:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px; line-height: 107%">&nbsp;</td>
    <td style="width: 24px; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares for services</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock options</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify; line-height: 107%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative liability</font></td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Warrants and shares issued for services</U></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Periodically, the Company has issued
equity instruments for services provided by employees and nonemployees. The equity instruments are valued at the fair value of
the instrument granted.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Stock options</U></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for these awards
under ASC 718, &ldquo;Compensation - Stock Compensation&rdquo; (&ldquo;ASC 718&rdquo;). ASC 718 requires measurement of compensation
cost for all stock-based awards at fair value on the date of grant and recognition of compensation over the requisite service period
for awards expected to vest. Compensation expense for unvested options to non-employees is revalued at each period end and is being
amortized over the vesting period of the options. The determination of grant-date fair value for stock option awards is estimated
using the Black-Scholes model, which includes variables such as the expected volatility of the Company&rsquo;s share price, the
anticipated exercise behavior of its grantee, interest rates, and dividend yields. These variables are projected based on the Company&rsquo;s
historical data, experience, and other factors. Changes in any of these variables could result in material adjustments to the expense
recognized for non-cash expenses. Such value is recognized as expense over the requisite service period, net of estimated forfeitures,
using the straight-line attribution method. The estimation of stock awards that will ultimately vest requires judgment, and to
the extent actual results or updated estimates differ from current estimates, such amounts are recorded as a cumulative adjustment
in the period estimates are revised. The Company considers many factors when estimating expected forfeitures, including type of
awards granted, employee class, and historical experience. Actual results and future estimates may differ substantially from current
estimates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Derivative liability</U></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for certain warrants
under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company&rsquo;s
own stock, on the understanding that in compliance with applicable securities laws, the warrants require the issuance of securities
upon exercise and do not sufficiently preclude an implied right to net cash settlement. The Company classifies warrants in its
balance sheet as a derivative liability which is fair valued at each reporting period subsequent to the initial issuance. As quoted
prices for the derivative liability are not available, the Company uses a simulated probability valuation model to value the warrants.
Determining the appropriate fair-value model and calculating the fair value of warrants requires considerable judgment. Any change
in the estimates used may cause the value to be higher or lower than that reported. The estimated volatility of the Company&rsquo;s
common stock at the date of issuance, and at each subsequent reporting period, is based on the historical volatility of similar
life sciences companies. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar
to the expected remaining life of the warrants at the valuation date. The expected life of the warrants is assumed to be equivalent
to their remaining contractual term.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not have any off balance sheet
arrangements.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Other Events</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In conjunction with our Series B preferred
Stock financing, we entered into a lock-up agreement with a former director limiting his share sales for a period ending June 30,
2017.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 3.</B><FONT STYLE="letter-spacing: 27pt">&nbsp;</FONT><B><A NAME="Quantitative"></A>Quantitative
and Qualitative Disclosures About Market Risk.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Not required for a smaller reporting company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 4.</B><FONT STYLE="letter-spacing: 27pt">&nbsp;</FONT><B><A NAME="Controls"></A>Controls
and Procedures. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">At the time that our Annual Report on Form 10-K for the year ended
June 30, 2015 was filed on September 3, 2015, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure
controls and procedures were effective as of June 30, 2015. Subsequent to that evaluation, our management, including our Chief
Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were not effective as of June
30, 2015, because of the material weakness in our internal control over financial reporting discussed in our Annual Report on Form
10-K/A filed on November 16, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Remediation Plan for the Material Weakness</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Management has been actively engaged in developing remediation plans
to address the above material weakness. The remediation efforts in process or expected to be implemented include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<UL STYLE="margin-top: 0in; list-style-type: disc; font-family: Times New Roman, Times, Serif">

<LI STYLE="margin: 0; font-size: 10pt">Engaging an industry expert to assist with the identification and assessment of non-routine,
financial instrument related transactions; and</LI>

</UL STYLE="font-family: Times New Roman, Times, Serif">

<UL STYLE="margin-top: 0in; list-style-type: disc; font-family: Times New Roman, Times, Serif">

<LI STYLE="margin: 0; font-size: 10pt">Re-designing controls to identify, research, evaluate and review the appropriate accounting
related to non-routine complex transactions and technical accounting matters. These include matters in the areas of share purchase
warrants, derivative liability and other equity transactions.</LI>

</UL STYLE="font-family: Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We believe that the controls that we are, and will be, implementing
will improve the effectiveness of our internal control over financial reporting. As we continue to evaluate and work to improve
our internal control over financial reporting, we may determine to take additional measures to address the material weakness or
determine to supplement or modify certain of the remediation measures described above. The remediation of the material weakness
was completed in the quarter ended December 31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Management, with the participation of the Chief Executive Officer
and Chief Financial Officer, conducted an evaluation (as required by Rule 13a-15 under the Exchange Act) of the effectiveness of
our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the
period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that
our disclosure controls and procedures were effective as of the end of the period covered by this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Changes in internal controls</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Other than as described above, there have been no changes in our
internal control over financial reporting that occurred during the quarter ended March 31, 2016 that have materially affected,
or are reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART II - OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><A NAME="item1"></A>Item 1. Legal Proceedings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">There are no legal proceedings to which the Company or any of its
property is the subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><A NAME="item1a"></A>Item 1A. Risk Factors. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Not required for a smaller reporting company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><A NAME="item2"></A>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><A NAME="item3"></A>Item 3. Defaults Upon Senior Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><A NAME="item4"></A>Item 4. Mine Safety Disclosures.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><A NAME="item5"></A>Item 5. Other Information.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><A NAME="item6"></A>Item 6. Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; padding: 0.75pt; width: 15%"><FONT STYLE="font-size: 10pt"><B>No.</B></FONT></TD>
    <TD STYLE="padding: 0.75pt; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; padding: 0.75pt; width: 80%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0.75pt"><FONT STYLE="font-size: 10pt">31.1</FONT></TD>
    <TD STYLE="padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.75pt"><FONT STYLE="font-size: 10pt">Rule 13a-14(a)/ 15d-14(a) Certification of Chief Executive Officer</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding: 0.75pt"><FONT STYLE="font-size: 10pt">31.2</FONT></TD>
    <TD STYLE="padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.75pt"><FONT STYLE="font-size: 10pt">Rule 13a-14(a)/ 15d-14(a) Certification of Chief Financial Officer</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0.75pt"><FONT STYLE="font-size: 10pt">32.1</FONT></TD>
    <TD STYLE="padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.75pt"><FONT STYLE="font-size: 10pt">Section 1350 Certification of Chief Executive Officer</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding: 0.75pt"><FONT STYLE="font-size: 10pt">32.2</FONT></TD>
    <TD STYLE="padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.75pt"><FONT STYLE="font-size: 10pt">Section 1350 Certification of Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.75pt; width: 15%"><FONT STYLE="font-size: 10pt">EX-101.INS</FONT></TD>
    <TD STYLE="padding: 0.75pt; width: 5%">&nbsp;</TD>
    <TD STYLE="padding: 0.75pt; width: 80%"><FONT STYLE="font-size: 10pt">XBRL INSTANCE DOCUMENT</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0.75pt"><FONT STYLE="font-size: 10pt">EX-101.SCH</FONT></TD>
    <TD STYLE="padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.75pt"><FONT STYLE="font-size: 10pt">XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.75pt"><FONT STYLE="font-size: 10pt">EX-101.CAL</FONT></TD>
    <TD STYLE="padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.75pt"><FONT STYLE="font-size: 10pt">XBRL TAXONOMY EXTENSION CALCULATION LINKBASE</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0.75pt"><FONT STYLE="font-size: 10pt">EX-101.LAB</FONT></TD>
    <TD STYLE="padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.75pt"><FONT STYLE="font-size: 10pt">XBRL TAXONOMY EXTENSION LABELS LINKBASE</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.75pt"><FONT STYLE="font-size: 10pt">EX-101.PRE</FONT></TD>
    <TD STYLE="padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.75pt"><FONT STYLE="font-size: 10pt">XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DelMar Pharmaceuticals, Inc.</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 12, 2016</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Jeffrey Bacha</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey
    Bacha</FONT><FONT STYLE="font-size: 10pt"><BR><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer
    (Principal Executive Officer)</FONT></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 12, 2016</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Scott Praill</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott
    Praill</FONT><FONT STYLE="font-size: 10pt"><BR><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer
    (Principal Financial and Accounting Officer)</FONT></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 52; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>f10q0316ex31i_delmarpharma.htm
<DESCRIPTION>CERTIFICATIONS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.1 </B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: center">Certifications</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 9pt 0 0">I, Jeffrey Bacha, certify that:</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt; line-height: 115%">1.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; line-height: 115%">I have reviewed this quarterly report on Form 10-Q of DelMar Pharmaceuticals, Inc.; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt; line-height: 115%">2.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; line-height: 115%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt; line-height: 115%">3.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; line-height: 115%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt; line-height: 115%">4.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; line-height: 115%">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 8%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%; font-size: 10pt"><FONT STYLE="font-size: 10pt; line-height: 115%">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt; line-height: 115%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt; line-height: 115%">(b)</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; line-height: 115%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt; line-height: 115%">(c)</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; line-height: 115%">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt; line-height: 115%">(d)</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; line-height: 115%">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt; line-height: 115%">5.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; line-height: 115%">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions): </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt; line-height: 115%">(a)</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; line-height: 115%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt; line-height: 115%">(b)</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; line-height: 115%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 9pt 0 0">Date: May 12, 2016</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0.75pt; border-bottom: black 0.75pt solid">/s/ Jeffrey Bacha</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt; line-height: 115%">Jeffrey Bacha</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt; line-height: 115%">Chief Executive Officer (Principal Executive Officer)</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>f10q0316ex31ii_delmarpharma.htm
<DESCRIPTION>CERTIFICATIONS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.2 </B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: center">Certifications</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 9pt 0 0">I, Scott Praill, certify that:</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt; line-height: 115%">1.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; line-height: 115%">I have reviewed this quarterly report on Form 10-Q of DelMar Pharmaceuticals, Inc.; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt; line-height: 115%">2.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; line-height: 115%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt; line-height: 115%">3.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; line-height: 115%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt; line-height: 115%">4.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; line-height: 115%">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 8%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%; font-size: 10pt"><FONT STYLE="font-size: 10pt; line-height: 115%">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt; line-height: 115%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt; line-height: 115%">(b)</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; line-height: 115%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt; line-height: 115%">(c)</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; line-height: 115%">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt; line-height: 115%">(d)</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; line-height: 115%">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt; line-height: 115%">5.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; line-height: 115%">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions): </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt; line-height: 115%">(a)</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; line-height: 115%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt; line-height: 115%">(b)</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; line-height: 115%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 9pt 0 0">Date: May 12, 2016</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0.75pt; border-bottom: black 0.75pt solid">/s/ Scott Praill</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt; line-height: 115%">Scott Praill</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">
        <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 12pt; text-indent: -12pt">Chief Financial Officer
(Principal Financial Officer)</P></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>f10q0316ex32i_delmarpharma.htm
<DESCRIPTION>CERTIFICATION PURSUANT TO
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1 </B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: center"><B>CERTIFICATION PURSUANT TO </B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>18 U.S.C. SECTION 1350, </B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO </B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002 </B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 9pt 0 0">In connection with the Quarterly Report of DelMar Pharmaceuticals,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended March 31, 2016, as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), I, Jeffrey Bacha, Chief Executive Officer of the Company, certify, pursuant to 18
U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 9pt 0 0; text-indent: 24.5pt">(1) the Report fully complies with
the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 9pt 0 0; text-indent: 24.5pt">(2) the information contained in
the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 9pt 0 0">Dated: May 12, 2016</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0.75pt; border-bottom: black 0.75pt solid">/s/ Jeffrey Bacha</P></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt; line-height: 115%">Jeffrey Bacha</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt; line-height: 115%">Chief Executive Officer (Principal Executive Officer)</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>f10q0316ex32ii_delmarpharma.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.2 </B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: center"><B>CERTIFICATION PURSUANT TO </B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>18 U.S.C. SECTION 1350, </B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO </B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002 </B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 9pt 0 0">In connection with the Quarterly Report of DelMar Pharmaceuticals,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended March 31, 2016, as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), I, Scott Praill, Chief Financial Officer of the Company, certify, pursuant to 18
U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 9pt 0 0; text-indent: 24.5pt">(1) the Report fully complies with
the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 9pt 0 0; text-indent: 24.5pt">(2) the information contained in
the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 9pt 0 0">Dated: May 12, 2016</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0.75pt; border-bottom: black 0.75pt solid">/s/ Scott Praill</P></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt; line-height: 115%">Scott Praill</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt; line-height: 115%">Chief Financial Officer (Principal Financial Officer)</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>dmpi-20160331.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated using Ez-XBRL version 8.0.0.0 [05/12/2016 11:31:39 PM] -->
<!-- Based on XBRL 2.1 -->
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Thursday, May 12, 2016 11:32:27 PM -->
<xbrli:xbrl xmlns:dmpi="http://www.delmarpharma.com/20160331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="dmpi-20160331.xsd"/>
<!-- Context Section  -->
<xbrli:context id="Context_As_Of_24_Jan_2013T00_00_00_TO_24_Jan_2013T00_00_00_DerivativeInstrumentRiskAxis_DividendWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dmpi:DividendWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-01-24
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2013T00_00_00_TO_24_Jan_2013T00_00_00_DerivativeInstrumentRiskAxis_DividendWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dmpi:DividendWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-01-24
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_06_Mar_2013T00_00_00_TO_06_Mar_2013T00_00_00_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_TwoThousandThirteenPlacementAgentWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dmpi:TwoThousandThirteenPlacementAgentWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-03-06
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_06_Mar_2013T00_00_00_TO_06_Mar_2013T00_00_00_RangeAxis_MinimumMember_SubsidiarySaleOfStockAxis_TwoThousandThirteenPlacementAgentWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dmpi:TwoThousandThirteenPlacementAgentWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-03-06
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2013T00_00_00_TO_06_Mar_2013T00_00_00_SubsidiarySaleOfStockAxis_TwoThousandThirteenPlacementAgentWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dmpi:TwoThousandThirteenPlacementAgentWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-03-01
</xbrli:startDate>
<xbrli:endDate>
2013-03-06
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_12_Sep_2013T00_00_00_TO_12_Sep_2013T00_00_00_DerivativeInstrumentRiskAxis_WarrantsIssuedForServicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dmpi:WarrantsIssuedForServicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-12
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Sep_2013T00_00_00_TO_12_Sep_2013T00_00_00_DerivativeInstrumentRiskAxis_WarrantsIssuedForServicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dmpi:WarrantsIssuedForServicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-09-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-12
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_LegalEntityAxis_ValentTechnologiesLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">dmpi:ValentTechnologiesLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_LegalEntityAxis_ValentTechnologiesLlcMember_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">dmpi:ValentTechnologiesLlcMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_28_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_LegalEntityAxis_ValentTechnologiesLlcMember_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">dmpi:ValentTechnologiesLlcMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-09-28
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_28_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-09-28
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_DerivativeInstrumentRiskAxis_DividendWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dmpi:DividendWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-10-01
</xbrli:startDate>
<xbrli:endDate>
2014-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Apr_2014T00_00_00_TO_31_Dec_2014T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsExchangeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dmpi:InvestorWarrantsExchangeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-04-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2015T00_00_00_TO_09_Feb_2015T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsExchangeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dmpi:InvestorWarrantsExchangeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-02-01
</xbrli:startDate>
<xbrli:endDate>
2015-02-09
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_LegalEntityAxis_ValentTechnologiesLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">dmpi:ValentTechnologiesLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OfficerAndDirectorMember_AgreementsAxis_ConsultingAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dmpi:OfficerAndDirectorMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dmpi:AgreementsAxis">dmpi:ConsultingAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dmpi:InvestorWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantExercisesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dmpi:InvestorWarrantExercisesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_LegalEntityAxis_ValentTechnologiesLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">dmpi:ValentTechnologiesLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dmpi:InvestorWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jul_2014T00_00_00_TO_30_Jun_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OfficerAndDirectorMember_AgreementsAxis_ConsultingAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dmpi:OfficerAndDirectorMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dmpi:AgreementsAxis">dmpi:ConsultingAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_15_Jul_2015T00_00_00_TO_15_Jul_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-07-15
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Jul_2015T00_00_00_TO_15_Jul_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-02
</xbrli:startDate>
<xbrli:endDate>
2015-07-15
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Jul_2015T00_00_00_TO_15_Jul_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-02
</xbrli:startDate>
<xbrli:endDate>
2015-07-15
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Jul_2015T00_00_00_TO_15_Jul_2015T00_00_00_DerivativeInstrumentRiskAxis_TwoZeroOneFiveOfferingWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dmpi:TwoZeroOneFiveOfferingWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-02
</xbrli:startDate>
<xbrli:endDate>
2015-07-15
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dmpi:InvestorWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dmpi:InvestorWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_SubsidiarySaleOfStockAxis_TwoThousandFifteenAgentWarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dmpi:TwoThousandFifteenAgentWarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_15_Mar_2016T00_00_00_TO_29_Mar_2016T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantAmendmentsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dmpi:InvestorWarrantAmendmentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-03-15
</xbrli:startDate>
<xbrli:endDate>
2016-03-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_LegalEntityAxis_ValentTechnologiesLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">dmpi:ValentTechnologiesLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_LegalEntityAxis_ValentTechnologiesLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">dmpi:ValentTechnologiesLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OfficerAndDirectorMember_AgreementsAxis_ConsultingAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dmpi:OfficerAndDirectorMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dmpi:AgreementsAxis">dmpi:ConsultingAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dmpi:InvestorWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantExercisesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dmpi:InvestorWarrantExercisesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_SubsidiarySaleOfStockAxis_TwoThousandFifteenAgentWarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dmpi:TwoThousandFifteenAgentWarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_DerivativeInstrumentRiskAxis_TwoZeroOneFiveAgentWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dmpi:TwoZeroOneFiveAgentWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_SubsidiarySaleOfStockAxis_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dmpi:TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheFourMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">dmpi:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_VestingAxis_ShareBasedCompensationAwardTrancheTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_VestingAxis_ShareBasedCompensationAwardTrancheThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_VestingAxis_ShareBasedCompensationAwardTrancheFiveMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">dmpi:ShareBasedCompensationAwardTrancheFiveMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_VestingAxis_ShareBasedCompensationAwardTrancheSixMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">dmpi:ShareBasedCompensationAwardTrancheSixMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_VestingAxis_ShareBasedCompensationAwardTrancheSevenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">dmpi:ShareBasedCompensationAwardTrancheSevenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_VestingAxis_ShareBasedCompensationAwardTrancheEightMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">dmpi:ShareBasedCompensationAwardTrancheEightMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_VestingAxis_ShareBasedCompensationAwardTrancheNineMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">dmpi:ShareBasedCompensationAwardTrancheNineMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointThreeNineMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmpi:ZeroPointThreeNineMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointSevenFourMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmpi:ZeroPointSevenFourMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointEightZeroMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmpi:ZeroPointEightZeroMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointNineFourMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmpi:ZeroPointNineFourMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnePointZeroZeroMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmpi:OnePointZeroZeroMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnepointzerofiveMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmpi:OnepointzerofiveMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnePointOneTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmpi:OnePointOneTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnePointFiveFourMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmpi:OnePointFiveFourMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_TwoPointThreeZeroMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmpi:TwoPointThreeZeroMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheFiveMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">dmpi:ShareBasedCompensationAwardTrancheFiveMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheSixMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">dmpi:ShareBasedCompensationAwardTrancheSixMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheSevenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">dmpi:ShareBasedCompensationAwardTrancheSevenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheEightMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">dmpi:ShareBasedCompensationAwardTrancheEightMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheNineMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">dmpi:ShareBasedCompensationAwardTrancheNineMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheTenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">dmpi:ShareBasedCompensationAwardTrancheTenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OfficerAndDirectorMember_AgreementsAxis_ConsultingAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dmpi:OfficerAndDirectorMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dmpi:AgreementsAxis">dmpi:ConsultingAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dmpi:InvestorWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_DerivativeInstrumentRiskAxis_TwoZeroOneFiveAgentWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dmpi:TwoZeroOneFiveAgentWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointThreeNineMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmpi:ZeroPointThreeNineMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointSevenFourMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmpi:ZeroPointSevenFourMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointEightZeroMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmpi:ZeroPointEightZeroMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointNineFourMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmpi:ZeroPointNineFourMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnePointZeroZeroMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmpi:OnePointZeroZeroMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnepointzerofiveMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmpi:OnepointzerofiveMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnePointOneTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmpi:OnePointOneTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnePointFiveFourMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmpi:OnePointFiveFourMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_TwoPointThreeZeroMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmpi:TwoPointThreeZeroMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_AgreementsAxis_ExchangeAgreementMember_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dmpi:AgreementsAxis">dmpi:ExchangeAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointNineTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmpi:ZeroPointNineTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2016T00_00_00_TO_10_Apr_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-04-01
</xbrli:startDate>
<xbrli:endDate>
2016-04-10
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_12_May_2016T00_00_00_TO_12_May_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-05-12
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_12_May_2016T00_00_00_TO_12_May_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-05-12
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_12_May_2016T00_00_00_TO_12_May_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-05-12
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2016T00_00_00_TO_12_May_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-05-01
</xbrli:startDate>
<xbrli:endDate>
2016-05-12
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2016T00_00_00_TO_12_May_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_InvestorWarrantAmendmentsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dmpi:InvestorWarrantAmendmentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-05-01
</xbrli:startDate>
<xbrli:endDate>
2016-05-12
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_29_Apr_2016T00_00_00_TO_12_May_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001498382</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-04-29
</xbrli:startDate>
<xbrli:endDate>
2016-05-12
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>IhkevEkirxw9=c444c555cT{h>:5HI=5;51I8E5189<=1=8JJ1FG:<7I<645<J -->
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="CAD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">DelMar Pharmaceuticals, Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">0001498382</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">--06-30</dei:CurrentFiscalYearEndDate>
<dei:TradingSymbol contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">dmpi</dei:TradingSymbol>
<dei:AmendmentFlag contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">false</dei:AmendmentFlag>
<dei:DocumentType contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">10-Q</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">2016-03-31</dei:DocumentPeriodEndDate>
<dei:EntityFilerCategory contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:DocumentFiscalYearFocus contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">2016</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">Q3</dei:DocumentFiscalPeriodFocus>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_12_May_2016T00_00_00_TO_12_May_2016T00_00_00" unitRef="shares" decimals="INF">40253056</dei:EntityCommonStockSharesOutstanding>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">4759711</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">3006598</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">1754433</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">937355</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<dmpi:TaxesAndOtherReceivablesCurrent contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">25831</dmpi:TaxesAndOtherReceivablesCurrent>
<dmpi:TaxesAndOtherReceivablesCurrent contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">32142</dmpi:TaxesAndOtherReceivablesCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">245038</us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">85292</us-gaap:PrepaidExpenseCurrent>
<us-gaap:DeferredCostsCurrent contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">550119</us-gaap:DeferredCostsCurrent>
<us-gaap:DeferredCostsCurrent contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">60647</us-gaap:DeferredCostsCurrent>
<us-gaap:DeferredCostsCurrent contextRef="Context_As_Of_12_May_2016T00_00_00_TO_12_May_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">2575421</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">1115436</us-gaap:AssetsCurrent>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">39875</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:Assets contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">2575421</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">1155311</us-gaap:Assets>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">762265</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">646948</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:DueToRelatedPartiesCurrent contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">90820</us-gaap:DueToRelatedPartiesCurrent>
<us-gaap:DueToRelatedPartiesCurrent contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OfficerAndDirectorMember_AgreementsAxis_ConsultingAgreementsMember" unitRef="USD" decimals="0">90820</us-gaap:DueToRelatedPartiesCurrent>
<us-gaap:DueToRelatedPartiesCurrent contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">29018</us-gaap:DueToRelatedPartiesCurrent>
<us-gaap:DueToRelatedPartiesCurrent contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OfficerAndDirectorMember_AgreementsAxis_ConsultingAgreementsMember" unitRef="USD" decimals="0">29018</us-gaap:DueToRelatedPartiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">853085</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">675966</us-gaap:LiabilitiesCurrent>
<dmpi:StockOptionLiabilityNoncurrent contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">179445</dmpi:StockOptionLiabilityNoncurrent>
<dmpi:StockOptionLiabilityNoncurrent contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">149698</dmpi:StockOptionLiabilityNoncurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">5111007</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">3443608</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">1487137</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember" unitRef="USD" decimals="0">1956471</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">2364381</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">1017250</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:Liabilities contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">3396911</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">1842914</us-gaap:Liabilities>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">278530</us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">278530</us-gaap:PreferredStockValue>
<dmpi:VotingShare contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<dmpi:VotingShare contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">39456</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">44309</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">17318479</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">17455279</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember" unitRef="USD" decimals="0">-136800</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">17363208</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">21805867</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">89432</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">6138426</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember" unitRef="USD" decimals="0">-6048994</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">89432</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">1190553</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">-18486525</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">-22715848</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember" unitRef="USD" decimals="0">4229323</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">-18613294</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-24028040</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">21178</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">21178</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">-821490</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">6138426</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">39456</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">17500008</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">39456</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">17500008</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">6138426</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember" unitRef="USD" decimals="0">-136800</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember" unitRef="USD" decimals="0">-6048994</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-687603</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">1190553</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">44309</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">21805867</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">39456</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember" unitRef="USD" decimals="0">17363208</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember" unitRef="USD" decimals="0">89432</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember" unitRef="USD" decimals="0">39456</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">2575421</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">1155311</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_LegalEntityAxis_ValentTechnologiesLlcMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD_per_Share" decimals="2">1.00</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_AgreementsAxis_ExchangeAgreementMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD_per_Share" decimals="0">1</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_12_May_2016T00_00_00_TO_12_May_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">8.00</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_LegalEntityAxis_ValentTechnologiesLlcMember" unitRef="shares" decimals="INF">278530</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_LegalEntityAxis_ValentTechnologiesLlcMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="0">278530</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">278530</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">278530</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_12_May_2016T00_00_00_TO_12_May_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">764363</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">278530</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">278530</us-gaap:PreferredStockSharesOutstanding>
<dmpi:PreferredStockSpecialVotingSharesIssued contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="shares" decimals="INF">1</dmpi:PreferredStockSpecialVotingSharesIssued>
<dmpi:PreferredStockSpecialVotingSharesIssued contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="shares" decimals="INF">1</dmpi:PreferredStockSpecialVotingSharesIssued>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="shares" decimals="INF">200000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="shares" decimals="INF">200000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_15_Jul_2015T00_00_00_TO_15_Jul_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD_per_Share" decimals="2">0.60</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="shares" decimals="INF">39455931</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="shares" decimals="INF">44309098</us-gaap:CommonStockSharesIssued>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">641839</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">1925635</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">790323</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">2183355</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">500753</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">1601982</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">630226</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">1994923</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">1142592</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">3527617</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">1420549</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">4178278</us-gaap:OperatingExpenses>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">-781152</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">-451794</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_FYE_01_Jul_2014T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">-627433</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">276584</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-943050</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
<dmpi:GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<dmpi:GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">-23658</dmpi:GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms>
<dmpi:GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">7000</dmpi:GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms>
<dmpi:GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">270965</dmpi:GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms>
<dmpi:GainLossOnExchangeOfWarrants contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">-156219</dmpi:GainLossOnExchangeOfWarrants>
<dmpi:GainLossOnExchangeOfWarrants contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">-249062</dmpi:GainLossOnExchangeOfWarrants>
<dmpi:GainLossOnExchangeOfWarrants contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<dmpi:GainLossOnExchangeOfWarrants contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">-6826</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">-16512</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">10523</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-16257</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:InterestExpense contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestExpense contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">2091</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_LegalEntityAxis_ValentTechnologiesLlcMember" unitRef="USD" decimals="0">2091</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestExpense contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestIncomeOther contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">70</us-gaap:InterestIncomeOther>
<us-gaap:InterestIncomeOther contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">331</us-gaap:InterestIncomeOther>
<us-gaap:InterestIncomeOther contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">41</us-gaap:InterestIncomeOther>
<us-gaap:InterestIncomeOther contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">71</us-gaap:InterestIncomeOther>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">-944127</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">-695470</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">280148</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-1230201</us-gaap:NonoperatingIncomeExpense>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">-2086719</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">-4223087</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-1140401</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-5408479</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:EarningsPerShareBasic contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD_per_Share" decimals="2">0.05</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD_per_Share" decimals="2">0.11</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.03</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.12</us-gaap:EarningsPerShareBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="shares" decimals="0">38976827</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="shares" decimals="0">37732995</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="shares" decimals="0">44309098</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="shares" decimals="0">43587549</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">2086719</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">1649136</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember" unitRef="USD" decimals="0">437583</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">-4223087</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">4048256</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember" unitRef="USD" decimals="0">174831</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-5408479</us-gaap:NetIncomeLoss>
<us-gaap:AdjustmentForAmortization contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentForAmortization contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentForAmortization contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">3858</us-gaap:AdjustmentForAmortization>
<us-gaap:AdjustmentForAmortization contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">6430</us-gaap:AdjustmentForAmortization>
<us-gaap:InterestExpenseDebt contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">2091</us-gaap:InterestExpenseDebt>
<us-gaap:InterestExpenseDebt contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:UnrealizedGainLossOnDerivatives contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">-781152</us-gaap:UnrealizedGainLossOnDerivatives>
<us-gaap:UnrealizedGainLossOnDerivatives contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">-343569</us-gaap:UnrealizedGainLossOnDerivatives>
<us-gaap:UnrealizedGainLossOnDerivatives contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember" unitRef="USD" decimals="0">-437583</us-gaap:UnrealizedGainLossOnDerivatives>
<us-gaap:UnrealizedGainLossOnDerivatives contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">-451794</us-gaap:UnrealizedGainLossOnDerivatives>
<us-gaap:UnrealizedGainLossOnDerivatives contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">-276963</us-gaap:UnrealizedGainLossOnDerivatives>
<us-gaap:UnrealizedGainLossOnDerivatives contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember" unitRef="USD" decimals="0">-174831</us-gaap:UnrealizedGainLossOnDerivatives>
<us-gaap:UnrealizedGainLossOnDerivatives contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-943050</us-gaap:UnrealizedGainLossOnDerivatives>
<dmpi:ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">-23658</dmpi:ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms>
<dmpi:ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms contextRef="Context_FYE_01_Jul_2014T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">-23658</dmpi:ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms>
<dmpi:ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">270965</dmpi:ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms>
<dmpi:IssuanceOfStockForServices contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<dmpi:IssuanceOfStockForServices contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">80400</dmpi:IssuanceOfStockForServices>
<us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">400389</us-gaap:AdjustmentOfWarrantsGrantedForServices>
<us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0" id="Footnote-1_1">429932</us-gaap:AdjustmentOfWarrantsGrantedForServices>
<us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true" id="Footnote-1_2"/>
<us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" id="Footnote-1_3"/>
<us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">323358</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">138711</us-gaap:ShareBasedCompensation>
<dmpi:NetIncomeLossAfterAdjustmentsOfNonCashItems contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">-3220440</dmpi:NetIncomeLossAfterAdjustmentsOfNonCashItems>
<dmpi:NetIncomeLossAfterAdjustmentsOfNonCashItems contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-3568534</dmpi:NetIncomeLossAfterAdjustmentsOfNonCashItems>
<dmpi:IncreaseDecreaseInTaxesAndOtherReceivables contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">39472</dmpi:IncreaseDecreaseInTaxesAndOtherReceivables>
<dmpi:IncreaseDecreaseInTaxesAndOtherReceivables contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">6311</dmpi:IncreaseDecreaseInTaxesAndOtherReceivables>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">14375</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-159746</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">241269</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-115317</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">-11457</us-gaap:IncreaseDecreaseInDueToRelatedParties>
<us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-61802</us-gaap:IncreaseDecreaseInDueToRelatedParties>
<us-gaap:IncreaseDecreaseInOperatingCapital contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">-175965</us-gaap:IncreaseDecreaseInOperatingCapital>
<us-gaap:IncreaseDecreaseInOperatingCapital contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">23684</us-gaap:IncreaseDecreaseInOperatingCapital>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">-3044475</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-3592218</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-16762</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-16762</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<dmpi:ProceedsFromIssuanceOfSharesAndWarrants contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<dmpi:ProceedsFromIssuanceOfSharesAndWarrants contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">2453633</dmpi:ProceedsFromIssuanceOfSharesAndWarrants>
<us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">4178</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
<us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">6267</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromWarrantExercises contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">1404177</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:ProceedsFromWarrantExercises contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsMember" unitRef="USD" decimals="0">470676</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:ProceedsFromWarrantExercises contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantExercisesMember" unitRef="USD" decimals="0">1266177</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:ProceedsFromWarrantExercises contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">405183</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:ProceedsFromWarrantExercises contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsMember" unitRef="USD" decimals="0">405183</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">108637</us-gaap:PaymentsOfDebtIssuanceCosts>
<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">60647</us-gaap:PaymentsOfDebtIssuanceCosts>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">1291362</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">2791902</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">-1753113</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-817078</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<dmpi:IssuanceOfPreferredSharesForTheSettlementOfTheLoanPayable contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">278530</dmpi:IssuanceOfPreferredSharesForTheSettlementOfTheLoanPayable>
<dmpi:IssuanceOfPreferredSharesForTheSettlementOfTheLoanPayable contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<dmpi:ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants contextRef="Context_Custom_01_Feb_2015T00_00_00_TO_09_Feb_2015T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsExchangeMember" unitRef="USD" decimals="0">423723</dmpi:ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants>
<dmpi:ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">1120257</dmpi:ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants>
<dmpi:ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants contextRef="Context_FYE_01_Jul_2014T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">391422</dmpi:ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants>
<dmpi:ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">247440</dmpi:ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants>
<dmpi:ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_DerivativeInstrumentRiskAxis_DividendWarrantsMember" unitRef="USD" decimals="0">975278</dmpi:ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants>
<dmpi:ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">975278</dmpi:ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants>
<dmpi:ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants contextRef="Context_Custom_15_Mar_2016T00_00_00_TO_29_Mar_2016T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantAmendmentsMember" unitRef="USD" decimals="0">65750</dmpi:ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants>
<dmpi:ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">2343300</dmpi:ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants>
<dmpi:ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_SubsidiarySaleOfStockAxis_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember" unitRef="USD" decimals="0">2277550</dmpi:ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants>
<dmpi:ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">38038</dmpi:ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions>
<dmpi:ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">29747</dmpi:ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions>
<dmpi:ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<dmpi:ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">29747</dmpi:ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions>
<dmpi:DeferredCostsRecognizedAsEquityIssueCosts contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<dmpi:DeferredCostsRecognizedAsEquityIssueCosts contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">550119</dmpi:DeferredCostsRecognizedAsEquityIssueCosts>
<us-gaap:NatureOfOperations contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;table style="font: bold 10pt/normal 'times new roman', times, serif; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 6pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top; text-align: justify;"&gt;
&lt;td style="width: 15pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 5pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Nature of operations and liquidity risk&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-weight: bold; font-stretch: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Nature of operations&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 12pt; margin: 0px 0px 13pt 21.55pt; text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif; background-color: white;"&gt;DelMar Pharmaceuticals, Inc. (the &amp;#8220;Company&amp;#8221;) is a clinical stage drug development company with a focus on the treatment of cancer.&amp;#160;&amp;#160;&amp;#160;We are conducting clinical trials in the United States with our product candidate, VAL-083, as a potential new treatment for glioblastoma multiforme (&amp;#8220;GBM&amp;#8221;), the most common and aggressive form of brain cancer.&amp;#160;&amp;#160;We have also acquired certain exclusive commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (&amp;#8220;CML&amp;#8221;) and lung cancer.&amp;#160;&amp;#160;In order to accelerate our development timelines and reduce technical risk, we leverage existing clinical and commercial data from a wide range of sources.&amp;#160;&amp;#160;We plan to seek marketing partnerships in China in order to potentially generate future royalty revenue.&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 12pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The Company is a Nevada corporation formed on June 24, 2009 under the name Berry Only Inc. On January 25, 2013 (the &amp;#8220;Closing Date&amp;#8221;), the Company entered into and closed an exchange agreement (the &amp;#8220;Exchange Agreement&amp;#8221;), with Del Mar Pharmaceuticals (BC) Ltd. (&amp;#8220;DelMar (BC)&amp;#8221;), 0959454 B.C. Ltd. (&amp;#8220;Callco&amp;#8221;), and 0959456 B.C. Ltd. (&amp;#8220;Exchangeco&amp;#8221;) and the security holders of DelMar (BC). Upon the closing of the Exchange Agreement, DelMar (BC) became a wholly-owned subsidiary of the Company (the &amp;#8220;Reverse Acquisition&amp;#8221;). As a result of the shareholders of DelMar (BC) having a controlling interest in the Company subsequent to the Reverse Acquisition, for accounting purposes the transaction is a capital transaction with DelMar (BC) being the accounting acquirer even though the legal acquirer is the Company.&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 12pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;DelMar Pharmaceuticals, Inc. is the parent company of DelMar (BC), a British Columbia, Canada corporation, and Callco and Exchangeco which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition.&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 12pt; margin: 0px 0px 13pt 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif; background-color: white;"&gt;The address of the Company&amp;#8217;s administrative offices is Suite 720 - 999 West Broadway, Vancouver, British Columbia, V5Z 1K5 and the Company&amp;#8217;s clinical operations are located at 3485 Edison Way, Suite R, Menlo Park, California, 94025.&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 12pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;References to the Company refer to the Company and its wholly-owned subsidiaries, DelMar (BC), Callco and Exchangeco.&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-weight: bold; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt; text-indent: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Liquidity risk&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times
 new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;For the nine-month period ended March 31, 2016, the Company reported a loss of $5,408,479 and an accumulated deficit of $24,028,040 at that date. As at March 31, 2016, the Company had cash and cash equivalents on hand of $937,355. The Company does not have the prospect of achieving revenues in the near future and the Company will require additional funding to maintain its research and development projects and for general operations. There is a great degree of uncertainty with respect to the expenses the Company will incur in executing its business plan. In addition, the Company has not begun to commercialize or generate revenues from its product candidate.&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Consequently, management is pursuing various financing alternatives to fund the Company&amp;#8217;s operations so it can continue as a going concern (note 9) in the medium to longer term. Subsequent to March 31, 2016, the Company completed a convertible preferred share private placement for gross proceeds of $6.1 million. We believe, based on our current estimates, that we will be able to fund our operations beyond the next twelve months.&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"&gt;There is no assurance that our cost estimates will prove to be accurate or that unforeseen events, problems or delays will not occur that would require us to seek additional debt and/or equity funding. The ability of the Company to meet its obligations and continue the research and development of its product candidate is dependent on its ability to continue to raise adequate financing. There can be no assurance that such financing will be available to the Company in the amount required at any time or for any period or, if available, that it can be obtained on terms satisfactory to the Company. The Company may tailor its drug candidate development program based on the amount of funding the Company raises.&lt;/p&gt;</us-gaap:NatureOfOperations>
<us-gaap:AccountingChangesAndErrorCorrectionsTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;table style="font: bold 10pt/13pt 'times new roman', times, serif; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 6pt; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 15pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5pt;"&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Restatement of previously issued financial statements&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-weight: normal; background-color: white;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-weight: normal; background-color: white;"&gt;In our 2015 Annual Report on Form 10-K/A, we restated our previously issued consolidated financial statements and the related disclosures for the fiscal years ended June 30, 2015 and June 30, 2014 and for each of the quarters ended March 31, 2013, June 30, 2013, September 30, 2013, December 31, 2013, March 31, 2014, September 30, 2014, December 31, 2014, and March 31, 2015 (the "Restated Periods").&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif; background-color: white;"&gt;The restatement is the result of our corrections for the effect of financial statement errors attributable to the incorrect accounting for certain warrants issued for placement agent services issued on March 6, 2013 (the &amp;#8220;2013 Placement Agent Warrants&amp;#8221;). The 2013 Placement Agent Warrants were improperly accounted for as equity instruments at the time they were issued. During the preparation of our financial statements for the first quarter of fiscal 2016, we discovered that the 2013 Placement Agent Warrants represented a derivative liability and should not have been recognized as equity. The exercise price of the 2013 Placement Agent Warrants is subject to adjustment in certain circumstances. The public equity financing that we completed in August 2015 resulted in the exercise price of the 2013 Placement Agent Warrants being reduced. Accordingly, we have classified the 2013 Placement Agent Warrants as a derivative liability on the Consolidated Balance Sheets at June 30, 2015 and June 30, 2014 as well as recognized the gain/loss from the revaluation of the derivative liability in the Consolidated Statement of Operations and Comprehensive Loss of the years ended June 30, 2015 and June 30, 2014. We have also reflected the cumulative impact of the fair value adjustments from March 6, 2013 to June 30, 2014 in the accumulated deficit.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="background-color: white;"&gt;The aggregate impacts of correcting the errors relating to the 2013 Placement Agent Warrants, as of, and for the three and nine months ended March 31, 2015 were as follows:&lt;/font&gt;&lt;/p&gt;&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10"&gt;Three Months Ended March 31, 2015&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;As previously reported&amp;#160;&lt;br /&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Restatement adjustment&amp;#160;&lt;br /&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;As restated&amp;#160;&lt;br /&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td
 style="font-weight: bold;
 padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 944.203125px; text-align: left; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Change in fair value of derivative liability&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 137px; font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;343,569&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;437,583&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;781,152&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Loss for the period&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1,649,136&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;437,583&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2,086,719&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Basic and diluted loss per share&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.04&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.01&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.05&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font
 style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td
 style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"&gt;&lt;/p&gt;&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center;" colspan="10"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10"&gt;Nine Months Ended March 31, 2015&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;As previously reported&amp;#160;&lt;br /&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Restatement adjustment&amp;#160;&lt;br /&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;As restated&amp;#160;&lt;br /&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 944.203125px; text-align: left; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Change in fair value of derivative liability&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 137px; font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;276,963&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times,
 serif;"&gt;174,831&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times,
 serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;451,794&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Loss for the period&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;4,048,256&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;174,831&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;4,223,087&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Basic and diluted loss per share&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.11&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.00&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.11&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font
 style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: bold; text-align: right; padding-bottom:
 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;As At March 31, 2015&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;As previously reported&lt;/font&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Restatement adjustment&lt;/font&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;As restated&lt;/font&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Derivative liability&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1,487,137&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1,956,471&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;3,443,608&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;
 background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Additional paid-in capital&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new
 roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;17,455,279&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(136,800&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;17,318,479&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;6,138,426&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(6,048,994&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;89,432&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Accumulated deficit&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(22,715,848&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;4,229,323&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-weight: normal;"&gt;(18,486,525&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;)&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;We assessed the impact of these errors on our previously issued
 financial statements and concluded that the combined impact of these errors was material to our financial statements. Consequently, we have restated the prior period financial statements identified above. All amounts in our consolidated financial statements in this Quarterly Report on Form 10-Q affected by the restatement
 adjustments reflect such amounts as restated.&lt;/font&gt;&lt;/p&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:AccountingChangesAndErrorCorrectionsTextBlock>
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;table style="font: bold 10pt/normal 'times new roman', times, serif; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 6pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 15pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;3&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5pt;"&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Significant accounting policies&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Basis of presentation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The consolidated condensed interim financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles (&amp;#8220;U.S. GAAP&amp;#8221;) and are presented in United States dollars. The Company&amp;#8217;s functional currency is the United States dollar.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The accompanying consolidated condensed interim financial statements include the accounts of the Company and its wholly-owned subsidiaries, DelMar BC, Callco, and Exchangeco. All intercompany balances and transactions have been eliminated.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The principal accounting policies applied in the preparation of these financial statements are set out below and have been consistently applied to all periods presented.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Unaudited interim financial data&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The accompanying unaudited March 31, 2016 consolidated condensed interim balance sheet, the consolidated condensed interim statements of loss and comprehensive loss for the three and nine months ended March 31, 2016 and 2015, and consolidated condensed cash flows for the nine months ended March 31, 2016 and 2015, and the related interim information contained within the notes to the consolidated condensed interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. These consolidated condensed interim financial statements should be read in conjunction with the audited financial statements of the Company as at June 30, 2015 filed in our amended Form 10-K/A filed with the Securities and Exchange Commission on November 16, 2015. In the opinion of management, the unaudited consolidated condensed interim financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company&amp;#8217;s financial position at March 31, 2016 and results of its operations for the three and nine months ended March 31, 2016 and 2015, and its cash flows for the nine months ended March 31, 2016 and 2015. The results for three and nine months ended March 31, 2016 are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2016 or for any other future annual or interim period.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Use of estimates&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant:
 normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The preparation of consolidated condensed interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end or during the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liability and the valuation of equity instruments issued for services. There have been no changes to the methodology used in determining these estimates from the period ended June 30, 2015.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;b&gt;Intangible assets&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;i&gt;Website development costs&lt;/i&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Website development costs are stated at cost less accumulated amortization. The Company capitalizes website development costs associated with graphics design and development of the website application and infrastructure. Costs related to planning, content input, and website operations are expensed as incurred. The Company amortizes website development costs on a straight-line basis over three years. The website costs consist of $16,762 in cash costs and $29,543 in non-cash consideration in the form of the issuance of warrants. The Company recognized $3,858 and $6,430 respectively, in amortization during the three and nine months ended March 31, 2016. There was no amortization in either the three or nine months ended March 31, 2015.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 16pt; margin: 0px;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Loss per share&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Loss per share is calculated based on the weighted average number of common shares outstanding. For the three and nine month periods ended March 31, 2016 and 2015 diluted loss per share does not differ from basic loss per share since the effect of the Company&amp;#8217;s warrants and stock options are anti-dilutive. At March 31, 2016, potential common shares of 18,388,945 (March 31, 2015 &amp;#8211; 13,472,870) relating to warrants and 3,465,000 (March 31, 2015 &amp;#8211; 3,595,000) relating to stock options were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Recent accounting pronouncements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times
 new roman', times, serif;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;i&gt;Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2014-15 - Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The objective of the guidance is to require management to explicitly assess an entity's ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management will assess if there is substantial doubt about an entity's ability to continue as a going concern within one year after the issuance date of an entity&amp;#8217;s financial statements. The new standard defines substantial doubt and provides examples of indicators thereof. The definition of substantial doubt incorporates a likelihood threshold of "probable" similar to the current use of that term in U.S. GAAP for loss contingencies. The new standard will be effective for all entities in the first annual period ending after March 15, 2016 (March 31, 2016 for calendar year-end entities). Earlier application is permitted. The Company is currently assessing this standard for its impact on future reporting periods.&lt;/font&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<dmpi:ValentTechnologiesLlcTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;div&gt;&lt;table style="font: bold 10pt/normal 'times new roman', times, serif; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 6pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 15pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;4&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5pt;"&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Valent Technologies, LLC&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: bold 10pt/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0pt; margin-bottom: 0pt; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 0px 21.55pt; color: #000000; text-transform: none; text-indent: 0in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-weight: normal;"&gt;On September 30, 2014, the Company entered into an exchange agreement (the &amp;#8220;Valent Exchange Agreement&amp;#8221;) with Valent Technologies, LLC (&amp;#8220;Valent&amp;#8221;), an entity owned by the Company&amp;#8217;s Chief Scientific Officer and director, and DelMar (BC). Pursuant to the Valent Exchange Agreement, Valent exchanged its loan payable in the outstanding amount of $278,530 (including aggregate accrued interest to March 31, 2015 of $28,530), issued to Valent by DelMar (BC), for 278,530 shares of the Company&amp;#8217;s Series A Preferred Stock. The shares of Series A Preferred Stock have a stated value of $1.00 per share (the &amp;#8220;Stated Value&amp;#8221;) and are not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3% of the Stated Value per year, payable quarterly in arrears.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 0px 21.55pt; color: #000000; text-transform: none; text-indent: 0in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-weight: normal;"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 0px 21.55pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;For the three and nine months ended March 31, 2016, the Company recorded $2,089 and $6,267 respectively related to the dividend payable to Valent. The dividends have been recorded as a direct increase in accumulated deficit. For the nine months ended March 31, 2015 the Company accrued $2,091 in interest expense on the loan payable to the date of the conversion on September 30, 2014 and $4,178 related to the dividend for the period from October 1, 2014 to March 31, 2015.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</dmpi:ValentTechnologiesLlcTextBlock>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;div&gt;&lt;table style="font: bold 10pt/13pt 'times new roman', times, serif; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 6pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 15pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;5&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5pt;"&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Related party transactions&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 13.33px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;i&gt;During the nine months ended March 31, 2016&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Pursuant to consulting agreements with the Company&amp;#8217;s officers, the Company recognized a total of $360,000 (2015 - $385,000) in compensation expense for the nine months ended March 31, 2016.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;At March 31, 2016 there is an aggregate amount of $29,018 (June 30, 2015 - $90,820) owed to the Company&amp;#8217;s officers and directors for fees and expenses. The Company pays related party payables incurred for fees and expenses under normal commercial terms.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The Company paid $127,583 in directors&amp;#8217; fees (2015 - $77,667) during the nine months ended March 31, 2016.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.3in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The Company recorded $6,267 in dividends related to the Series A Preferred Stock issued to Valent (note 4).&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;i&gt;During the nine months ended March 31, 2015&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Effective September 30, 2014, the Company entered into and closed an agreement with Valent to exchange its loan with Valent for 278,530 shares of preferred stock of the Company (note 4).&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 21.55pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The Company accrued $2,091 in interest expense on the loan payable to Valent to the date of the conversion on September 30, 2014 and $4,178 related to the dividend on the Series A Preferred Stock for the period from October 1, 2014 to March 31, 2015 (note 4).&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;table style="font: bold 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0pt;"&gt;&lt;/td&gt;&lt;td style="width: 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;6&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Derivative liability&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 12pt; margin: 0px 0px 13pt 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The Company has issued common stock purchase warrants. Based on the terms of certain of these warrants the Company determined that the warrants were a derivative liability which is recognized at fair value at the date of the transaction and re-measured at fair value each reporting period with the changes in fair value recorded in the consolidated condensed statement of loss and comprehensive loss.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;i&gt;Investor Warrants&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;In connection with the Reverse Acquisition (note 1), during the quarter ended March 31, 2013 the Company issued units consisting of one share of common stock and one five-year warrant (the &amp;#8220;Investor Warrants&amp;#8221;) to purchase one share of common stock at an exercise price of $0.80. The exercise price of the Investor Warrants is subject to adjustment in the event that the Company issues common stock at a price lower than the exercise price, subject to certain exceptions. As a result of the financing completed by the Company during the three months ended September 30, 2015 (note 7) the exercise price of the Investor Warrants was reduced from $0.80 to $0.786. As a result of the price being reduced, the Company has recognized a loss of $8,098 on the revaluation of the warrants&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;u&gt;Investor Warrant exercises&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;During the nine months ended March 31, 2016, 515,500 Investor Warrants were exercised at an exercise price of $0.786 per share. The Company received proceeds of $405,183 from these exercises. The warrants that have been exercised were revalued at their exercise date and then the reclassification to equity was recorded resulting in $247,440 of the derivative liability being reclassified to equity.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;During the nine months ended March 31, 2015 the Company concluded a tender offer whereby the holders of the Investor Warrants had the opportunity to exercise their warrants at an exercise price of $0.65. Under the tender offer, a total of 762,227 warrants were exercised for net proceeds of $470,676 after payment by the Company of a 5% warrant agent fee of $24,772. In addition, during the nine months ended March 31, 2015, 1,223,847 warrants were exercised at an exercise price of $0.65 per warrant. The Company received proceeds of $795,501 from these exercises.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;
 font-stretch:
 normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;As a result of all of the Investor Warrant exercises during the nine months ended March 31, 2015, the Company received net proceeds of $1,266,177 from the exercise of 1,986,074 warrants. The Investor Warrants that have been exercised were revalued at their exercise date and then the reclassification to equity was recorded resulting in $391,422 of the derivative liability being reclassified to equity.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;u&gt;Investor Warrant exchanges&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;On December 31, 2014, the Company issued 414,889 shares of common stock in exchange for 1,244,666 Investor Warrants. The Investor Warrants that have been exchanged were revalued at their exchange date and then a reclassification to equity was recorded. The reclassification to equity upon the exchange was $305,112. The Company recognized a loss of $92,843 at the time of the exchange.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;On January 8, 2015, the Company filed a tender offer statement with the Securities and Exchange Commission, and on January 23, 2015, the Company filed an amendment thereto. The tender offer provided the holders of the Investor Warrants with the opportunity to receive one&amp;#160;share of common stock for every three Investor Warrants tendered. On February 9, 2015 the Company&amp;#8217;s tender offer expired. A total of 1,591,875 Investor Warrants were exchanged for 530,625 shares of common stock. The Investor Warrants that have been exchanged were revalued at their exchange date and then a reclassification to equity was recorded. The reclassification to equity upon the exchange was $423,723. The Company recognized a loss of $156,219 at the time of the exchange&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;u&gt;Investor Warrant amendments&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt; background-color: white;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;On March 29, 2016, the Company entered into amendments (the &amp;#8220;Investor Warrant Amendments&amp;#8221;) with the holders of certain Investor Warrants. Pursuant to the Investor Warrant Amendments, 250,000 Investor Warrants were amended to extend the expiration date to March 31, 2019 and remove the provision requiring an adjustment of the exercise price in the event the Company sells common stock at a purchase price lower than the current warrant exercise price. As a result of the Investor Warrant Amendments, the Company has recognized a loss of $7,000 and has reclassified $65,750 from the derivative liability to equity resulting in an increase to equity of $58,750. The Investor Warrants were revalued to the date of the amendment and were then reclassified to equity.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;i&gt;2013 Placement Agent Warrants&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Also in connection with the Reverse Acquisition (note 1), on March 6, 2013 the Company issued 5,250,000 warrants (the &amp;#8220;2013 Placement Agent Warrants&amp;#8221;) that are exercisable at $0.80 per share until March 6, 2018 but can be exercised on a cashless basis. The exercise price of the 2013 Placement Agent Warrants is subject to adjustment in the event that the Company sells common stock at a price lower than the exercise price, subject to certain exceptions. As a result of the financing completed by the Company during the quarter ended September 30, 2015 (note 7) the exercise price of the 2013 Placement Agent Warrants was reduced from $0.80 to $0.786. As a result of the price being reduced, the Company has recognized a loss of $13,467.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing:
 0px;
 -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt; background-color: white;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;On December 30, 2015, the Company entered into amendments (the &amp;#8220;2013 Placement Agent Warrant Amendments&amp;#8221;) with the holders of the 2013 Placement Agent Warrants. Pursuant to the 2013 Placement Agent Warrant Amendments, 5,050,000 2013 Placement Agent Warrants were amended to extend the expiration date to June 30, 2019 and remove the provision requiring an adjustment of the exercise price in the event the Company sells common stock at a purchase price lower than the current warrant exercise price. As a result of the 2013 Placement Agent Warrant Amendments, the Company has recognized a loss of $242,400 and has reclassified $2,277,550 from the derivative liability to equity resulting in an increase to equity of $2,035,150. The 2013 Placement Agent Warrants were revalued to the date of the amendment and were then reclassified to equity.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;i&gt;Dividend Warrants&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;In connection with the Reverse Acquisition (note 1), effective January 24, 2013, the Company effected a warrant dividend (the &amp;#8220;Warrant Dividend&amp;#8221;) pursuant to which the Company issued one five-year warrant to purchase one share of common stock at an exercise price of $1.25 for each outstanding share of common stock (the &amp;#8220;Dividend Warrants&amp;#8221;). Pursuant to the Warrant Dividend, the Company issued an aggregate of 3,250,007 Dividend Warrants.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;On October 31, 2014, the Company and all of its Dividend Warrant holders entered into amendments to the Dividend Warrants such that the Company&amp;#8217;s redemption rights and certain provisions of the Dividend Warrant agreements relating to potential cash settlement of the Dividend Warrants were removed. The Dividend Warrants were revalued to the date of the amendment on October 31, 2014 which resulted in a reclassification to equity of $975,278.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;i&gt;2015 Agent Warrants&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;As part of the Company&amp;#8217;s financing completed during the quarter ended September 30, 2015 (note 7), the Company issued 93,908 warrants to certain placement agents (&amp;#8220;2015 Agent Warrants&amp;#8221;). The 2015 Agent Warrants are exercisable at a per share price equal to $0.75 during the five-year period commencing six months from the effective date of the Public Offering, which period shall not extend further than five years from the effective date of the Public Offering. Therefore, all 2015 Agent Warrants expire on July 15, 2020.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;i&gt;Warrants issued for services&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;In a prior period, the Company issued 300,000 warrants for services. The warrants were issued on September 12, 2013 and are exercisable on a cashless basis at an exercise price of $1.76 for five years.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new
 roman',
 times, serif;"&gt;The Company&amp;#8217;s derivative liability is summarized as follows:&lt;/font&gt;&lt;/p&gt;&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;March 31,&amp;#160;&lt;br /&gt;2016&amp;#160;&lt;br /&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;June 30,&amp;#160;&lt;br /&gt;2015&amp;#160;&lt;br /&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(as restated)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1155px; font-weight: bold; text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Opening balance&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2,364,381&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;5,111,007&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Issuance of 2015 Agent Warrants&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;29,594&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Change in fair value of warrants&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;943,050&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(627,433&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;
 text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman',
 times, serif;"&gt;Change in fair value due to change in warrant terms&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;270,965&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(23,658&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Reclassification to equity upon amendment of warrants&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(2,343,300&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(975,278&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Reclassification to equity upon exchange of warrants&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(728,835&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Reclassification to equity upon exercise of warrants&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(247,440&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(391,422&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: bold; text-align: left; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Closing balance&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1,017,250&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman',
 times, serif;"&gt;2,364,381&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times,
 serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;table style="font: bold 10pt/normal 'times new roman', times, serif; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 6pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top; text-align: justify;"&gt;
&lt;td style="width: 15pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;7&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 5pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Stockholders&amp;#8217; equity&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Preferred stock&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;i&gt;Authorized&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 0.6in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;5,000,000 preferred shares, $0.001 par value&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 0.6in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px; text-indent: 20pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;i&gt;Issued and outstanding&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px; text-indent: 40pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Special voting shares &amp;#8211; at March 31, 2016 &amp;#8211; 1 (June 30, 2015 &amp;#8211; 1)&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px; text-indent: 40pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px; text-indent: 40pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Series A shares &amp;#8211; at March 31, 2016 &amp;#8211; 278,530 (June 30, 2015 &amp;#8211; 278,530)&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px
 0px 0px 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Effective September 30, 2014 pursuant to the Company&amp;#8217;s Valent Exchange Agreement (note 4), the Company filed the Series A Certificate of Designation with the Secretary of State of Nevada. Pursuant to the Series A Certificate of Designation, the Company designated 278,530 shares of preferred stock as Series A Preferred Stock. The shares of Series A Preferred Stock have a stated value of $1.00 per share (the &amp;#8220;Stated Value&amp;#8221;) and are not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3% of the Stated Value per year, payable quarterly in arrears. Upon any liquidation of the Company, the holder of the Series A Preferred Stock will be entitled to be paid, out of any assets of the Company available for distribution to stockholders, the Stated Value of the shares of Series A Preferred Stock held by such holder, plus any accrued but unpaid dividends thereon, prior to any payments being made with respect to the common stock.&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 21.55pt;"&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Common stock&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;i&gt;Authorized&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-indent: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;200,000,000 common shares, $0.001 par value&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-indent: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;i&gt;Issued and outstanding&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 0.3in; text-indent: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;March 31, 2016 &amp;#8211; 44,309,098 (June 30, 2015 &amp;#8211; 39,455,931)&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The issued and outstanding common shares at March 31, 2016 include 4,056,042 shares of common stock on an as-exchanged basis with respect to the shares of Exchangeco that can be exchanged for shares of common stock of the Company.&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal;
 widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;
&lt;p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 10.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Shares of common stock&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 10.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;outstanding&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Common stock&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Additional paid-in capital&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;
&lt;p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 10.5pt; font-family: 'times new roman', times, serif; margin: 0px 0.1in 0px 0px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 10.5pt; font-family: 'times new roman', times, serif; margin: 0px 0.1in 0px 0px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 10.5pt; font-family: 'times new roman', times, serif; margin: 0px 0.1in 0px 0px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 10.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold; text-align: right; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font
 style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 790px; font-weight: bold; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;June 30, 2015 &amp;#8211; as previously reported&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 137px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;39,455,931&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;39,456&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;17,500,008&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;6,138,426&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Restatement adjustments&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(136,800&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(6,048,994&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-weight: bold; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;June 30, 2015 &amp;#8211; as restated&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;39,455,931&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;39,456&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;17,363,208&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman',
 times, serif;"&gt;89,432&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Issuance of shares and warrants &amp;#8211; net of issue costs (i)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;4,277,667&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;4,278&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1,198,453&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;671,189&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Reclassification of warrants (ii)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2,343,300&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Exercise of warrants for cash (iii)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;515,500&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;515&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman',
 times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;652,108&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Warrants issued for services (iv)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;429,932&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Shares issued for services (v)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;60,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;60&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;80,340&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Stock-based compensation&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;138,711&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Reclassification of stock option liability&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times
 new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;29,747&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-weight: bold; padding: 0px 0px 4pt; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;March 31, 2016&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;44,309,098&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;44,309&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;21,805,867&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1,190,553&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div&gt;&amp;#160;&lt;/div&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start;
 text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(i) On July 15, 2015 the Company&amp;#8217;s Registration Statement on Form S-1 relating to a public offering by the Company of common stock and common stock purchase warrants (the &amp;#8220;Public Offering&amp;#8221;) was declared effective by the Securities and Exchange Commission. Pursuant to the Offering, the Company issued 4,277,667 shares of common stock at $0.60 per share and 4,277,667 warrants (the &amp;#8220;2015 Public Offering Warrants&amp;#8221;) to purchase shares of common stock at $0.001 per warrant for total gross proceeds of $2,566,660. The 2015 Public Offering Warrants are exercisable at $0.75 per share for a period of five years until they expire on July 31, 2020.&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;The Company engaged certain placement agents for the sale of a portion of the shares and 2015 Public Offering Warrants. Under the Company&amp;#8217;s engagement agreements with these placement agents, the Company agreed to pay up to a 7% cash commission and issue warrants to purchase shares of common stock (the &amp;#8220;2015 Agent Warrants&amp;#8221;) up to the number of shares of our common stock equal to 5% of the aggregate number of shares sold in the Offering by such placement agents. Pursuant to the placement agent agreements the Company paid a total cash commission of $80,575 and issued 93,908 2015 Agent Warrants (note 6). The 2015 Agent Warrants are exercisable at a per share price equal to $0.75 during the five-year period commencing six months from the effective date of the Public Offering, which period shall not extend further than five years from the effective date of the 2015 Public Offering. Therefore, all 2015 Agent Warrants expire on July 15, 2020.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;In addition to the cash commission of $80,575 the Company also incurred additional cash issue and closing costs of $582,511 (including costs deferred at June 30, 2015 of $550,119) resulting in net cash proceeds of $1,903,514. The 2015 Agent Warrants have been recognized as non-cash issue costs of $29,594.&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(ii) Upon the amendment of the Investor Warrants and the 2013 Placement Agent Warrants, the Company reclassified the related derivative liability to equity (note 6).&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(iii) During the nine months ended March 31, 2016, 515,500 Investor Warrants were exercised for proceeds of $405,183 (note 6).&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;(iv) During the nine months ended March 31, 2016, the Company issued 1,060,000 warrants for services. All warrants have an exercise price of $0.75. Of these warrants, 60,000 expire on July 31, 2020, 500,000 expire March 1, 2020, and 500,000 expire February 1, 2021.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(v) During the nine months ended March 31, 2016, the Company issued 60,000 shares of common stock for services.&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.25in; text-indent: 0.05in;"&gt;&lt;font style="font-family: 'times new roman', times,
 serif;"&gt;&lt;b&gt;Stock Options&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.25in; text-indent: 0.05in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.25in; text-indent: 0.05in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The following table sets forth the stock options outstanding:&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.25in; text-indent: 0.05in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;
&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;stock&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;options&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;outstanding&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;
&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;exercise&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="width: 15px; font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new
 roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1110px; font-weight: bold; text-align: left; padding: 0px; text-indent: 0px; vertical-align: top;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;June 30, 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 142px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;3,595,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 145px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.94&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding: 0px; text-indent: 0px; vertical-align: top;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Granted&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;390,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1.01&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding: 0px; text-indent: 0px; vertical-align: top;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(470,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1.08&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding: 0px; text-align: left; text-indent: 0px; vertical-align: top;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Cancelled&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(50,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1.05&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding: 0px; font-weight: bold; text-align: left; text-indent: 0px; vertical-align: top;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;March 31, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;3,465,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;
 text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.92&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The following table summarizes stock options currently outstanding and exercisable at March 31, 2016:&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Weighted average exercise price&amp;#160;&lt;br /&gt;$&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Number&amp;#160;&lt;br /&gt;outstanding at&amp;#160;&lt;br /&gt;March 31,&amp;#160;&lt;br /&gt;2016&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Weighted&amp;#160;&lt;br /&gt;average&amp;#160;&lt;br /&gt;remaining&amp;#160;&lt;br /&gt;contractual&amp;#160;&lt;br /&gt;life&amp;#160;&lt;br /&gt;(years)&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Number&amp;#160;&lt;br /&gt;exercisable&amp;#160;&lt;br /&gt;at&amp;#160;&lt;br /&gt;March 31,&amp;#160;&lt;br /&gt;2016&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Weighted average&amp;#160;&lt;br /&gt;exercise&amp;#160;&lt;br /&gt;price&amp;#160;&lt;br /&gt;$&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 283px; text-align: right;"&gt;0.39&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 267px; text-align: right;"&gt;775,000&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 267px; text-align: right;"&gt;5.88&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 266px; text-align: right;"&gt;775,000&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 266px; text-align: right;"&gt;0.39&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.74&lt;/td&gt;
&lt;td style="text-align:
 left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;180,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;8.84&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;180,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.74&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;120,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;9.00&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;120,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.94&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;180,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;9.75&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;15,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.94&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.00&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;140,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;4.92&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;140,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.00&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.05&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,770,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;7.37&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,696,796&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.05&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.12&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;120,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;9.77&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;9,333&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.12&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.54&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;60,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;7.00&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;60,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.54&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;2.30&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;120,000&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;7.17&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;120,000&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;2.30&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align:
 left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;0.92&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;3,465,000&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;3,116,129&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;0.91&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Included in the number of stock options outstanding are 775,000 stock options granted at an exercise price of CDN $0.50. The exercise prices shown in the above table have been converted to $0.39 using the period ending closing exchange rate.&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Certain stock options have been granted to non-employees and will be revalued at each reporting date until they have fully vested. The stock options have been re-valued using a Black-Scholes pricing model using the following assumptions:&lt;/font&gt;&lt;/p&gt;
&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold; text-align: right; padding: 0px 0px 1.5pt; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;
&lt;p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;March 31,&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2016&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold; text-align: right; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr
 style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 1279px; text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Dividend rate&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 194px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Volatility&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;84.8% to 118&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Risk-free rate&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Term - years&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.5 to 3.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div&gt;&amp;#160;&lt;/div&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt;"&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;The Company has recognized the following amounts as stock option expense for the periods noted:&amp;#160; &amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"&gt;&lt;/p&gt;
&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 18pt; font-weight: bold; text-align: right; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;
&lt;p style="margin-top: 0px; text-align: center; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Three months ended&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top: 0px; text-align: center; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;March 31,&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;
&lt;p style="margin-top: 0px; text-align: center; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Nine months ended&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top: 0px; text-align: center; margin-bottom: 0px;"&gt;&lt;/p&gt;
&lt;p style="margin-top: 0px; text-align: center; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;March 31,&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 18pt; font-weight: bold; text-align: right; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times,
 serif;"&gt;2016&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2015&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2016&amp;#160;&lt;br /&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2015&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 761.203125px; text-align: left; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Research and development&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 137px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;20,165&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;26,853&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;36,395&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;39,909&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;3,678&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td
 style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;35,995&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;102,316&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;102,262&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 4pt; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;23,843&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;62,848&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;138,711&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;142,171&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font
 style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div&gt;&amp;#160;&lt;/div&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;All of the total stock option expense of $138,711 for the nine months ended March 31, 2016 has been recognized as additional paid in capital. Of the stock option expense of $142,171 for the nine months ended March 31, 2015 $142,447 has been recognized as additional paid in capital and $276 has been recognized as a reduction of the stock option liability. The aggregate intrinsic value of stock options outstanding at March 31, 2016 was $396,538 (March 31, 2015 - $345,131) and the aggregate intrinsic value of stock options exercisable at March 31, 2016 was $396,538 (March 31, 2015 - $333,139). As of March 31, 2016 there was $93,016 in unrecognized compensation expense that will be recognized over the next three years. No stock options granted under the plan have been exercised to March 31, 2016. Upon the exercise of stock options new shares will be issued.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;A summary of status of the Company&amp;#8217;s unvested stock options under the plan is presented below:&lt;/p&gt;
&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 18pt; font-weight: bold; text-align: right; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-size: 18pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;
&lt;p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Number of&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Options&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;
&lt;p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;average&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-weight: bold;
 font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;exercise&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;price&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;
&lt;p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;average&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;grant date&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;fair value&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 866px; font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Unvested at June 30, 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 16px; font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 167px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;722,361&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 167px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.95&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 167px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.41&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family:
 'times new roman', times, serif;"&gt;Granted&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;390,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1.01&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.73&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Vested&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(481,634&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.91&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.64&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(260,370&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.92&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.24&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Cancelled&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(21,486&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1.05&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.57&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times,
 serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Unvested at March 31, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;348,871&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1.02&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.55&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div&gt;&amp;#160;&lt;/div&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;Certain of the Company&amp;#8217;s warrants have been recognized as a derivative liability (note 6). The following table&amp;#160;summarizes all of the Company&amp;#8217;s outstanding warrants as of March 31, 2016:&lt;/p&gt;
&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold; text-indent: 0px; padding-top: 0px; padding-right: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-left: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Description&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times,
 serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 1337px; font-weight: bold; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Balance &amp;#8211; June 30, 2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;13,472,870&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2015 Public Offering Warrants (i)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;4,277,667&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2015 Agent Warrants (ii)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;93,908&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Warrants issued for services (iii)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1,060,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Warrants exercised for cash (iv)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(515,500&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-weight: bold; padding: 0px 0px 4pt; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Balance - March 31, 2016&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;18,388,945&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div&gt;&amp;#160;&lt;/div&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 13pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.6in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;i)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Issued as part of the Company&amp;#8217;s financing completed in August 2015. Warrants are exercisable at $0.75 until July 31, 2020.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 13pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align:
 top;"&gt;
&lt;td style="width: 0.6in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;ii)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Issued as part of the Company&amp;#8217;s financing completed in August 2015. The 2015 Agent Warrants are exercisable at a price of $0.75 during the period commencing January 15, 2016 until their expiry on July 15, 2020.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 13pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.6in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;iii)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Warrants have an exercise price of $0.75. Of the total, 60,000 vest in tranches of 20,000 warrants each on November 30, 2015, March 31, 2016, and January 31, 2016 and are exercisable commencing January 1, 2016 until they expire on July 31, 2020. In addition, 500,000 of the warrants vest in tranches of 150,000 on March 1, 2015, and 50,000 on each of March 31, 2016, January 31, 2016, February 29, 2016, March 31, 2016, April 30, 2016, May 31, 2016, and June 30, 2016 until they expire on March 1, 2020. Also, 500,000 of the warrants vest in tranches of 83,333 on each of February 29, 2016, March 31, 2016, April 30, 2016, May 31, 2016, June 30, 2016 and July 31, 2016 until they expire on February 1, 2021.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 13pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.6in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;iv)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;515,500 Investor Warrants were exercised for cash at $0.786 per share for proceeds of $405,183.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;div&gt;&lt;table style="font: bold 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 13pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;8&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Financial instruments&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The Company has financial instruments that are measured at fair value. To determine the fair value, we use the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.3in;"&gt;&lt;/td&gt;&lt;td style="width: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Level one&amp;#160;- inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.3in;"&gt;&lt;/td&gt;&lt;td style="width: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Level two&amp;#160;- inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals;&amp;#160;and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.3in;"&gt;&lt;/td&gt;&lt;td style="width: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Level three&amp;#160;- unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The Company&amp;#8217;s financial instruments consist of cash and cash equivalents, other receivables, accounts payable, related party payables and derivative liability. The carrying values of cash and cash equivalents, other receivables, accounts payable and related party payables approximate their fair values due to the immediate or short-term maturity of these financial instruments.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;u&gt;Derivative liability&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The Company
 accounts for certain warrants under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company&amp;#8217;s own stock, on the understanding that in compliance with applicable securities laws, the warrants require the issuance of securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. The Company classifies these warrants on its balance sheet as a derivative liability which is fair valued at each reporting period subsequent to the initial issuance. The Company has used a simulated probability valuation model to value the warrants. Determining the appropriate fair-value model and calculating the fair value of warrants requires considerable judgment. Any change in the estimates (specifically probabilities) used may cause the value to be higher or lower than that reported. The estimated volatility of the Company&amp;#8217;s common stock at the date of issuance, and at each subsequent reporting period, is based on the historical volatility of similar life sciences companies. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining life of the warrants at the valuation date. The expected life of the warrants is assumed to be equivalent to their remaining contractual term.&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 13pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.3in;"&gt;&lt;/td&gt;&lt;td style="width: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;a)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Fair value of derivative liability&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 20pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The derivative is not traded in an active market and the fair value is determined using valuation techniques. The Company uses judgment to select a variety of methods to make assumptions that are based on specific management plans and market conditions at the end of each reporting period. The Company uses a fair value estimate to determine the fair value of the derivative liability. The carrying value of the derivative liability would be higher or lower as management estimates around specific probabilities change. The estimates may be significantly different from those recorded in the consolidated financial statements because of the use of judgment and the inherent uncertainty in estimating the fair value of these instruments that are not quoted in an active market. All changes in the fair value are recorded in the consolidated statement of operations and comprehensive loss each reporting period. This is considered to be a Level 2 financial &lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The Company has the following liabilities under the fair value hierarchy:&lt;/font&gt;&lt;/p&gt;&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 18pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;March 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; font-size: 18pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 915.4px; text-align: left; padding-left: 0.6in; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Liability&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 137px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Level 1&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new
 roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Level 2&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Level 3&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -0.3in; padding-bottom: 1.5pt; padding-left: 0.9in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Derivative liability&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1,017,250&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br style="font: 13.33px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; clear: both; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;" /&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 18pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="11"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;June 30, 2015&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; font-size: 18pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="11"&gt;&lt;font style="font-family: 'times new roman',
 times, serif;"&gt;(as restated)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; font-size: 18pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 915.4px; text-align: left; padding-left: 0.6in; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Liability&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 137px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Level 1&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Level 2&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Level 3&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -0.3in; padding-bottom: 1.5pt; padding-left: 0.9in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Derivative liability&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2,364,381&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font
 style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;table style="font: bold 10pt/normal 'times new roman', times, serif; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 6pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top; text-align: justify;"&gt;
&lt;td style="width: 15pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;9&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 5pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Subsequent events&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"&gt;&lt;b&gt;Series B Preferred Share Issuance&lt;/b&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"&gt;&lt;b&gt;&lt;/b&gt;On April 29, 2016, May 4, 2016, and May 12, 2016 the Company entered into Securities Purchase Agreements (the &amp;#8220;Purchase Agreements&amp;#8221;), pursuant to which it issued an aggregate of 764,363 shares of Series B Preferred Stock at a purchase price of at $8.00 per share for total gross proceeds of $6.1 million. Each share of Series B Preferred Stock is convertible into ten shares of common stock equating to a conversion price of $0.80 (the &amp;#8220;Conversion Price&amp;#8221;) and will automatically convert to common stock at the earlier of 24 hours following regulatory approval of VAL-083 with a minimum closing bid price of $2 or five years from the final closing dates. The holders of the Series B Preferred Stocks are entitled to an annual cumulative, in arrears dividend at the rate of 9% payable quarterly. The 9% dividend shall accrue quarterly commencing on the date of issue and be payable quarterly on June 30, September 30, December 31, and March 31&amp;#160;of each year commencing on June 30, 2016. Dividends shall be payable solely by delivery of shares of common stock (the &amp;#8220;PIK Shares&amp;#8221;), in an amount for each holder equal to the aggregate dividend payable to such holder with respect to the shares of Series B Preferred Stock held by such holder divided by the Conversion Price. The Series B Preferred Shares do not contain any repricing features.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 14px; margin: 2pt 0px 2pt 21.55pt;"&gt;In addition, the Company and the holders entered into a royalty agreement, pursuant to which the Company will pay the holders of the Series B preferred shares, in aggregate, a low, single-digit royalty based on their pro rata ownership of the Series B preferred shares on products sold directly by the Company or sold pursuant to a licensing or partnering arrangement (the &amp;#8220;Royalty Agreement&amp;#8221;).&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 14px; margin: 2pt 0px 2pt 21.55pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: left;"&gt;Upon conversion of a holder&amp;#8217;s shares to common stock, such holder shall no longer receive ongoing royalty payments under the Royalty Agreement but will be entitled to receive any residual royalty payments that have vested. Rights to the royalties shall vest during the first three years following the applicable closing date, in equal thirds to holders of the Series B Preferred Stock on each of the three vesting dates, upon which vesting dates such royalty amounts shall become &amp;#8220;Vested Royalties&amp;#8221;.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height:
 normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: left;"&gt;The Company engaged certain placement agents for the sale of a portion of the Series B Preferred Stock. Under the Company&amp;#8217;s engagement agreements with these placement agents, the Company agreed to pay up to an 8% cash commission and issue warrants to purchase shares of common stock (the &amp;#8220;2016 Agent Warrants&amp;#8221;) up to the number of shares of our common stock equal to 8% of the aggregate number of shares underlying the Series B Preferred Stock sold in the offering by such placement agents. Pursuant to the placement agent agreements the Company paid a total cash commission of approximately $283,000 and issued 356,050 2016 Agent Warrants. The 2016 Agent Warrants are exercisable at a per share price equal to $1.00 during the five-year period commencing six months from May 12, 2016 which period shall not extend further than five years from the closing dates. Therefore, all 2016 Agent Warrants expire on May 12, 2021.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.3in; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.3in; text-align: left;"&gt;In addition to the cash commission the Company also incurred additional cash issue and closing costs of approximately $340,000 (including costs deferred at March 31, 2016 of $60,647) resulting in net cash proceeds of approximately $5.5 million.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.3in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"&gt;&lt;b&gt;Investor Warrant Amendments&lt;/b&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"&gt;Subsequent to March 31, 2016, the Company amended an additional 1,970,238 Investor Warrants (note 6). As a result of the amendments, the Company has reclassified a portion of its derivative liability to equity resulting in an increase in equity of approximately $500,000.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"&gt;&lt;b&gt;Stock Options&lt;/b&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"&gt;Subsequent to March 31, 2016, 320,000 stock options were granted and 270,000 stock options were forfeited.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Basis of presentation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The consolidated condensed interim financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles (&amp;#8220;U.S. GAAP&amp;#8221;) and are presented in United States dollars. The Company&amp;#8217;s functional currency is the United States dollar.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The accompanying consolidated condensed interim financial statements include the accounts of the Company and its wholly-owned subsidiaries, DelMar BC, Callco, and Exchangeco. All intercompany balances and transactions have been eliminated.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The principal accounting policies applied in the preparation of these financial statements are set out below and have been consistently applied to all periods presented.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<dmpi:UnauditedInterimFinancialDataPolicyTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Unaudited interim financial data&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The accompanying unaudited March 31, 2016 consolidated condensed interim balance sheet, the consolidated condensed interim statements of loss and comprehensive loss for the three and nine months ended March 31, 2016 and 2015, and consolidated condensed cash flows for the nine months ended March 31, 2016 and 2015, and the related interim information contained within the notes to the consolidated condensed interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. These consolidated condensed interim financial statements should be read in conjunction with the audited financial statements of the Company as at June 30, 2015 filed in our amended Form 10-K/A filed with the Securities and Exchange Commission on November 16, 2015. In the opinion of management, the unaudited consolidated condensed interim financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company&amp;#8217;s financial position at March 31, 2016 and results of its operations for the three and nine months ended March 31, 2016 and 2015, and its cash flows for the nine months ended March 31, 2016 and 2015. The results for three and nine months ended March 31, 2016 are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2016 or for any other future annual or interim period.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</dmpi:UnauditedInterimFinancialDataPolicyTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Use of estimates&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 21.55pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The preparation of consolidated condensed interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end or during the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liability and the valuation of equity instruments issued for services. There have been no changes to the methodology used in determining these estimates from the period ended June 30, 2015.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
<us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;b&gt;Intangible assets&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"&gt;&lt;i&gt;Website development costs&lt;/i&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Website development costs are stated at cost less accumulated amortization. The Company capitalizes website development costs associated with graphics design and development of the website application and infrastructure. Costs related to planning, content input, and website operations are expensed as incurred. The Company amortizes website development costs on a straight-line basis over three years. The website costs consist of $16,762 in cash costs and $29,543 in non-cash consideration in the form of the issuance of warrants. The Company recognized $3,858 and $6,430 respectively, in amortization during the three and nine months ended March 31, 2016. There was no amortization in either the three or nine months ended March 31, 2015.&lt;/font&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Loss per share&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 0px 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Loss per share is calculated based on the weighted average number of common shares outstanding. For the three and nine month periods ended March 31, 2016 and 2015 diluted loss per share does not differ from basic loss per share since the effect of the Company&amp;#8217;s warrants and stock options are anti-dilutive. At March 31, 2016, potential common shares of 18,388,945 (March 31, 2015 &amp;#8211; 13,472,870) relating to warrants and 3,465,000 (March 31, 2015 &amp;#8211; 3,595,000) relating to stock options were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Recent accounting pronouncements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;i&gt;Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2014-15 - Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 0px 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 0px 21.55pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The objective of the guidance is to require management to explicitly assess an entity's ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management will assess if there is substantial doubt about an entity's ability to continue as a going concern within one year after the issuance date of an entity&amp;#8217;s financial statements. The new standard defines substantial doubt and provides examples of indicators thereof. The definition of substantial doubt incorporates a likelihood threshold of "probable" similar to the current use of that term in U.S. GAAP for loss contingencies. The new standard will be effective for all entities in the first annual period ending after March 15, 2016 (March 31, 2016 for calendar year-end entities). Earlier application is permitted. The Company is currently assessing this standard for its impact on future reporting periods.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;" colspan="10"&gt;Three Months Ended March 31, 2015&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;As previously reported&amp;#160;&lt;br /&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Restatement adjustment&amp;#160;&lt;br /&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;As restated&amp;#160;&lt;br /&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 944.203px; text-align: left; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Change in fair value of derivative liability&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 137px; font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;343,569&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;437,583&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;781,152&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Loss for the period&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1,649,136&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;437,583&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family:
 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td
 style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2,086,719&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Basic and diluted loss per share&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.04&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.01&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.05&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"&gt;&lt;/p&gt;&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center;" colspan="10"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;" colspan="10"&gt;Nine Months Ended March 31, 2015&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;As previously reported&amp;#160;&lt;br /&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Restatement adjustment&amp;#160;&lt;br /&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;As restated&amp;#160;&lt;br /&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr
 style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times,
 serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 944.203px; text-align: left; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Change in fair value of derivative liability&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 137px; font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;276,963&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;174,831&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;451,794&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Loss for the period&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;4,048,256&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;174,831&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;4,223,087&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Basic and diluted loss per share&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.11&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.00&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.11&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align:
 left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times,
 serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;" colspan="10"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;As At March 31, 2015&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;"&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;As previously reported&lt;/font&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;"&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Restatement adjustment&lt;/font&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;"&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;As restated&lt;/font&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new
 roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times
 new
 roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Derivative liability&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1,487,137&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1,956,471&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;3,443,608&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Additional paid-in capital&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;17,455,279&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(136,800&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;17,318,479&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;6,138,426&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(6,048,994&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;89,432&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Accumulated deficit&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(22,715,848&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times,
 serif;"&gt;4,229,323&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align:
 left;"&gt;&lt;font
 style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-weight: normal;"&gt;(18,486,525&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;)&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
<us-gaap:ScheduleOfDerivativeInstrumentsTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;div&gt;&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;March 31,&amp;#160;&lt;br /&gt;2016&amp;#160;&lt;br /&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;June 30,&amp;#160;&lt;br /&gt;2015&amp;#160;&lt;br /&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(as restated)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px; width: 1155px; text-align: left; text-indent: 0px; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Opening balance&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2,364,381&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;5,111,007&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Issuance of 2015 Agent Warrants&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;29,594&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Change in fair value of warrants&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;943,050&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(627,433&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Change in fair value due to change in warrant
 terms&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;270,965&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(23,658&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Reclassification to equity upon amendment of warrants&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(2,343,300&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(975,278&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Reclassification to equity upon exchange of warrants&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(728,835&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Reclassification to equity upon exercise of warrants&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(247,440&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(391,422&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Closing balance&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1,017,250&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2,364,381&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
<us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 0px 21.55pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;p style="font: bold 10pt/10.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Shares of common stock&lt;/font&gt;&lt;/p&gt;&lt;p style="font: bold 10pt/10.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;outstanding&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Common stock&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Additional paid-in capital&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;p style="font: bold 10pt/10.5pt 'times new roman', times, serif; margin: 0px 0.1in 0px 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: bold 10pt/10.5pt 'times new roman', times, serif; margin: 0px 0.1in 0px 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: bold 10pt/10.5pt 'times new roman', times, serif; margin: 0px 0.1in 0px 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: bold 10pt/10.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font
 style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px; width: 790px; text-indent: 0px; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;June 30, 2015 &amp;#8211; as previously reported&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 137px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;39,455,931&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;39,456&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;17,500,008&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;6,138,426&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Restatement adjustments&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(136,800&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(6,048,994&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;June 30, 2015 &amp;#8211; as restated&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;39,455,931&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;39,456&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;17,363,208&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;89,432&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times,
 serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Issuance of shares and warrants &amp;#8211; net of issue costs (i)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;4,277,667&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;4,278&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1,198,453&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;671,189&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Reclassification of warrants (ii)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2,343,300&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Exercise of warrants for cash (iii)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;515,500&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;515&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;652,108&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font
 style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Warrants issued for services (iv)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;429,932&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Shares issued for services (v)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;60,000&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;60&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;80,340&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Stock-based compensation&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;138,711&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Reclassification of stock option liability&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times,
 serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;29,747&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px 0px 4pt; text-indent: 0px; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;March 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;44,309,098&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;44,309&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;21,805,867&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1,190,553&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;div&gt;&lt;br class="apple-interchange-newline" /&gt;&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;stock&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;options&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;outstanding&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;exercise&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 15px; text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 1110px; text-align: left; text-indent: 0px; font-weight: bold; vertical-align: top;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;June 30, 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;3,595,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 145px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.94&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; vertical-align: top;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;390,000&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font
 style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1.01&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; vertical-align: top;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(470,000&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1.08&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; vertical-align: top;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Cancelled&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(50,000&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1.05&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-weight: bold; vertical-align: top;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;March 31, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;3,465,000&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.92&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Weighted average exercise price&amp;#160;&lt;br /&gt;$&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Number&amp;#160;&lt;br /&gt;outstanding at&amp;#160;&lt;br /&gt;March 31,&amp;#160;&lt;br /&gt;2016&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Weighted&amp;#160;&lt;br /&gt;average&amp;#160;&lt;br /&gt;remaining&amp;#160;&lt;br /&gt;contractual&amp;#160;&lt;br /&gt;life&amp;#160;&lt;br /&gt;(years)&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Number&amp;#160;&lt;br /&gt;exercisable&amp;#160;&lt;br /&gt;at&amp;#160;&lt;br /&gt;March 31,&amp;#160;&lt;br /&gt;2016&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Weighted average&amp;#160;&lt;br /&gt;exercise&amp;#160;&lt;br /&gt;price&amp;#160;&lt;br /&gt;$&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 283px; text-align: right;"&gt;0.39&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 267px; text-align: right;"&gt;775,000&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 267px; text-align: right;"&gt;5.88&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 266px; text-align: right;"&gt;775,000&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 266px; text-align: right;"&gt;0.39&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.74&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;180,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;8.84&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;180,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.74&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;120,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;9.00&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;120,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.94&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;180,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;9.75&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;15,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.94&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.00&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;140,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;4.92&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;140,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.00&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.05&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,770,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;7.37&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,696,796&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.05&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.12&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;120,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;9.77&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;9,333&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.12&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.54&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;60,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;7.00&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;60,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.54&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;2.30&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;120,000&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;7.17&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;120,000&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;2.30&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;0.92&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;3,465,000&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;3,116,129&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;0.91&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align:
 left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: right; padding: 0px 0px 1.5pt; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;March 31,&lt;/font&gt;&lt;/p&gt;&lt;p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2016&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: right; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1279px; text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Dividend rate&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 194px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Volatility&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;84.8% to 118&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Risk-free rate&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1.00&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Term - years&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.5 to 3.0&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 13px/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt; font-size: 18pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;&lt;p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Three months ended March 31,&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;&lt;p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Nine months ended&lt;/font&gt;&lt;/p&gt;&lt;p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;March 31,&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt; font-size: 18pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2016&lt;/font&gt;&lt;/p&gt;&lt;p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2016&amp;#160;&lt;br /&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td
 style="width:
 761px; text-align: left; text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Research and development&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 137px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;20,165&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;26,853&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;36,395&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;39,909&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -0.3in; padding-bottom: 1.5pt; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;3,678&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;35,995&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;102,316&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;102,262&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: -0.3in; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: -0.3in; padding-bottom: 4pt; padding-left: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td
 style="text-align: left;
 padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;23,843&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;62,848&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;138,711&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;142,171&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
<us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt; font-size: 18pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 18pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Number of&lt;/font&gt;&lt;/p&gt;&lt;p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Options&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;&lt;p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;average&lt;/font&gt;&lt;/p&gt;&lt;p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;exercise&lt;/font&gt;&lt;/p&gt;&lt;p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;price&lt;/font&gt;&lt;/p&gt;&lt;p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;&lt;p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;average&lt;/font&gt;&lt;/p&gt;&lt;p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;grant date&lt;/font&gt;&lt;/p&gt;&lt;p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;fair value&lt;/font&gt;&lt;/p&gt;&lt;p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times,
 serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 866px; text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Unvested at June 30, 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 167px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;722,361&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 167px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.95&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 167px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.41&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;390,000&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1.01&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.73&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Vested&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(481,634&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.91&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.64&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(260,370&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.92&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.24&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Cancelled&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td
 style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(21,486&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1.05&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.57&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold; vertical-align: bottom;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Unvested at March 31, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;348,871&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1.02&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0.55&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br style="font: 13.33px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; clear: both; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;" /&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
<dmpi:ScheduleOfOutstandingWarrantsTableTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-indent: 0px; padding-top: 0px; padding-right: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-left: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Description&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1337px; font-weight: bold; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Balance &amp;#8211; June 30, 2015&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;13,472,870&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2015 Public Offering Warrants (i)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;4,277,667&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2015 Agent Warrants (ii)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;93,908&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Warrants issued for services (iii)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1,060,000&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Warrants exercised for cash (iv)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(515,500&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0px; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-weight: bold; padding: 0px 0px 4pt; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Balance - March 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-weight: bold; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;18,388,945&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;p style="color: #000000;
 font-family: 'times new roman', times, serif; font-size: 10pt;
 font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 13pt; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.6in;"&gt;&lt;/td&gt;&lt;td style="width: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;i)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Issued as part of the Company&amp;#8217;s financing completed in August 2015. Warrants are exercisable at $0.75 until July 31, 2020.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 13pt; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.6in;"&gt;&lt;/td&gt;&lt;td style="width: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;ii)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Issued as part of the Company&amp;#8217;s financing completed in August 2015. The 2015 Agent Warrants are exercisable at a price of $0.75 during the period commencing January 15, 2016 until their expiry on July 15, 2020.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 13pt; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.6in;"&gt;&lt;/td&gt;&lt;td style="width: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;iii)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Warrants have an exercise price of $0.75. Of the total, 60,000 vest in tranches of 20,000 warrants each on November 30, 2015, March 31, 2016, and January 31, 2016 and are exercisable commencing January 1, 2016 until they expire on July 31, 2020. In addition, 500,000 of the warrants vest in tranches of 150,000 on March 1, 2015, and 50,000 on each of March 31, 2016, January 31, 2016, February 29, 2016, March 31, 2016, April 30, 2016, May 31, 2016, and June 30, 2016 until they expire on March 1, 2020. Also, 500,000 of the warrants vest in tranches of 83,333 on each of February 29, 2016, March 31, 2016, April 30, 2016, May 31, 2016, June 30, 2016 and July 31, 2016 until they expire on February 1, 2021.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 13pt; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.6in;"&gt;&lt;/td&gt;&lt;td style="width: 0.3in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;iv)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;515,500 Investor Warrants were exercised for cash at $0.786 per share for proceeds of $405,183.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</dmpi:ScheduleOfOutstandingWarrantsTableTextBlock>
<us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00">&lt;div&gt;&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 18pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;March 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; font-size: 18pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 915.4px; text-align: left; padding-left: 0.6in; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Liability&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 137px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Level 1&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Level 2&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Level 3&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -0.3in; padding-bottom: 1.5pt; padding-left: 0.9in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Derivative liability&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td
 style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1,017,250&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br style="font: 13.33px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; clear: both; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;" /&gt;&lt;p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 18pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="11"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;June 30, 2015&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; font-size: 18pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="11"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(as restated)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; font-size: 18pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 915.4px; text-align: left; padding-left: 0.6in; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Liability&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 137px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Level 1&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Level 2&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 136px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Level 3&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; font-weight:
 bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -0.3in; padding-bottom: 1.5pt; padding-left: 0.9in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Derivative liability&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2,364,381&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
<us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="-5">6100000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD_per_Share" decimals="2">0.05</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember" unitRef="USD_per_Share" decimals="2">0.04</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD_per_Share" decimals="2">0.11</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember" unitRef="USD_per_Share" decimals="2">0.11</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">3595000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">13472870</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">3465000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">18388945</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:PaymentsForSoftware contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">16762</us-gaap:PaymentsForSoftware>
<us-gaap:PaymentsForSoftware contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">29543</us-gaap:PaymentsForSoftware>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_LegalEntityAxis_ValentTechnologiesLlcMember" unitRef="USD" decimals="0">278530</us-gaap:LoansPayableCurrent>
<us-gaap:InterestPayableCurrent contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_LegalEntityAxis_ValentTechnologiesLlcMember" unitRef="USD" decimals="0">28530</us-gaap:InterestPayableCurrent>
<us-gaap:PreferredStockDividendRatePercentage contextRef="Context_Custom_28_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_LegalEntityAxis_ValentTechnologiesLlcMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="pure" decimals="2">0.03</us-gaap:PreferredStockDividendRatePercentage>
<us-gaap:PreferredStockDividendRatePercentage contextRef="Context_Custom_28_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="pure" decimals="2">0.03</us-gaap:PreferredStockDividendRatePercentage>
<us-gaap:PreferredStockDividendRatePercentage contextRef="Context_Custom_29_Apr_2016T00_00_00_TO_12_May_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="pure" decimals="2">0.09</us-gaap:PreferredStockDividendRatePercentage>
<us-gaap:Dividends contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_LegalEntityAxis_ValentTechnologiesLlcMember" unitRef="USD" decimals="0">2089</us-gaap:Dividends>
<us-gaap:Dividends contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_LegalEntityAxis_ValentTechnologiesLlcMember" unitRef="USD" decimals="0">6267</us-gaap:Dividends>
<us-gaap:OfficersCompensation contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OfficerAndDirectorMember_AgreementsAxis_ConsultingAgreementsMember" unitRef="USD" decimals="0">385000</us-gaap:OfficersCompensation>
<us-gaap:OfficersCompensation contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OfficerAndDirectorMember_AgreementsAxis_ConsultingAgreementsMember" unitRef="USD" decimals="0">360000</us-gaap:OfficersCompensation>
<us-gaap:ProfessionalFees contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OfficerAndDirectorMember_AgreementsAxis_ConsultingAgreementsMember" unitRef="USD" decimals="0">77667</us-gaap:ProfessionalFees>
<us-gaap:ProfessionalFees contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OfficerAndDirectorMember_AgreementsAxis_ConsultingAgreementsMember" unitRef="USD" decimals="0">127583</us-gaap:ProfessionalFees>
<dmpi:IssuanceOfAgentWarrants contextRef="Context_FYE_01_Jul_2014T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<dmpi:IssuanceOfAgentWarrants contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">29594</dmpi:IssuanceOfAgentWarrants>
<dmpi:ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants contextRef="Context_FYE_01_Jul_2014T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">-975278</dmpi:ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants>
<dmpi:ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-2343300</dmpi:ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants>
<dmpi:ReclassificationOfDerivativeLiabilityToEquityUponExchangeOfInvestorWarrants contextRef="Context_FYE_01_Jul_2014T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">-728835</dmpi:ReclassificationOfDerivativeLiabilityToEquityUponExchangeOfInvestorWarrants>
<dmpi:ReclassificationOfDerivativeLiabilityToEquityUponExchangeOfInvestorWarrants contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<dmpi:ReverseAcquisitionDescription contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsMember">The Company issued units consisting of one share of common stock and one five-year warrant (the "Investor Warrants") to purchase one share of common stock at an exercise price of $0.80.</dmpi:ReverseAcquisitionDescription>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_24_Jan_2013T00_00_00_TO_24_Jan_2013T00_00_00_DerivativeInstrumentRiskAxis_DividendWarrantsMember" unitRef="USD_per_Share" decimals="2">1.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_06_Mar_2013T00_00_00_TO_06_Mar_2013T00_00_00_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_TwoThousandThirteenPlacementAgentWarrantsMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_06_Mar_2013T00_00_00_TO_06_Mar_2013T00_00_00_RangeAxis_MinimumMember_SubsidiarySaleOfStockAxis_TwoThousandThirteenPlacementAgentWarrantsMember" unitRef="USD_per_Share" decimals="3">0.786</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_12_Sep_2013T00_00_00_TO_12_Sep_2013T00_00_00_DerivativeInstrumentRiskAxis_WarrantsIssuedForServicesMember" unitRef="USD_per_Share" decimals="2">1.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsMember" unitRef="USD_per_Share" decimals="2">0.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="1">0.8</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="3">0.786</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_SubsidiarySaleOfStockAxis_TwoThousandFifteenAgentWarrantMember" unitRef="USD_per_Share" decimals="2">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsMember" unitRef="USD_per_Share" decimals="3">0.786</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_DerivativeInstrumentRiskAxis_TwoZeroOneFiveAgentWarrantsMember" unitRef="USD_per_Share" decimals="2">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings contextRef="Context_Custom_01_Mar_2013T00_00_00_TO_06_Mar_2013T00_00_00_SubsidiarySaleOfStockAxis_TwoThousandThirteenPlacementAgentWarrantsMember" unitRef="USD" decimals="0">13467</us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings>
<us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings contextRef="Context_9ME_01_Apr_2014T00_00_00_TO_31_Dec_2014T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsExchangeMember" unitRef="USD" decimals="0">92843</us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings>
<us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings contextRef="Context_Custom_01_Feb_2015T00_00_00_TO_09_Feb_2015T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsExchangeMember" unitRef="USD" decimals="0">156219</us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings>
<us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings contextRef="Context_Custom_15_Mar_2016T00_00_00_TO_29_Mar_2016T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantAmendmentsMember" unitRef="USD" decimals="0">7000</us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings>
<us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsMember" unitRef="USD" decimals="0">8098</us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings>
<us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_SubsidiarySaleOfStockAxis_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember" unitRef="USD" decimals="0">242400</us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings>
<dmpi:ClassOfWarrantOrRightExercised contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsMember" unitRef="shares" decimals="INF">762227</dmpi:ClassOfWarrantOrRightExercised>
<dmpi:ClassOfWarrantOrRightExercised contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_SubsidiarySaleOfStockAxis_TwoThousandFifteenAgentWarrantMember" unitRef="shares" decimals="INF">93908</dmpi:ClassOfWarrantOrRightExercised>
<dmpi:ClassOfWarrantOrRightExercised contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsMember" unitRef="shares" decimals="INF">515500</dmpi:ClassOfWarrantOrRightExercised>
<dmpi:WarrantsAgentFee contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsMember" unitRef="USD" decimals="0">24772</dmpi:WarrantsAgentFee>
<dmpi:PercentageOfWarrantAgentFee contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsMember" unitRef="pure" decimals="2">0.05</dmpi:PercentageOfWarrantAgentFee>
<dmpi:GrossProceedsFromExerciseOfWarrants contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsMember" unitRef="USD" decimals="0">795501</dmpi:GrossProceedsFromExerciseOfWarrants>
<dmpi:NumberOfCommonStockIssuedUponExerciseOfWarrants contextRef="Context_9ME_01_Apr_2014T00_00_00_TO_31_Dec_2014T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsExchangeMember" unitRef="shares" decimals="INF">414889</dmpi:NumberOfCommonStockIssuedUponExerciseOfWarrants>
<dmpi:NumberOfCommonStockIssuedUponExerciseOfWarrants contextRef="Context_Custom_01_Feb_2015T00_00_00_TO_09_Feb_2015T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsExchangeMember" unitRef="shares" decimals="INF">1591875</dmpi:NumberOfCommonStockIssuedUponExerciseOfWarrants>
<dmpi:NumberOfCommonStockIssuedUponExerciseOfWarrants contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="shares" decimals="INF">1986074</dmpi:NumberOfCommonStockIssuedUponExerciseOfWarrants>
<dmpi:NumberOfCommonStockIssuedUponExerciseOfWarrants contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsMember" unitRef="shares" decimals="INF">1223847</dmpi:NumberOfCommonStockIssuedUponExerciseOfWarrants>
<dmpi:NumberOfCommonStockIssuedUponExerciseOfWarrants contextRef="Context_Custom_02_Jul_2015T00_00_00_TO_15_Jul_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">4277667</dmpi:NumberOfCommonStockIssuedUponExerciseOfWarrants>
<dmpi:NumberOfCommonStockIssuedUponExerciseOfWarrants contextRef="Context_Custom_02_Jul_2015T00_00_00_TO_15_Jul_2015T00_00_00_DerivativeInstrumentRiskAxis_TwoZeroOneFiveOfferingWarrantsMember" unitRef="shares" decimals="INF">4277667</dmpi:NumberOfCommonStockIssuedUponExerciseOfWarrants>
<dmpi:NumberOfCommonStockIssuedUponExerciseOfWarrants contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_SubsidiarySaleOfStockAxis_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember" unitRef="shares" decimals="INF">5050000</dmpi:NumberOfCommonStockIssuedUponExerciseOfWarrants>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_Custom_02_Jul_2015T00_00_00_TO_15_Jul_2015T00_00_00_DerivativeInstrumentRiskAxis_TwoZeroOneFiveOfferingWarrantsMember">2020-07-31</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_Custom_15_Mar_2016T00_00_00_TO_29_Mar_2016T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantAmendmentsMember">2019-03-31</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantExercisesMember">2021-02-01</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_SubsidiarySaleOfStockAxis_TwoThousandFifteenAgentWarrantMember">2020-07-15</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_DerivativeInstrumentRiskAxis_TwoZeroOneFiveAgentWarrantsMember">2020-07-15</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheOneMember">2020-07-31</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheTwoMember">2020-07-31</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheThreeMember">2020-07-31</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_SubsidiarySaleOfStockAxis_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember">2019-06-30</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheFourMember">2020-03-01</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_VestingAxis_ShareBasedCompensationAwardTrancheTwoMember">2020-03-01</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_VestingAxis_ShareBasedCompensationAwardTrancheThreeMember">2020-03-01</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_VestingAxis_ShareBasedCompensationAwardTrancheFiveMember">2020-03-01</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_VestingAxis_ShareBasedCompensationAwardTrancheSixMember">2020-03-01</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_VestingAxis_ShareBasedCompensationAwardTrancheSevenMember">2020-03-01</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_VestingAxis_ShareBasedCompensationAwardTrancheEightMember">2020-03-01</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_VestingAxis_ShareBasedCompensationAwardTrancheNineMember">2020-03-01</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheFiveMember">2021-02-01</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheSixMember">2021-02-01</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheSevenMember">2021-02-01</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheEightMember">2021-02-01</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheNineMember">2021-02-01</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheTenMember">2021-02-01</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_Custom_01_May_2016T00_00_00_TO_12_May_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_WarrantMember">2021-05-12</invest:InvestmentWarrantsExpirationDate>
<us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="Context_Custom_15_Mar_2016T00_00_00_TO_29_Mar_2016T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantAmendmentsMember" unitRef="USD" decimals="0">58750</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
<us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_SubsidiarySaleOfStockAxis_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember" unitRef="USD" decimals="0">2035150</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
<dmpi:TermOfWarrants contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_12_Sep_2013T00_00_00_DerivativeInstrumentRiskAxis_WarrantsIssuedForServicesMember">P5Y</dmpi:TermOfWarrants>
<dmpi:ClassOfWarrantOrRightIssued contextRef="Context_Custom_01_Jan_2013T00_00_00_TO_24_Jan_2013T00_00_00_DerivativeInstrumentRiskAxis_DividendWarrantsMember" unitRef="shares" decimals="INF">3250007</dmpi:ClassOfWarrantOrRightIssued>
<dmpi:ClassOfWarrantOrRightIssued contextRef="Context_Custom_01_Mar_2013T00_00_00_TO_06_Mar_2013T00_00_00_SubsidiarySaleOfStockAxis_TwoThousandThirteenPlacementAgentWarrantsMember" unitRef="shares" decimals="INF">5250000</dmpi:ClassOfWarrantOrRightIssued>
<dmpi:ClassOfWarrantOrRightIssued contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_12_Sep_2013T00_00_00_DerivativeInstrumentRiskAxis_WarrantsIssuedForServicesMember" unitRef="shares" decimals="INF">300000</dmpi:ClassOfWarrantOrRightIssued>
<dmpi:ClassOfWarrantOrRightIssued contextRef="Context_9ME_01_Apr_2014T00_00_00_TO_31_Dec_2014T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsExchangeMember" unitRef="shares" decimals="INF">1244666</dmpi:ClassOfWarrantOrRightIssued>
<dmpi:ClassOfWarrantOrRightIssued contextRef="Context_Custom_01_Feb_2015T00_00_00_TO_09_Feb_2015T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsExchangeMember" unitRef="shares" decimals="INF">530625</dmpi:ClassOfWarrantOrRightIssued>
<dmpi:ClassOfWarrantOrRightIssued contextRef="Context_Custom_15_Mar_2016T00_00_00_TO_29_Mar_2016T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantAmendmentsMember" unitRef="shares" decimals="INF">250000</dmpi:ClassOfWarrantOrRightIssued>
<dmpi:ReclassificationOfDerivativeLiabilityUponTheExchangeOfInvestorWarrants contextRef="Context_9ME_01_Apr_2014T00_00_00_TO_31_Dec_2014T00_00_00_DerivativeInstrumentRiskAxis_InvestorWarrantsExchangeMember" unitRef="USD" decimals="0">305112</dmpi:ReclassificationOfDerivativeLiabilityUponTheExchangeOfInvestorWarrants>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">39455931</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember" unitRef="shares" decimals="INF">39455931</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">44309098</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMember" unitRef="shares" decimals="INF">39455931</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMember" unitRef="shares" decimals="INF">39455931</us-gaap:SharesOutstanding>
<dmpi:StockIssuedDuringPeriodSharesAndWarrantsValue contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0" id="Footnote-2_1">671189</dmpi:StockIssuedDuringPeriodSharesAndWarrantsValue>
<dmpi:StockIssuedDuringPeriodSharesAndWarrantsValue contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Footnote-2_2">4278</dmpi:StockIssuedDuringPeriodSharesAndWarrantsValue>
<dmpi:StockIssuedDuringPeriodSharesAndWarrantsValue contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Footnote-2_3">1198453</dmpi:StockIssuedDuringPeriodSharesAndWarrantsValue>
<dmpi:StockIssuedDuringPeriodSharesAndWarrantsShares contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Footnote-2_4">4277667</dmpi:StockIssuedDuringPeriodSharesAndWarrantsShares>
<dmpi:StockIssuedDuringPeriodValueReclassificationOfWarrants contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" xsi:nil="true" id="Footnote-3_1"/>
<dmpi:StockIssuedDuringPeriodValueReclassificationOfWarrants contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true" id="Footnote-3_2"/>
<dmpi:StockIssuedDuringPeriodValueReclassificationOfWarrants contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Footnote-3_3">2343300</dmpi:StockIssuedDuringPeriodValueReclassificationOfWarrants>
<dmpi:StockIssuedDuringPeriodValueStockWarrantExercised contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" xsi:nil="true" id="Footnote-4_1"/>
<dmpi:StockIssuedDuringPeriodValueStockWarrantExercised contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Footnote-4_2">515</dmpi:StockIssuedDuringPeriodValueStockWarrantExercised>
<dmpi:StockIssuedDuringPeriodValueStockWarrantExercised contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Footnote-4_3">652108</dmpi:StockIssuedDuringPeriodValueStockWarrantExercised>
<dmpi:StockIssuedDuringPeriodSharesStockWarrantExercised contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="shares" decimals="INF" id="Footnote-5_1">515500</dmpi:StockIssuedDuringPeriodSharesStockWarrantExercised>
<dmpi:StockIssuedDuringPeriodSharesStockWarrantExercised contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Footnote-4_4">515500</dmpi:StockIssuedDuringPeriodSharesStockWarrantExercised>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" xsi:nil="true" id="Footnote-6_1"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Footnote-6_2">60</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Footnote-6_3">80340</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Footnote-6_4">60000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">142447</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">138711</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">3595000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">3465000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointThreeNineMember" unitRef="shares" decimals="INF">775000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointSevenFourMember" unitRef="shares" decimals="INF">180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointEightZeroMember" unitRef="shares" decimals="INF">120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointNineFourMember" unitRef="shares" decimals="INF">180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnePointZeroZeroMember" unitRef="shares" decimals="INF">140000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnepointzerofiveMember" unitRef="shares" decimals="INF">1770000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnePointOneTwoMember" unitRef="shares" decimals="INF">120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnePointFiveFourMember" unitRef="shares" decimals="INF">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_TwoPointThreeZeroMember" unitRef="shares" decimals="INF">120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointNineTwoMember" unitRef="shares" decimals="INF">3465000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="shares" decimals="INF">390000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">390000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_10_Apr_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">320000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">470000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_10_Apr_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">270000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<dmpi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="shares" decimals="INF">-21486</dmpi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross>
<dmpi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">-50000</dmpi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="CAD_per_Share" decimals="2">0.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">1.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">1.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<dmpi:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">1.05</dmpi:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointThreeNineMember">P5Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointSevenFourMember">P8Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointEightZeroMember">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointNineFourMember">P9Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnePointZeroZeroMember">P4Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnepointzerofiveMember">P7Y4M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnePointOneTwoMember">P9Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnePointFiveFourMember">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_TwoPointThreeZeroMember">P7Y2M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointThreeNineMember" unitRef="shares" decimals="INF">775000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointSevenFourMember" unitRef="shares" decimals="INF">180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointEightZeroMember" unitRef="shares" decimals="INF">120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointNineFourMember" unitRef="shares" decimals="INF">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnePointZeroZeroMember" unitRef="shares" decimals="INF">140000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnepointzerofiveMember" unitRef="shares" decimals="INF">1696796</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnePointOneTwoMember" unitRef="shares" decimals="INF">9333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnePointFiveFourMember" unitRef="shares" decimals="INF">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_TwoPointThreeZeroMember" unitRef="shares" decimals="INF">120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointNineTwoMember" unitRef="shares" decimals="INF">3116129</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointThreeNineMember" unitRef="USD_per_Share" decimals="2">0.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointSevenFourMember" unitRef="USD_per_Share" decimals="2">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointEightZeroMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointNineFourMember" unitRef="USD_per_Share" decimals="2">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnePointZeroZeroMember" unitRef="USD_per_Share" decimals="2">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnepointzerofiveMember" unitRef="USD_per_Share" decimals="2">1.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnePointOneTwoMember" unitRef="USD_per_Share" decimals="2">1.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnePointFiveFourMember" unitRef="USD_per_Share" decimals="2">1.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_TwoPointThreeZeroMember" unitRef="USD_per_Share" decimals="2">2.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointNineTwoMember" unitRef="USD_per_Share" decimals="2">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="pure" decimals="3">0.848</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="pure" decimals="2">1.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="4">0.0100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">62848</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">26853</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">35995</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">142171</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">39909</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">102262</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">23843</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">20165</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">3678</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">138711</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">36395</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">102316</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="shares" decimals="INF">722361</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="shares" decimals="INF">348871</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="shares" decimals="INF">481634</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="shares" decimals="INF">260370</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
<dmpi:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD_per_Share" decimals="2">0.95</dmpi:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice>
<dmpi:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD_per_Share" decimals="2">1.02</dmpi:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice>
<dmpi:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD_per_Share" decimals="2">1.01</dmpi:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice>
<dmpi:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.91</dmpi:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice>
<dmpi:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.92</dmpi:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice>
<dmpi:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsCancelledWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD_per_Share" decimals="2">1.05</dmpi:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsCancelledWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD_per_Share" decimals="2">0.41</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.55</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.64</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.24</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
<dmpi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageGrantDateFairValue contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.57</dmpi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="shares" decimals="INF">13472870</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="shares" decimals="INF">18388945</us-gaap:ClassOfWarrantOrRightOutstanding>
<dmpi:NumberOfOfferingWarrants contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="shares" decimals="INF" id="Footnote-7_1">4277667</dmpi:NumberOfOfferingWarrants>
<dmpi:NumberOfWarrantsIssuedToAgents contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="shares" decimals="INF" id="Footnote-8_1">93908</dmpi:NumberOfWarrantsIssuedToAgents>
<dmpi:NumberOfWarrantsIssuedForServices contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="shares" decimals="INF" id="Footnote-9_1">1060000</dmpi:NumberOfWarrantsIssuedForServices>
<dmpi:StockIssuedAndOutstandingOnExchangedBasis contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="shares" decimals="INF">4056042</dmpi:StockIssuedAndOutstandingOnExchangedBasis>
<dmpi:StockOptionExpense contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">142171</dmpi:StockOptionExpense>
<dmpi:StockOptionExpense contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">138711</dmpi:StockOptionExpense>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">345131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">396538</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">333139</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">396538</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">93016</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
<invest:InvestmentWarrantsExercisePrice contextRef="Context_Custom_02_Jul_2015T00_00_00_TO_15_Jul_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="3">0.001</invest:InvestmentWarrantsExercisePrice>
<invest:InvestmentWarrantsExercisePrice contextRef="Context_Custom_02_Jul_2015T00_00_00_TO_15_Jul_2015T00_00_00_DerivativeInstrumentRiskAxis_TwoZeroOneFiveOfferingWarrantsMember" unitRef="USD_per_Share" decimals="2">0.75</invest:InvestmentWarrantsExercisePrice>
<invest:InvestmentWarrantsExercisePrice contextRef="Context_Custom_01_May_2016T00_00_00_TO_12_May_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.00</invest:InvestmentWarrantsExercisePrice>
<us-gaap:SaleOfStockDescriptionOfTransaction contextRef="Context_Custom_02_Jul_2015T00_00_00_TO_15_Jul_2015T00_00_00_DerivativeInstrumentRiskAxis_TwoZeroOneFiveOfferingWarrantsMember">The Company agreed to pay up to a 7% cash commission and issue warrants to purchase shares of common stock (the "2015 Agent Warrants") up to the number of shares of our common stock equal to 5% of the aggregate number of shares sold in the Offering by such placement agents.</us-gaap:SaleOfStockDescriptionOfTransaction>
<dmpi:CashCommission contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_DerivativeInstrumentRiskAxis_TwoZeroOneFiveAgentWarrantsMember" unitRef="USD" decimals="0">80575</dmpi:CashCommission>
<us-gaap:PaymentsOfDerivativeIssuanceCosts contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">582511</us-gaap:PaymentsOfDerivativeIssuanceCosts>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_Custom_02_Jul_2015T00_00_00_TO_15_Jul_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">2566660</us-gaap:ProceedsFromIssuanceOfWarrants>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">1903514</us-gaap:ProceedsFromIssuanceOfWarrants>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">405183</us-gaap:ProceedsFromIssuanceOfWarrants>
<dmpi:NoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_DerivativeInstrumentRiskAxis_TwoZeroOneFiveAgentWarrantsMember" unitRef="USD" decimals="0">29594</dmpi:NoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="shares" decimals="0">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="0">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheOneMember" unitRef="shares" decimals="INF">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheTwoMember" unitRef="shares" decimals="INF">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheThreeMember" unitRef="shares" decimals="INF">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheFourMember" unitRef="shares" decimals="0">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_VestingAxis_ShareBasedCompensationAwardTrancheTwoMember" unitRef="shares" decimals="0">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_VestingAxis_ShareBasedCompensationAwardTrancheThreeMember" unitRef="shares" decimals="0">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_VestingAxis_ShareBasedCompensationAwardTrancheFiveMember" unitRef="shares" decimals="0">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_VestingAxis_ShareBasedCompensationAwardTrancheSixMember" unitRef="shares" decimals="0">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_VestingAxis_ShareBasedCompensationAwardTrancheSevenMember" unitRef="shares" decimals="0">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_VestingAxis_ShareBasedCompensationAwardTrancheEightMember" unitRef="shares" decimals="0">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_VestingAxis_ShareBasedCompensationAwardTrancheNineMember" unitRef="shares" decimals="0">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheFiveMember" unitRef="shares" decimals="INF">83333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheSixMember" unitRef="shares" decimals="INF">83333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheSevenMember" unitRef="shares" decimals="INF">83333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheEightMember" unitRef="shares" decimals="INF">83333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheNineMember" unitRef="shares" decimals="INF">83333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_VestingAxis_ShareBasedCompensationAwardTrancheTenMember" unitRef="shares" decimals="INF">83333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<dmpi:ReductionInStockOptionLiability contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">276</dmpi:ReductionInStockOptionLiability>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" decimals="0">2364381</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" decimals="0">1017250</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="Context_Custom_29_Apr_2016T00_00_00_TO_12_May_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" decimals="-5">6100000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="Context_As_Of_12_May_2016T00_00_00_TO_12_May_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">8.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
<us-gaap:ConversionOfStockDescription contextRef="Context_Custom_29_Apr_2016T00_00_00_TO_12_May_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementClassOfStockAxis_SeriesBPreferredStockMember">Each share of Series B Preferred Stock is convertible into ten shares of common stock equating to a conversion price of $0.80 (the "Conversion Price") and will automatically convert to common stock at the earlier of 24 hours following regulatory approval of VAL-083 with a minimum closing bid price of $2 or five years from the final closing dates.</us-gaap:ConversionOfStockDescription>
<dmpi:EngagementAgreementPrivatePlacementDescription contextRef="Context_9ME_01_Jul_2014T00_00_00_TO_31_Mar_2015T00_00_00">The Company engaged certain placement agents for the sale of a portion of the Series B Preferred Stock. Under the Company's engagement agreements with these placement agents, the Company agreed to pay up to an 8% cash commission and issue warrants to purchase shares of common stock (the "2016 Agent Warrants") up to the number of shares of our common stock equal to 8% of the aggregate number of shares underlying the Series B Preferred Stock sold in the offering by such placement agents.</dmpi:EngagementAgreementPrivatePlacementDescription>
<us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1 contextRef="Context_Custom_01_May_2016T00_00_00_TO_12_May_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">356050</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
<us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1 contextRef="Context_Custom_01_May_2016T00_00_00_TO_12_May_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_InvestorWarrantAmendmentsMember" unitRef="shares" decimals="INF">1970238</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
<dmpi:CommissionPaidInLeiuOfIssuanceOfWarrants contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">340000</dmpi:CommissionPaidInLeiuOfIssuanceOfWarrants>
<dmpi:CommissionPaidInLeiuOfIssuanceOfWarrants contextRef="Context_Custom_01_May_2016T00_00_00_TO_12_May_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">283000</dmpi:CommissionPaidInLeiuOfIssuanceOfWarrants>
<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="-5">5500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
<dmpi:DerivativeLiabilityEquityIssuanceReclassified contextRef="Context_Custom_01_May_2016T00_00_00_TO_12_May_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_InvestorWarrantAmendmentsMember" unitRef="USD" decimals="0">500000</dmpi:DerivativeLiabilityEquityIssuanceReclassified>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointThreeNineMember" unitRef="USD_per_Share" decimals="2">0.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointSevenFourMember" unitRef="USD_per_Share" decimals="2">0.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointEightZeroMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ZeroPointNineFourMember" unitRef="USD_per_Share" decimals="2">0.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnePointZeroZeroMember" unitRef="USD_per_Share" decimals="2">1.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnepointzerofiveMember" unitRef="USD_per_Share" decimals="2">1.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnePointOneTwoMember" unitRef="USD_per_Share" decimals="2">1.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OnePointFiveFourMember" unitRef="USD_per_Share" decimals="2">1.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2015T00_00_00_TO_31_Mar_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_TwoPointThreeZeroMember" unitRef="USD_per_Share" decimals="2">2.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<link:loc xlink:type="locator" xlink:href="#Footnote-1_1" xlink:label="lab_Footnote-1_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-1_2" xlink:label="lab_Footnote-1_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-1_3" xlink:label="lab_Footnote-1_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_3"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_1" xlink:label="lab_Footnote-2_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_2" xlink:label="lab_Footnote-2_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_3" xlink:label="lab_Footnote-2_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_3"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_4" xlink:label="lab_Footnote-2_4"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_4"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-3_1" xlink:label="lab_Footnote-3_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-3" xlink:from="lab_Footnote-3_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-3_2" xlink:label="lab_Footnote-3_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-3" xlink:from="lab_Footnote-3_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-3_3" xlink:label="lab_Footnote-3_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-3" xlink:from="lab_Footnote-3_3"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-4_1" xlink:label="lab_Footnote-4_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-4" xlink:from="lab_Footnote-4_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-4_2" xlink:label="lab_Footnote-4_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-4" xlink:from="lab_Footnote-4_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-4_3" xlink:label="lab_Footnote-4_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-4" xlink:from="lab_Footnote-4_3"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-5_1" xlink:label="lab_Footnote-5_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-5" xlink:from="lab_Footnote-5_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-4_4" xlink:label="lab_Footnote-4_4"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-4" xlink:from="lab_Footnote-4_4"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-6_1" xlink:label="lab_Footnote-6_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-6" xlink:from="lab_Footnote-6_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-6_2" xlink:label="lab_Footnote-6_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-6" xlink:from="lab_Footnote-6_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-6_3" xlink:label="lab_Footnote-6_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-6" xlink:from="lab_Footnote-6_3"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-6_4" xlink:label="lab_Footnote-6_4"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-6" xlink:from="lab_Footnote-6_4"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-7_1" xlink:label="lab_Footnote-7_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-7" xlink:from="lab_Footnote-7_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-8_1" xlink:label="lab_Footnote-8_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-8" xlink:from="lab_Footnote-8_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-9_1" xlink:label="lab_Footnote-9_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-9" xlink:from="lab_Footnote-9_1"/>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-1">During the period ended March 31, 2016, the Company issued 1,060,000 warrants for services. All warrants have an exercise price of $0.75. Of these warrants, 60,000 expire on July 31, 2020, 500,000 expire March 1, 2020, and 500,000 expire February 1, 2021.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-2">On July 15, 2015 the Company's Registration Statement on Form S-1 relating to a public offering by the Company of common stock and common stock purchase warrants (the "Offering") was declared effective by the Securities and Exchange Commission. Pursuant to the Offering, the Company issued 4,277,667 shares of common stock at $0.60 per share and 4,277,667 warrants (the "2015 Offering Warrants") to purchase shares of common stock at $0.001 per warrant for total gross proceeds of $2,566,660. The 2015 Offering Warrants are exercisable at $0.75 per share for a period of five years until they expire on July 31, 2020. The Company engaged certain placement agents for the sale of a portion of the shares and 2015 Offering Warrants. Under the Company's engagement agreements with these placement agents, the Company agreed to pay up to a 7% cash commission and issue warrants to purchase shares of common stock (the "2015 Agent Warrants") up to the number of shares of our common stock equal to 5% of the aggregate number of shares sold in the Offering by such placement agents. Pursuant to the placement agent agreements the Company paid a total cash commission of $80,575 and issued 93,908 2015 Agent Warrants (note 6). The 2015 Agent Warrants are exercisable at a per share price equal to $0.75 during the five-year period commencing six months from the effective date of the Offering, which period shall not extend further than five years from the effective date of the 2015 Offering. Therefore, all 2015 Agent Warrants expire on July 15, 2020. In addition to the cash commission of $80,575 the Company also incurred additional cash issue and closing costs of $582,511 (including costs deferred at June 30, 2015 of $550,119) resulting in net cash proceeds of $1,903,514. The 2015 Agent Warrants have been recognized as non-cash issue costs of $29,594.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-3">Upon the amendment of the Investor Warrants and the 2013 Placement Agent Warrants, the Company reclassified the related derivative liability to equity (note 6).</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-4">During the period ended March 31, 2016, 515,500 Investor Warrants were exercised for proceeds of $405,183 (note 6).</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-5">515,500 Investor Warrants were exercised for cash at $0.786 per share for proceeds of $405,183.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-6">During the period ended March 31, 2016, the Company issued 60,000 shares of common stock for services.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-7">Issued as part of the Company's financing completed in August 2015. Warrants are exercisable at $0.75 until July 31, 2020.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-8">Issued as part of the Company's financing completed in August 2015. The 2015 Agent Warrants are exercisable at a price of $0.75 during the period commencing January 15, 2016 until their expiry on July 15, 2020.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-9">Warrants have an exercise price of $0.75. Of the total, 60,000 vest in tranches of 20,000 warrants each on November 30, 2015, March 31, 2016, and January 31, 2016 and are exercisable commencing January 1, 2016 until they expire on July 31, 2020. In addition, 500,000 of the warrants vest in tranches of 150,000 on March 1, 2015, and 50,000 on each of March 31, 2016, January 31, 2016, February 29, 2016, March 31, 2016, April 30, 2016, May 31, 2016, and June 30, 2016 until they expire on March 1, 2020. Also, 500,000 of the warrants vest in tranches of 83,333 on each of February 29, 2016, March 31, 2016, April 30, 2016, May 31, 2016, June 30, 2016 and July 31, 2016 until they expire on February 1, 2021.</link:footnote>
</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>dmpi-20160331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Thursday, May 12, 2016 11:32:27 PM -->
<schema targetNamespace="http://www.delmarpharma.com/20160331" elementFormDefault="qualified" xmlns:dmpi="http://www.delmarpharma.com/20160331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
<annotation><appinfo>
<link:roleType roleURI="http://www.delmarpharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/ConsolidatedCondensedInterimBalanceSheetsUnaudited" id="ConsolidatedCondensedInterimBalanceSheetsUnaudited">
<link:definition>002 - Statement - Consolidated Condensed Interim Balance Sheets (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/Consolidatedcondensedinterimbalancesheetsunauditedparenthetical" id="Consolidatedcondensedinterimbalancesheetsunauditedparenthetical">
<link:definition>003 - Statement - Consolidated Condensed Interim Balance Sheets (Unaudited) (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/ConsolidatedcondensedinterimstatementoflossandcomprehensivelossUnaudited" id="ConsolidatedcondensedinterimstatementoflossandcomprehensivelossUnaudited">
<link:definition>004 - Statement - Consolidated Condensed Interim Statement of Loss and Comprehensive Loss (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/ConsolidatedCondensedInterimStatementOfCashFlowsUnaudited" id="ConsolidatedCondensedInterimStatementOfCashFlowsUnaudited">
<link:definition>005 - Statement - Consolidated Condensed Interim Statement of Cash Flows (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/NatureOfOperationsAndLiquidityRisk" id="NatureOfOperationsAndLiquidityRisk">
<link:definition>006 - Disclosure - Nature of Operations and Liquidity Risk</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/Restatementofpreviouslyissuedfinancialstatements" id="Restatementofpreviouslyissuedfinancialstatements">
<link:definition>007 - Disclosure - Restatement of Previously Issued Financial Statements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
<link:definition>008 - Disclosure - Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/ValentTechnologiesLlc" id="ValentTechnologiesLlc">
<link:definition>009 - Disclosure - Valent Technologies, LLC</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>010 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/DerivativeLiability" id="DerivativeLiability">
<link:definition>011 - Disclosure - Derivative Liability</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/Stockholdersequity" id="Stockholdersequity">
<link:definition>012 - Disclosure - Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/Financialinstruments" id="Financialinstruments">
<link:definition>013 - Disclosure - Financial instruments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>014 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
<link:definition>015 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/Restatementofpreviouslyissuedfinancialstatementstables" id="Restatementofpreviouslyissuedfinancialstatementstables">
<link:definition>016 - Disclosure - Restatement of Previously Issued Financial Statements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/DerivativeliabilityTables" id="DerivativeliabilityTables">
<link:definition>017 - Disclosure - Derivative Liability (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/Stockholdersequitytables" id="Stockholdersequitytables">
<link:definition>018 - Disclosure - Stockholders' Equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/Financialinstrumentstables" id="Financialinstrumentstables">
<link:definition>019 - Disclosure - Financial instruments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/NatureOfOperationsAndLiquidityRiskDetailsTextual" id="NatureOfOperationsAndLiquidityRiskDetailsTextual">
<link:definition>020 - Disclosure - Nature of Operations and Liquidity Risk (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails" id="RestatementOfPreviouslyIssuedFinancialStatementsDetails">
<link:definition>021 - Disclosure - Restatement of Previously Issued Financial Statements (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/Significantaccountingpoliciesdetails" id="Significantaccountingpoliciesdetails">
<link:definition>022 - Disclosure - Significant Accounting Policies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/ValentTechnologiesLlcDetails" id="ValentTechnologiesLlcDetails">
<link:definition>023 - Disclosure - Valent Technologies LLC (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
<link:definition>024 - Disclosure - Related Party Transactions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/DerivativeLiabilityDetails" id="DerivativeLiabilityDetails">
<link:definition>025 - Disclosure - Derivative Liability (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/DerivativeLiabilityDetailsTextual" id="DerivativeLiabilityDetailsTextual">
<link:definition>026 - Disclosure - Derivative Liability (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/Stockholdersequitydetails" id="Stockholdersequitydetails">
<link:definition>027 - Disclosure - Stockholders' Equity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/Stockholdersequitydetails1" id="Stockholdersequitydetails1">
<link:definition>028 - Disclosure - Stockholders' Equity (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/Stockholdersequitydetails2" id="Stockholdersequitydetails2">
<link:definition>029 - Disclosure - Stockholders' Equity (Details 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/Stockholdersequitydetails3" id="Stockholdersequitydetails3">
<link:definition>030 - Disclosure - Stockholders' Equity (Details 3)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/Stockholdersequitydetails4" id="Stockholdersequitydetails4">
<link:definition>031 - Disclosure - Stockholders' Equity (Details 4)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/Stockholdersequitydetails5" id="Stockholdersequitydetails5">
<link:definition>032 - Disclosure - Stockholders' Equity (Details 5)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/Stockholdersequitydetails6" id="Stockholdersequitydetails6">
<link:definition>033 - Disclosure - Stockholders' Equity (Details 6)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/StockholdersEquityDetailsTextual" id="StockholdersEquityDetailsTextual">
<link:definition>034 - Disclosure - Stockholders' Equity (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/StockholdersEquityDetailsTextual1" id="StockholdersEquityDetailsTextual1">
<link:definition>035 - Disclosure - Stockholders' Equity (Details Textual 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/Financialinstrumentsdetails" id="Financialinstrumentsdetails">
<link:definition>036 - Disclosure - Financial instruments (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.delmarpharma.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
<link:definition>037 - Disclosure - Subsequent Events (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="dmpi-20160331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="dmpi-20160331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="dmpi-20160331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="dmpi-20160331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="dmpi_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TaxesAndOtherReceivablesCurrent" id="dmpi_TaxesAndOtherReceivablesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockOptionLiabilityNoncurrent" id="dmpi_StockOptionLiabilityNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="VotingShare" id="dmpi_VotingShare" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PreferredStockSpecialVotingSharesIssued" id="dmpi_PreferredStockSpecialVotingSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" id="dmpi_GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GainLossOnExchangeOfWarrants" id="dmpi_GainLossOnExchangeOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" id="dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfStockForServices" id="dmpi_IssuanceOfStockForServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NetIncomeLossAfterAdjustmentsOfNonCashItems" id="dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncreaseDecreaseInTaxesAndOtherReceivables" id="dmpi_IncreaseDecreaseInTaxesAndOtherReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProceedsFromIssuanceOfSharesAndWarrants" id="dmpi_ProceedsFromIssuanceOfSharesAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfPreferredSharesForTheSettlementOfTheLoanPayable" id="dmpi_IssuanceOfPreferredSharesForTheSettlementOfTheLoanPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants" id="dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants" id="dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions" id="dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DeferredCostsRecognizedAsEquityIssueCosts" id="dmpi_DeferredCostsRecognizedAsEquityIssueCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ValentTechnologiesLlcAbstract" id="dmpi_ValentTechnologiesLlcAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ValentTechnologiesLlcTextBlock" id="dmpi_ValentTechnologiesLlcTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UnauditedInterimFinancialDataPolicyTextBlock" id="dmpi_UnauditedInterimFinancialDataPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ScheduleOfOutstandingWarrantsTableTextBlock" id="dmpi_ScheduleOfOutstandingWarrantsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NatureOfOperationsAndLiquidityRiskTextualAbstract" id="dmpi_NatureOfOperationsAndLiquidityRiskTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SignificantAccountingPoliciesTextualAbstract" id="dmpi_SignificantAccountingPoliciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AgreementTable" id="dmpi_AgreementTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="ValentTechnologiesLlcMember" id="dmpi_ValentTechnologiesLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AgreementsLineItems" id="dmpi_AgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OfficerAndDirectorMember" id="dmpi_OfficerAndDirectorMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AgreementsAxis" id="dmpi_AgreementsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="AgreementsDomain" id="dmpi_AgreementsDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConsultingAgreementsMember" id="dmpi_ConsultingAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RelatedPartyTransactionsTextualsAbstract" id="dmpi_RelatedPartyTransactionsTextualsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ScheduleOfDerivativeLiabilitiesRollForward" id="dmpi_ScheduleOfDerivativeLiabilitiesRollForward" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfAgentWarrants" id="dmpi_IssuanceOfAgentWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants" id="dmpi_ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ReclassificationOfDerivativeLiabilityToEquityUponExchangeOfInvestorWarrants" id="dmpi_ReclassificationOfDerivativeLiabilityToEquityUponExchangeOfInvestorWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="InvestorWarrantsMember" id="dmpi_InvestorWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="InvestorWarrantExercisesMember" id="dmpi_InvestorWarrantExercisesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsIssuedForServicesMember" id="dmpi_WarrantsIssuedForServicesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="InvestorWarrantsExchangeMember" id="dmpi_InvestorWarrantsExchangeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="InvestorWarrantAmendmentsMember" id="dmpi_InvestorWarrantAmendmentsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DividendWarrantsMember" id="dmpi_DividendWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoThousandFifteenAgentWarrantMember" id="dmpi_TwoThousandFifteenAgentWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoThousandThirteenPlacementAgentWarrantsMember" id="dmpi_TwoThousandThirteenPlacementAgentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember" id="dmpi_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ReverseAcquisitionDescription" id="dmpi_ReverseAcquisitionDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClassOfWarrantOrRightExercised" id="dmpi_ClassOfWarrantOrRightExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsAgentFee" id="dmpi_WarrantsAgentFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfWarrantAgentFee" id="dmpi_PercentageOfWarrantAgentFee" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GrossProceedsFromExerciseOfWarrants" id="dmpi_GrossProceedsFromExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfCommonStockIssuedUponExerciseOfWarrants" id="dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantOutstanding" id="dmpi_WarrantOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TermOfWarrants" id="dmpi_TermOfWarrants" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClassOfWarrantOrRightIssued" id="dmpi_ClassOfWarrantOrRightIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ReclassificationOfDerivativeLiabilityUponTheExchangeOfInvestorWarrants" id="dmpi_ReclassificationOfDerivativeLiabilityUponTheExchangeOfInvestorWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ScheduleOfCommonStockIssuedAndOutstandingTable" id="dmpi_ScheduleOfCommonStockIssuedAndOutstandingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="ScheduleOfCommonStockIssuedAndOutstandingLineItems" id="dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodSharesAndWarrantsValue" id="dmpi_StockIssuedDuringPeriodSharesAndWarrantsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodSharesAndWarrantsShares" id="dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodValueReclassificationOfWarrants" id="dmpi_StockIssuedDuringPeriodValueReclassificationOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodValueStockWarrantExercised" id="dmpi_StockIssuedDuringPeriodValueStockWarrantExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodSharesStockWarrantExercised" id="dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross" id="dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" id="dmpi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ZeroPointThreeNineMember" id="dmpi_ZeroPointThreeNineMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ZeroPointSevenFourMember" id="dmpi_ZeroPointSevenFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ZeroPointEightZeroMember" id="dmpi_ZeroPointEightZeroMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ZeroPointNineFourMember" id="dmpi_ZeroPointNineFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OnePointZeroZeroMember" id="dmpi_OnePointZeroZeroMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OnepointzerofiveMember" id="dmpi_OnepointzerofiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OnePointOneTwoMember" id="dmpi_OnePointOneTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OnePointFiveFourMember" id="dmpi_OnePointFiveFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoPointThreeZeroMember" id="dmpi_TwoPointThreeZeroMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ZeroPointNineTwoMember" id="dmpi_ZeroPointNineTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward" id="dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice" id="dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice" id="dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice" id="dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice" id="dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsCancelledWeightedAverageExercisePrice" id="dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsCancelledWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" id="dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfWarrantsRollForward" id="dmpi_NumberOfWarrantsRollForward" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfOfferingWarrants" id="dmpi_NumberOfOfferingWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfWarrantsIssuedToAgents" id="dmpi_NumberOfWarrantsIssuedToAgents" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfWarrantsIssuedForServices" id="dmpi_NumberOfWarrantsIssuedForServices" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockholdersEquityNoteTable" id="dmpi_StockholdersEquityNoteTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="ExchangeAgreementMember" id="dmpi_ExchangeAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockholdersEquityNoteLineItems" id="dmpi_StockholdersEquityNoteLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedAndOutstandingOnExchangedBasis" id="dmpi_StockIssuedAndOutstandingOnExchangedBasis" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="BrokerWarrantsMember" id="dmpi_BrokerWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="InvestorWarrantExchangeMember" id="dmpi_InvestorWarrantExchangeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoZeroOneFiveAgentWarrantsMember" id="dmpi_TwoZeroOneFiveAgentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoZeroOneFiveOfferingWarrantsMember" id="dmpi_TwoZeroOneFiveOfferingWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationAwardTrancheFourMember" id="dmpi_ShareBasedCompensationAwardTrancheFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationAwardTrancheFiveMember" id="dmpi_ShareBasedCompensationAwardTrancheFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationAwardTrancheSixMember" id="dmpi_ShareBasedCompensationAwardTrancheSixMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationAwardTrancheSevenMember" id="dmpi_ShareBasedCompensationAwardTrancheSevenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationAwardTrancheEightMember" id="dmpi_ShareBasedCompensationAwardTrancheEightMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationAwardTrancheNineMember" id="dmpi_ShareBasedCompensationAwardTrancheNineMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationAwardTrancheTenMember" id="dmpi_ShareBasedCompensationAwardTrancheTenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockOptionExpense" id="dmpi_StockOptionExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CashCommission" id="dmpi_CashCommission" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued" id="dmpi_NoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ReductionInStockOptionLiability" id="dmpi_ReductionInStockOptionLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EngagementAgreementPrivatePlacementDescription" id="dmpi_EngagementAgreementPrivatePlacementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommissionPaidInLeiuOfIssuanceOfWarrants" id="dmpi_CommissionPaidInLeiuOfIssuanceOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DerivativeLiabilityEquityIssuanceReclassified" id="dmpi_DerivativeLiabilityEquityIssuanceReclassified" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>dmpi-20160331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Thursday, May 12, 2016 11:32:27 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#ConsolidatedCondensedInterimBalanceSheetsUnaudited" roleURI="http://www.delmarpharma.com/role/ConsolidatedCondensedInterimBalanceSheetsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/ConsolidatedCondensedInterimBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TaxesAndOtherReceivablesCurrent" xlink:label="loc_dmpi_TaxesAndOtherReceivablesCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_dmpi_TaxesAndOtherReceivablesCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaap_DeferredCostsCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_DeferredCostsCurrent" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockOptionLiabilityNoncurrent" xlink:label="loc_dmpi_StockOptionLiabilityNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_dmpi_StockOptionLiabilityNoncurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_VotingShare" xlink:label="loc_dmpi_VotingShare"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_dmpi_VotingShare" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding" order="50" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="60" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="70" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="20" use="optional" weight="1"/></calculationLink>





<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#ConsolidatedcondensedinterimstatementoflossandcomprehensivelossUnaudited" roleURI="http://www.delmarpharma.com/role/ConsolidatedcondensedinterimstatementoflossandcomprehensivelossUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/ConsolidatedcondensedinterimstatementoflossandcomprehensivelossUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" xlink:label="loc_dmpi_GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_dmpi_GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_GainLossOnExchangeOfWarrants" xlink:label="loc_dmpi_GainLossOnExchangeOfWarrants"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_dmpi_GainLossOnExchangeOfWarrants" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" order="50" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestIncomeOther" order="60" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OperatingExpenses" order="10" use="optional" weight="-1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" order="20" use="optional" weight="1"/></calculationLink>


<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#ConsolidatedCondensedInterimStatementOfCashFlowsUnaudited" roleURI="http://www.delmarpharma.com/role/ConsolidatedCondensedInterimStatementOfCashFlowsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/ConsolidatedCondensedInterimStatementOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems" xlink:label="loc_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems" xlink:to="loc_us-gaap_AdjustmentForAmortization" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems" xlink:to="loc_us-gaap_InterestExpenseDebt" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives" order="40" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" xlink:label="loc_dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems" xlink:to="loc_dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_GainLossOnExchangeOfWarrants" xlink:label="loc_dmpi_GainLossOnExchangeOfWarrants"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems" xlink:to="loc_dmpi_GainLossOnExchangeOfWarrants" order="60" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_IssuanceOfStockForServices" xlink:label="loc_dmpi_IssuanceOfStockForServices"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems" xlink:to="loc_dmpi_IssuanceOfStockForServices" order="70" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices" order="80" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems" xlink:to="loc_us-gaap_ShareBasedCompensation" order="90" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital"/><loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_IncreaseDecreaseInTaxesAndOtherReceivables" xlink:label="loc_dmpi_IncreaseDecreaseInTaxesAndOtherReceivables"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:to="loc_dmpi_IncreaseDecreaseInTaxesAndOtherReceivables" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="30" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties" order="40" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/><loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ProceedsFromIssuanceOfSharesAndWarrants" xlink:label="loc_dmpi_ProceedsFromIssuanceOfSharesAndWarrants"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_dmpi_ProceedsFromIssuanceOfSharesAndWarrants" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts" order="40" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" order="30" use="optional" weight="1"/></calculationLink>





</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>dmpi-20160331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Thursday, May 12, 2016 11:32:27 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Consolidatedcondensedinterimbalancesheetsunauditedparenthetical" roleURI="http://www.delmarpharma.com/role/Consolidatedcondensedinterimbalancesheetsunauditedparenthetical"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#RestatementOfPreviouslyIssuedFinancialStatementsDetails" roleURI="http://www.delmarpharma.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Significantaccountingpoliciesdetails" roleURI="http://www.delmarpharma.com/role/Significantaccountingpoliciesdetails"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#ValentTechnologiesLlcDetails" roleURI="http://www.delmarpharma.com/role/ValentTechnologiesLlcDetails"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#RelatedPartyTransactionsDetails" roleURI="http://www.delmarpharma.com/role/RelatedPartyTransactionsDetails"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#DerivativeLiabilityDetailsTextual" roleURI="http://www.delmarpharma.com/role/DerivativeLiabilityDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Stockholdersequitydetails" roleURI="http://www.delmarpharma.com/role/Stockholdersequitydetails"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Stockholdersequitydetails1" roleURI="http://www.delmarpharma.com/role/Stockholdersequitydetails1"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Stockholdersequitydetails2" roleURI="http://www.delmarpharma.com/role/Stockholdersequitydetails2"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Stockholdersequitydetails3" roleURI="http://www.delmarpharma.com/role/Stockholdersequitydetails3"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Stockholdersequitydetails4" roleURI="http://www.delmarpharma.com/role/Stockholdersequitydetails4"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#StockholdersEquityDetailsTextual" roleURI="http://www.delmarpharma.com/role/StockholdersEquityDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#StockholdersEquityDetailsTextual1" roleURI="http://www.delmarpharma.com/role/StockholdersEquityDetailsTextual1"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Financialinstrumentsdetails" roleURI="http://www.delmarpharma.com/role/Financialinstrumentsdetails"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#SubsequentEventsDetails" roleURI="http://www.delmarpharma.com/role/SubsequentEventsDetails"/>
<definitionLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Consolidatedcondensedinterimbalancesheetsunauditedparenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_PreferredStockSpecialVotingSharesIssued" xlink:label="loc_dmpi_PreferredStockSpecialVotingSharesIssued_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dmpi_PreferredStockSpecialVotingSharesIssued_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_10" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_11" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_12" order="80" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_2" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_2" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_3" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_3" xlink:to="loc_us-gaap_RestatementAdjustmentMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_7" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_8" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_9" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_10" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_11" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_12" order="70" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Significantaccountingpoliciesdetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_WarrantMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_SignificantAccountingPoliciesTextualAbstract" xlink:label="loc_dmpi_SignificantAccountingPoliciesTextualAbstract_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_dmpi_SignificantAccountingPoliciesTextualAbstract_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_SignificantAccountingPoliciesTextualAbstract_11" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForSoftware" xlink:label="loc_us-gaap_PaymentsForSoftware_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_SignificantAccountingPoliciesTextualAbstract_11" xlink:to="loc_us-gaap_PaymentsForSoftware_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_SignificantAccountingPoliciesTextualAbstract_11" xlink:to="loc_us-gaap_AdjustmentForAmortization_14" order="20" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/ValentTechnologiesLlcDetails">
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_AgreementsLineItems" xlink:label="loc_dmpi_AgreementsLineItems_0"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_AgreementTable" xlink:label="loc_dmpi_AgreementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dmpi_AgreementsLineItems_0" xlink:to="loc_dmpi_AgreementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dmpi_AgreementTable_1" xlink:to="loc_dei_LegalEntityAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ValentTechnologiesLlcMember" xlink:label="loc_dmpi_ValentTechnologiesLlcMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_dmpi_ValentTechnologiesLlcMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dmpi_AgreementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_AgreementsLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaap_LoansPayableCurrent_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_AgreementsLineItems_0" xlink:to="loc_us-gaap_LoansPayableCurrent_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_AgreementsLineItems_0" xlink:to="loc_us-gaap_InterestPayableCurrent_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_AgreementsLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_AgreementsLineItems_0" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_12" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_AgreementsLineItems_0" xlink:to="loc_us-gaap_InterestExpense_13" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_AgreementsLineItems_0" xlink:to="loc_us-gaap_Dividends_14" order="70" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_OfficerAndDirectorMember" xlink:label="loc_dmpi_OfficerAndDirectorMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_dmpi_OfficerAndDirectorMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_AgreementsAxis" xlink:label="loc_dmpi_AgreementsAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_dmpi_AgreementsAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_AgreementsDomain" xlink:label="loc_dmpi_AgreementsDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dmpi_AgreementsAxis_5" xlink:to="loc_dmpi_AgreementsDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_AgreementsDomain" xlink:label="loc_dmpi_AgreementsDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dmpi_AgreementsAxis_5" xlink:to="loc_dmpi_AgreementsDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ConsultingAgreementsMember" xlink:label="loc_dmpi_ConsultingAgreementsMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_AgreementsDomain_6" xlink:to="loc_dmpi_ConsultingAgreementsMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_dei_LegalEntityAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_8" xlink:to="loc_dei_EntityDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_8" xlink:to="loc_dei_EntityDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ValentTechnologiesLlcMember" xlink:label="loc_dmpi_ValentTechnologiesLlcMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9" xlink:to="loc_dmpi_ValentTechnologiesLlcMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_RelatedPartyTransactionsTextualsAbstract" xlink:label="loc_dmpi_RelatedPartyTransactionsTextualsAbstract_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_dmpi_RelatedPartyTransactionsTextualsAbstract_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_RelatedPartyTransactionsTextualsAbstract_11" xlink:to="loc_us-gaap_OfficersCompensation_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_RelatedPartyTransactionsTextualsAbstract_11" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_RelatedPartyTransactionsTextualsAbstract_11" xlink:to="loc_us-gaap_ProfessionalFees_14" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_RelatedPartyTransactionsTextualsAbstract_11" xlink:to="loc_us-gaap_InterestExpense_15" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_RelatedPartyTransactionsTextualsAbstract_11" xlink:to="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_16" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_RelatedPartyTransactionsTextualsAbstract_11" xlink:to="loc_us-gaap_PreferredStockSharesIssued_17" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/DerivativeLiabilityDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_us-gaap_DerivativeTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_InvestorWarrantsMember" xlink:label="loc_dmpi_InvestorWarrantsMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3" xlink:to="loc_dmpi_InvestorWarrantsMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_InvestorWarrantExercisesMember" xlink:label="loc_dmpi_InvestorWarrantExercisesMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3" xlink:to="loc_dmpi_InvestorWarrantExercisesMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_WarrantsIssuedForServicesMember" xlink:label="loc_dmpi_WarrantsIssuedForServicesMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3" xlink:to="loc_dmpi_WarrantsIssuedForServicesMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_InvestorWarrantsExchangeMember" xlink:label="loc_dmpi_InvestorWarrantsExchangeMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3" xlink:to="loc_dmpi_InvestorWarrantsExchangeMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_InvestorWarrantAmendmentsMember" xlink:label="loc_dmpi_InvestorWarrantAmendmentsMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3" xlink:to="loc_dmpi_InvestorWarrantAmendmentsMember_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_DividendWarrantsMember" xlink:label="loc_dmpi_DividendWarrantsMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3" xlink:to="loc_dmpi_DividendWarrantsMember_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_RangeAxis_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_10" xlink:to="loc_us-gaap_RangeMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_11_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_10" xlink:to="loc_us-gaap_RangeMember_11_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_11" xlink:to="loc_us-gaap_MaximumMember_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_11" xlink:to="loc_us-gaap_MinimumMember_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_14" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_14" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_14" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TwoThousandFifteenAgentWarrantMember" xlink:label="loc_dmpi_TwoThousandFifteenAgentWarrantMember_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15" xlink:to="loc_dmpi_TwoThousandFifteenAgentWarrantMember_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TwoThousandThirteenPlacementAgentWarrantsMember" xlink:label="loc_dmpi_TwoThousandThirteenPlacementAgentWarrantsMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15" xlink:to="loc_dmpi_TwoThousandThirteenPlacementAgentWarrantsMember_17" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember" xlink:label="loc_dmpi_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15" xlink:to="loc_dmpi_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember_18" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReverseAcquisitionDescription" xlink:label="loc_dmpi_ReverseAcquisitionDescription_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_dmpi_ReverseAcquisitionDescription_19" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:label="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_21" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ClassOfWarrantOrRightExercised" xlink:label="loc_dmpi_ClassOfWarrantOrRightExercised_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_dmpi_ClassOfWarrantOrRightExercised_22" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_WarrantsAgentFee" xlink:label="loc_dmpi_WarrantsAgentFee_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_dmpi_WarrantsAgentFee_23" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_PercentageOfWarrantAgentFee" xlink:label="loc_dmpi_PercentageOfWarrantAgentFee_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_dmpi_PercentageOfWarrantAgentFee_24" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_GrossProceedsFromExerciseOfWarrants" xlink:label="loc_dmpi_GrossProceedsFromExerciseOfWarrants_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_dmpi_GrossProceedsFromExerciseOfWarrants_25" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_26" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants" xlink:label="loc_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants_27" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_WarrantOutstanding" xlink:label="loc_dmpi_WarrantOutstanding_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_dmpi_WarrantOutstanding_28" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_invest_InvestmentWarrantsExpirationDate_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_invest_InvestmentWarrantsExpirationDate_29" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_30" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TermOfWarrants" xlink:label="loc_dmpi_TermOfWarrants_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_dmpi_TermOfWarrants_31" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ClassOfWarrantOrRightIssued" xlink:label="loc_dmpi_ClassOfWarrantOrRightIssued_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_dmpi_ClassOfWarrantOrRightIssued_32" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants" xlink:label="loc_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants_33" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReclassificationOfDerivativeLiabilityUponTheExchangeOfInvestorWarrants" xlink:label="loc_dmpi_ReclassificationOfDerivativeLiabilityUponTheExchangeOfInvestorWarrants_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_dmpi_ReclassificationOfDerivativeLiabilityUponTheExchangeOfInvestorWarrants_34" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants" xlink:label="loc_dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants_35" order="170" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Stockholdersequitydetails">
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems" xlink:label="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_0"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ScheduleOfCommonStockIssuedAndOutstandingTable" xlink:label="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_0" xlink:to="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingTable_1" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_7" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_8_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_7" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_8_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_8" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_8" xlink:to="loc_us-gaap_RestatementAdjustmentMember_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedDuringPeriodSharesAndWarrantsValue" xlink:label="loc_dmpi_StockIssuedDuringPeriodSharesAndWarrantsValue_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_0" xlink:to="loc_dmpi_StockIssuedDuringPeriodSharesAndWarrantsValue_13" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares" xlink:label="loc_dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_0" xlink:to="loc_dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares_14" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedDuringPeriodValueReclassificationOfWarrants" xlink:label="loc_dmpi_StockIssuedDuringPeriodValueReclassificationOfWarrants_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_0" xlink:to="loc_dmpi_StockIssuedDuringPeriodValueReclassificationOfWarrants_15" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedDuringPeriodValueStockWarrantExercised" xlink:label="loc_dmpi_StockIssuedDuringPeriodValueStockWarrantExercised_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_0" xlink:to="loc_dmpi_StockIssuedDuringPeriodValueStockWarrantExercised_16" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised" xlink:label="loc_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_0" xlink:to="loc_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised_17" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_0" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_18" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_19" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_20" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_21" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions" xlink:label="loc_dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_0" xlink:to="loc_dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions_22" order="120" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Stockholdersequitydetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross" xlink:label="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross_9" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_13" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:label="loc_dmpi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_10" xlink:to="loc_dmpi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_14" order="30" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Stockholdersequitydetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ZeroPointThreeNineMember" xlink:label="loc_dmpi_ZeroPointThreeNineMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_dmpi_ZeroPointThreeNineMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ZeroPointSevenFourMember" xlink:label="loc_dmpi_ZeroPointSevenFourMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_dmpi_ZeroPointSevenFourMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ZeroPointEightZeroMember" xlink:label="loc_dmpi_ZeroPointEightZeroMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_dmpi_ZeroPointEightZeroMember_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ZeroPointNineFourMember" xlink:label="loc_dmpi_ZeroPointNineFourMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_dmpi_ZeroPointNineFourMember_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_OnePointZeroZeroMember" xlink:label="loc_dmpi_OnePointZeroZeroMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_dmpi_OnePointZeroZeroMember_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_OnepointzerofiveMember" xlink:label="loc_dmpi_OnepointzerofiveMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_dmpi_OnepointzerofiveMember_12" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_OnePointOneTwoMember" xlink:label="loc_dmpi_OnePointOneTwoMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_dmpi_OnePointOneTwoMember_13" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_OnePointFiveFourMember" xlink:label="loc_dmpi_OnePointFiveFourMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_dmpi_OnePointFiveFourMember_14" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TwoPointThreeZeroMember" xlink:label="loc_dmpi_TwoPointThreeZeroMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_dmpi_TwoPointThreeZeroMember_15" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ZeroPointNineTwoMember" xlink:label="loc_dmpi_ZeroPointNineTwoMember_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_dmpi_ZeroPointNineTwoMember_16" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_17" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_18" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_19" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_20" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_21" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Stockholdersequitydetails3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_12" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Stockholdersequitydetails4">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6" order="10" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/StockholdersEquityDetailsTextual">
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockholdersEquityNoteLineItems" xlink:label="loc_dmpi_StockholdersEquityNoteLineItems_0"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockholdersEquityNoteTable" xlink:label="loc_dmpi_StockholdersEquityNoteTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_dmpi_StockholdersEquityNoteTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_AgreementsAxis" xlink:label="loc_dmpi_AgreementsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dmpi_StockholdersEquityNoteTable_1" xlink:to="loc_dmpi_AgreementsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_AgreementsDomain" xlink:label="loc_dmpi_AgreementsDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dmpi_AgreementsAxis_2" xlink:to="loc_dmpi_AgreementsDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_AgreementsDomain" xlink:label="loc_dmpi_AgreementsDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dmpi_AgreementsAxis_2" xlink:to="loc_dmpi_AgreementsDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ExchangeAgreementMember" xlink:label="loc_dmpi_ExchangeAgreementMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_AgreementsDomain_3" xlink:to="loc_dmpi_ExchangeAgreementMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dmpi_StockholdersEquityNoteTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_PreferredStockSpecialVotingSharesIssued" xlink:label="loc_dmpi_PreferredStockSpecialVotingSharesIssued_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_dmpi_PreferredStockSpecialVotingSharesIssued_12" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_13" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_14" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_15" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_16" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_17" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedAndOutstandingOnExchangedBasis" xlink:label="loc_dmpi_StockIssuedAndOutstandingOnExchangedBasis_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_dmpi_StockIssuedAndOutstandingOnExchangedBasis_18" order="110" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/StockholdersEquityDetailsTextual1">
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockholdersEquityNoteLineItems" xlink:label="loc_dmpi_StockholdersEquityNoteLineItems_0"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockholdersEquityNoteTable" xlink:label="loc_dmpi_StockholdersEquityNoteTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_dmpi_StockholdersEquityNoteTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dmpi_StockholdersEquityNoteTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_BrokerWarrantsMember" xlink:label="loc_dmpi_BrokerWarrantsMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_dmpi_BrokerWarrantsMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dmpi_StockholdersEquityNoteTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_InvestorWarrantExercisesMember" xlink:label="loc_dmpi_InvestorWarrantExercisesMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6" xlink:to="loc_dmpi_InvestorWarrantExercisesMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_InvestorWarrantExchangeMember" xlink:label="loc_dmpi_InvestorWarrantExchangeMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6" xlink:to="loc_dmpi_InvestorWarrantExchangeMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TwoZeroOneFiveAgentWarrantsMember" xlink:label="loc_dmpi_TwoZeroOneFiveAgentWarrantsMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6" xlink:to="loc_dmpi_TwoZeroOneFiveAgentWarrantsMember_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TwoZeroOneFiveOfferingWarrantsMember" xlink:label="loc_dmpi_TwoZeroOneFiveOfferingWarrantsMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6" xlink:to="loc_dmpi_TwoZeroOneFiveOfferingWarrantsMember_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dmpi_StockholdersEquityNoteTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_11" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_11" xlink:to="loc_us-gaap_EquityComponentDomain_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_12_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_11" xlink:to="loc_us-gaap_EquityComponentDomain_12_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_12" xlink:to="loc_us-gaap_CommonStockMember_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_12" xlink:to="loc_us-gaap_WarrantMember_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dmpi_StockholdersEquityNoteTable_1" xlink:to="loc_us-gaap_VestingAxis_15" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_15" xlink:to="loc_us-gaap_VestingDomain_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_16_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_15" xlink:to="loc_us-gaap_VestingDomain_16_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_16" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_16" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_18" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_16" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_19" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationAwardTrancheFourMember" xlink:label="loc_dmpi_ShareBasedCompensationAwardTrancheFourMember_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_16" xlink:to="loc_dmpi_ShareBasedCompensationAwardTrancheFourMember_20" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationAwardTrancheFiveMember" xlink:label="loc_dmpi_ShareBasedCompensationAwardTrancheFiveMember_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_16" xlink:to="loc_dmpi_ShareBasedCompensationAwardTrancheFiveMember_21" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationAwardTrancheSixMember" xlink:label="loc_dmpi_ShareBasedCompensationAwardTrancheSixMember_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_16" xlink:to="loc_dmpi_ShareBasedCompensationAwardTrancheSixMember_22" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationAwardTrancheSevenMember" xlink:label="loc_dmpi_ShareBasedCompensationAwardTrancheSevenMember_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_16" xlink:to="loc_dmpi_ShareBasedCompensationAwardTrancheSevenMember_23" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationAwardTrancheEightMember" xlink:label="loc_dmpi_ShareBasedCompensationAwardTrancheEightMember_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_16" xlink:to="loc_dmpi_ShareBasedCompensationAwardTrancheEightMember_24" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationAwardTrancheNineMember" xlink:label="loc_dmpi_ShareBasedCompensationAwardTrancheNineMember_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_16" xlink:to="loc_dmpi_ShareBasedCompensationAwardTrancheNineMember_25" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationAwardTrancheTenMember" xlink:label="loc_dmpi_ShareBasedCompensationAwardTrancheTenMember_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_16" xlink:to="loc_dmpi_ShareBasedCompensationAwardTrancheTenMember_26" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_27" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockOptionExpense" xlink:label="loc_dmpi_StockOptionExpense_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_dmpi_StockOptionExpense_28" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_29" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised" xlink:label="loc_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised_30" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_31" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockOptionLiabilityNoncurrent" xlink:label="loc_dmpi_StockOptionLiabilityNoncurrent_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_dmpi_StockOptionLiabilityNoncurrent_32" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_33" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_34" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_35" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_36" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ClassOfWarrantOrRightIssued" xlink:label="loc_dmpi_ClassOfWarrantOrRightIssued_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_dmpi_ClassOfWarrantOrRightIssued_37" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_38" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants" xlink:label="loc_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants_39" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares" xlink:label="loc_dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares_40" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_41" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_invest_InvestmentWarrantsExercisePrice_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_invest_InvestmentWarrantsExercisePrice_42" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_43" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_44" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_CashCommission" xlink:label="loc_dmpi_CashCommission_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_dmpi_CashCommission_45" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NumberOfWarrantsIssuedToAgents" xlink:label="loc_dmpi_NumberOfWarrantsIssuedToAgents_46"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_dmpi_NumberOfWarrantsIssuedToAgents_46" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_47"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_47" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_48"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_48" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued" xlink:label="loc_dmpi_NoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued_49"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_dmpi_NoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued_49" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_50"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_50" order="240" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaap_DeferredCostsCurrent_51"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_DeferredCostsCurrent_51" order="250" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_52"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_52" order="260" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NumberOfWarrantsIssuedForServices" xlink:label="loc_dmpi_NumberOfWarrantsIssuedForServices_53"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_dmpi_NumberOfWarrantsIssuedForServices_53" order="270" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_invest_InvestmentWarrantsExpirationDate_54"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_invest_InvestmentWarrantsExpirationDate_54" order="280" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReductionInStockOptionLiability" xlink:label="loc_dmpi_ReductionInStockOptionLiability_55"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_0" xlink:to="loc_dmpi_ReductionInStockOptionLiability_55" order="290" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Financialinstrumentsdetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_DerivativeLiabilities_7" order="10" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9" xlink:to="loc_us-gaap_PrivatePlacementMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_11" xlink:to="loc_us-gaap_EquityComponentDomain_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_12_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_11" xlink:to="loc_us-gaap_EquityComponentDomain_12_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_12" xlink:to="loc_us-gaap_WarrantMember_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_InvestorWarrantAmendmentsMember" xlink:label="loc_dmpi_InvestorWarrantAmendmentsMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_12" xlink:to="loc_dmpi_InvestorWarrantAmendmentsMember_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_15" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_15" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_16_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_15" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_16_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_16" xlink:to="loc_us-gaap_EmployeeStockOptionMember_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_18" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_19" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_20" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_21" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_22" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockDescription" xlink:label="loc_us-gaap_ConversionOfStockDescription_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ConversionOfStockDescription_23" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_EngagementAgreementPrivatePlacementDescription" xlink:label="loc_dmpi_EngagementAgreementPrivatePlacementDescription_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_dmpi_EngagementAgreementPrivatePlacementDescription_24" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_25" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_CommissionPaidInLeiuOfIssuanceOfWarrants" xlink:label="loc_dmpi_CommissionPaidInLeiuOfIssuanceOfWarrants_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_dmpi_CommissionPaidInLeiuOfIssuanceOfWarrants_26" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_invest_InvestmentWarrantsExercisePrice_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_invest_InvestmentWarrantsExercisePrice_27" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_invest_InvestmentWarrantsExpirationDate_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_invest_InvestmentWarrantsExpirationDate_28" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaap_DeferredCostsCurrent_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_DeferredCostsCurrent_29" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_31" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_32" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_DerivativeLiabilityEquityIssuanceReclassified" xlink:label="loc_dmpi_DerivativeLiabilityEquityIssuanceReclassified_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_dmpi_DerivativeLiabilityEquityIssuanceReclassified_33" order="160" use="optional"/>
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>dmpi-20160331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Thursday, May 12, 2016 11:32:27 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_DocumentAndEntityInformationAbstract" xlink:label="loc_GH138J37563K_dmpi_DocumentAndEntityInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_DocumentAndEntityInformationAbstract" xlink:to="lab_IJ350L59785M_dmpi_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_16IJ4626J9F6903449KK_dei_EntityRegistrantName"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dei_EntityRegistrantName" xlink:to="lab_38KL6848L1H8125661MM_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_GH138J37563K_dei_EntityCentralIndexKey"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dei_EntityCentralIndexKey" xlink:to="lab_IJ350L59785M_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_16IJ4626J9F6903449KK_dei_CurrentFiscalYearEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dei_CurrentFiscalYearEndDate" xlink:to="lab_38KL6848L1H8125661MM_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_GH138J37563K_dei_TradingSymbol"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dei_TradingSymbol" xlink:to="lab_IJ350L59785M_dei_TradingSymbol"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_16IJ4626J9F6903449KK_dei_AmendmentFlag"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dei_AmendmentFlag" xlink:to="lab_38KL6848L1H8125661MM_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_GH138J37563K_dei_DocumentType"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dei_DocumentType" xlink:to="lab_IJ350L59785M_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_16IJ4626J9F6903449KK_dei_DocumentPeriodEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dei_DocumentPeriodEndDate" xlink:to="lab_38KL6848L1H8125661MM_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_GH138J37563K_dei_EntityFilerCategory"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dei_EntityFilerCategory" xlink:to="lab_IJ350L59785M_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_16IJ4626J9F6903449KK_dei_DocumentFiscalYearFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dei_DocumentFiscalYearFocus" xlink:to="lab_38KL6848L1H8125661MM_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_GH138J37563K_dei_DocumentFiscalPeriodFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dei_DocumentFiscalPeriodFocus" xlink:to="lab_IJ350L59785M_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_16IJ4626J9F6903449KK_dei_EntityCommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_38KL6848L1H8125661MM_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_GH138J37563K_us-gaap_StatementOfFinancialPositionAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_IJ350L59785M_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_AssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_AssetsAbstract" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_GH138J37563K_us-gaap_AssetsCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_AssetsCurrentAbstract" xlink:to="lab_IJ350L59785M_us-gaap_AssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, At Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents - beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents - end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents on hand</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TaxesAndOtherReceivablesCurrent" xlink:label="loc_GH138J37563K_dmpi_TaxesAndOtherReceivablesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_TaxesAndOtherReceivablesCurrent" xml:lang="en-US">Taxes and other receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_TaxesAndOtherReceivablesCurrent" xml:lang="en-US">Taxes and other receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_IJ350L59785M_dmpi_TaxesAndOtherReceivablesCurrent" xml:lang="en-US">Taxes and other receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_TaxesAndOtherReceivablesCurrent" xml:lang="en-US">This element represents taxes and other receivables.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_TaxesAndOtherReceivablesCurrent" xlink:to="lab_IJ350L59785M_dmpi_TaxesAndOtherReceivablesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_PrepaidExpenseCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_PrepaidExpenseCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_GH138J37563K_us-gaap_DeferredCostsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_DeferredCostsCurrent" xml:lang="en-US">Deferred Costs, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_DeferredCostsCurrent" xml:lang="en-US">Deferred costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_DeferredCostsCurrent" xlink:to="lab_IJ350L59785M_us-gaap_DeferredCostsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_AssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_AssetsCurrent" xml:lang="en-US">Assets current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_AssetsCurrent" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_GH138J37563K_us-gaap_FiniteLivedIntangibleAssetsNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Intangible assets - net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_IJ350L59785M_us-gaap_FiniteLivedIntangibleAssetsNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_Assets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_Assets" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_GH138J37563K_us-gaap_LiabilitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_LiabilitiesAbstract" xlink:to="lab_IJ350L59785M_us-gaap_LiabilitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_LiabilitiesCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_LiabilitiesCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_GH138J37563K_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_IJ350L59785M_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued liabilities total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_IJ350L59785M_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_DueToRelatedPartiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_DueToRelatedPartiesCurrent" xml:lang="en-US">Due to Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_DueToRelatedPartiesCurrent" xml:lang="en-US">Aggregate amount owing to officers and directors for fees and expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_DueToRelatedPartiesCurrent" xml:lang="en-US">Related party payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_DueToRelatedPartiesCurrent" xml:lang="en-US">Payable to related parties (note 8)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_DueToRelatedPartiesCurrent" xml:lang="en-US">Payable to related parties (note 10)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_DueToRelatedPartiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_GH138J37563K_us-gaap_LiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total of current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_IJ350L59785M_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_LiabilitiesCurrent" xlink:to="lab_IJ350L59785M_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockOptionLiabilityNoncurrent" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_StockOptionLiabilityNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockOptionLiabilityNoncurrent" xml:lang="en-US">Stock Option Liability Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockOptionLiabilityNoncurrent" xml:lang="en-US">Stock option liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockOptionLiabilityNoncurrent" xml:lang="en-US">This element represent stock option outstanding as of balance sheet date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_StockOptionLiabilityNoncurrent" xlink:to="lab_38KL6848L1H8125661MM_dmpi_StockOptionLiabilityNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_GH138J37563K_us-gaap_DerivativeLiabilitiesNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Derivative Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Derivative liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_IJ350L59785M_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Opening balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_IJ350L59785M_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Closing balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_IJ350L59785M_us-gaap_DerivativeLiabilitiesNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_Liabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_Liabilities" xml:lang="en-US">Total of liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_Liabilities" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_GH138J37563K_us-gaap_StockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_StockholdersEquityAbstract" xlink:to="lab_IJ350L59785M_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_PreferredStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock Authorized 5,000,000 shares, $0.001 par value Issued and outstanding 278,530 Series A shares at March 31, 2016 (June 30, 2015 - 278,530)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock Authorized 5,000,000 shares, $0.001 par value 1 share outstanding as of March 31, 2013(December 31, 2012 - nil)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_PreferredStockValue" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_PreferredStockValue"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_VotingShare" xlink:label="loc_GH138J37563K_dmpi_VotingShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_VotingShare" xml:lang="en-US">Voting Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_VotingShare" xml:lang="en-US">1 special voting share at March 31, 2016 (June 30, 2015 - 1)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_VotingShare" xml:lang="en-US">Voting Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_VotingShare" xml:lang="en-US">Voting share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_VotingShare" xlink:to="lab_IJ350L59785M_dmpi_VotingShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_CommonStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_CommonStockValue" xml:lang="en-US">Common stock Authorized 200,000,000 shares, $0.001 par value, 44,309,098 issued at March 31, 2016 (June 30, 2015 - 39,455,931)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_CommonStockValue" xml:lang="en-US">Common stock Authorized 200,000,000 shares, $0.001 par value Issued and outstanding 30,635,009 at March 31, 2013 (December 31, 2012 - 13,050,000)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_CommonStockValue" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_CommonStockValue" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_CommonStockValue" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_GH138J37563K_us-gaap_AdditionalPaidInCapitalCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid In Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_IJ350L59785M_us-gaap_AdditionalPaidInCapitalCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_WarrantsAndRightsOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants and Rights Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_WarrantsAndRightsOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_GH138J37563K_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Deficit accumulated during the development stage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_IJ350L59785M_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_IJ350L59785M_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net Of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_GH138J37563K_us-gaap_StockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_StockholdersEquity" xml:lang="en-US">Total of stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_IJ350L59785M_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' equity, total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_IJ350L59785M_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_IJ350L59785M_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_StockholdersEquity" xlink:to="lab_IJ350L59785M_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_LiabilitiesAndStockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Of Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_GH138J37563K_us-gaap_StatementTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_StatementTable" xlink:to="lab_IJ350L59785M_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_StatementClassOfStockAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_StatementClassOfStockAxis" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_StatementClassOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_GH138J37563K_us-gaap_ClassOfStockDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ClassOfStockDomain" xlink:to="lab_IJ350L59785M_us-gaap_ClassOfStockDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_SeriesAPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_SeriesAPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_GH138J37563K_us-gaap_StatementLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_StatementLineItems" xlink:to="lab_IJ350L59785M_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par Or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, par value (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_GH138J37563K_us-gaap_PreferredStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_IJ350L59785M_us-gaap_PreferredStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_PreferredStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_PreferredStockSharesIssued" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_PreferredStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_GH138J37563K_us-gaap_PreferredStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_IJ350L59785M_us-gaap_PreferredStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_PreferredStockSpecialVotingSharesIssued" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_PreferredStockSpecialVotingSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_PreferredStockSpecialVotingSharesIssued" xml:lang="en-US">Preferred Stock Special Voting Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_PreferredStockSpecialVotingSharesIssued" xml:lang="en-US">Preferred stock special voting shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_PreferredStockSpecialVotingSharesIssued" xml:lang="en-US">Represents number of special voting preferred stock issued.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_PreferredStockSpecialVotingSharesIssued" xlink:to="lab_38KL6848L1H8125661MM_dmpi_PreferredStockSpecialVotingSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_GH138J37563K_us-gaap_CommonStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_IJ350L59785M_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_CommonStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_GH138J37563K_us-gaap_CommonStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_IJ350L59785M_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Number of shares issued to former shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_CommonStockSharesIssued" xlink:to="lab_IJ350L59785M_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_IncomeStatementAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_IncomeStatementAbstract" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_GH138J37563K_us-gaap_OperatingExpensesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_OperatingExpensesAbstract" xlink:to="lab_IJ350L59785M_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ResearchAndDevelopmentExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_GH138J37563K_us-gaap_GeneralAndAdministrativeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_IJ350L59785M_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_IJ350L59785M_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_OperatingExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_OperatingExpenses" xml:lang="en-US">Operating expenses, total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_OperatingExpenses" xml:lang="en-US">Operating expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_OperatingExpenses" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_GH138J37563K_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other (income) loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_IJ350L59785M_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Gain (Loss) On Derivative Instruments, Net, Pretax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Change in fair value of derivative liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Change in fair value of derivative liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Change in fair value of unexercised warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Change in fair value of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Change in fair value of derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" xlink:label="loc_GH138J37563K_dmpi_GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" xml:lang="en-US">Gain Loss On Change In Fair Value Of Derivative Liability Due To Change In Warrant Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" xml:lang="en-US">Change in fair value of derivative liability due to change in warrant terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" xml:lang="en-US">Change in fair value of derivative liability due to change in warrant termsChange in fair value of derivative liability due to change in warrant terms.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_IJ350L59785M_dmpi_GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" xml:lang="en-US">Change in fair value of derivative liability due to change in warrant terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" xlink:to="lab_IJ350L59785M_dmpi_GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_GainLossOnExchangeOfWarrants" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_GainLossOnExchangeOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_GainLossOnExchangeOfWarrants" xml:lang="en-US">Gain Loss On Exchange Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_GainLossOnExchangeOfWarrants" xml:lang="en-US">Loss on exchange of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_GainLossOnExchangeOfWarrants" xml:lang="en-US">Gain loss on exchange of warrants.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_GainLossOnExchangeOfWarrants" xml:lang="en-US">Loss on exchange of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_GainLossOnExchangeOfWarrants" xlink:to="lab_38KL6848L1H8125661MM_dmpi_GainLossOnExchangeOfWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_GH138J37563K_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign exchange loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign exchange</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_IJ350L59785M_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign exchange (gain) loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_IJ350L59785M_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_InterestExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_InterestExpense" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_InterestExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_GH138J37563K_us-gaap_InterestIncomeOther"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest Income, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_IJ350L59785M_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_IJ350L59785M_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_InterestIncomeOther" xlink:to="lab_IJ350L59785M_us-gaap_InterestIncomeOther"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_NonoperatingIncomeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Other (income) loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Other (income) loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_NonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_GH138J37563K_us-gaap_ComprehensiveIncomeNetOfTax"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Net and comprehensive loss (income) for the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_IJ350L59785M_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Net and comprehensive loss for the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_IJ350L59785M_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Net and comprehensive loss for the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_IJ350L59785M_us-gaap_ComprehensiveIncomeNetOfTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_EarningsPerShareBasic"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_EarningsPerShareBasic" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_EarningsPerShareBasic"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_GH138J37563K_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic weighted average number of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_IJ350L59785M_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_StatementOfCashFlowsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_GH138J37563K_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_IJ350L59785M_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_NetIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_NetIncomeLoss" xml:lang="en-US">Loss for the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_NetIncomeLoss" xml:lang="en-US">Net and comprehensive loss (income) for the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_NetIncomeLoss" xml:lang="en-US">Loss for the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_NetIncomeLoss" xml:lang="en-US">Net and comprehensive loss (income) for the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_NetIncomeLoss" xml:lang="en-US">Net and comprehensive loss (income) for the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_NetIncomeLoss" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_GH138J37563K_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments, Noncash Items, To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Items not affecting cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_IJ350L59785M_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_AdjustmentForAmortization"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_AdjustmentForAmortization" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_AdjustmentForAmortization"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_GH138J37563K_us-gaap_InterestExpenseDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest Expense, Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_InterestExpenseDebt" xml:lang="en-US">Accrued interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_InterestExpenseDebt" xlink:to="lab_IJ350L59785M_us-gaap_InterestExpenseDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_UnrealizedGainLossOnDerivatives"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_UnrealizedGainLossOnDerivatives" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_UnrealizedGainLossOnDerivatives" xml:lang="en-US">Change in fair value of derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_UnrealizedGainLossOnDerivatives"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" xlink:label="loc_GH138J37563K_dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" xml:lang="en-US">Change In Fair Value Of Derivative Liability Due To Change In Warrant Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" xml:lang="en-US">Change in fair value due to change in warrant terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" xml:lang="en-US">Change in fair value of derivative liability due to change in warrant terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" xml:lang="en-US">Change in fair value of derivative liability due to change in warrant termsChange in fair value of derivative liability due to change in warrant terms.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_IJ350L59785M_dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" xml:lang="en-US">Change in fair value due to change in warrant terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" xlink:to="lab_IJ350L59785M_dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_IssuanceOfStockForServices" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_IssuanceOfStockForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_IssuanceOfStockForServices" xml:lang="en-US">Issuance Of Stock For Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_IssuanceOfStockForServices" xml:lang="en-US">Shares issued for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_IssuanceOfStockForServices" xml:lang="en-US">Fair value of share-based compensation granted to nonemployees as payment for services rendered.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_IssuanceOfStockForServices" xlink:to="lab_38KL6848L1H8125661MM_dmpi_IssuanceOfStockForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_GH138J37563K_us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_AdjustmentOfWarrantsGrantedForServices" xml:lang="en-US">Adjustment of Warrants Granted for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_AdjustmentOfWarrantsGrantedForServices" xml:lang="en-US">Warrants issued for services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:to="lab_IJ350L59785M_us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock option expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensation" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems" xlink:label="loc_GH138J37563K_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems" xml:lang="en-US">Net Income Loss After Adjustments Of Non Cash Items</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems" xml:lang="en-US">Adjustment Before Working Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_IJ350L59785M_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems" xml:lang="en-US">Net income (loss) after adjustments of non-cash items</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems" xml:lang="en-US">Represents the net income (loss) after adjustments of non cash items during the period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems" xlink:to="lab_IJ350L59785M_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) In Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in non-cash working capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_IncreaseDecreaseInTaxesAndOtherReceivables" xlink:label="loc_GH138J37563K_dmpi_IncreaseDecreaseInTaxesAndOtherReceivables"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_IncreaseDecreaseInTaxesAndOtherReceivables" xml:lang="en-US">Increase Decrease In Taxes and Other Receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_IncreaseDecreaseInTaxesAndOtherReceivables" xml:lang="en-US">Taxes and other receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_IncreaseDecreaseInTaxesAndOtherReceivables" xml:lang="en-US">This element represents Taxes, excluding payroll, income and excise taxes, if not included elsewhere, that could include production, real and personal property, and other selling and distribution-related taxes and Carrying amounts due as of the balance sheet date from parties or arising from transactions not otherwise specified in the taxonomy.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_IJ350L59785M_dmpi_IncreaseDecreaseInTaxesAndOtherReceivables" xml:lang="en-US">Taxes and other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_IncreaseDecreaseInTaxesAndOtherReceivables" xlink:to="lab_IJ350L59785M_dmpi_IncreaseDecreaseInTaxesAndOtherReceivables"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_IncreaseDecreaseInPrepaidExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Prepaid expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_IncreaseDecreaseInPrepaidExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_GH138J37563K_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) In Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_IJ350L59785M_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_IJ350L59785M_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_IncreaseDecreaseInDueToRelatedParties" xml:lang="en-US">Increase (Decrease) In Due To Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_IncreaseDecreaseInDueToRelatedParties" xml:lang="en-US">Related party payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_IncreaseDecreaseInDueToRelatedParties" xml:lang="en-US">Related party payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_GH138J37563K_us-gaap_IncreaseDecreaseInOperatingCapital"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_IncreaseDecreaseInOperatingCapital" xml:lang="en-US">Increase (Decrease) in Operating Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_IJ350L59785M_us-gaap_IncreaseDecreaseInOperatingCapital" xml:lang="en-US">Total changes in non-cash working capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_IJ350L59785M_us-gaap_IncreaseDecreaseInOperatingCapital" xml:lang="en-US">Total changes in non-cash working capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_IJ350L59785M_us-gaap_IncreaseDecreaseInOperatingCapital" xml:lang="en-US">Total changes in non-cash working capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:to="lab_IJ350L59785M_us-gaap_IncreaseDecreaseInOperatingCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash flows from operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_GH138J37563K_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_IJ350L59785M_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xml:lang="en-US">Finite-Lived Intangible Assets, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_GH138J37563K_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_IJ350L59785M_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash flows from investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_IJ350L59785M_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ProceedsFromIssuanceOfSharesAndWarrants" xlink:label="loc_GH138J37563K_dmpi_ProceedsFromIssuanceOfSharesAndWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ProceedsFromIssuanceOfSharesAndWarrants" xml:lang="en-US">Proceeds From Issuance Of Shares And Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_ProceedsFromIssuanceOfSharesAndWarrants" xml:lang="en-US">Net proceeds from issuance of shares and warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_ProceedsFromIssuanceOfSharesAndWarrants" xml:lang="en-US">Proceeds from issuance of shares and warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ProceedsFromIssuanceOfSharesAndWarrants" xlink:to="lab_IJ350L59785M_dmpi_ProceedsFromIssuanceOfSharesAndWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xml:lang="en-US">Payments of Ordinary Dividends, Preferred Stock and Preference Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xml:lang="en-US">Series A preferred stock dividend</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xml:lang="en-US">Series A preferred stock dividend</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_GH138J37563K_us-gaap_ProceedsFromWarrantExercises"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from Warrant Exercises</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Net proceeds from the exercise of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Net proceeds from the exercise of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_IJ350L59785M_us-gaap_ProceedsFromWarrantExercises"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_PaymentsOfDebtIssuanceCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Payments of Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Deferred costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_PaymentsOfDebtIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_GH138J37563K_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_IJ350L59785M_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash flows from financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_IJ350L59785M_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">(Decrease) increase in cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Decrease in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_GH138J37563K_us-gaap_SupplementalCashFlowInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplementary information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_IJ350L59785M_us-gaap_SupplementalCashFlowInformationAbstract"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_IssuanceOfPreferredSharesForTheSettlementOfTheLoanPayable" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_IssuanceOfPreferredSharesForTheSettlementOfTheLoanPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_IssuanceOfPreferredSharesForTheSettlementOfTheLoanPayable" xml:lang="en-US">Issuance Of Preferred Shares For The Settlement Of The Loan Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_IssuanceOfPreferredSharesForTheSettlementOfTheLoanPayable" xml:lang="en-US">Issuance of preferred shares for the settlement of the loan payable to Valent (note 4)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_IssuanceOfPreferredSharesForTheSettlementOfTheLoanPayable" xml:lang="en-US">Issuance of shares for the settlement of accounts payable (notes 8)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_IssuanceOfPreferredSharesForTheSettlementOfTheLoanPayable" xml:lang="en-US">The element of issuance of preferred shares for the settlement of the loan payable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_IssuanceOfPreferredSharesForTheSettlementOfTheLoanPayable" xlink:to="lab_38KL6848L1H8125661MM_dmpi_IssuanceOfPreferredSharesForTheSettlementOfTheLoanPayable"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants" xlink:label="loc_GH138J37563K_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants" xml:lang="en-US">Reclassification Of Derivative Liability To Equity Upon Exercise Of Investor Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants" xml:lang="en-US">Reclassification of derivative liability upon the exercise or exchange of Investor Warrants (note 6)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants" xml:lang="en-US">Reclassification to equity upon exercise of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants" xml:lang="en-US">Reclassification of derivative liability upon the exercise of investor warrants.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_IJ350L59785M_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants" xml:lang="en-US">Reclassification to equity upon exercise of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_IJ350L59785M_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants" xml:lang="en-US">Reclassification of derivative liability to equity upon exercise of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_IJ350L59785M_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants" xml:lang="en-US">Reclassification to equity upon exercise of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants" xlink:to="lab_IJ350L59785M_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants" xml:lang="en-US">Reclassification Of Derivative Liability Upon The Amendment Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants" xml:lang="en-US">Reclassification of derivative liability upon the amendment of warrants (note 6)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants" xml:lang="en-US">Reclassification of derivative liability upon the amendment of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants" xlink:to="lab_38KL6848L1H8125661MM_dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions" xlink:label="loc_GH138J37563K_dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions" xml:lang="en-US">Reclassification Of Stock Option Liability Upon The Forfeiture Of Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions" xml:lang="en-US">Reclassification of stock option liability upon the forfeiture of stock options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions" xml:lang="en-US">Reclassification of stock option liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions" xml:lang="en-US">Reclassification of stock option liability upon the forfeiture of stock options.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions" xlink:to="lab_IJ350L59785M_dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_DeferredCostsRecognizedAsEquityIssueCosts" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_DeferredCostsRecognizedAsEquityIssueCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_DeferredCostsRecognizedAsEquityIssueCosts" xml:lang="en-US">Deferred Costs Recognized As Equity Issue Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_DeferredCostsRecognizedAsEquityIssueCosts" xml:lang="en-US">Deferred costs recognized as equity issue costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_DeferredCostsRecognizedAsEquityIssueCosts" xml:lang="en-US">Deferred costs recognized as equity issue costs.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_DeferredCostsRecognizedAsEquityIssueCosts" xlink:to="lab_38KL6848L1H8125661MM_dmpi_DeferredCostsRecognizedAsEquityIssueCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_GH138J37563K_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Nature of Operations and Liquidity Risk [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_IJ350L59785M_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_NatureOfOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of Operations [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of operations and liquidity risk</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_NatureOfOperations" xml:lang="en-US">Restatement, going concern, nature of operations, and corporate history</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_NatureOfOperations" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_NatureOfOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_GH138J37563K_us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xml:lang="en-US">Restatement of Previously Issued Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="lab_IJ350L59785M_us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xml:lang="en-US">Accounting Changes and Error Corrections [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xml:lang="en-US">Restatement of previously issued financial statements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_GH138J37563K_us-gaap_AccountingPoliciesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Significant Accounting Policies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_IJ350L59785M_us-gaap_AccountingPoliciesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_SignificantAccountingPoliciesTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant accounting policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_SignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ValentTechnologiesLlcAbstract" xlink:label="loc_GH138J37563K_dmpi_ValentTechnologiesLlcAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ValentTechnologiesLlcAbstract" xml:lang="en-US">Valent Technologies, LLC [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_ValentTechnologiesLlcAbstract" xml:lang="en-US">Valent Technologies Llc Agreement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ValentTechnologiesLlcAbstract" xlink:to="lab_IJ350L59785M_dmpi_ValentTechnologiesLlcAbstract"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ValentTechnologiesLlcTextBlock" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_ValentTechnologiesLlcTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ValentTechnologiesLlcTextBlock" xml:lang="en-US">Valent Technologies Llc [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ValentTechnologiesLlcTextBlock" xml:lang="en-US">Valent Technologies, LLC</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ValentTechnologiesLlcTextBlock" xml:lang="en-US">The entire disclosure for Valent Technologies LLC loan agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_ValentTechnologiesLlcTextBlock" xlink:to="lab_38KL6848L1H8125661MM_dmpi_ValentTechnologiesLlcTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_GH138J37563K_us-gaap_RelatedPartyTransactionsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_IJ350L59785M_us-gaap_RelatedPartyTransactionsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related party transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_GH138J37563K_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xml:lang="en-US">Derivative Liability [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_IJ350L59785M_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">Derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_GH138J37563K_us-gaap_EquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_EquityAbstract" xml:lang="en-US">Stockholders' Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_EquityAbstract" xlink:to="lab_IJ350L59785M_us-gaap_EquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_GH138J37563K_us-gaap_FairValueDisclosuresAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Financial Instruments [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Financial Instruments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_IJ350L59785M_us-gaap_FairValueDisclosuresAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_FinancialInstrumentsDisclosureTextBlock" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_FinancialInstrumentsDisclosureTextBlock" xml:lang="en-US">Financial instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_GH138J37563K_us-gaap_SubsequentEventsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_SubsequentEventsAbstract" xlink:to="lab_IJ350L59785M_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_SubsequentEventsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_GH138J37563K_us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_IJ350L59785M_us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_UnauditedInterimFinancialDataPolicyTextBlock" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_UnauditedInterimFinancialDataPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_UnauditedInterimFinancialDataPolicyTextBlock" xml:lang="en-US">Unaudited Interim Financial Data [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_UnauditedInterimFinancialDataPolicyTextBlock" xml:lang="en-US">Unaudited interim financial data</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_UnauditedInterimFinancialDataPolicyTextBlock" xml:lang="en-US">Disclosure of unaudited interim financial data.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_UnauditedInterimFinancialDataPolicyTextBlock" xlink:to="lab_38KL6848L1H8125661MM_dmpi_UnauditedInterimFinancialDataPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_GH138J37563K_us-gaap_UseOfEstimates"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_UseOfEstimates" xml:lang="en-US">Use of estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_UseOfEstimates" xlink:to="lab_IJ350L59785M_us-gaap_UseOfEstimates"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_GH138J37563K_us-gaap_EarningsPerSharePolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_IJ350L59785M_us-gaap_EarningsPerSharePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent accounting pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="loc_GH138J37563K_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xml:lang="en-US">Schedule of aggregate impacts of correcting the errors relating to the Placement Agent Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="lab_IJ350L59785M_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xml:lang="en-US">Schedule of derivative liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="loc_GH138J37563K_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xml:lang="en-US">Schedule of Common Stock Outstanding Roll Forward [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xml:lang="en-US">Schedule of common stock issued and outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="lab_IJ350L59785M_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule Of Share-Based Compensation, Stock Options, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of stock options outstanding under the plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_GH138J37563K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Schedule of stock options currently outstanding and exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule Of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of stock options valuation assumptions using a Black-Scholes pricing model</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_GH138J37563K_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Schedule Of Employee Service Share-Based Compensation, Allocation Of Recognized Period Costs [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Schedule of stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_IJ350L59785M_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xml:lang="en-US">Schedule Of Nonvested Share Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xml:lang="en-US">Schedule of unvested stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ScheduleOfOutstandingWarrantsTableTextBlock" xlink:label="loc_GH138J37563K_dmpi_ScheduleOfOutstandingWarrantsTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ScheduleOfOutstandingWarrantsTableTextBlock" xml:lang="en-US">Schedule Of Outstanding Warrants [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_ScheduleOfOutstandingWarrantsTableTextBlock" xml:lang="en-US">Schedule of outstanding warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_ScheduleOfOutstandingWarrantsTableTextBlock" xml:lang="en-US">Tabular disclosure of warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ScheduleOfOutstandingWarrantsTableTextBlock" xlink:to="lab_IJ350L59785M_dmpi_ScheduleOfOutstandingWarrantsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xml:lang="en-US">Schedule of derivative liabilities under the fair value hierarchy</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NatureOfOperationsAndLiquidityRiskTextualAbstract" xlink:label="loc_GH138J37563K_dmpi_NatureOfOperationsAndLiquidityRiskTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_NatureOfOperationsAndLiquidityRiskTextualAbstract" xml:lang="en-US">Nature Of Operations And Liquidity Risk Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_NatureOfOperationsAndLiquidityRiskTextualAbstract" xml:lang="en-US">Nature of Operations and Liquidity Risk (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_NatureOfOperationsAndLiquidityRiskTextualAbstract" xlink:to="lab_IJ350L59785M_dmpi_NatureOfOperationsAndLiquidityRiskTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from private placement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_GH138J37563K_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="lab_IJ350L59785M_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xml:lang="en-US">Adjustments for Error Corrections [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_GH138J37563K_us-gaap_AdjustmentsForErrorCorrectionDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_AdjustmentsForErrorCorrectionDomain" xml:lang="en-US">Adjustments for Error Correction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:to="lab_IJ350L59785M_us-gaap_AdjustmentsForErrorCorrectionDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ScenarioPreviouslyReportedMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ScenarioPreviouslyReportedMember" xml:lang="en-US">Scenario, Previously Reported [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ScenarioPreviouslyReportedMember" xml:lang="en-US">As previously reported [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ScenarioPreviouslyReportedMember" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ScenarioPreviouslyReportedMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_GH138J37563K_us-gaap_RestatementAdjustmentMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_RestatementAdjustmentMember" xml:lang="en-US">Restatement Adjustment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_RestatementAdjustmentMember" xml:lang="en-US">Restatement adjustment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_RestatementAdjustmentMember" xlink:to="lab_IJ350L59785M_us-gaap_RestatementAdjustmentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_GH138J37563K_us-gaap_EarningsPerShareBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_IJ350L59785M_us-gaap_EarningsPerShareBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_GH138J37563K_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_IJ350L59785M_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_GH138J37563K_us-gaap_EmployeeStockOptionMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_EmployeeStockOptionMember" xlink:to="lab_IJ350L59785M_us-gaap_EmployeeStockOptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_StatementEquityComponentsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_GH138J37563K_us-gaap_EquityComponentDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_EquityComponentDomain" xlink:to="lab_IJ350L59785M_us-gaap_EquityComponentDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_WarrantMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_WarrantMember" xml:lang="en-US">Issued for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_WarrantMember" xml:lang="en-US">Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_WarrantMember" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_WarrantMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_GH138J37563K_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_IJ350L59785M_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_GH138J37563K_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xml:lang="en-US">Software and Software Development Costs [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xml:lang="en-US">Website development costs [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_IJ350L59785M_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_SignificantAccountingPoliciesTextualAbstract" xlink:label="loc_GH138J37563K_dmpi_SignificantAccountingPoliciesTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_SignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Significant Accounting Policies Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_SignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Significant Accounting Policies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_SignificantAccountingPoliciesTextualAbstract" xlink:to="lab_IJ350L59785M_dmpi_SignificantAccountingPoliciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Anti-dilutive securities excluded from computation of earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForSoftware" xlink:label="loc_GH138J37563K_us-gaap_PaymentsForSoftware"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_PaymentsForSoftware" xml:lang="en-US">Payments for Software</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_PaymentsForSoftware" xml:lang="en-US">Website cost in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_PaymentsForSoftware" xlink:to="lab_IJ350L59785M_us-gaap_PaymentsForSoftware"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_AgreementTable" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_AgreementTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_AgreementTable" xml:lang="en-US">Agreement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_AgreementTable" xml:lang="en-US">Agreement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_AgreementTable" xml:lang="en-US">Represents the information about agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_AgreementTable" xlink:to="lab_38KL6848L1H8125661MM_dmpi_AgreementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_GH138J37563K_dei_LegalEntityAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dei_LegalEntityAxis" xlink:to="lab_IJ350L59785M_dei_LegalEntityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_16IJ4626J9F6903449KK_dei_EntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dei_EntityDomain" xlink:to="lab_38KL6848L1H8125661MM_dei_EntityDomain"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ValentTechnologiesLlcMember" xlink:label="loc_GH138J37563K_dmpi_ValentTechnologiesLlcMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ValentTechnologiesLlcMember" xml:lang="en-US">Valent Technologies Llc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_ValentTechnologiesLlcMember" xml:lang="en-US">Valent Technologies, LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_ValentTechnologiesLlcMember" xml:lang="en-US">Represents Valent Technologies LLC.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ValentTechnologiesLlcMember" xlink:to="lab_IJ350L59785M_dmpi_ValentTechnologiesLlcMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_AgreementsLineItems" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_AgreementsLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_AgreementsLineItems" xml:lang="en-US">Agreements [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_AgreementsLineItems" xml:lang="en-US">Agreement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_AgreementsLineItems" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_AgreementsLineItems" xlink:to="lab_38KL6848L1H8125661MM_dmpi_AgreementsLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_GH138J37563K_us-gaap_LoansPayableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_LoansPayableCurrent" xml:lang="en-US">Loans Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_LoansPayableCurrent" xml:lang="en-US">Loan payable, including accrued interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_LoansPayableCurrent" xml:lang="en-US">Loan payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_IJ350L59785M_us-gaap_LoansPayableCurrent" xml:lang="en-US">Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_LoansPayableCurrent" xlink:to="lab_IJ350L59785M_us-gaap_LoansPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_InterestPayableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_InterestPayableCurrent" xml:lang="en-US">Interest Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_InterestPayableCurrent" xml:lang="en-US">Aggregate accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_InterestPayableCurrent" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_InterestPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_GH138J37563K_us-gaap_PreferredStockDividendRatePercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_PreferredStockDividendRatePercentage" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_PreferredStockDividendRatePercentage" xml:lang="en-US">Preferred Stock, rate of dividend</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_PreferredStockDividendRatePercentage" xlink:to="lab_IJ350L59785M_us-gaap_PreferredStockDividendRatePercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Dividends" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_Dividends"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_Dividends" xml:lang="en-US">Dividends</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_Dividends" xml:lang="en-US">Dividend payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_Dividends" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_Dividends"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_GH138J37563K_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule Of Related Party Transactions, By Related Party [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_IJ350L59785M_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_GH138J37563K_us-gaap_RelatedPartyDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_RelatedPartyDomain" xlink:to="lab_IJ350L59785M_us-gaap_RelatedPartyDomain"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_OfficerAndDirectorMember" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_OfficerAndDirectorMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_OfficerAndDirectorMember" xml:lang="en-US">Officer and Director [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_OfficerAndDirectorMember" xml:lang="en-US">Officer and Director [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_OfficerAndDirectorMember" xml:lang="en-US">Represents officer and directors of the company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_OfficerAndDirectorMember" xlink:to="lab_38KL6848L1H8125661MM_dmpi_OfficerAndDirectorMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_AgreementsAxis" xlink:label="loc_GH138J37563K_dmpi_AgreementsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_AgreementsAxis" xml:lang="en-US">Agreements [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_AgreementsAxis" xml:lang="en-US">Agreements [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_AgreementsAxis" xml:lang="en-US">Represents the entire information about agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_AgreementsAxis" xlink:to="lab_IJ350L59785M_dmpi_AgreementsAxis"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_AgreementsDomain" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_AgreementsDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_AgreementsDomain" xml:lang="en-US">Agreements [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_AgreementsDomain" xml:lang="en-US">Agreements [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_AgreementsDomain" xml:lang="en-US">Represents the entire information about agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_AgreementsDomain" xlink:to="lab_38KL6848L1H8125661MM_dmpi_AgreementsDomain"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ConsultingAgreementsMember" xlink:label="loc_GH138J37563K_dmpi_ConsultingAgreementsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ConsultingAgreementsMember" xml:lang="en-US">Consulting Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_ConsultingAgreementsMember" xml:lang="en-US">Consulting Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_ConsultingAgreementsMember" xml:lang="en-US">Represents the consulting agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ConsultingAgreementsMember" xlink:to="lab_IJ350L59785M_dmpi_ConsultingAgreementsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_RelatedPartyTransactionLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_RelatedPartyTransactionLineItems"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_RelatedPartyTransactionsTextualsAbstract" xlink:label="loc_GH138J37563K_dmpi_RelatedPartyTransactionsTextualsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_RelatedPartyTransactionsTextualsAbstract" xml:lang="en-US">Related Party Transactions Textuals [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_RelatedPartyTransactionsTextualsAbstract" xml:lang="en-US">Related Party Transactions (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_RelatedPartyTransactionsTextualsAbstract" xlink:to="lab_IJ350L59785M_dmpi_RelatedPartyTransactionsTextualsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_OfficersCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_OfficersCompensation" xml:lang="en-US">Officers' Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_OfficersCompensation" xml:lang="en-US">Cash compensation to officers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_OfficersCompensation" xml:lang="en-US">Cash compensation to officers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_OfficersCompensation" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_OfficersCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_GH138J37563K_us-gaap_ProfessionalFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ProfessionalFees" xml:lang="en-US">Professional Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ProfessionalFees" xml:lang="en-US">Consulting fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ProfessionalFees" xml:lang="en-US">Director fees recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ProfessionalFees" xlink:to="lab_IJ350L59785M_us-gaap_ProfessionalFees"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ScheduleOfDerivativeLiabilitiesRollForward" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_ScheduleOfDerivativeLiabilitiesRollForward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ScheduleOfDerivativeLiabilitiesRollForward" xml:lang="en-US">Schedule Of Derivative Liabilities [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ScheduleOfDerivativeLiabilitiesRollForward" xml:lang="en-US">Schedule of derivative liabilities [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ScheduleOfDerivativeLiabilitiesRollForward" xml:lang="en-US">This element represents roll forward of derivatives liabilities from the beginning of a period to the end of a period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_ScheduleOfDerivativeLiabilitiesRollForward" xlink:to="lab_38KL6848L1H8125661MM_dmpi_ScheduleOfDerivativeLiabilitiesRollForward"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_IssuanceOfAgentWarrants" xlink:label="loc_GH138J37563K_dmpi_IssuanceOfAgentWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_IssuanceOfAgentWarrants" xml:lang="en-US">Issuance Of Agent Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_IssuanceOfAgentWarrants" xml:lang="en-US">Issuance of 2015 Agent Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_IssuanceOfAgentWarrants" xml:lang="en-US">Issuance of agent warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_IssuanceOfAgentWarrants" xlink:to="lab_IJ350L59785M_dmpi_IssuanceOfAgentWarrants"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants" xml:lang="en-US">Reclassification Of Derivative Liability To Equity Upon Amendment Of Dividend Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants" xml:lang="en-US">Reclassification of derivative liability to equity upon the amendment of Dividend Warrants (note 5)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants" xml:lang="en-US">Reclassification to equity upon amendment of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants" xml:lang="en-US">Reclassification of derivative liability to equity upon the amendment of Dividend Warrants.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants" xml:lang="en-US">Reclassification of derivative liability to equity upon amendment of warrant terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants" xlink:to="lab_38KL6848L1H8125661MM_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReclassificationOfDerivativeLiabilityToEquityUponExchangeOfInvestorWarrants" xlink:label="loc_GH138J37563K_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponExchangeOfInvestorWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponExchangeOfInvestorWarrants" xml:lang="en-US">Reclassification Of Derivative Liability To Equity Upon Exchange Of Investor Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponExchangeOfInvestorWarrants" xml:lang="en-US">Reclassification to equity upon exchange of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponExchangeOfInvestorWarrants" xml:lang="en-US">Reclassification of derivative liability to equity upon the exchange of Investor Warrants (note 5)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponExchangeOfInvestorWarrants" xml:lang="en-US">Reclassification of derivative liability to equity upon the exchange of Investor Warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponExchangeOfInvestorWarrants" xlink:to="lab_IJ350L59785M_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponExchangeOfInvestorWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_DerivativeTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_DerivativeTable" xml:lang="en-US">Derivative [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_DerivativeTable" xml:lang="en-US">Derivative [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_DerivativeTable" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_DerivativeTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_GH138J37563K_us-gaap_DerivativeInstrumentRiskAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative, by Nature [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_IJ350L59785M_us-gaap_DerivativeInstrumentRiskAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_DerivativeContractTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_DerivativeContractTypeDomain"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_InvestorWarrantsMember" xlink:label="loc_GH138J37563K_dmpi_InvestorWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_InvestorWarrantsMember" xml:lang="en-US">Investor Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_InvestorWarrantsMember" xml:lang="en-US">Investor Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_InvestorWarrantsMember" xml:lang="en-US">Represents investor warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_InvestorWarrantsMember" xlink:to="lab_IJ350L59785M_dmpi_InvestorWarrantsMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_InvestorWarrantExercisesMember" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_InvestorWarrantExercisesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_InvestorWarrantExercisesMember" xml:lang="en-US">Investor Warrant Exercises [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_InvestorWarrantExercisesMember" xlink:to="lab_38KL6848L1H8125661MM_dmpi_InvestorWarrantExercisesMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_WarrantsIssuedForServicesMember" xlink:label="loc_GH138J37563K_dmpi_WarrantsIssuedForServicesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_WarrantsIssuedForServicesMember" xml:lang="en-US">Warrants Issued For Services [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_WarrantsIssuedForServicesMember" xml:lang="en-US">Warrants Issued for Services [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_WarrantsIssuedForServicesMember" xml:lang="en-US">Warrants issued for services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_WarrantsIssuedForServicesMember" xlink:to="lab_IJ350L59785M_dmpi_WarrantsIssuedForServicesMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_InvestorWarrantsExchangeMember" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_InvestorWarrantsExchangeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_InvestorWarrantsExchangeMember" xml:lang="en-US">Investor Warrants Exchange [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_InvestorWarrantsExchangeMember" xml:lang="en-US">Investor Warrants Exchange [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_InvestorWarrantsExchangeMember" xml:lang="en-US">Investor warrants exchange.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_InvestorWarrantsExchangeMember" xlink:to="lab_38KL6848L1H8125661MM_dmpi_InvestorWarrantsExchangeMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_InvestorWarrantAmendmentsMember" xlink:label="loc_GH138J37563K_dmpi_InvestorWarrantAmendmentsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_InvestorWarrantAmendmentsMember" xml:lang="en-US">Investor Warrant Amendments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_InvestorWarrantAmendmentsMember" xml:lang="en-US">Investor warrant amendments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_InvestorWarrantAmendmentsMember" xlink:to="lab_IJ350L59785M_dmpi_InvestorWarrantAmendmentsMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_DividendWarrantsMember" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_DividendWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_DividendWarrantsMember" xml:lang="en-US">Dividend Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_DividendWarrantsMember" xml:lang="en-US">Dividend Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_DividendWarrantsMember" xml:lang="en-US">Dividend warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_DividendWarrantsMember" xlink:to="lab_38KL6848L1H8125661MM_dmpi_DividendWarrantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_GH138J37563K_us-gaap_RangeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_RangeAxis" xlink:to="lab_IJ350L59785M_us-gaap_RangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_RangeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_RangeMember" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_RangeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_GH138J37563K_us-gaap_MaximumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_MaximumMember" xlink:to="lab_IJ350L59785M_us-gaap_MaximumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_MinimumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_MinimumMember" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_MinimumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_GH138J37563K_us-gaap_SubsidiarySaleOfStockAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_IJ350L59785M_us-gaap_SubsidiarySaleOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TwoThousandFifteenAgentWarrantMember" xlink:label="loc_GH138J37563K_dmpi_TwoThousandFifteenAgentWarrantMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_TwoThousandFifteenAgentWarrantMember" xml:lang="en-US">Two Thousand Fifteen Agent Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_TwoThousandFifteenAgentWarrantMember" xml:lang="en-US">2015 Agent Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_TwoThousandFifteenAgentWarrantMember" xml:lang="en-US">A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_TwoThousandFifteenAgentWarrantMember" xlink:to="lab_IJ350L59785M_dmpi_TwoThousandFifteenAgentWarrantMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TwoThousandThirteenPlacementAgentWarrantsMember" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_TwoThousandThirteenPlacementAgentWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_TwoThousandThirteenPlacementAgentWarrantsMember" xml:lang="en-US">Two Thousand Thirteen Placement Agent Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_TwoThousandThirteenPlacementAgentWarrantsMember" xml:lang="en-US">2013 Placement Agent Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_TwoThousandThirteenPlacementAgentWarrantsMember" xml:lang="en-US">Two Thousand Thirteen Placement Agent Warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_TwoThousandThirteenPlacementAgentWarrantsMember" xlink:to="lab_38KL6848L1H8125661MM_dmpi_TwoThousandThirteenPlacementAgentWarrantsMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember" xlink:label="loc_GH138J37563K_dmpi_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember" xml:lang="en-US">Two Thousand Thirteen Placement Agent Warrants Amendments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember" xml:lang="en-US">2013 Placement Agent Warrant Amendments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember" xml:lang="en-US">Two thousand thirteen placement agent warrants amendments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember" xlink:to="lab_IJ350L59785M_dmpi_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_DerivativeLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_DerivativeLineItems" xml:lang="en-US">Derivative [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_DerivativeLineItems" xml:lang="en-US">Derivative [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_DerivativeLineItems" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_DerivativeLineItems"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReverseAcquisitionDescription" xlink:label="loc_GH138J37563K_dmpi_ReverseAcquisitionDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ReverseAcquisitionDescription" xml:lang="en-US">Reverse Acquisition Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_ReverseAcquisitionDescription" xml:lang="en-US">Reverse acquisition description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_ReverseAcquisitionDescription" xml:lang="en-US">Reverse acquisition description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ReverseAcquisitionDescription" xlink:to="lab_IJ350L59785M_dmpi_ReverseAcquisitionDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price of warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price of warrants (in Canadian dollars per warrant)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Price per share for one common stock share acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/zeroLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price of warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of warrant or right, exercise price of warrants or rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise of CA $0.50 unit warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:label="loc_GH138J37563K_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xml:lang="en-US">Gain (Loss) on Fair Value Hedges Recognized in Earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xml:lang="en-US">Recognized loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:to="lab_IJ350L59785M_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ClassOfWarrantOrRightExercised" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_ClassOfWarrantOrRightExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ClassOfWarrantOrRightExercised" xml:lang="en-US">Class Of Warrant Or Right Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ClassOfWarrantOrRightExercised" xml:lang="en-US">Number of warrants of exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ClassOfWarrantOrRightExercised" xml:lang="en-US">Class Of Warrant Or Right Exercised.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_ClassOfWarrantOrRightExercised" xlink:to="lab_38KL6848L1H8125661MM_dmpi_ClassOfWarrantOrRightExercised"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_WarrantsAgentFee" xlink:label="loc_GH138J37563K_dmpi_WarrantsAgentFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_WarrantsAgentFee" xml:lang="en-US">Warrants Agent Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_WarrantsAgentFee" xml:lang="en-US">Agent fee of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_WarrantsAgentFee" xml:lang="en-US">Agent fee of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_WarrantsAgentFee" xlink:to="lab_IJ350L59785M_dmpi_WarrantsAgentFee"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_PercentageOfWarrantAgentFee" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_PercentageOfWarrantAgentFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_PercentageOfWarrantAgentFee" xml:lang="en-US">Percentage Of Warrant Agent Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_PercentageOfWarrantAgentFee" xml:lang="en-US">Percentage of agent fee of warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_PercentageOfWarrantAgentFee" xml:lang="en-US">Percentage of warrant agent fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_PercentageOfWarrantAgentFee" xlink:to="lab_38KL6848L1H8125661MM_dmpi_PercentageOfWarrantAgentFee"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_GrossProceedsFromExerciseOfWarrants" xlink:label="loc_GH138J37563K_dmpi_GrossProceedsFromExerciseOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_GrossProceedsFromExerciseOfWarrants" xml:lang="en-US">Gross Proceeds From Exercise Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_GrossProceedsFromExerciseOfWarrants" xml:lang="en-US">Gross proceeds from exercise of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_GrossProceedsFromExerciseOfWarrants" xml:lang="en-US">Gross proceeds from exercise of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_GrossProceedsFromExerciseOfWarrants" xlink:to="lab_IJ350L59785M_dmpi_GrossProceedsFromExerciseOfWarrants"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants" xml:lang="en-US">Number Of Common Stock Issued Upon Exercise Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants" xml:lang="en-US">Common stock shares issued on exercise of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants" xml:lang="en-US">The number of shares issued on the exercise of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants" xlink:to="lab_38KL6848L1H8125661MM_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_WarrantOutstanding" xlink:label="loc_GH138J37563K_dmpi_WarrantOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_WarrantOutstanding" xml:lang="en-US">Warrant Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_WarrantOutstanding" xml:lang="en-US">Number of warrants outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_WarrantOutstanding" xml:lang="en-US">Closing balance of warrants outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_IJ350L59785M_dmpi_WarrantOutstanding" xml:lang="en-US">Balance - December 31, 2012</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_IJ350L59785M_dmpi_WarrantOutstanding" xml:lang="en-US">Balance - March 31, 2013</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_WarrantOutstanding" xml:lang="en-US">Aggregate amount of each class of warrants outstanding.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_WarrantOutstanding" xlink:to="lab_IJ350L59785M_dmpi_WarrantOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_16IJ4626J9F6903449KK_invest_InvestmentWarrantsExpirationDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_invest_InvestmentWarrantsExpirationDate" xml:lang="en-US">Investment Warrants Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_invest_InvestmentWarrantsExpirationDate" xml:lang="en-US">Warrants expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_invest_InvestmentWarrantsExpirationDate" xlink:to="lab_38KL6848L1H8125661MM_invest_InvestmentWarrantsExpirationDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_GH138J37563K_us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xml:lang="en-US">Derivaitve liability increase to equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_IJ350L59785M_us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TermOfWarrants" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_TermOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_TermOfWarrants" xml:lang="en-US">Term Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_TermOfWarrants" xml:lang="en-US">Term of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_TermOfWarrants" xml:lang="en-US">Represents the term of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_TermOfWarrants" xlink:to="lab_38KL6848L1H8125661MM_dmpi_TermOfWarrants"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ClassOfWarrantOrRightIssued" xlink:label="loc_GH138J37563K_dmpi_ClassOfWarrantOrRightIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ClassOfWarrantOrRightIssued" xml:lang="en-US">Class Of Warrant Or Right Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_ClassOfWarrantOrRightIssued" xml:lang="en-US">Number of investor warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_ClassOfWarrantOrRightIssued" xml:lang="en-US">Number of warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_IJ350L59785M_dmpi_ClassOfWarrantOrRightIssued" xml:lang="en-US">Number of warrants issued to valent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_ClassOfWarrantOrRightIssued" xml:lang="en-US">Aggregate amount of each class of warrants or rights issued.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ClassOfWarrantOrRightIssued" xlink:to="lab_IJ350L59785M_dmpi_ClassOfWarrantOrRightIssued"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReclassificationOfDerivativeLiabilityUponTheExchangeOfInvestorWarrants" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_ReclassificationOfDerivativeLiabilityUponTheExchangeOfInvestorWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ReclassificationOfDerivativeLiabilityUponTheExchangeOfInvestorWarrants" xml:lang="en-US">Reclassification Of Derivative Liability Upon The Exchange Of Investor Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ReclassificationOfDerivativeLiabilityUponTheExchangeOfInvestorWarrants" xml:lang="en-US">Reclassification of derivative liability upon the exchange of Investor Warrants (note 6)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ReclassificationOfDerivativeLiabilityUponTheExchangeOfInvestorWarrants" xml:lang="en-US">Reclassification of derivative liability upon the exchange of Investor Warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_ReclassificationOfDerivativeLiabilityUponTheExchangeOfInvestorWarrants" xlink:to="lab_38KL6848L1H8125661MM_dmpi_ReclassificationOfDerivativeLiabilityUponTheExchangeOfInvestorWarrants"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ScheduleOfCommonStockIssuedAndOutstandingTable" xlink:label="loc_GH138J37563K_dmpi_ScheduleOfCommonStockIssuedAndOutstandingTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ScheduleOfCommonStockIssuedAndOutstandingTable" xml:lang="en-US">Schedule Of Common Stock Issued And Outstanding [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_ScheduleOfCommonStockIssuedAndOutstandingTable" xml:lang="en-US">Represents the tabular information associated with common stock issued and outstanding.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ScheduleOfCommonStockIssuedAndOutstandingTable" xlink:to="lab_IJ350L59785M_dmpi_ScheduleOfCommonStockIssuedAndOutstandingTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_CommonStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_CommonStockMember" xml:lang="en-US">Common stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_CommonStockMember" xml:lang="en-US">Common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_CommonStockMember" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_CommonStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_GH138J37563K_us-gaap_AdditionalPaidInCapitalMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional paid-in capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_IJ350L59785M_us-gaap_AdditionalPaidInCapitalMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems" xml:lang="en-US">Schedule Of Common Stock Issued And Outstanding [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems" xlink:to="lab_38KL6848L1H8125661MM_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_GH138J37563K_us-gaap_SharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_IJ350L59785M_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_IJ350L59785M_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_SharesOutstanding" xlink:to="lab_IJ350L59785M_us-gaap_SharesOutstanding"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedDuringPeriodSharesAndWarrantsValue" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_StockIssuedDuringPeriodSharesAndWarrantsValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockIssuedDuringPeriodSharesAndWarrantsValue" xml:lang="en-US">Stock Issued During Period Shares And Warrants Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockIssuedDuringPeriodSharesAndWarrantsValue" xml:lang="en-US">Issuance of shares and warrants - net of issue costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockIssuedDuringPeriodSharesAndWarrantsValue" xml:lang="en-US">Stock issued during period shares and warrants value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_StockIssuedDuringPeriodSharesAndWarrantsValue" xlink:to="lab_38KL6848L1H8125661MM_dmpi_StockIssuedDuringPeriodSharesAndWarrantsValue"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares" xlink:label="loc_GH138J37563K_dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares" xml:lang="en-US">Stock Issued During Period Shares And Warrants Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares" xml:lang="en-US">Issuance of shares and warrants - net of issue costs, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares" xml:lang="en-US">Warrants issued for services (iii)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares" xml:lang="en-US">Number of shares and warrants issued during the period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares" xlink:to="lab_IJ350L59785M_dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedDuringPeriodValueReclassificationOfWarrants" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_StockIssuedDuringPeriodValueReclassificationOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockIssuedDuringPeriodValueReclassificationOfWarrants" xml:lang="en-US">Stock Issued During Period Value Reclassification Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockIssuedDuringPeriodValueReclassificationOfWarrants" xml:lang="en-US">Reclassification of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockIssuedDuringPeriodValueReclassificationOfWarrants" xml:lang="en-US">Value of stock issued during the period upon the reclassification of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_StockIssuedDuringPeriodValueReclassificationOfWarrants" xlink:to="lab_38KL6848L1H8125661MM_dmpi_StockIssuedDuringPeriodValueReclassificationOfWarrants"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedDuringPeriodValueStockWarrantExercised" xlink:label="loc_GH138J37563K_dmpi_StockIssuedDuringPeriodValueStockWarrantExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_StockIssuedDuringPeriodValueStockWarrantExercised" xml:lang="en-US">Stock Issued During Period Value Stock Warrant Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_StockIssuedDuringPeriodValueStockWarrantExercised" xml:lang="en-US">Exercise of warrants for cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_StockIssuedDuringPeriodValueStockWarrantExercised" xml:lang="en-US">Value of stock issued as a result of the exercise of stock warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_StockIssuedDuringPeriodValueStockWarrantExercised" xlink:to="lab_IJ350L59785M_dmpi_StockIssuedDuringPeriodValueStockWarrantExercised"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised" xml:lang="en-US">Stock Issued During Period Shares Stock Warrant Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised" xml:lang="en-US">Exercise of warrants for cash, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised" xml:lang="en-US">Warrants issued for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised" xml:lang="en-US">Number of sharewarrants (or share units) exercised during the current period.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised" xml:lang="en-US">Warrants exercised for cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised" xlink:to="lab_38KL6848L1H8125661MM_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_GH138J37563K_us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Shares issued for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Warrants issued for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_IJ350L59785M_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Shares issued for services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_IJ350L59785M_us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Shares of common stock for services to unrelated parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Warrants issued for services, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Shares issued for services, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Shares issued for services, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_GH138J37563K_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock option recognized as additional paid in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock option recognized as additional paid in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_IJ350L59785M_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation (note 9)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_IJ350L59785M_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule Of Share-Based Compensation Arrangements By Share-Based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_GH138J37563K_us-gaap_AwardTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_AwardTypeAxis" xlink:to="lab_IJ350L59785M_us-gaap_AwardTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_GH138J37563K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Number of stock options outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_GH138J37563K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of stock options outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of options, granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Granted stock option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of unvested options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of options, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_GH138J37563K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Number of options, forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross" xml:lang="en-US">Number of options, Cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross" xml:lang="en-US">Cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross" xml:lang="en-US">Gross number of share options (or share units) cancelled during the period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross" xlink:to="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_GH138J37563K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Weighted average exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_GH138J37563K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price unvested, granted (in Dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price unvested, granted (in Candian dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Issued (in Dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Exercise price (in Canadian dollar)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:label="loc_GH138J37563K_dmpi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average per share amount at which cancelled can acquire shares of common stock by exercise of options.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:to="lab_IJ350L59785M_dmpi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US">Exercise Price Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_GH138J37563K_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_IJ350L59785M_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ZeroPointThreeNineMember" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_ZeroPointThreeNineMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ZeroPointThreeNineMember" xml:lang="en-US">Zero Point Three Nine [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ZeroPointThreeNineMember" xml:lang="en-US">0.39 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ZeroPointThreeNineMember" xml:lang="en-US">Exercise price range starts from zero point three nine.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_ZeroPointThreeNineMember" xlink:to="lab_38KL6848L1H8125661MM_dmpi_ZeroPointThreeNineMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ZeroPointSevenFourMember" xlink:label="loc_GH138J37563K_dmpi_ZeroPointSevenFourMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ZeroPointSevenFourMember" xml:lang="en-US">Zero Point Seven Four [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_ZeroPointSevenFourMember" xml:lang="en-US">0.74 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_ZeroPointSevenFourMember" xml:lang="en-US">Zero point seven four.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ZeroPointSevenFourMember" xlink:to="lab_IJ350L59785M_dmpi_ZeroPointSevenFourMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ZeroPointEightZeroMember" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_ZeroPointEightZeroMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ZeroPointEightZeroMember" xml:lang="en-US">Zero Point Eight Zero [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ZeroPointEightZeroMember" xml:lang="en-US">0.80 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ZeroPointEightZeroMember" xml:lang="en-US">Zero point eight zero.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_ZeroPointEightZeroMember" xlink:to="lab_38KL6848L1H8125661MM_dmpi_ZeroPointEightZeroMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ZeroPointNineFourMember" xlink:label="loc_GH138J37563K_dmpi_ZeroPointNineFourMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ZeroPointNineFourMember" xml:lang="en-US">Zero Point Nine Four [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_ZeroPointNineFourMember" xml:lang="en-US">0.94 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_ZeroPointNineFourMember" xml:lang="en-US">Exercise price range starts from zero point nine four.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ZeroPointNineFourMember" xlink:to="lab_IJ350L59785M_dmpi_ZeroPointNineFourMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_OnePointZeroZeroMember" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_OnePointZeroZeroMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_OnePointZeroZeroMember" xml:lang="en-US">One Point Zero Zero [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_OnePointZeroZeroMember" xml:lang="en-US">1.00 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_OnePointZeroZeroMember" xlink:to="lab_38KL6848L1H8125661MM_dmpi_OnePointZeroZeroMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_OnepointzerofiveMember" xlink:label="loc_GH138J37563K_dmpi_OnepointzerofiveMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_OnepointzerofiveMember" xml:lang="en-US">Onepointzerofivemember [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_OnepointzerofiveMember" xml:lang="en-US">1.05 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_OnepointzerofiveMember" xml:lang="en-US">Exercise price.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_OnepointzerofiveMember" xlink:to="lab_IJ350L59785M_dmpi_OnepointzerofiveMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_OnePointOneTwoMember" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_OnePointOneTwoMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_OnePointOneTwoMember" xml:lang="en-US">One Point One Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_OnePointOneTwoMember" xml:lang="en-US">1.12 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_OnePointOneTwoMember" xml:lang="en-US">Exercise price range starts from one point one two.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_OnePointOneTwoMember" xlink:to="lab_38KL6848L1H8125661MM_dmpi_OnePointOneTwoMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_OnePointFiveFourMember" xlink:label="loc_GH138J37563K_dmpi_OnePointFiveFourMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_OnePointFiveFourMember" xml:lang="en-US">One Point Five Four [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_OnePointFiveFourMember" xml:lang="en-US">1.54 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_OnePointFiveFourMember" xlink:to="lab_IJ350L59785M_dmpi_OnePointFiveFourMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TwoPointThreeZeroMember" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_TwoPointThreeZeroMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_TwoPointThreeZeroMember" xml:lang="en-US">Two Point Three Zero [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_TwoPointThreeZeroMember" xml:lang="en-US">2.30 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_TwoPointThreeZeroMember" xlink:to="lab_38KL6848L1H8125661MM_dmpi_TwoPointThreeZeroMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ZeroPointNineTwoMember" xlink:label="loc_GH138J37563K_dmpi_ZeroPointNineTwoMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ZeroPointNineTwoMember" xml:lang="en-US">Zero Point Nine Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_ZeroPointNineTwoMember" xml:lang="en-US">0.92 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ZeroPointNineTwoMember" xlink:to="lab_IJ350L59785M_dmpi_ZeroPointNineTwoMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_GH138J37563K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted average remaining contractual life (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Number of stock options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_GH138J37563K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_GH138J37563K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk Free Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_GH138J37563K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Initial Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Term - years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Initial term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_IncomeStatementLocationAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_IncomeStatementLocationAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_GH138J37563K_us-gaap_IncomeStatementLocationDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_IJ350L59785M_us-gaap_IncomeStatementLocationDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ResearchAndDevelopmentExpenseMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and development [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ResearchAndDevelopmentExpenseMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_GH138J37563K_us-gaap_GeneralAndAdministrativeExpenseMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_IJ350L59785M_us-gaap_GeneralAndAdministrativeExpenseMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_AllocatedShareBasedCompensationExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-Based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock-based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_AllocatedShareBasedCompensationExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="loc_GH138J37563K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xml:lang="en-US">Number of Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xml:lang="en-US">Number of options unvested, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xml:lang="en-US">Number of options unvested, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_GH138J37563K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Number of options, Vested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Number of options, Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xml:lang="en-US">Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xml:lang="en-US">Number of options, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xml:lang="en-US">Number of options, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward" xlink:label="loc_GH138J37563K_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward" xml:lang="en-US">Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward" xml:lang="en-US">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward" xlink:to="lab_IJ350L59785M_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price unvested, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price unvested, Ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice" xml:lang="en-US">Represents the weighted average price unvested stock options.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice" xlink:to="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice" xlink:label="loc_GH138J37563K_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Stock Options Granted Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price unvested, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice" xml:lang="en-US">Represents the weighted average price granted stock options during the period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice" xlink:to="lab_IJ350L59785M_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Stock Options Vested Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price unvested, Vested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice" xml:lang="en-US">Represents the weighted average price vested stock options during the period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice" xlink:to="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice" xlink:label="loc_GH138J37563K_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Stock Options Forfeited Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice" xml:lang="en-US">Weighted average excercise price unvested, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice" xml:lang="en-US">Represents the weighted average price forfeited stock options during the period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice" xlink:to="lab_IJ350L59785M_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsCancelledWeightedAverageExercisePrice" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsCancelledWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsCancelledWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Stock Options Cancelled Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsCancelledWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price unvested, Cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsCancelledWeightedAverageExercisePrice" xml:lang="en-US">Represents the weighted average price cancelled stock options during the period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsCancelledWeightedAverageExercisePrice" xlink:to="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsCancelledWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="loc_GH138J37563K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xml:lang="en-US">Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value, unvested, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value, unvested, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_GH138J37563K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value, unvested, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value, unvested, granted (in Dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value, unvested, Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_GH138J37563K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value, unvested,Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value, unvested, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value, unvested, Cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant-date fair value of non-vested options cancelled.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NumberOfWarrantsRollForward" xlink:label="loc_GH138J37563K_dmpi_NumberOfWarrantsRollForward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_NumberOfWarrantsRollForward" xml:lang="en-US">Number Of Warrants [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_NumberOfWarrantsRollForward" xml:lang="en-US">Number of Warrants [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_NumberOfWarrantsRollForward" xml:lang="en-US">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_NumberOfWarrantsRollForward" xlink:to="lab_IJ350L59785M_dmpi_NumberOfWarrantsRollForward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ClassOfWarrantOrRightOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Closing balance of warrants outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Number of warrants exercised on a cashless shares of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Warrants outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightOutstanding"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NumberOfOfferingWarrants" xlink:label="loc_GH138J37563K_dmpi_NumberOfOfferingWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_NumberOfOfferingWarrants" xml:lang="en-US">Number Of Offering Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_NumberOfOfferingWarrants" xml:lang="en-US">2015 Public Offering Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_NumberOfOfferingWarrants" xml:lang="en-US">Number of offering warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_NumberOfOfferingWarrants" xlink:to="lab_IJ350L59785M_dmpi_NumberOfOfferingWarrants"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NumberOfWarrantsIssuedToAgents" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_NumberOfWarrantsIssuedToAgents"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_NumberOfWarrantsIssuedToAgents" xml:lang="en-US">Number Of Warrants Issued To Agents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_NumberOfWarrantsIssuedToAgents" xml:lang="en-US">2015 Agent Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_NumberOfWarrantsIssuedToAgents" xml:lang="en-US">Number of warrants issued to agents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_NumberOfWarrantsIssuedToAgents" xml:lang="en-US">Number of warrants issued to agents.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_NumberOfWarrantsIssuedToAgents" xlink:to="lab_38KL6848L1H8125661MM_dmpi_NumberOfWarrantsIssuedToAgents"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NumberOfWarrantsIssuedForServices" xlink:label="loc_GH138J37563K_dmpi_NumberOfWarrantsIssuedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_NumberOfWarrantsIssuedForServices" xml:lang="en-US">Number Of Warrants Issued For Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_NumberOfWarrantsIssuedForServices" xml:lang="en-US">Number of warrants issued for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_NumberOfWarrantsIssuedForServices" xml:lang="en-US">Warrants issued for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_NumberOfWarrantsIssuedForServices" xml:lang="en-US">Number of warrants issued for services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_NumberOfWarrantsIssuedForServices" xlink:to="lab_IJ350L59785M_dmpi_NumberOfWarrantsIssuedForServices"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockholdersEquityNoteTable" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_StockholdersEquityNoteTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockholdersEquityNoteTable" xml:lang="en-US">Stockholders Equity Note [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockholdersEquityNoteTable" xml:lang="en-US">Stockholders Equity Note [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockholdersEquityNoteTable" xml:lang="en-US">Table for shareholders' equity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_StockholdersEquityNoteTable" xlink:to="lab_38KL6848L1H8125661MM_dmpi_StockholdersEquityNoteTable"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ExchangeAgreementMember" xlink:label="loc_GH138J37563K_dmpi_ExchangeAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ExchangeAgreementMember" xml:lang="en-US">Exchange Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_ExchangeAgreementMember" xml:lang="en-US">Reverse Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_ExchangeAgreementMember" xml:lang="en-US">Exchange Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_ExchangeAgreementMember" xml:lang="en-US">Represents information about exchange agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ExchangeAgreementMember" xlink:to="lab_IJ350L59785M_dmpi_ExchangeAgreementMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockholdersEquityNoteLineItems" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_StockholdersEquityNoteLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockholdersEquityNoteLineItems" xml:lang="en-US">Stockholders Equity Note [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockholdersEquityNoteLineItems" xml:lang="en-US">Stockholders Equity Note [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockholdersEquityNoteLineItems" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_StockholdersEquityNoteLineItems" xlink:to="lab_38KL6848L1H8125661MM_dmpi_StockholdersEquityNoteLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_GH138J37563K_us-gaap_CommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, Shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/zeroLabel" xlink:label="lab_IJ350L59785M_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Number of outstanding shares of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_IJ350L59785M_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_IJ350L59785M_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_IJ350L59785M_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedAndOutstandingOnExchangedBasis" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_StockIssuedAndOutstandingOnExchangedBasis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockIssuedAndOutstandingOnExchangedBasis" xml:lang="en-US">Stock Issued And Outstanding On Exchanged Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockIssuedAndOutstandingOnExchangedBasis" xml:lang="en-US">Stock issued and outstanding on exchanged basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_StockIssuedAndOutstandingOnExchangedBasis" xml:lang="en-US">Issued and outstanding of common stock on an as-exchanged basis.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_StockIssuedAndOutstandingOnExchangedBasis" xlink:to="lab_38KL6848L1H8125661MM_dmpi_StockIssuedAndOutstandingOnExchangedBasis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_GH138J37563K_us-gaap_ClassOfWarrantOrRightAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_IJ350L59785M_us-gaap_ClassOfWarrantOrRightAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ClassOfWarrantOrRightDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightDomain"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_BrokerWarrantsMember" xlink:label="loc_GH138J37563K_dmpi_BrokerWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_BrokerWarrantsMember" xml:lang="en-US">Broker Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_BrokerWarrantsMember" xlink:to="lab_IJ350L59785M_dmpi_BrokerWarrantsMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_InvestorWarrantExchangeMember" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_InvestorWarrantExchangeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_InvestorWarrantExchangeMember" xml:lang="en-US">Investor Warrant Exchange [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_InvestorWarrantExchangeMember" xlink:to="lab_38KL6848L1H8125661MM_dmpi_InvestorWarrantExchangeMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TwoZeroOneFiveAgentWarrantsMember" xlink:label="loc_GH138J37563K_dmpi_TwoZeroOneFiveAgentWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_TwoZeroOneFiveAgentWarrantsMember" xml:lang="en-US">Two Zero One Five Agent Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_TwoZeroOneFiveAgentWarrantsMember" xml:lang="en-US">2015 Agent Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_TwoZeroOneFiveAgentWarrantsMember" xml:lang="en-US">It represents about agent warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_TwoZeroOneFiveAgentWarrantsMember" xlink:to="lab_IJ350L59785M_dmpi_TwoZeroOneFiveAgentWarrantsMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TwoZeroOneFiveOfferingWarrantsMember" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_TwoZeroOneFiveOfferingWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_TwoZeroOneFiveOfferingWarrantsMember" xml:lang="en-US">Two Zero One Five Offering Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_TwoZeroOneFiveOfferingWarrantsMember" xml:lang="en-US">2015 offering warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_TwoZeroOneFiveOfferingWarrantsMember" xml:lang="en-US">It represents about offering warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_TwoZeroOneFiveOfferingWarrantsMember" xlink:to="lab_38KL6848L1H8125661MM_dmpi_TwoZeroOneFiveOfferingWarrantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_GH138J37563K_us-gaap_VestingAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_VestingAxis" xlink:to="lab_IJ350L59785M_us-gaap_VestingAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_VestingDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_VestingDomain" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_VestingDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_GH138J37563K_us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">November 30, 2015 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_IJ350L59785M_us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xml:lang="en-US">Share-based Compensation Award, Tranche Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xml:lang="en-US">March 31, [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_GH138J37563K_us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xml:lang="en-US">Share-based Compensation Award, Tranche Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xml:lang="en-US">January 31, 2016 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_IJ350L59785M_us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationAwardTrancheFourMember" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_ShareBasedCompensationAwardTrancheFourMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationAwardTrancheFourMember" xml:lang="en-US">Share Based Compensation Award Tranche Four [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationAwardTrancheFourMember" xml:lang="en-US">March 1, 2015 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationAwardTrancheFourMember" xml:lang="en-US">Four portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_ShareBasedCompensationAwardTrancheFourMember" xlink:to="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationAwardTrancheFourMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationAwardTrancheFiveMember" xlink:label="loc_GH138J37563K_dmpi_ShareBasedCompensationAwardTrancheFiveMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationAwardTrancheFiveMember" xml:lang="en-US">Share Based Compensation Award Tranche Five [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationAwardTrancheFiveMember" xml:lang="en-US">February 29, 2016 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationAwardTrancheFiveMember" xml:lang="en-US">Five portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ShareBasedCompensationAwardTrancheFiveMember" xlink:to="lab_IJ350L59785M_dmpi_ShareBasedCompensationAwardTrancheFiveMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationAwardTrancheSixMember" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_ShareBasedCompensationAwardTrancheSixMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationAwardTrancheSixMember" xml:lang="en-US">Share Based Compensation Award Tranche Six [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationAwardTrancheSixMember" xml:lang="en-US">March 31, 2016 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationAwardTrancheSixMember" xml:lang="en-US">six portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.ShareBasedCompensationAwardTranchesixMember</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_ShareBasedCompensationAwardTrancheSixMember" xlink:to="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationAwardTrancheSixMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationAwardTrancheSevenMember" xlink:label="loc_GH138J37563K_dmpi_ShareBasedCompensationAwardTrancheSevenMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationAwardTrancheSevenMember" xml:lang="en-US">Share Based Compensation Award Tranche Seven [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationAwardTrancheSevenMember" xml:lang="en-US">April 30, 2016 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationAwardTrancheSevenMember" xml:lang="en-US">seven portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ShareBasedCompensationAwardTrancheSevenMember" xlink:to="lab_IJ350L59785M_dmpi_ShareBasedCompensationAwardTrancheSevenMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationAwardTrancheEightMember" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_ShareBasedCompensationAwardTrancheEightMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationAwardTrancheEightMember" xml:lang="en-US">Share Based Compensation Award Tranche Eight [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationAwardTrancheEightMember" xml:lang="en-US">May 31, 2016 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationAwardTrancheEightMember" xml:lang="en-US">Eight portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_ShareBasedCompensationAwardTrancheEightMember" xlink:to="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationAwardTrancheEightMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationAwardTrancheNineMember" xlink:label="loc_GH138J37563K_dmpi_ShareBasedCompensationAwardTrancheNineMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationAwardTrancheNineMember" xml:lang="en-US">Share Based Compensation Award Tranche Nine [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationAwardTrancheNineMember" xml:lang="en-US">June 30, 2016 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_ShareBasedCompensationAwardTrancheNineMember" xml:lang="en-US">Nine portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_ShareBasedCompensationAwardTrancheNineMember" xlink:to="lab_IJ350L59785M_dmpi_ShareBasedCompensationAwardTrancheNineMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationAwardTrancheTenMember" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_ShareBasedCompensationAwardTrancheTenMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationAwardTrancheTenMember" xml:lang="en-US">Share Based Compensation Award Tranche Ten [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationAwardTrancheTenMember" xml:lang="en-US">July 31, 2016 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationAwardTrancheTenMember" xml:lang="en-US">Ten portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_ShareBasedCompensationAwardTrancheTenMember" xlink:to="lab_38KL6848L1H8125661MM_dmpi_ShareBasedCompensationAwardTrancheTenMember"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockOptionExpense" xlink:label="loc_GH138J37563K_dmpi_StockOptionExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_StockOptionExpense" xml:lang="en-US">Stock Option Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_StockOptionExpense" xml:lang="en-US">Stock Option Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_StockOptionExpense" xml:lang="en-US">Stock option expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_StockOptionExpense" xlink:to="lab_IJ350L59785M_dmpi_StockOptionExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate intrinsic value of stock options outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_GH138J37563K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Aggregate intrinsic value of stock options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_IJ350L59785M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Unrecognized compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_GH138J37563K_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Unrecognized compensation expense, period of recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_IJ350L59785M_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Number of common stock called by warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Outstanding warrants to purchase common shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Number of shares of common stock called by warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_GH138J37563K_invest_InvestmentWarrantsExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_invest_InvestmentWarrantsExercisePrice" xml:lang="en-US">Investment Warrants, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_invest_InvestmentWarrantsExercisePrice" xml:lang="en-US">Warrants exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_invest_InvestmentWarrantsExercisePrice" xlink:to="lab_IJ350L59785M_invest_InvestmentWarrantsExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_SaleOfStockDescriptionOfTransaction"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Sale of Stock, Description of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Sale of stock description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_SaleOfStockDescriptionOfTransaction"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_CashCommission" xlink:label="loc_GH138J37563K_dmpi_CashCommission"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_CashCommission" xml:lang="en-US">Cash Commission</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_CashCommission" xml:lang="en-US">Total cash commission</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_CashCommission" xml:lang="en-US">Expenses recognized in the period that are directly related to the commission.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_CashCommission" xlink:to="lab_IJ350L59785M_dmpi_CashCommission"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_PaymentsOfDerivativeIssuanceCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PaymentsOfDerivativeIssuanceCosts" xml:lang="en-US">Payments of Derivative Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PaymentsOfDerivativeIssuanceCosts" xml:lang="en-US">Issuance of cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_PaymentsOfDerivativeIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_GH138J37563K_us-gaap_ProceedsFromIssuanceOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Gross proceeds from exercise of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Gross proceeds from exercise of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_IJ350L59785M_us-gaap_ProceedsFromIssuanceOfWarrants"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_NoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_NoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued" xml:lang="en-US">Noncash Financial Or Equity Instrument Consideration, Warrants Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_NoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued" xml:lang="en-US">Issuance of noncash finance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_NoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued" xml:lang="en-US">The amount of warrants issued as [noncash or part noncash] consideration for a business or asset acquired.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_NoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued" xlink:to="lab_38KL6848L1H8125661MM_dmpi_NoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_GH138J37563K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Warrants vest in tranches</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_IJ350L59785M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReductionInStockOptionLiability" xlink:label="loc_16IJ4626J9F6903449KK_dmpi_ReductionInStockOptionLiability"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ReductionInStockOptionLiability" xml:lang="en-US">Reduction In Stock Option Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ReductionInStockOptionLiability" xml:lang="en-US">Reduction in stock option liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_38KL6848L1H8125661MM_dmpi_ReductionInStockOptionLiability" xml:lang="en-US">Reduction in stock option liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_dmpi_ReductionInStockOptionLiability" xlink:to="lab_38KL6848L1H8125661MM_dmpi_ReductionInStockOptionLiability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_GH138J37563K_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_IJ350L59785M_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_GH138J37563K_us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_IJ350L59785M_us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_FairValueInputsLevel1Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_FairValueInputsLevel1Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_GH138J37563K_us-gaap_FairValueInputsLevel2Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_IJ350L59785M_us-gaap_FairValueInputsLevel2Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_FairValueInputsLevel3Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_FairValueInputsLevel3Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_GH138J37563K_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_IJ350L59785M_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_DerivativeLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_DerivativeLiabilities" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_DerivativeLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_GH138J37563K_us-gaap_SubsequentEventTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_SubsequentEventTable" xlink:to="lab_IJ350L59785M_us-gaap_SubsequentEventTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_SubsequentEventTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_SubsequentEventTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_GH138J37563K_us-gaap_SubsequentEventTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_IJ350L59785M_us-gaap_SubsequentEventTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_SubsequentEventMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_SubsequentEventMember" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_SubsequentEventMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_GH138J37563K_us-gaap_SeriesBPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B preferred stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_IJ350L59785M_us-gaap_SeriesBPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_PrivatePlacementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PrivatePlacementMember" xml:lang="en-US">Placement Agent Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_PrivatePlacementMember" xml:lang="en-US">Placement Agents [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_PrivatePlacementMember" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_PrivatePlacementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_GH138J37563K_us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="lab_IJ350L59785M_us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_GH138J37563K_us-gaap_SubsequentEventLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_SubsequentEventLineItems" xlink:to="lab_IJ350L59785M_us-gaap_SubsequentEventLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US">Gross proceeds from preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_GH138J37563K_us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Conversion price of Series B Preferred Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_IJ350L59785M_us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockDescription" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_ConversionOfStockDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ConversionOfStockDescription" xml:lang="en-US">Conversion of Stock, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_ConversionOfStockDescription" xml:lang="en-US">Series B Preferred Share conversion terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_ConversionOfStockDescription" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_ConversionOfStockDescription"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_EngagementAgreementPrivatePlacementDescription" xlink:label="loc_GH138J37563K_dmpi_EngagementAgreementPrivatePlacementDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_EngagementAgreementPrivatePlacementDescription" xml:lang="en-US">Engagement Agreement Private Placement Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_EngagementAgreementPrivatePlacementDescription" xml:lang="en-US">Engagement agreement private placement description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_EngagementAgreementPrivatePlacementDescription" xml:lang="en-US">Engagement agreement private placement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_EngagementAgreementPrivatePlacementDescription" xlink:to="lab_IJ350L59785M_dmpi_EngagementAgreementPrivatePlacementDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Warrants or Options Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xml:lang="en-US">Warrant issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_CommissionPaidInLeiuOfIssuanceOfWarrants" xlink:label="loc_GH138J37563K_dmpi_CommissionPaidInLeiuOfIssuanceOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_CommissionPaidInLeiuOfIssuanceOfWarrants" xml:lang="en-US">Commission Paid In Leiu Of Issuance Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_IJ350L59785M_dmpi_CommissionPaidInLeiuOfIssuanceOfWarrants" xml:lang="en-US">Cash commission</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_CommissionPaidInLeiuOfIssuanceOfWarrants" xml:lang="en-US">Commission Paid In Leiu Of Issuance Of Warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_CommissionPaidInLeiuOfIssuanceOfWarrants" xlink:to="lab_IJ350L59785M_dmpi_CommissionPaidInLeiuOfIssuanceOfWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_16IJ4626J9F6903449KK_us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_38KL6848L1H8125661MM_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Net cash proceeds from private placement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_16IJ4626J9F6903449KK_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_38KL6848L1H8125661MM_us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_DerivativeLiabilityEquityIssuanceReclassified" xlink:label="loc_GH138J37563K_dmpi_DerivativeLiabilityEquityIssuanceReclassified"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IJ350L59785M_dmpi_DerivativeLiabilityEquityIssuanceReclassified" xml:lang="en-US">Derivative Liability Equity Issuance Reclassified</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IJ350L59785M_dmpi_DerivativeLiabilityEquityIssuanceReclassified" xml:lang="en-US">Derivative liability, equity issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_IJ350L59785M_dmpi_DerivativeLiabilityEquityIssuanceReclassified" xml:lang="en-US">Derivative liability equity issuance reclassified.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_GH138J37563K_dmpi_DerivativeLiabilityEquityIssuanceReclassified" xlink:to="lab_IJ350L59785M_dmpi_DerivativeLiabilityEquityIssuanceReclassified"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>dmpi-20160331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Thursday, May 12, 2016 11:32:27 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#DocumentAndEntityInformation" roleURI="http://www.delmarpharma.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#ConsolidatedCondensedInterimBalanceSheetsUnaudited" roleURI="http://www.delmarpharma.com/role/ConsolidatedCondensedInterimBalanceSheetsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Consolidatedcondensedinterimbalancesheetsunauditedparenthetical" roleURI="http://www.delmarpharma.com/role/Consolidatedcondensedinterimbalancesheetsunauditedparenthetical"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#ConsolidatedcondensedinterimstatementoflossandcomprehensivelossUnaudited" roleURI="http://www.delmarpharma.com/role/ConsolidatedcondensedinterimstatementoflossandcomprehensivelossUnaudited"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#ConsolidatedCondensedInterimStatementOfCashFlowsUnaudited" roleURI="http://www.delmarpharma.com/role/ConsolidatedCondensedInterimStatementOfCashFlowsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#NatureOfOperationsAndLiquidityRisk" roleURI="http://www.delmarpharma.com/role/NatureOfOperationsAndLiquidityRisk"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Restatementofpreviouslyissuedfinancialstatements" roleURI="http://www.delmarpharma.com/role/Restatementofpreviouslyissuedfinancialstatements"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#SignificantAccountingPolicies" roleURI="http://www.delmarpharma.com/role/SignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#ValentTechnologiesLlc" roleURI="http://www.delmarpharma.com/role/ValentTechnologiesLlc"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#RelatedPartyTransactions" roleURI="http://www.delmarpharma.com/role/RelatedPartyTransactions"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#DerivativeLiability" roleURI="http://www.delmarpharma.com/role/DerivativeLiability"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Stockholdersequity" roleURI="http://www.delmarpharma.com/role/Stockholdersequity"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Financialinstruments" roleURI="http://www.delmarpharma.com/role/Financialinstruments"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#SubsequentEvents" roleURI="http://www.delmarpharma.com/role/SubsequentEvents"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://www.delmarpharma.com/role/SignificantAccountingPoliciesPolicies"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Restatementofpreviouslyissuedfinancialstatementstables" roleURI="http://www.delmarpharma.com/role/Restatementofpreviouslyissuedfinancialstatementstables"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#DerivativeliabilityTables" roleURI="http://www.delmarpharma.com/role/DerivativeliabilityTables"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Stockholdersequitytables" roleURI="http://www.delmarpharma.com/role/Stockholdersequitytables"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Financialinstrumentstables" roleURI="http://www.delmarpharma.com/role/Financialinstrumentstables"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#NatureOfOperationsAndLiquidityRiskDetailsTextual" roleURI="http://www.delmarpharma.com/role/NatureOfOperationsAndLiquidityRiskDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#RestatementOfPreviouslyIssuedFinancialStatementsDetails" roleURI="http://www.delmarpharma.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Significantaccountingpoliciesdetails" roleURI="http://www.delmarpharma.com/role/Significantaccountingpoliciesdetails"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#ValentTechnologiesLlcDetails" roleURI="http://www.delmarpharma.com/role/ValentTechnologiesLlcDetails"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#RelatedPartyTransactionsDetails" roleURI="http://www.delmarpharma.com/role/RelatedPartyTransactionsDetails"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#DerivativeLiabilityDetails" roleURI="http://www.delmarpharma.com/role/DerivativeLiabilityDetails"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#DerivativeLiabilityDetailsTextual" roleURI="http://www.delmarpharma.com/role/DerivativeLiabilityDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Stockholdersequitydetails" roleURI="http://www.delmarpharma.com/role/Stockholdersequitydetails"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Stockholdersequitydetails1" roleURI="http://www.delmarpharma.com/role/Stockholdersequitydetails1"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Stockholdersequitydetails2" roleURI="http://www.delmarpharma.com/role/Stockholdersequitydetails2"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Stockholdersequitydetails3" roleURI="http://www.delmarpharma.com/role/Stockholdersequitydetails3"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Stockholdersequitydetails4" roleURI="http://www.delmarpharma.com/role/Stockholdersequitydetails4"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Stockholdersequitydetails5" roleURI="http://www.delmarpharma.com/role/Stockholdersequitydetails5"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Stockholdersequitydetails6" roleURI="http://www.delmarpharma.com/role/Stockholdersequitydetails6"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#StockholdersEquityDetailsTextual" roleURI="http://www.delmarpharma.com/role/StockholdersEquityDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#StockholdersEquityDetailsTextual1" roleURI="http://www.delmarpharma.com/role/StockholdersEquityDetailsTextual1"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#Financialinstrumentsdetails" roleURI="http://www.delmarpharma.com/role/Financialinstrumentsdetails"/>
<roleRef xlink:type="simple" xlink:href="dmpi-20160331.xsd#SubsequentEventsDetails" roleURI="http://www.delmarpharma.com/role/SubsequentEventsDetails"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_DocumentAndEntityInformationAbstract" xlink:label="loc_dmpi_DocumentAndEntityInformationAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_TradingSymbol_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_7" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_8" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_9" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_10" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_11" order="100" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/ConsolidatedCondensedInterimBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TaxesAndOtherReceivablesCurrent" xlink:label="loc_dmpi_TaxesAndOtherReceivablesCurrent_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_dmpi_TaxesAndOtherReceivablesCurrent_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaap_DeferredCostsCurrent_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_DeferredCostsCurrent_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_AssetsCurrent_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAbstract_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_10" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_11" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_11" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_11" xlink:to="loc_us-gaap_LiabilitiesCurrent_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockOptionLiabilityNoncurrent" xlink:label="loc_dmpi_StockOptionLiabilityNoncurrent_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_10" xlink:to="loc_dmpi_StockOptionLiabilityNoncurrent_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_10" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_10" xlink:to="loc_us-gaap_Liabilities_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_10" xlink:to="loc_us-gaap_StockholdersEquityAbstract_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_PreferredStockValue_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_VotingShare" xlink:label="loc_dmpi_VotingShare_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_dmpi_VotingShare_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_CommonStockValue_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_25" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_StockholdersEquity_26" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_10" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_27" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Consolidatedcondensedinterimbalancesheetsunauditedparenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_PreferredStockSharesIssued_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_PreferredStockSpecialVotingSharesIssued" xlink:label="loc_dmpi_PreferredStockSpecialVotingSharesIssued_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dmpi_PreferredStockSpecialVotingSharesIssued_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_CommonStockSharesIssued_13" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/ConsolidatedcondensedinterimstatementoflossandcomprehensivelossUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_OperatingExpenses_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" xlink:label="loc_dmpi_GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5" xlink:to="loc_dmpi_GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_GainLossOnExchangeOfWarrants" xlink:label="loc_dmpi_GainLossOnExchangeOfWarrants_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5" xlink:to="loc_dmpi_GainLossOnExchangeOfWarrants_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5" xlink:to="loc_us-gaap_InterestExpense_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5" xlink:to="loc_us-gaap_InterestIncomeOther_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasic_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/ConsolidatedCondensedInterimStatementOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AdjustmentForAmortization_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_InterestExpenseDebt_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" xlink:label="loc_dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_GainLossOnExchangeOfWarrants" xlink:label="loc_dmpi_GainLossOnExchangeOfWarrants_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_dmpi_GainLossOnExchangeOfWarrants_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_IssuanceOfStockForServices" xlink:label="loc_dmpi_IssuanceOfStockForServices_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_dmpi_IssuanceOfStockForServices_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_ShareBasedCompensation_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems" xlink:label="loc_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_13" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_IncreaseDecreaseInTaxesAndOtherReceivables" xlink:label="loc_dmpi_IncreaseDecreaseInTaxesAndOtherReceivables_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_13" xlink:to="loc_dmpi_IncreaseDecreaseInTaxesAndOtherReceivables_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_13" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_13" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_13" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_13" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ProceedsFromIssuanceOfSharesAndWarrants" xlink:label="loc_dmpi_ProceedsFromIssuanceOfSharesAndWarrants_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" xlink:to="loc_dmpi_ProceedsFromIssuanceOfSharesAndWarrants_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" xlink:to="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_26" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_27" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_29" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_32" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_IssuanceOfPreferredSharesForTheSettlementOfTheLoanPayable" xlink:label="loc_dmpi_IssuanceOfPreferredSharesForTheSettlementOfTheLoanPayable_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_32" xlink:to="loc_dmpi_IssuanceOfPreferredSharesForTheSettlementOfTheLoanPayable_33" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants" xlink:label="loc_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_32" xlink:to="loc_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants_34" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants" xlink:label="loc_dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_32" xlink:to="loc_dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants_35" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions" xlink:label="loc_dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_32" xlink:to="loc_dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions_36" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_DeferredCostsRecognizedAsEquityIssueCosts" xlink:label="loc_dmpi_DeferredCostsRecognizedAsEquityIssueCosts_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_32" xlink:to="loc_dmpi_DeferredCostsRecognizedAsEquityIssueCosts_37" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/NatureOfOperationsAndLiquidityRisk">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_NatureOfOperations_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Restatementofpreviouslyissuedfinancialstatements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_0" xlink:to="loc_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/SignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/ValentTechnologiesLlc">
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ValentTechnologiesLlcAbstract" xlink:label="loc_dmpi_ValentTechnologiesLlcAbstract_0"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ValentTechnologiesLlcTextBlock" xlink:label="loc_dmpi_ValentTechnologiesLlcTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ValentTechnologiesLlcAbstract_0" xlink:to="loc_dmpi_ValentTechnologiesLlcTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/DerivativeLiability">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Stockholdersequity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Financialinstruments">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/SignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_UnauditedInterimFinancialDataPolicyTextBlock" xlink:label="loc_dmpi_UnauditedInterimFinancialDataPolicyTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_dmpi_UnauditedInterimFinancialDataPolicyTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Restatementofpreviouslyissuedfinancialstatementstables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/DerivativeliabilityTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Stockholdersequitytables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ScheduleOfOutstandingWarrantsTableTextBlock" xlink:label="loc_dmpi_ScheduleOfOutstandingWarrantsTableTextBlock_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_dmpi_ScheduleOfOutstandingWarrantsTableTextBlock_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Financialinstrumentstables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/NatureOfOperationsAndLiquidityRiskDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NatureOfOperationsAndLiquidityRiskTextualAbstract" xlink:label="loc_dmpi_NatureOfOperationsAndLiquidityRiskTextualAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_dmpi_NatureOfOperationsAndLiquidityRiskTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_NatureOfOperationsAndLiquidityRiskTextualAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_NatureOfOperationsAndLiquidityRiskTextualAbstract_1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_NatureOfOperationsAndLiquidityRiskTextualAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_NatureOfOperationsAndLiquidityRiskTextualAbstract_1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_2" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_3" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_3" xlink:to="loc_us-gaap_RestatementAdjustmentMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_6" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_6" xlink:to="loc_us-gaap_NetIncomeLoss_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_6" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_6" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_6" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Significantaccountingpoliciesdetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_WarrantMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_SignificantAccountingPoliciesTextualAbstract" xlink:label="loc_dmpi_SignificantAccountingPoliciesTextualAbstract_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_11" xlink:to="loc_dmpi_SignificantAccountingPoliciesTextualAbstract_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_SignificantAccountingPoliciesTextualAbstract_12" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForSoftware" xlink:label="loc_us-gaap_PaymentsForSoftware_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_SignificantAccountingPoliciesTextualAbstract_12" xlink:to="loc_us-gaap_PaymentsForSoftware_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_SignificantAccountingPoliciesTextualAbstract_12" xlink:to="loc_us-gaap_AdjustmentForAmortization_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/ValentTechnologiesLlcDetails">
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ValentTechnologiesLlcAbstract" xlink:label="loc_dmpi_ValentTechnologiesLlcAbstract_0"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_AgreementTable" xlink:label="loc_dmpi_AgreementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ValentTechnologiesLlcAbstract_0" xlink:to="loc_dmpi_AgreementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_AgreementTable_1" xlink:to="loc_dei_LegalEntityAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ValentTechnologiesLlcMember" xlink:label="loc_dmpi_ValentTechnologiesLlcMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_dmpi_ValentTechnologiesLlcMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_AgreementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_AgreementsLineItems" xlink:label="loc_dmpi_AgreementsLineItems_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_AgreementTable_1" xlink:to="loc_dmpi_AgreementsLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_AgreementsLineItems_8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaap_LoansPayableCurrent_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_AgreementsLineItems_8" xlink:to="loc_us-gaap_LoansPayableCurrent_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_AgreementsLineItems_8" xlink:to="loc_us-gaap_InterestPayableCurrent_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_AgreementsLineItems_8" xlink:to="loc_us-gaap_PreferredStockSharesIssued_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_AgreementsLineItems_8" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_AgreementsLineItems_8" xlink:to="loc_us-gaap_InterestExpense_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_AgreementsLineItems_8" xlink:to="loc_us-gaap_Dividends_15" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_OfficerAndDirectorMember" xlink:label="loc_dmpi_OfficerAndDirectorMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_dmpi_OfficerAndDirectorMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_AgreementsAxis" xlink:label="loc_dmpi_AgreementsAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_dmpi_AgreementsAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_AgreementsDomain" xlink:label="loc_dmpi_AgreementsDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_AgreementsAxis_5" xlink:to="loc_dmpi_AgreementsDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ConsultingAgreementsMember" xlink:label="loc_dmpi_ConsultingAgreementsMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_AgreementsDomain_6" xlink:to="loc_dmpi_ConsultingAgreementsMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_dei_LegalEntityAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_8" xlink:to="loc_dei_EntityDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ValentTechnologiesLlcMember" xlink:label="loc_dmpi_ValentTechnologiesLlcMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9" xlink:to="loc_dmpi_ValentTechnologiesLlcMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_RelatedPartyTransactionsTextualsAbstract" xlink:label="loc_dmpi_RelatedPartyTransactionsTextualsAbstract_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_dmpi_RelatedPartyTransactionsTextualsAbstract_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_RelatedPartyTransactionsTextualsAbstract_12" xlink:to="loc_us-gaap_OfficersCompensation_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_RelatedPartyTransactionsTextualsAbstract_12" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_RelatedPartyTransactionsTextualsAbstract_12" xlink:to="loc_us-gaap_ProfessionalFees_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_RelatedPartyTransactionsTextualsAbstract_12" xlink:to="loc_us-gaap_InterestExpense_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_RelatedPartyTransactionsTextualsAbstract_12" xlink:to="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_RelatedPartyTransactionsTextualsAbstract_12" xlink:to="loc_us-gaap_PreferredStockSharesIssued_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/DerivativeLiabilityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ScheduleOfDerivativeLiabilitiesRollForward" xlink:label="loc_dmpi_ScheduleOfDerivativeLiabilitiesRollForward_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_dmpi_ScheduleOfDerivativeLiabilitiesRollForward_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfDerivativeLiabilitiesRollForward_1" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_IssuanceOfAgentWarrants" xlink:label="loc_dmpi_IssuanceOfAgentWarrants_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfDerivativeLiabilitiesRollForward_1" xlink:to="loc_dmpi_IssuanceOfAgentWarrants_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfDerivativeLiabilitiesRollForward_1" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms" xlink:label="loc_dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfDerivativeLiabilitiesRollForward_1" xlink:to="loc_dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants" xlink:label="loc_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfDerivativeLiabilitiesRollForward_1" xlink:to="loc_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReclassificationOfDerivativeLiabilityToEquityUponExchangeOfInvestorWarrants" xlink:label="loc_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponExchangeOfInvestorWarrants_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfDerivativeLiabilitiesRollForward_1" xlink:to="loc_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponExchangeOfInvestorWarrants_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants" xlink:label="loc_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfDerivativeLiabilitiesRollForward_1" xlink:to="loc_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfDerivativeLiabilitiesRollForward_1" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_9" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/DerivativeLiabilityDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_DerivativeTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_InvestorWarrantsMember" xlink:label="loc_dmpi_InvestorWarrantsMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3" xlink:to="loc_dmpi_InvestorWarrantsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_InvestorWarrantExercisesMember" xlink:label="loc_dmpi_InvestorWarrantExercisesMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3" xlink:to="loc_dmpi_InvestorWarrantExercisesMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_WarrantsIssuedForServicesMember" xlink:label="loc_dmpi_WarrantsIssuedForServicesMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3" xlink:to="loc_dmpi_WarrantsIssuedForServicesMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_InvestorWarrantsExchangeMember" xlink:label="loc_dmpi_InvestorWarrantsExchangeMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3" xlink:to="loc_dmpi_InvestorWarrantsExchangeMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_InvestorWarrantAmendmentsMember" xlink:label="loc_dmpi_InvestorWarrantAmendmentsMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3" xlink:to="loc_dmpi_InvestorWarrantAmendmentsMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_DividendWarrantsMember" xlink:label="loc_dmpi_DividendWarrantsMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3" xlink:to="loc_dmpi_DividendWarrantsMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_RangeAxis_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_10" xlink:to="loc_us-gaap_RangeMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_11" xlink:to="loc_us-gaap_MaximumMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_11" xlink:to="loc_us-gaap_MinimumMember_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_14" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TwoThousandFifteenAgentWarrantMember" xlink:label="loc_dmpi_TwoThousandFifteenAgentWarrantMember_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15" xlink:to="loc_dmpi_TwoThousandFifteenAgentWarrantMember_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TwoThousandThirteenPlacementAgentWarrantsMember" xlink:label="loc_dmpi_TwoThousandThirteenPlacementAgentWarrantsMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15" xlink:to="loc_dmpi_TwoThousandThirteenPlacementAgentWarrantsMember_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember" xlink:label="loc_dmpi_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15" xlink:to="loc_dmpi_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_DerivativeLineItems_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReverseAcquisitionDescription" xlink:label="loc_dmpi_ReverseAcquisitionDescription_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_19" xlink:to="loc_dmpi_ReverseAcquisitionDescription_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_19" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:label="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_19" xlink:to="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ClassOfWarrantOrRightExercised" xlink:label="loc_dmpi_ClassOfWarrantOrRightExercised_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_19" xlink:to="loc_dmpi_ClassOfWarrantOrRightExercised_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_WarrantsAgentFee" xlink:label="loc_dmpi_WarrantsAgentFee_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_19" xlink:to="loc_dmpi_WarrantsAgentFee_24" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_PercentageOfWarrantAgentFee" xlink:label="loc_dmpi_PercentageOfWarrantAgentFee_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_19" xlink:to="loc_dmpi_PercentageOfWarrantAgentFee_25" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_GrossProceedsFromExerciseOfWarrants" xlink:label="loc_dmpi_GrossProceedsFromExerciseOfWarrants_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_19" xlink:to="loc_dmpi_GrossProceedsFromExerciseOfWarrants_26" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_19" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_27" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants" xlink:label="loc_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_19" xlink:to="loc_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants_28" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_WarrantOutstanding" xlink:label="loc_dmpi_WarrantOutstanding_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_19" xlink:to="loc_dmpi_WarrantOutstanding_29" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_invest_InvestmentWarrantsExpirationDate_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_19" xlink:to="loc_invest_InvestmentWarrantsExpirationDate_30" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_19" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_31" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TermOfWarrants" xlink:label="loc_dmpi_TermOfWarrants_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_19" xlink:to="loc_dmpi_TermOfWarrants_32" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ClassOfWarrantOrRightIssued" xlink:label="loc_dmpi_ClassOfWarrantOrRightIssued_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_19" xlink:to="loc_dmpi_ClassOfWarrantOrRightIssued_33" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants" xlink:label="loc_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_19" xlink:to="loc_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants_34" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReclassificationOfDerivativeLiabilityUponTheExchangeOfInvestorWarrants" xlink:label="loc_dmpi_ReclassificationOfDerivativeLiabilityUponTheExchangeOfInvestorWarrants_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_19" xlink:to="loc_dmpi_ReclassificationOfDerivativeLiabilityUponTheExchangeOfInvestorWarrants_35" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants" xlink:label="loc_dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_19" xlink:to="loc_dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants_36" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Stockholdersequitydetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ScheduleOfCommonStockIssuedAndOutstandingTable" xlink:label="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingTable_1" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_7" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_8" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_8" xlink:to="loc_us-gaap_RestatementAdjustmentMember_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems" xlink:label="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingTable_1" xlink:to="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_11" xlink:to="loc_us-gaap_StockholdersEquity_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_11" xlink:to="loc_us-gaap_SharesOutstanding_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedDuringPeriodSharesAndWarrantsValue" xlink:label="loc_dmpi_StockIssuedDuringPeriodSharesAndWarrantsValue_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_11" xlink:to="loc_dmpi_StockIssuedDuringPeriodSharesAndWarrantsValue_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares" xlink:label="loc_dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_11" xlink:to="loc_dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedDuringPeriodValueReclassificationOfWarrants" xlink:label="loc_dmpi_StockIssuedDuringPeriodValueReclassificationOfWarrants_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_11" xlink:to="loc_dmpi_StockIssuedDuringPeriodValueReclassificationOfWarrants_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedDuringPeriodValueStockWarrantExercised" xlink:label="loc_dmpi_StockIssuedDuringPeriodValueStockWarrantExercised_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_11" xlink:to="loc_dmpi_StockIssuedDuringPeriodValueStockWarrantExercised_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised" xlink:label="loc_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_11" xlink:to="loc_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_11" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_19" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_11" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_20" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_11" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_21" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_11" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_22" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions" xlink:label="loc_dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_11" xlink:to="loc_dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions_23" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_11" xlink:to="loc_us-gaap_StockholdersEquity_24" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems_11" xlink:to="loc_us-gaap_SharesOutstanding_25" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Stockholdersequitydetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross" xlink:label="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:label="loc_dmpi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_dmpi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Stockholdersequitydetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ZeroPointThreeNineMember" xlink:label="loc_dmpi_ZeroPointThreeNineMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_dmpi_ZeroPointThreeNineMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ZeroPointSevenFourMember" xlink:label="loc_dmpi_ZeroPointSevenFourMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_dmpi_ZeroPointSevenFourMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ZeroPointEightZeroMember" xlink:label="loc_dmpi_ZeroPointEightZeroMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_dmpi_ZeroPointEightZeroMember_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ZeroPointNineFourMember" xlink:label="loc_dmpi_ZeroPointNineFourMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_dmpi_ZeroPointNineFourMember_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_OnePointZeroZeroMember" xlink:label="loc_dmpi_OnePointZeroZeroMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_dmpi_OnePointZeroZeroMember_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_OnepointzerofiveMember" xlink:label="loc_dmpi_OnepointzerofiveMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_dmpi_OnepointzerofiveMember_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_OnePointOneTwoMember" xlink:label="loc_dmpi_OnePointOneTwoMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_dmpi_OnePointOneTwoMember_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_OnePointFiveFourMember" xlink:label="loc_dmpi_OnePointFiveFourMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_dmpi_OnePointFiveFourMember_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TwoPointThreeZeroMember" xlink:label="loc_dmpi_TwoPointThreeZeroMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_dmpi_TwoPointThreeZeroMember_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ZeroPointNineTwoMember" xlink:label="loc_dmpi_ZeroPointNineTwoMember_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_dmpi_ZeroPointNineTwoMember_16" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Stockholdersequitydetails3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Stockholdersequitydetails4">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Stockholdersequitydetails5">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross" xlink:label="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_1" xlink:to="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward" xlink:label="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice" xlink:label="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward_8" xlink:to="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice" xlink:label="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward_8" xlink:to="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice" xlink:label="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward_8" xlink:to="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice" xlink:label="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward_8" xlink:to="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsCancelledWeightedAverageExercisePrice" xlink:label="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsCancelledWeightedAverageExercisePrice_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward_8" xlink:to="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsCancelledWeightedAverageExercisePrice_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice" xlink:label="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward_8" xlink:to="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_15" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_15" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_15" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_15" xlink:to="loc_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_15" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_21" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Stockholdersequitydetails6">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NumberOfWarrantsRollForward" xlink:label="loc_dmpi_NumberOfWarrantsRollForward_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_dmpi_NumberOfWarrantsRollForward_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_NumberOfWarrantsRollForward_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NumberOfOfferingWarrants" xlink:label="loc_dmpi_NumberOfOfferingWarrants_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_NumberOfWarrantsRollForward_1" xlink:to="loc_dmpi_NumberOfOfferingWarrants_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NumberOfWarrantsIssuedToAgents" xlink:label="loc_dmpi_NumberOfWarrantsIssuedToAgents_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_NumberOfWarrantsRollForward_1" xlink:to="loc_dmpi_NumberOfWarrantsIssuedToAgents_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NumberOfWarrantsIssuedForServices" xlink:label="loc_dmpi_NumberOfWarrantsIssuedForServices_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_NumberOfWarrantsRollForward_1" xlink:to="loc_dmpi_NumberOfWarrantsIssuedForServices_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised" xlink:label="loc_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_NumberOfWarrantsRollForward_1" xlink:to="loc_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_NumberOfWarrantsRollForward_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/StockholdersEquityDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockholdersEquityNoteTable" xlink:label="loc_dmpi_StockholdersEquityNoteTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_dmpi_StockholdersEquityNoteTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_AgreementsAxis" xlink:label="loc_dmpi_AgreementsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteTable_1" xlink:to="loc_dmpi_AgreementsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_AgreementsDomain" xlink:label="loc_dmpi_AgreementsDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_AgreementsAxis_2" xlink:to="loc_dmpi_AgreementsDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ExchangeAgreementMember" xlink:label="loc_dmpi_ExchangeAgreementMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_AgreementsDomain_3" xlink:to="loc_dmpi_ExchangeAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockholdersEquityNoteLineItems" xlink:label="loc_dmpi_StockholdersEquityNoteLineItems_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteTable_1" xlink:to="loc_dmpi_StockholdersEquityNoteLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_8" xlink:to="loc_us-gaap_PreferredStockSharesIssued_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_PreferredStockSpecialVotingSharesIssued" xlink:label="loc_dmpi_PreferredStockSpecialVotingSharesIssued_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_8" xlink:to="loc_dmpi_PreferredStockSpecialVotingSharesIssued_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_15" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_8" xlink:to="loc_us-gaap_CommonStockSharesIssued_16" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_17" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_8" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_18" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedAndOutstandingOnExchangedBasis" xlink:label="loc_dmpi_StockIssuedAndOutstandingOnExchangedBasis_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_8" xlink:to="loc_dmpi_StockIssuedAndOutstandingOnExchangedBasis_19" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/StockholdersEquityDetailsTextual1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockholdersEquityNoteTable" xlink:label="loc_dmpi_StockholdersEquityNoteTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_dmpi_StockholdersEquityNoteTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_BrokerWarrantsMember" xlink:label="loc_dmpi_BrokerWarrantsMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_dmpi_BrokerWarrantsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_InvestorWarrantExercisesMember" xlink:label="loc_dmpi_InvestorWarrantExercisesMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6" xlink:to="loc_dmpi_InvestorWarrantExercisesMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_InvestorWarrantExchangeMember" xlink:label="loc_dmpi_InvestorWarrantExchangeMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6" xlink:to="loc_dmpi_InvestorWarrantExchangeMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TwoZeroOneFiveAgentWarrantsMember" xlink:label="loc_dmpi_TwoZeroOneFiveAgentWarrantsMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6" xlink:to="loc_dmpi_TwoZeroOneFiveAgentWarrantsMember_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_TwoZeroOneFiveOfferingWarrantsMember" xlink:label="loc_dmpi_TwoZeroOneFiveOfferingWarrantsMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6" xlink:to="loc_dmpi_TwoZeroOneFiveOfferingWarrantsMember_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_11" xlink:to="loc_us-gaap_EquityComponentDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_12" xlink:to="loc_us-gaap_CommonStockMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_12" xlink:to="loc_us-gaap_WarrantMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteTable_1" xlink:to="loc_us-gaap_VestingAxis_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_15" xlink:to="loc_us-gaap_VestingDomain_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_16" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_16" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_16" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationAwardTrancheFourMember" xlink:label="loc_dmpi_ShareBasedCompensationAwardTrancheFourMember_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_16" xlink:to="loc_dmpi_ShareBasedCompensationAwardTrancheFourMember_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationAwardTrancheFiveMember" xlink:label="loc_dmpi_ShareBasedCompensationAwardTrancheFiveMember_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_16" xlink:to="loc_dmpi_ShareBasedCompensationAwardTrancheFiveMember_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationAwardTrancheSixMember" xlink:label="loc_dmpi_ShareBasedCompensationAwardTrancheSixMember_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_16" xlink:to="loc_dmpi_ShareBasedCompensationAwardTrancheSixMember_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationAwardTrancheSevenMember" xlink:label="loc_dmpi_ShareBasedCompensationAwardTrancheSevenMember_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_16" xlink:to="loc_dmpi_ShareBasedCompensationAwardTrancheSevenMember_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationAwardTrancheEightMember" xlink:label="loc_dmpi_ShareBasedCompensationAwardTrancheEightMember_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_16" xlink:to="loc_dmpi_ShareBasedCompensationAwardTrancheEightMember_24" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationAwardTrancheNineMember" xlink:label="loc_dmpi_ShareBasedCompensationAwardTrancheNineMember_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_16" xlink:to="loc_dmpi_ShareBasedCompensationAwardTrancheNineMember_25" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ShareBasedCompensationAwardTrancheTenMember" xlink:label="loc_dmpi_ShareBasedCompensationAwardTrancheTenMember_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_16" xlink:to="loc_dmpi_ShareBasedCompensationAwardTrancheTenMember_26" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockholdersEquityNoteLineItems" xlink:label="loc_dmpi_StockholdersEquityNoteLineItems_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteTable_1" xlink:to="loc_dmpi_StockholdersEquityNoteLineItems_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_28" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockOptionExpense" xlink:label="loc_dmpi_StockOptionExpense_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_dmpi_StockOptionExpense_29" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_30" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised" xlink:label="loc_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised_31" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_32" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockOptionLiabilityNoncurrent" xlink:label="loc_dmpi_StockOptionLiabilityNoncurrent_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_dmpi_StockOptionLiabilityNoncurrent_33" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_34" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_35" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_36" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_37" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ClassOfWarrantOrRightIssued" xlink:label="loc_dmpi_ClassOfWarrantOrRightIssued_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_dmpi_ClassOfWarrantOrRightIssued_38" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_39" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants" xlink:label="loc_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants_40" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares" xlink:label="loc_dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares_41" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_42" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_invest_InvestmentWarrantsExercisePrice_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_invest_InvestmentWarrantsExercisePrice_43" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_44" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_45" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_CashCommission" xlink:label="loc_dmpi_CashCommission_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_dmpi_CashCommission_46" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NumberOfWarrantsIssuedToAgents" xlink:label="loc_dmpi_NumberOfWarrantsIssuedToAgents_47"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_dmpi_NumberOfWarrantsIssuedToAgents_47" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_48"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_48" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_49"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_49" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued" xlink:label="loc_dmpi_NoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued_50"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_dmpi_NoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued_50" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_51"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_51" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaap_DeferredCostsCurrent_52"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_us-gaap_DeferredCostsCurrent_52" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_53"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_53" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_NumberOfWarrantsIssuedForServices" xlink:label="loc_dmpi_NumberOfWarrantsIssuedForServices_54"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_dmpi_NumberOfWarrantsIssuedForServices_54" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_invest_InvestmentWarrantsExpirationDate_55"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_invest_InvestmentWarrantsExpirationDate_55" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_ReductionInStockOptionLiability" xlink:label="loc_dmpi_ReductionInStockOptionLiability_56"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dmpi_StockholdersEquityNoteLineItems_27" xlink:to="loc_dmpi_ReductionInStockOptionLiability_56" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/Financialinstrumentsdetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7" xlink:to="loc_us-gaap_DerivativeLiabilities_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.delmarpharma.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9" xlink:to="loc_us-gaap_PrivatePlacementMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_11" xlink:to="loc_us-gaap_EquityComponentDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_12" xlink:to="loc_us-gaap_WarrantMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_InvestorWarrantAmendmentsMember" xlink:label="loc_dmpi_InvestorWarrantAmendmentsMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_12" xlink:to="loc_dmpi_InvestorWarrantAmendmentsMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_15" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_16" xlink:to="loc_us-gaap_EmployeeStockOptionMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_us-gaap_PreferredStockSharesIssued_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockDescription" xlink:label="loc_us-gaap_ConversionOfStockDescription_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_us-gaap_ConversionOfStockDescription_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_EngagementAgreementPrivatePlacementDescription" xlink:label="loc_dmpi_EngagementAgreementPrivatePlacementDescription_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_dmpi_EngagementAgreementPrivatePlacementDescription_25" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_26" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_CommissionPaidInLeiuOfIssuanceOfWarrants" xlink:label="loc_dmpi_CommissionPaidInLeiuOfIssuanceOfWarrants_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_dmpi_CommissionPaidInLeiuOfIssuanceOfWarrants_27" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_invest_InvestmentWarrantsExercisePrice_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_invest_InvestmentWarrantsExercisePrice_28" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_invest_InvestmentWarrantsExpirationDate_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_invest_InvestmentWarrantsExpirationDate_29" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaap_DeferredCostsCurrent_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_us-gaap_DeferredCostsCurrent_30" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_31" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_32" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_33" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="dmpi-20160331.xsd#dmpi_DerivativeLiabilityEquityIssuanceReclassified" xlink:label="loc_dmpi_DerivativeLiabilityEquityIssuanceReclassified_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_dmpi_DerivativeLiabilityEquityIssuanceReclassified_34" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #8 6 # 2(  A$! Q$!_\0
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MR @B5)"Q'M@TQ?A?,D>R/Q=K0"C"J).!Z"J48OJ7-P=N5'4'P?X8'7PYI/\
MX!Q_X4?\(?X8_P"A<TG_ , X_P#"N$\ ^)KS2=2O_#?B*<(;1F=;FXD)9LGI
MD]J]2C=98EDC.Y&&58="*4X\KL39VN9'_"'^&/\ H7-)_P# ./\ PH_X0_PQ
M_P!"YI/_ (!Q_P"%;-%2(QO^$/\ #'_0N:3_ . <?^%'_"'^&/\ H7-)_P#
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M_P"A<TG_ , X_P#"MFB@#&_X0_PQ_P!"YI/_ (!Q_P"%'_"(>&/^A<TG_P
MX_\ "MFB@#&_X1#PQ_T+FD_^ <?^%'_"'^&/^A<TG_P#C_PK9HH QO\ A#_#
M'_0N:3_X!Q_X4?\ "'^&/^A<TG_P#C_PK9HH QO^$/\ #'_0N:3_ . <?^%'
M_"'^&/\ H7-)_P# ./\ PK9HH QO^$/\,?\ 0N:3_P" <?\ A1_PA_AC_H7-
M)_\  ./_  K9HH QO^$/\,?]"YI/_@''_A6/XK\*>'8/"&MSPZ!I<<L=A,Z.
MEH@*D(2"#CK78UC>,/\ D2-?_P"P=/\ ^@&@#9JCK%__ &7I-S>_N\Q+\OFM
MM3)X&3V%7JQ?%]X^G>$M3NXXX)#'%DK.,ICH21WXH X^[\6>+;'5(H)VT4F4
M*0J,YB7<<+N?'&3P*]$M7N)+2)[J(0W!4&2-6W!6[@'N*\7\,Z>%;^W);^'4
M=,2=?)MKJ80'R1@B39_LGH#Z5[3;W,%Y;QW-M*LL$HW)(O1AZT 2US&L^.=-
MT/4;BUNXY!%:HK7,^0 F[[N!U;\*Z>N=USP=I_B+4X[K4L2PQQF,0^6 <GN6
MZ_A0!-I?BBUOYI(+J+^SYU19E2>11OC;[K YK)\(21S>,?&DD4B2(UU!AD.1
M_J_6K-EX#TL,TFL$:Q-@1Q2W,8!BB'1!CTJEX(LK;3_%/C*TLX4AMTNH-L:#
M@?NZ .VHHHH X#QI\.#XHU-]4MM2:"Z,2Q"(J-F!ZGK7$:IX=USPY<VT&H^(
M;Z.TD.U)8)20 !Z=J]VQQBJ.KZ5:ZQITMI=1JZ.."1]T^HJG4FE[KV-Z$X*2
M5171Y]X0UW7M$U'1_#.JQQ7:7WF2PWXN/,9E'/->GUX%KFD^(-&U"QB1I(9[
M!V%G(@R'W<\'W]*]5\"^*!XET%&N74:I;DQW41P&##OCL#3YO:1Y^O4,1A_8
MRT=XO9G444?2BH, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *Q?&'_(D:__ -@Z?_T UM5C>,/^1(U__L'3
M_P#H!H V:IZO-);Z1<S1V!U!T3(M1C,OMSQ5RE'4<T >1V]S87&NP+<_#7[/
M/-*JO)).GR$]RN?TKUI8TA01QHJ(@PJJ, #V%>(W,>B?\)^MM?7=_9:E]N&#
M&/.65=V5Y'W<G@D]J]P;.XT )6;<:]IEIJR:9<72I>/&90A' 4=<GMQ6E7'Z
MYX.O-;\2M?/?1QV3VK0%0O[Q<C!P>] &]HNOZ=KZ2OI\DC>2^UPZ%#]0#V/8
MUA>%?^1U\:_]?4'_ *+J"R\#7%U<&YUN^DCG2);6'^S9FB!B7H7]6IG@2QCT
MWQ+XQLXI)I4CNH</,^]SE.Y/6@#N:*** "BBB@#+US0++7[5(+L/^[;=&R-@
MJWK7C5WI^I?#7QK%J4,<US:@?O9%0[75NH)Z9KWFHKFWANX&AN(EEB;JK#(-
M5!\KN:QJOEY):H\_TCXMV6I:W::?-I-U:"Z?8LLC J">E>B].XKQC7_#(L_$
M#:;<P,UK=N397&_:(9".O'IZ5T7PM\3)=Z6VA7]V9-2L7=1O4C,8. <GK37+
M.+E%:KH5B*'L6FG>+V/1:*.H!!!!Z$&BH, HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K&\8?\B1K_P#V#I__ $ U
MLUC>,/\ D2-?_P"P=/\ ^@&@#9J&ZMS=VDMN)I(3(NWS(SAE]Q4U*, @GI0!
MXO;S^&M"\;1Z5+J6L6VHM=#$:,)%F;/5CU />O9SU/ 'TKR&.74_#?BI]^E2
M1V5UJ6!=S0Q.?F/9NH'I7K[<,10 E9[:]I(U?^R3J%N-0V[OLQ;Y\?2M"N7U
M?0KC5]4OI/(AMC':-%9W0 WM(PY8GKP./QH W--U;3M7CDETZ]ANDBD\N1HF
MSM8=C7.>%/\ D=?&O_7U!_Z+JKX=T+789YIT6/0U$,<!@$:RB9EZR\=,U)X)
MCGB\5^,DN9Q/,+J'=($VY_=^E ':T9HHH **** "BBB@#E/B!I*:CX;DN%!,
M]GF6(AL?6L>V\):!XXTZVUJX\Z*\-N(G-M*5"D>H'4UWMW;I=6DT$BAD="I4
MC@UY]\/-8M=.,WA^X1X;S[2YC0J0",]/RK-2=.I>.ESMA'VN%:ZQ93\):G;>
M"?%FJ>&=5UV22UCB1[5[HX4$\D9KTNPU"SU.U%S8W,=S!DCS(CD9%9NK^%-"
MUV42ZEIL-Q,J[5D9>17#7_@[Q#X,TE9O"^LW5Q##,9IK1]J)L')_PKJ?+/U.
M!'J=%8_AC7H_$F@6FI*8A)*F98XVSY;>AK8K)IK1E!1112 **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **.U% !6-XP_Y$C7_ /L'3_\
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M"U&VU;Q+XQOK1F:"2ZAVEE*GA/0T =M/!'<V\MO,H>*5"CJ>X/!%<V/ 6DM
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M;?4(KY$C>3?%L:U5F !<'UYH ]$HIL9)AC).244D^O%.H *Q?&'_ ")&O_\
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M"6A2L[-IT9>2/RF?/)3=NQGZUC^7X)%KKEVLJ"SA7R=10.PCC_X#V/N*[(Y
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M%.X!QZ+^5''HOY444KA8,#^ZOY48']U?RHHHN 4444 %8WC#_D2-?_[!T_\
MZ :V:QO&'_(D:_\ ]@Z?_P! - &U6/XJU>?0?#%_JEM#YTUO'N1,9R<X_P#K
MUKT$!A@@$>A&: /#O"5QI\OC VNKW]S)-(5NXKFUED2%Y6/^K*GCBO<3U-,%
MO ,8@B&.1A!3S0 5RNMZ1J.I:_<)#:K'9W&FO:F]$@#JY.1\O4BNJH[T <%I
M?A379+AKI[U] 984MO*L]D@G"_\ +1N.":E\"6TUGXF\86]Q=R7DJ74.Z>10
M&;]WZ#BNW5U?[CJP!QE3G\*Y'PI_R.OC7_KZ@_\ 1= '0:WJ8T;1KG4#"9O(
M7(CW!=Q)QU/2L_1/%5MJ=I=/=HEE-9R;)D,H=<D9!5APPY[5I:OID.LZ5<:=
M<$B&< /@9XSFL^?P?H\L5H(+<6DEIDV[P<!#ZD=#^- $.I>+[>PUB.S^S/);
MCR_M%R& $/F?<XZG-.\0>*1H%SL:S>:VAB\Z\G#@"VBZ!L'[U,O?!UO?ZG%>
MW%Y*1A/M,00!;EDY0GTP?2FZEX.&K%1?:I.Z2*T=V@C4"YB)R$/H!ZB@"FGC
MTR6-Y<)I+EH[4WMHAE&;JW'5_P#9^AKJM/NUU#3;6]12BW$2RA3U&1G%<PG@
M&&.RO+9-4N!YML;.V<QKFU@/5%]?J:Z72[+^S-)M+#SFG^SQ+$)'&"P QDT
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MSFEJ"RLX=/LHK2W!6&)=J@G)Q]:GJD<[M?0****8@K%\8?\ (D:__P!@Z?\
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MC)\U&*Y,C=L9XH N?\55Z:1_X_1_Q57II'_C];=% &)_Q5/II'_C]'_%5?\
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9BBB@ K%\8?\ (D:__P!@Z?\ ] -%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %! G@# 2(  A$! Q$!_\0
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M&C_XFC[?K7_0%B_\#1_\30!L45D?;]:_Z D?_@:/_B:/M^M?] 2/_P #1_\
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MD:O_ '@#^= #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?E"@'G^'YMW'O7HL;(Z@HP*^JG-54@X.S5BITYP=I*QS?_"0ZY)_J?#$TF>
M3-L&??<H(^N*MPWWB*>W+-H=K;R\@))?[L^ARJ=*V\+ZTK$!3QGVJ"#SK0W\
M:+XYUI[J'1)(62#S8HY9%91M.S:Q7D]<Y KHYM7\16\KK_PC(EB!XDBOE.[_
M ("5!K*T(--X\UJ0_P!K1@+ VV; C^ZW#>WI7;X&*;=P.7/BF]C.+C2TMF[B
M>5U_41D8]\U/#X@NKD@01:7(6Z!=1Y/X;*Z$*!5>XT^RN@?M%I!+GJ7C!)I
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M6HH R?.U[_GQL/\ P*?_ .(H\[7O^?&P_P# I_\ XBM:B@#)\[7O^?&P_P#
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M=',T332/N/'.2Q(Z#H:JR_#_ ,+36-M9MI$8AMBQBV2.CKN.6^<,&.3R<DT
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M?G3/^_#_ /Q=:U% &3Y?B'_GYTS_ +\/_P#%TGE>(#_R\Z9_WX?_ .+K7HH
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M ,71Y7B'_GYTS_P'?_XNM>B@#(\GQ!_S\Z9_X#O_ /%T>5X@Q_Q\Z9_X#O\
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M.?<U[+BEQ0!YSXWN]>G\,W4LD,,>C-<6[>=8S2-/):&0>867:"HV==I)QFN
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MIM<8_ U-B.5D7]GZQ_T'3_X")1_9^L?]!T_^ B5EZ?X]TV_O6MA!>0D9VO)
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MOE8;/N*]#TR[.H:39WK*$-Q DI4'(&Y0<?K0!;H/2B@]* .<O?\ D?\ 2/\
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M1_=K-!_*NBI" 34<S(YC@8O^%@IK:PW$J/IWF8,\,<.=G8@'G]*ZD6&I<_\
M$[G_ / >+_XFM0+S2XIRGS=+>A4Y\[6B7H<7XF@N(-*UL7%X]R3I;$%D5=HW
M'CY0*["U_P"/6'_KFO\ *N8\9?\ (-UG_L%-_P"A&NGM?^/6'_KFO\JD@FHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH PQXNT?^TM8L9+DQ2:1&DEX\JE
M416&0=QX/ J#0_&NE^(+F.&SAU%$F0R03SV4D44ZCJ4=A@^M>9>)]!U36]5^
M)MII]M.\TT5BT2A2!,$ 9E4]"<"NU@^(NE#P]++I]E?SW=E9&:2Q-I)$8]@
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M,(IU,7E.N&104^Z#R._3.:Z7_A']6_Z&W4_^_,'_ ,;H_P"$?U;_ *&W4_\
MOS!_\;H HO\ #?0I-0N;\_:/M%QIO]FLV\8$>T(7 Q]_: ,UU-E:QV%A;V<1
M8QP1+$A8Y)"@ 9]^*Q/^$?U;_H;=3_[\P?\ QNC_ (1_5O\ H;=3_P"_,'_Q
MN@#HJ#TJO9PRV]M'%-<27#J,&60 ,WN0 !5@]* .<O?^1_TC_KQN/_0DKHZY
MR]_Y'_2/^O&X_P#0DKHZ "BBB@#-US3)-6TBXLHKCR'E Q)C.,$'!&1D'&#]
M:31=*;2-/%L9O-/F/(<#"KN.=JCLHZ 5IT4 <_9>%DLTD2/5=257EDEPDP50
M78L0 !TYJ2XTJ&UB,MQK>HQ1C&7>Z"J,G Y(K<K.UK2+;7=-DT^\!-O(R%UP
M#NVL&P<]N* ,IUTN.[^R/XGNUN=VWR3>KOSZ8Q5T:%G_ )BVJ\?]//\ ]:JV
MG^$;#3M02\BDN&D2::91(P8 R!01G&< *,>E="HQ0!S9TG[ LTE_XCU#RVE)
MC9K@($4XPO3GZU/)ID$2*\FMZDB,0 S78 )/3G'>KFKZ3%J]N(979-K;E90"
M0?;-9,G@FQDN/.>YNW(D23:\@.2I!YXY'RC@],G'6@"]_8F/^8KJW_@1_P#6
MI#HR @'6-4!8X -R.3^59TW@2QF>.0WNH!XY-Z_OR<#LOT';O2V_@;3K>_L;
MQ);CS;-]Z;R"&8[LD\=3NQGV% %^#P]*BN)=<U64ER5)F VCLO [>M-N--MK
M- ]SKNHPH2%#27049_$5NK6/KF@0ZX+?S9I8C 7P8P#N#*58'(/8F@".32X(
MO+\S7-13S&"Q[KL#>3T XY-2C0L_\Q;5?_ C_P"M1<Z#;W,5C"SR"*QEBE@4
M $J8Q@<D9Y[_ $K64=<T 8J^'I1<.YUS5FC8 +'YX 4]SG&3FI#H6!_R%M5_
M\"/_ *U;%(W2@##BTN"??Y.MZE)L8HVRZ!VL.H/'!]JE_L'_ *BVJ_\ @1_]
M:I]/TN#3'O7A+?Z7<&YD! P&( ./;BKHFB,C()%+KU4'D?44 8L7AVX6ZG>3
M7=3>%]OE1^<!Y>!SSCG)HN=-M[2,R7.NZC$@.-SW0 S^5;N?\XK,UK2_[8L&
MM#=2VP<C<\2J6([CD' /M0!2GLK.UCC>X\07\22L$C+W8 =CT XY/TJR-"R,
M_P!K:K_X$?\ UJKZAX7M-2BM5F=T%J,0F-%4QC !VG'RGCJ.1VK=CP$&.GJ.
M<T 8T?AZ5996?7-5=&(*)YP'EC'3('///-2'0L?\Q;5?_ C_ .M6J9%7.6 Q
MUR>E!(8>QH PH+"UNI)8[?7[^5XFV2+'=ABC>AP.#5G^P?\ J+:K_P"!'_UJ
M9HWAZTT.6X>U+XF()3 "CDG. .6.>6/)K8WC.,C)YQGF@##7P]<"\ED?7=4:
M!E41Q"8#81G)SCG/'TQ4DFBK&A=]8U15 R2;D  ?E6QO7(!(!/0>M13".XB:
M(LK+(A!'!R#Q0!B1VMC))%''XAOG>5=\:B\!+KZCCD5:_L'//]K:K_X$?_6K
M/L_!EC:7-K,DUPR6RP[(VVXW1*RHV0,]&/'2NG PH% &(GAZ59I6;6]5:-L;
M$,X&S'7G&3GWITFC)$I>36=355&2S7. !^5;50W,1GMY(@Y0NI <*&V^^#Q0
M!@"#3R8 /$=Z3<$B$"]7,A'4+QSBK@T+/35M5_\  G_ZU9]OX)LH9+25IYI+
MBW;=Y^U5D<[MW+ 9&3UQU'!XKIU7':@#%'AZ7[0[G7-6,14 1^>/E/<YQGG^
ME/.AX/\ R%M5_P# C_ZU;-17$*W$$D+\I(I5L>A&#0!SR)IDJJT?B:[=7?RU
M*WJD,WH..35X:%D?\A;5?_ C_P"M6/\ \*_TQ515GN%B5"CQ(%5"F5;  'R\
MH/NXSSZUI6/B*74;**[M-&OI()1E&S&,C..A;B@ /AZX^W"7^W-3%MY94P^:
M,ELC#;L>F1CWHGTR"V3?/KFHQ)D+NDNPHR>@R1U-6/[6O3_S KW_ +[B_P#B
MZH:OYNLZ>UG<Z'?B-G1\JT.058,,9;U% #WL[*.22.3Q#?(\:[G5KP J/4\<
M5/!I$5S$LL.M:E)&PR&6Z!!_2N1U&QTZZU.Z^T1WL5S)*;@1?:+8&)\+EL%L
MD80<'CK6[8:E!X?L([;^S[B-)':16FN( 9&8[B1\_J>U $7B71C9>'];O/[0
MO+@/I[1>7.X8#G.0<9KJ[7_CUA_W%_E7%>*?$\-UX4O8Q9S".ZC>".=9(W3?
MM)P2K'T-=K:_\>L/_7-?Y4 34444 %%%% !1110 4444 %%%% !1110 4444
M %5K^T^W6,MKY\]OYBX\VW?9(GNI[&K-% '%2?#+27M0@O\ 54NC)+)-?)<@
M3S^8H5PYVXP0JC@#&!C%==96<&GV5O9VR".WMXUBC0'.U5& /R%3T4 %<GXX
MU&[T.'2];AN7CL;.]1=1B&-K6[_(6/\ NDJWX&NLJ*XMH+N"2"YACFAD7:\<
MBAE8>A!X(H \JO\ QA>KX9N=6?4Y[9-=U06VEM&F_P"S6JG:TJJ 2255VZ'[
MPIFF^.;F\TOPF[ZJRNFL/I^HRR8C\Y51RI8,!C<-C=!UKU1-.LHC;F.T@0VR
ME(-L8'E*1@A?[HQQQ5>Z\/Z-?>9]LTFPN!*XDD$UNC[V P&.1R<<9]* .7\9
M>+-2T_PYK4VF:=<QK;VWF0:H3$\#9*@E0&+' )/*X^6N+U#Q'JUDVI:-9>*+
MB^B34+2.VNFFB66821%Y(A/MV)@@'<1P..]>RQV-I#9BSBM84M53RQ L8"!?
M[NWICVJJ/#NB#33IPT?3Q8EMYMOLR>5N]=N,9]Z /'=2\3ZXWP[L=3@\1W O
M+99OM&+F")UV2D992O[_   5^0J&(SWKTV^L=8URUTV_TK7I-/5;<3!3; B>
M1@I7S%/\.,Y4$')Z\5JR>'M%FCM8Y='T]TM/^/=6MD(A_P!P8^7\*T<"@#RS
MQ#<:KIVK:)I-EXQN)-<!B:XBD\J.W$(/[R24$9YZ* <] /6KM[\2#&[6Q6SC
MF.LSZ80;C#)&B,5EP>Y('M7:7GAW0]1NOM5]HVGW5QQ^]GMD=^.G)&>*HV?@
MK0+66_D?3+:ZDO;IKJ9[J%)&+,<X!(^Z#T':@#R[1_&'B5O#<7A^;4)IM<U:
M.*ZL+]E&Y+=U+2L>V4V,/^!"O4? E[<:EX%T:]NYVGN)K57DE?JY]36LFE:=
M&T3)86JM#&8HBL*@HAZJO' /H.*GM[>&T@2"VACAAC&U(XU"JH] !P* )*#T
MHHH YR]_Y'_2/^O&X_\ 0DKHZYK5C+;>+]+OOLMS+;):SQN\,1DVL2A ('/8
MUH?V]!_SYZC_ . 4G^% &K165_;T'_/GJ/\ X!2?X4?V]!_SYZC_ . 4G^%
M&K165_;T'_/GJ/\ X!2?X4?V]!_SYZC_ . 4G^% &K165_;T'_/GJ/\ X!2?
MX4?V]!_SYZC_ . 4G^% &K165_;T'_/GJ/\ X!2?X4?V]!_SYZC_ . 4G^%
M&K165_;T'_/GJ/\ X!2?X4?V]!_SYZC_ . 4G^% &K165_;T'_/GJ/\ X!2?
MX4?V]!_SYZC_ . 4G^% &K165_;T'_/GJ/\ X!2?X4?V]!_SYZC_ . 4G^%
M&K165_;T'_/GJ/\ X!2?X4?V]!_SYZC_ . 4G^% &K165_;T'_/GJ/\ X!2?
MX4?V]!_SYZC_ . 4G^% &H:Y9/"4L,-Q%#J'E;V9DG6$>?\ ,VXJSYR5[=N*
MU?[>@_Y\]1_\ I/\*/[>@_Y\]1_\ I/\* ,A/"-P S2:W=F41%8=K,%@<G.Y
M1NYQTPQ-%SX3OY[2>%/$-[&\D@?S%ZMC/#<^_P##CH*U_P"WH/\ GSU'_P
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M4 /Y4 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5#=74%E:R7-S*L4,:[G=C@**FK \;C_BB
M]6_ZX'^8H LCQ%9%01'>X/\ TYR__$T?\)#9?\\[W_P"E_\ B:TH?]1'_NC^
M524 9/\ PD-E_P \[W_P"E_^)H_X2&R_YYWO_@%+_P#$UK44 9/_  D-E_SS
MO?\ P"E_^)H_X2&R_P">=[_X!2__ !-:U% &3_PD-E_SSO?_  "E_P#B:/\
MA(;+_GG>_P#@%+_\36M10!D_\)#9?\\[W_P"E_\ B:/^$ALO^>=[_P" 4O\
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MSKJ1B]A@VX6*08?+!>&Y'4U'-XMAT[P\-8U:"2VA$FQ]@+[!V.."?P% %_\
MX2&R_P">=[_X!2__ !-'_"0V7_/.]_\  *7_ .)K%N?B+HMHL+2K=A9; ZB"
M(P<0 @%CSUYZ=:L:QXSMM/LDN+-$OG8K_HZR;)6W $!5(Y8CMQCOB@#2_P"$
MALO^>=[_ . 4O_Q-'_"0V7_/.]_\ I?_ (FF:7K\.I:M?Z9Y<D-W8B)I4?\
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MLAYP%G; 3-OEQ$H\QAR"W')^M%QI5C=.SW%G;3,P 8R1*Q('(ZCM3_[0L_\
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MH NT56LM0L]2MQ<6-U#<P$X$D,@=<_459H **** "BBB@ HHHH ***0G )H
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M4[E[&RDN8;(7'E@LR!E4[0,DY-2'5+ #F^MO^_R_XU2U74K!M'OE%];$FWD
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M'AT9\R\G;)YVSX_]DJT/A)X7^02&9U0853=MC_T"@#=\">/K+QIYB1VS6MW
M59X6;<"I/4&MWQEKVHZ=J]FNGW(BM[)!>Z@I (>$R*F"3T&"[9']VL_PYH.C
M>&1Y6DV=I 9&&]_.9G?GN2M=M>V>E^3=SW\5LL4L0BN))\!6CYPK$]N3U]:
M.(U+Q?J1UM=0LY'_ +$MK.YNA J@_:T0 "0DC(4NPVXZ@$]ZU[;4+FTU+2(=
M2O[V6ZU!3(&A6/[*<)O90/O  ?Q?3UKIDT^Q5Q+';0AO)$ 8*/\ 5#HG^[[5
M5CT31-.62X2RM8%$;*TA4 *G<9/W5]<8% '%Z-XQU))KP7C_ &R;4@MSHUK@
M*2K.ZA>!]T!58D] 33(K_7I?!4%V^M7#:C>ZI]FM98E15VM+M^[MY 56(]J[
MV+3=,W6]Q#:VV8H?*@D11\D1Q\JGLIP.E/72K!(K6);.$1VC;K=0@Q$<$97T
MX)_.@"2TMVM8?+:XFGY)WS$%OT JQ1C%% !7/^.&"^"=69C@"W))_$5T%<U\
M0O\ DGVN?]>C4 =#!_J(_P#='\JDJ.#_ (]X_P#='\JDH *S[S1--OV=KJSB
ME9]FYF')VDE>?;)Q]:T*HZEJEOI-JUS=,1&&"C:N22>@H CM]!TRTNC=6UC!
M%,0!O1<8XQQZ<<5F^*XT<:(CHK*VK0 AAD'ANU6K/Q/IE]>1VUO<%WEX0["%
M+;=Q7)_BV\X]*K>*V"_V(S,% U: DDX X:@#8.FV'_/E;?\ ?I?\*YKQ7HVG
M/<Z&38P'S-02%\1@90JQ*G';@5U)N[4C_CYA_P"^Q6?J.G:+JS0M?&*4PG=&
M?/*[3ZC!'/O34G%W0XR<7>+L4I? WA>>5I6T*P$K=7$"@U#)X%T52#%;1)["
M%-OY "N@BELH45$N(@J@* 9 >/Q-/-W:G_EYA_[[%/GEW'S,YH>$;:'F*RL<
M]-T8>)C^()KG_&.E10:!)'_9E^AE^0O:WA.T$'D\'C\/QKT3[7:_\_$/_?8K
M&\2SV3Z+<(]W*NY&5/LTAW,Q4X!V\X_2JA-1DFU<<)14DYQNCE_">DZ7;>%M
M.BFN=1C(A',@W _1BAX]!70QZ1H\W$>J.WT>/_XFF>#Y;.+PW9Q"ZG\Q(8UE
M6YD;*,%&5&[M]*W'&G2C]ZUJ_P#O%32E)-MVL$G%O16,[_A'8U_U5[(%[[X(
M9/U*4R;P\1!(1J13Y3\XLX/EXZ_<[5;^PZ2.8Y4A;L8I]N/UJK>VTS6LL=AK
MK13,,(TKJX7^M))-[B23=KV.-^'VF3/87L']O6]\ZW<Q'G::I8#=C=GCJ><=
MJ[,:/>)]TZ5-_P!=+';CZ8-<WX)74+2&\N);^*[0W,D9A:XVC<&.YQV))YKK
M1KMK'Q<;K?U+X*_]] D552-I.S3]"JE-0ERQ=_-%?^S;].EEHDWMY+1X_1J#
M:7D?+:'I4H/:-\$?7<E:\5]:31+)'=0.C=&60$&E:[MB.+F'_OL5F9GG^CW&
MI2^-]>@?PC D:I!AWN(]HP#C'R_Q<GIVKJ/)N>WAJQ_[_)_\17/Z+?*OCO6$
MDUF24D0*5:V"J^%;@MC QZ]Z[D7=K_S\P_\ ?8H; QA:WLG"Z#I<1'>60'/_
M 'RE+]@O\?\ (*T3\V_^(K8^UVO_ #\0_P#?8H-W;=KB'_OL47 \]U*R\0?\
M)_HRQV'A\6QMYB4(;)'R[LG;UZ8X]:ZG[->(<-H&F2Y_BCD  ^N4J&_MKJ?Q
M'9ZG;7VFK%;1/&(Y22S;]N>0<<;>*WA=VV.;B'_OX*;8&-B53B3PM&Q]87B8
M?KBCS88R/.\,3)GIL@BD_P#03Q6U]KM?^?B'_OL4?:[7_GYA_P"^Q2N!Y_XT
MUO2]+L--N;C1KR%$U*%B!8Y+*"<@8SZ]#UKI5U'19%#_ -FS?,,\Z:^?_0:K
M>*[G>NF"WBDN?*OXIW\C#;44\D\UOP7]O*BR&94W#.UV (^HSQ3Z 97V_1/^
M@9)_X+7_ /B:/M^B?] R7_P6O_\ $UM?;+;_ )^8?^_@H^UVO_/S%_W\%*X'
M&>+-5TNU\,:A=6UK=6\T,+/&\6GL"& XSE,8I_A[4M$N='M[S[+J$WVA ^;G
M3R6'TPF,5T&M06^KZ7/8#4EMTG0H[HRD[3U S4E@4L[1()M32X*# =BB\=A@
M4]+ 43J&A+S)8F->[26#*H^IVT?VGX9]+7_P&/\ \36S]KMO^?F+_OX*7[7;
M?\_,7_?8I7 Q3JGA@ DBU '4_9C_ /$US7A#Q#X5O4U<02VMRPU&9E6.W+'8
M2-N!MZ=:[XW=L<?Z3%_WV*Y[PG):0)K.UX(\ZK<="JYY%%U8"Q]MTEO]5HT\
MS#JJZ>01_P!] 4>;$XS#X7F<?[<42'/T)K:^UVO_ #\Q?]_!1]KM?^?B'_OX
M* ,4PW3\+X<T]">C/*I ^H"US&G6.OO\0M722ST!+86T)P(F<@9;;CIS][/X
M5WYO+8=+B+_OL5S%AJ'_ !6>H7+6MS';W$$,22N@"[D+YR<\#D<^]-/R O\
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M3AC61[<-SM/(QZG') Z?C6M0 5SOCR&2X\":W%$N7-HY SZ#)_E715D^*?\
MD4M8_P"O*;_T T :40*P(#U"C^58OB373H=G]I/DA%4LQD#DG'90HY/-;B_<
M'TKD_&MEILL5I=:@UOF-_+B27?EV8C 4*RY.0.O'TH U/#VKW&L6)NY;<11E
MB$RK*QP<'*L.GH>]7[W3K;4;<P7<0DC)#8)(P1T((Z&J&@&>:R,CBWCB8G9%
M#!Y>WGDGYCUJWJ6K66CV9NK^<0PA@NXCJQZ >I- $%IX;TJQN_M5M9I',/ND
M$X4XVY S@''&16?XM@CE318I462-]5@#(PR#PW45HV_B+3+N[2U@NUDED&4
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MT%_L/2/^@79?]^%_PH_L/2/^@79?]^%_PIBZB;9MEZGE]A*O*'\>WXU?$J$
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MF.784;KGHQ!YZJ: -3P7X;\2:#?WDNK7.DW0O9&GN;J%)!/+)_""6.T*HX
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M?] NU_[]BC_A&=$_Z!=K_P!^Q6K10!E?\(SHG_0+M?\ OV*/^$9T3_H%VO\
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MG]14T=[;2G]W/$WT<&HLS.S*?_",:/\ \^?_ )$?_&C_ (1C1_\ GS_\B/\
MXUJ9ST-&><9I",O_ (1G1_\ GS_\B/\ XUBZUH]A8:QX=EM;<1N=0QG>QX\M
M_4UV':N<\3?\A/PY_P!A(?\ HMZ .B P,44M% !1110 4444 %%%% !1110
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MJKHHOA&<H9,+P>>=NW- %2V^(TL^L0[M*1-$N+^73X;P3YD,L:EBQCV\*=K
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M'_Z!\/Y&M3/UHS]: ,O_ (1O1_\ H'P_D:/^$;T?_H'P_D:U,_6C/UH R_\
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MU)#;6 ZC*@_A0!2FTKP_!?6UG*A2YN=WDQF>7+[1DXY["K0\-:01G[,__?\
MD_\ BJM/I=M+=6US('>:V=WB9G)VEA@_I5T# H Q(O"6DQ/*WE3OYC;L/<R$
M+QC ^;@5*?#.D_\ /L__ '_D_P#BJUZ0\T <]9Z5X>O_ #Q:HTOV>4PRXGD^
M5QC*GGW%6SX8TG_GV?\ [_R?_%5<M;"WLI+EX$*FYE,TN6)RY &?R J7[5 +
MC[/Y\7GXSY>\;L>N.M &0/">D_:3,8I_N;-GVF39USG&[K[TZ;P_HMO$TLD#
MA%&2?/D.!_WU6U44\2SP.A=U# C<C%6&?0]C0!S+Q^$X])FU21]EE"2)9'GE
M&PCJ""<YSVZU?M="T.]M8[F""1HI%W*3-(,CZ%JEB\.V,.FQZ>AG-O'DJ&E)
M(.<YSU)!YR:NZ?:VMC9):6:JL,.5"ALX.<G/ODT 9L_A/290H\J=-KA_W=S(
M,X['YNGM4H\,:3WMG_[_ ,G_ ,56LSH@!9@H)P,G&3Z4*ZR+N1@RGN#D4 <S
M?VGAC3+BVM[O,<UT^R"/SI2TA[X /ZU?'AK222/LS_\ ?^3_ .*J?4-%L=4>
M,W<1?9Q@,1N&<X..HR ?PJ\[QQ*7=U51P2QP* ,2]\(Z7<V[1(MQ 25/F17,
M@88.?7\/I4__  C.DY_X]G_[_P G_P 56LSJBEG(55&22< "F?:8,-^^C^0!
MF^8?*#T)]* ,&?3/#EM?0V4P*7,R,\:&>7YE7[QZXXIFGV/AG5 YL@9MF-V)
MY1P>AY/0]CT-;-SIUI?7-O=2Q[Y(%<1,&. '&&Z=<BH-)T&PT2)DLHG&Y50L
M[EVVJ,*N3V X% $3>%])92!;R#(ZBXD!'T^:FP^%-)AA2/R9GV*%W/<R%F]R
M=W)K;HH YN^T[PYIJ*]VCQJQQN,TI ]S@\#W-1V]IX8N]4N--M\R7=L 9D6:
M4[,C(!.<9]JU]2T>VU7R!<-.%AD$JK'*4!8="0.N/>B'1;&#4VU!(C]I8, 2
MQPN[&[ ]\#/TH @/AG2<?\>S_P#?^3_XJHH/">DPA@89WW.6^>YD.,]A\W ]
M!6[10!@W>BZ#86LMU=1F*WA0O)(]Q( H'4GYJSK<^$;IK=8G)-P%,6991G=]
MWJ>,X.,]<5U%W:PWEN\$Z;HW&",XKFK[0]"T")]7>VG;R61V D9M\F[Y6()P
M6W,>?>@#4_X1C2/^?9_^_P#)_P#%5$OA+25GDE\J<[P 4-S)M&/0;N/>IAJ.
MJC_F!O\ ^!4=']HZM_T G_\  J.@"M?:/X?TVRFO;R-HK>%=TDAGD(4>O!JF
M8_"8N)(&D57C0NVZXE   W-SG&0""1VR*O7LM_J%E-9W&@.\,R%'7[6@RIZ\
MYK EL].%Y<QSZ0OG7 9&B?4X\@NH5MJ[N"0 /PH VK'2_#VIPF6TC:1 VQOW
M\H*GT()R#T_.J.LZ/8Z?K'AR6UA9'.H;<F5VX\M_4FIK6[_L!#;C3%A:1O,8
MSZA'OD. -Q).3P /PJOJNH7%_J?AMVLA% VH K,MPDBM^[?@;30!V0Z44+R.
M:* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+NSM[^UEM;N&
M.>WE7;)%*H97'H0>M3T4 4H]*L(3:&*RMT^QJ4MML8'DJ1@A/[HQQQ56\\+Z
M%J(E%[H^GW(ED$LGG6ZMO?&-QR.3CC/I6O10!5CTVRAT\:?%:P)9"/RA;K&!
M&$_N[>F/:J(\*>'AI1TL:'IO]GE_,-M]E3R]W][;C&?>MBB@#'E\*>'YHK2*
M30]->.S_ ./96M4(AYS\HQQT[5KA<# P*6B@"O<V5O>(B74$4Z(ZR(LB!@KJ
M<JPSW!Z&L&V\ ^'(9K^:XTRUO9KZZ:ZEENX$D;<3G:#C[H/2NFHH SX]$TR)
MX'CT^T1[>(P0LL*@QQGJB^@/I5JUM8+*UCMK6&.&")=J1QJ%51Z #I4U% !6
M!XV_Y$O5O^N!_F*WZQ?%MK/>^%-2MK:)I9Y(2$1>K&@#6@_U$?\ NC^525CQ
M:_9K$BF.]R  ?]#E_P#B:?\ \)!9?\\[W_P#E_\ B: -6BLK_A(++_GG>_\
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M_P" <O\ \31_PD%E_P \[W_P#E_^)H U37.R>%U:ZO)([V2)+MVE;;&OF(Y
M&5D/*CCI5W_A(++_ )YWO_@'+_\ $T?\)!9?\\[W_P  Y?\ XF@#(B\$PAT:
MXU"ZE5=^(@2L8+  ,%SU&,]>M3/X4>1]S:Q?EC;" N&P^0N-P/8GJ>.M:/\
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%110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" "J 0L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V6JC:OIJ?
M>U"V4^<(.95_UAZ)U^][=:MFO+(-$M=;\7W<<-XMK&+N97C-Q"TI(8EOW>W=
MR2V&SD ^U 'J>:6L5M6FB\6G3)9(%M38FX!/#JP<+R<XQSZ5S+>.-4>80I]C
MC-P'>.1T)$ 0RC8_S<L?*&.G4\<4 >@4F:JZ7=M?Z5:7CIY;7$"2E/[I90<?
MK6-<^.M#LKUK2\DGMI%Z[X&_IFFDWL)M+<Z/-&:YK_A8/AC_ *"1_P"_+_X5
M;TSQ=H6KW8M;+4$DF(R$964GZ9 IN$DKM I)[&W129I:D84444 %%%% !111
M0 4444 %%%% !13/,3GYUX..O?TH$B-C:ZG/3!ZT /HIAEC5BI=00-Q!/('K
M]*19HF("R*Q9=P 8<CU^E $E%,:1$QO95R<#)QD^E*'5F90P++]X ]/K0 ZB
MBHEGB>:2%9%:2/!= >5STR.V: ):*89$#A"RAB,A<\FGT %%%% !1110!#=1
M-/;21+*\3.I42)C<A(^\,]Q7%:1=QQ>.FT^:ZGDN09"@5+>1& '5W10Z-[-U
M]Z[:YB,]M)")7B,BE1)&<,F1C(/J*XK1+Q;?QM-I1NKR1RTC[87AEA.!UE*J
M&1_][OW- '73:5I]Q<-<3V-M+,R;&D>)2Q7TR1T]J1]'TZ195>PM669P\H:%
M3O8=&/')]ZNT4 -5=HP.!Z"LFQ16\1:MN4'B'J,_PFM>L+3([D>*-59K@-&/
M+RFS&<CY>?8<>] &UY4?_/-/^^17&>/?#$EW$NMZ6FR_LQDA!S(@_J*[>D(X
MJHR<7<35T<7X4\:1ZA:1K>M@GY?,/8^C?XUV2L"!CD5YMXETE?"NM_VM% 9-
M'OFVW<2#F)C_ !+Z<\C\1WK=L=1GT1(C))]LTN<!H;A.< ]/_P!585+T7S;P
M>S[>3-X)5E:.DUT[^:_R.N%+4-O<Q7,*S0R+(C<A@:E!YK1--71BU;06BBBF
M 4444 %%%% '/>)=/\1WTD!T+58;%4!\T.N2Q[<X-8G]@?$'_H9[;_OG_P"Q
MKNJ*TC4<5:R^XAP3=S@V\-^)HYV9IK>Z9HOM#2!M@-V$,:<8Z8(8GU2I-&\/
MZYHM]9)]E@DM[3[1'$T4ORHLOED'#$$@,K9'7GBNX%+@5G>^I:. U?PIKE]>
MWDWE6\LDP9C<+)L\Q3&B>4%.2 &4L,G;^9J;2?#.IVMYH<DMI&AL7D:67>F"
MC;\ A1G=\PX!V#G Z5W/%&* .#O/#FL7>CWEG);2R22W.^ /-&8H1DGY=Q9@
MI[X(;TQ21>&-?COI9(6^RL\A$]Q!.%>Y4R.^[U& 57GGTXKO>*.* /.+N/Q9
MI]QIMO<W5_+%++&TK0/O<G;&'4$# &[?P>,9K0FTCQ#=V\E]92S6=S>2SSR*
M)!&P(VK ISV"KT]S7;X%&!0!QL6B:NVM:8][;&XAL;B65;PS*9BI9A&K'@E0
MK9/<G [5V0Z4A*JI8D #J2:7(]10 M%%% !1110 AZ5Q6C3ZEIGBN339A<I9
MWMU<2Q&6U0*YY; D$A)'<97I78W)D6WD,*AI0I**3@%L<9_&N&\/6MXWB:#5
MI/#\5F+D/'*SVS+*K[ 7DW%CM#.2H'<<T =*/$<)\0?V3]GE^_Y/GY&WS=GF
M;,=?N<YZ=JS/^$^M7GNK>'3[B6>WF,0C#("Q&\MG)^4@1L<'DC'K6I/X:LYM
M3DU'S+F.>3G]W+@*^W9Y@'9MORY]*I'P+I&^216NTD=B5=)L-&"6)53Z'>V<
MYZT ;ME=QWUE!=PY,5Q&LB$CG:PR/YUEZ9=6\GB35%2>-B_E;0&!W84YQ]*U
M[>WBM;>*WA0)%$@1%'15 P!61IEK;Q^(]4*01J4\K:0H&W*G./K0!N4E+10!
M6OK*#4+.6TNHQ)#,I5U/<5P47A'QEID$FG:;JUJVG;SY:3#)P?4%3BO1J2KC
M-Q5NA+BF[GF)T7QYH<#RV^HP>6>76/YL>^"M7_"/C"_.L-HWB"9'EF&;:<*%
M#'^[QZ]J[XC.:XSQ?X)&IP&ZTP>5=QG>BCC)Z\'L?ZTE/WE%I<ODMO,JR:;N
M^;\SLP:=7*>#/%0UJS^QWS>5J=K\D\;C!?'&X#^8]:ZK(]:4HN,G%B3NKBT4
ME%(8M%)10!EZL=8#1_V6L17G?OQG/;K6?N\6?W+;_P =KHZ,5A*DY._,_O-8
MU>56Y4_D<1-:^(HM7=VMI)82OV\^5)\IG2,HL(&>[;6].#4&BVOB#2;O3X[V
MQO)([>>4EDF\X'S(QU/H)-W;@$5WV!2X%;+1&;=W<\_UK3_$=SJEU.EI.+AH
MOD>VN#Y2Q>4RM&I./F,A4]*;I6E:Q#)H>^UNO,M[IS(QRBF ENN7.P<C]V02
M>.:]"P*,#TIB.%U?5_%%G=3)Y=S';BZ\M)8X$<NCRJ$"9ZG86Z]ZM7J^)VM-
M$NT$WVU+>;[1#'MV-*8_D\P>FX=NAKL-J^@HVCTH X^:WU;4?"=Q'J O6D%T
M&A_<*9I(U*D!T4J,$[AP1QBJKGQH(P84>UV186WBC1T4K"K !FR3F3*]?\:[
MK HP* /-[/6-1\175YH]W+(ZW-XL/E+& D4"NQ<[@."50+M//.>]:4$GBX7:
M/<^=);-(/,@$,8^0O(K*".>$$9'.<FNU"*,X4#)R<#K2X'I0!S_@N"XM]&D^
MTP7%L\MP\@MI\_N%)X122<@#OZYKH:3%+0 4444 -8@#)X KB-'UV;4O%4:I
MXBM+N SSQ):P'<60;CN88X(.T YQA>^ZNX-<+X>AEA\87B," MS,#Y-]%Y:@
MY95,*C.<<_J: .[HK/\ [;T_^U_[*^T?Z7C[FTXSC=C=C&<<XSG'-5Y_%&DV
M\<LLD[^7%+Y6]87(=QG(7 ^;&TYQG&#0!KUA:8]U_P )1J@>*,1GR]S!N1Q\
MO'N,YK:AFCGA2:-P\<BAD8'((/(-9NG_ /(Q:M](?_030!K4444 %%%% !2-
MS2T4 >>^/=!FL;I?%.E*5FBQ]J5.,C^__0_@:VO#'BVUU2R'VJZACE4 Y=PN
MX>^>]=+)&LD;(ZAE8$%2,@CTKSW7_AYH]I#]LM;>8HKYEC\TX"GT]*<Y0Y5*
M;>G;73_@#@I-\D4M>_?_ ()W U;3<?\ (0M?^_R_XTO]K:;_ -!"U_[_ "_X
MUR5I\-_"E[:QW$27)209'[_I[5-_PJWPS_SSN?\ O]6B5%JZD_N,W[1.S1TW
M]K:;_P!!"U_[_+_C2_VMIO\ T$+7_O\ +_C7,?\ "K/#/_/.Y_[_ %'_  JS
MPS_SSN?^_P!3Y:/\S^X5Y]CI_P"UM-_Z"%K_ -_E_P :/[6TW_H(6O\ W^7_
M !KF/^%6>&?^>=S_ -_J/^%6>&?^>=S_ -_J.6C_ #/[@O/L=/\ VMIO_00M
M?^_R_P"-)_:VF_\ 00M?^_R_XUS/_"K/#/\ SSN?^_U'_"K/#/\ SSN?^_U'
M+1_F?W!>?8Z;^UM-_P"@A:_]_E_QJVCJZ!E8,IY!!R#7&M\+/#6"!'= GOYW
M2JGA/4;KPWK+^$=7?*@YL)VZ.I_A_'M[Y%+DBT^1WL',T_>1W]%-6G5D:!11
M10 4444 %%%% !1110!%<O)%;220Q>=*JDI'N"[SC@9/3/3-</HU@4\9?:W@
MN8H))Y3$C3V[1K+AM^"IWM]Y^#TSSTKNWQM.>G>O-?"6GQQ>,/M6F6=D]@T]
MP!-;P!_*&6'^MW'!/R'&.0WH* .JF\,S'7)-2M[]8\R&XCC:'=MF,?E9)R,K
MM[>O>LU? #P2RRVNJF)_-9X@8=R@-OW;AN^9L2$ C' %=G10!7L+./3["WLH
MB3';Q+$I;KA0 ,_E6/I.FP0>)=19/,S#LVYD)^\"3GU_I705A:9=*_BC5(Q'
M*"WE\E.!M&.3[]O6@#>HHHH **** "BBB@ ICQK(C(X!5A@@]Q3Z* .8TUVT
M+67TN9C]FG.Z!CV/I_2NE!ZUEZ_IAU&Q/EC$\1WQ$>OI67;^+)(X42XT^=Y5
M7#LHQDUQQFJ#<);=/\CKE!UTIQWZ_P"9U&:6N;/B\?\ 0,N:T=*URUU3<B9B
MF7K$_6M85Z<G9,RG0JP5Y(TZ*,TM;F(E%+10 E<[XQ\-+XATW]R1'?VYWVTO
M0@_W<^A_G71TASZ4XR<7=":35F<QX*\3-K=B]I>CR]3L_DN(VX+8XW?X^]=/
MFN%\9Z1=:3J$?B_1EQ<6_P#Q]Q#I*G<G\.#^![5U>BZO:ZWI<.H6C9CE'([H
MW=3[BM*D5;GCL_S)B]>5FA1116184444 %%%% !1110!6U'R?[-N?M$OE0F%
MO,DS]Q<')_ 5S'A/2$L;HS6GB>._@9%B>!((U#>6NU>5YR._KBNND19$*.H9
M6&&4C((]*\^\/:<MAXU:.WTJ*W GGWQKIP1;>/\ @=9L?,6XXR>I&!B@#O?M
M,/VC[/YT?G[=WE;QNQZXZXILE]:0^89;J",1$"3?(!L)Z9],]JYN?0=3C\52
M:K!#;RHLIN$=I-KO^Y$7E'@X7/S9_2LNX\&:V+Z^NF:QOQ/,LI1P4\TE)4^;
M.1\H=<?[O:@#OP<UDZ?_ ,C%J_TA_P#035S3+1['2K2SDD\Q[>!(V?\ O%5
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M?]!NR_[Y'_Q%=W13]L^R^X7LUW9PG]E_$C_H-V7_ 'R/_B*/[+^)'_0;LO\
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M% '94F*HPZWILWE!;V!7E@%PL;R!7\LC.XKU Q4%QXHT6V,(;4K=S.SI$(Y
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@<"'#9$C,I4YX&&P1["NHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6835363296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>May. 12, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DelMar Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001498382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">dmpi<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,253,056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6835718144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Interim Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 937,355<span></span>
</td>
<td class="nump">$ 1,754,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_TaxesAndOtherReceivablesCurrent', window );">Taxes and other receivables</a></td>
<td class="nump">32,142<span></span>
</td>
<td class="nump">25,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">85,292<span></span>
</td>
<td class="nump">245,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred costs</a></td>
<td class="nump">60,647<span></span>
</td>
<td class="nump">550,119<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Assets current</a></td>
<td class="nump">1,115,436<span></span>
</td>
<td class="nump">$ 2,575,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets - net</a></td>
<td class="nump">39,875<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,155,311<span></span>
</td>
<td class="nump">$ 2,575,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">646,948<span></span>
</td>
<td class="nump">762,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party payables</a></td>
<td class="nump">29,018<span></span>
</td>
<td class="nump">90,820<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Liabilities current</a></td>
<td class="nump">675,966<span></span>
</td>
<td class="nump">853,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockOptionLiabilityNoncurrent', window );">Stock option liability</a></td>
<td class="nump">149,698<span></span>
</td>
<td class="nump">179,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="nump">1,017,250<span></span>
</td>
<td class="nump">2,364,381<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,842,914<span></span>
</td>
<td class="nump">3,396,911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' accumulated deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock Authorized 5,000,000 shares, $0.001 par value Issued and outstanding 278,530 Series A shares at March 31, 2016 (June 30, 2015 - 278,530)</a></td>
<td class="nump">$ 278,530<span></span>
</td>
<td class="nump">$ 278,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_VotingShare', window );">1 special voting share at March 31, 2016 (June 30, 2015 - 1)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock Authorized 200,000,000 shares, $0.001 par value, 44,309,098 issued at March 31, 2016 (June 30, 2015 - 39,455,931)</a></td>
<td class="nump">$ 44,309<span></span>
</td>
<td class="nump">$ 39,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">21,805,867<span></span>
</td>
<td class="nump">17,363,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">1,190,553<span></span>
</td>
<td class="nump">89,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(24,028,040)<span></span>
</td>
<td class="num">(18,613,294)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">21,178<span></span>
</td>
<td class="nump">21,178<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity, total</a></td>
<td class="num">(687,603)<span></span>
</td>
<td class="num">(821,490)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Liabilities and equity</a></td>
<td class="nump">$ 1,155,311<span></span>
</td>
<td class="nump">$ 2,575,421<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_StockOptionLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represent stock option outstanding as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_StockOptionLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_TaxesAndOtherReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents taxes and other receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_TaxesAndOtherReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_VotingShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Voting share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_VotingShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6835411904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Interim Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_PreferredStockSpecialVotingSharesIssued', window );">Preferred stock special voting shares issued</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">44,309,098<span></span>
</td>
<td class="nump">39,455,931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="nump">278,530<span></span>
</td>
<td class="nump">278,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">278,530<span></span>
</td>
<td class="nump">278,530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_PreferredStockSpecialVotingSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of special voting preferred stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_PreferredStockSpecialVotingSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6835480096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Condensed Interim Statement of Loss and Comprehensive Loss (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 790,323<span></span>
</td>
<td class="nump">$ 641,839<span></span>
</td>
<td class="nump">$ 2,183,355<span></span>
</td>
<td class="nump">$ 1,925,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">630,226<span></span>
</td>
<td class="nump">500,753<span></span>
</td>
<td class="nump">1,994,923<span></span>
</td>
<td class="nump">1,601,982<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">1,420,549<span></span>
</td>
<td class="nump">1,142,592<span></span>
</td>
<td class="nump">4,178,278<span></span>
</td>
<td class="nump">3,527,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (income) loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of derivative liability</a></td>
<td class="num">(276,584)<span></span>
</td>
<td class="nump">$ 781,152<span></span>
</td>
<td class="nump">943,050<span></span>
</td>
<td class="nump">451,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms', window );">Change in fair value of derivative liability due to change in warrant terms</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 270,965<span></span>
</td>
<td class="num">(23,658)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_GainLossOnExchangeOfWarrants', window );">Loss on exchange of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 156,219<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">249,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange (gain) loss</a></td>
<td class="num">$ (10,523)<span></span>
</td>
<td class="nump">$ 6,826<span></span>
</td>
<td class="nump">$ 16,257<span></span>
</td>
<td class="nump">16,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="num">$ (41)<span></span>
</td>
<td class="num">$ (70)<span></span>
</td>
<td class="num">$ (71)<span></span>
</td>
<td class="num">(331)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (income) loss</a></td>
<td class="num">(280,148)<span></span>
</td>
<td class="nump">944,127<span></span>
</td>
<td class="nump">1,230,201<span></span>
</td>
<td class="nump">695,470<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net and comprehensive loss for the period</a></td>
<td class="nump">$ 1,140,401<span></span>
</td>
<td class="nump">$ 2,086,719<span></span>
</td>
<td class="nump">$ 5,408,479<span></span>
</td>
<td class="nump">$ 4,223,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share</a></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average number of shares</a></td>
<td class="nump">44,309,098<span></span>
</td>
<td class="nump">38,976,827<span></span>
</td>
<td class="nump">43,587,549<span></span>
</td>
<td class="nump">37,732,995<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of derivative liability due to change in warrant termsChange in fair value of derivative liability due to change in warrant terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_GainLossOnChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_GainLossOnExchangeOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain loss on exchange of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_GainLossOnExchangeOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6828477264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Condensed Interim Statement of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period</a></td>
<td class="num">$ (5,408,479)<span></span>
</td>
<td class="num">$ (4,223,087)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Items not affecting cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 6,430<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative liability</a></td>
<td class="nump">$ 943,050<span></span>
</td>
<td class="nump">451,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms', window );">Change in fair value of derivative liability due to change in warrant terms</a></td>
<td class="nump">$ 270,965<span></span>
</td>
<td class="num">(23,658)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_GainLossOnExchangeOfWarrants', window );">Loss on exchange of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 249,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_IssuanceOfStockForServices', window );">Shares issued for services</a></td>
<td class="nump">$ 80,400<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Warrants issued for services</a></td>
<td class="nump">400,389<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock option expense</a></td>
<td class="nump">138,711<span></span>
</td>
<td class="nump">$ 323,358<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems', window );">Net income (loss) after adjustments of non-cash items</a></td>
<td class="num">(3,568,534)<span></span>
</td>
<td class="num">(3,220,440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in non-cash working capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_IncreaseDecreaseInTaxesAndOtherReceivables', window );">Taxes and other receivables</a></td>
<td class="num">(6,311)<span></span>
</td>
<td class="num">(39,472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">159,746<span></span>
</td>
<td class="num">(14,375)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(115,317)<span></span>
</td>
<td class="nump">241,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Related party payables</a></td>
<td class="num">(61,802)<span></span>
</td>
<td class="num">(11,457)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapital', window );">Total changes in non-cash working capital</a></td>
<td class="num">(23,684)<span></span>
</td>
<td class="nump">175,965<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows from operating activities</a></td>
<td class="num">(3,592,218)<span></span>
</td>
<td class="num">$ (3,044,475)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Intangible assets</a></td>
<td class="num">(16,762)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows from investing activities</a></td>
<td class="num">(16,762)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ProceedsFromIssuanceOfSharesAndWarrants', window );">Net proceeds from issuance of shares and warrants</a></td>
<td class="nump">2,453,633<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock', window );">Series A preferred stock dividend</a></td>
<td class="num">(6,267)<span></span>
</td>
<td class="num">$ (4,178)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from the exercise of warrants</a></td>
<td class="nump">405,183<span></span>
</td>
<td class="nump">1,404,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Deferred costs</a></td>
<td class="num">(60,647)<span></span>
</td>
<td class="num">(108,637)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows from financing activities</a></td>
<td class="nump">2,791,902<span></span>
</td>
<td class="nump">1,291,362<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Decrease in cash and cash equivalents</a></td>
<td class="num">(817,078)<span></span>
</td>
<td class="num">(1,753,113)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents - beginning of period</a></td>
<td class="nump">1,754,433<span></span>
</td>
<td class="nump">4,759,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents - end of period</a></td>
<td class="nump">$ 937,355<span></span>
</td>
<td class="nump">3,006,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_IssuanceOfPreferredSharesForTheSettlementOfTheLoanPayable', window );">Issuance of preferred shares for the settlement of the loan payable to Valent (note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">278,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants', window );">Reclassification of derivative liability upon the exercise or exchange of Investor Warrants (note 6)</a></td>
<td class="nump">$ 247,440<span></span>
</td>
<td class="nump">1,120,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants', window );">Reclassification of derivative liability upon the amendment of warrants (note 6)</a></td>
<td class="nump">2,343,300<span></span>
</td>
<td class="nump">975,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions', window );">Reclassification of stock option liability upon the forfeiture of stock options</a></td>
<td class="nump">29,747<span></span>
</td>
<td class="nump">$ 38,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_DeferredCostsRecognizedAsEquityIssueCosts', window );">Deferred costs recognized as equity issue costs</a></td>
<td class="nump">$ 550,119<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of derivative liability due to change in warrant termsChange in fair value of derivative liability due to change in warrant terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_DeferredCostsRecognizedAsEquityIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred costs recognized as equity issue costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_DeferredCostsRecognizedAsEquityIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_GainLossOnExchangeOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain loss on exchange of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_GainLossOnExchangeOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_IncreaseDecreaseInTaxesAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents Taxes, excluding payroll, income and excise taxes, if not included elsewhere, that could include production, real and personal property, and other selling and distribution-related taxes and Carrying amounts due as of the balance sheet date from parties or arising from transactions not otherwise specified in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_IncreaseDecreaseInTaxesAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_IssuanceOfPreferredSharesForTheSettlementOfTheLoanPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The element of issuance of preferred shares for the settlement of the loan payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_IssuanceOfPreferredSharesForTheSettlementOfTheLoanPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_IssuanceOfStockForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_IssuanceOfStockForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the net income (loss) after adjustments of non cash items during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_NetIncomeLossAfterAdjustmentsOfNonCashItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ProceedsFromIssuanceOfSharesAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of shares and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ProceedsFromIssuanceOfSharesAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of derivative liability upon the amendment of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of derivative liability upon the exercise of investor warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of stock option liability upon the forfeiture of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment for noncash service expenses paid for by granting of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentOfWarrantsGrantedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6826370144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Liquidity Risk<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Operations and Liquidity Risk [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of operations and liquidity risk</a></td>
<td class="text"><table style="font: bold 10pt/normal 'times new roman', times, serif; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 6pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 15pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">1</font></td>
<td style="width: 5pt;"></td>
<td style="text-align: justify;"><font style="font-family: 'times new roman', times, serif;">Nature of operations and liquidity risk</font></td>
</tr>
</table>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-weight: bold; font-stretch: normal; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;"><b>Nature of operations</b></font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 12pt; margin: 0px 0px 13pt 21.55pt; text-align: justify;"><font style="font-family: 'times new roman', times, serif; background-color: white;">DelMar Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a clinical stage drug development company with a focus on the treatment of cancer.&#160;&#160;&#160;We are conducting clinical trials in the United States with our product candidate, VAL-083, as a potential new treatment for glioblastoma multiforme (&#8220;GBM&#8221;), the most common and aggressive form of brain cancer.&#160;&#160;We have also acquired certain exclusive commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (&#8220;CML&#8221;) and lung cancer.&#160;&#160;In order to accelerate our development timelines and reduce technical risk, we leverage existing clinical and commercial data from a wide range of sources.&#160;&#160;We plan to seek marketing partnerships in China in order to potentially generate future royalty revenue.</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 12pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">The Company is a Nevada corporation formed on June 24, 2009 under the name Berry Only Inc. On January 25, 2013 (the &#8220;Closing Date&#8221;), the Company entered into and closed an exchange agreement (the &#8220;Exchange Agreement&#8221;), with Del Mar Pharmaceuticals (BC) Ltd. (&#8220;DelMar (BC)&#8221;), 0959454 B.C. Ltd. (&#8220;Callco&#8221;), and 0959456 B.C. Ltd. (&#8220;Exchangeco&#8221;) and the security holders of DelMar (BC). Upon the closing of the Exchange Agreement, DelMar (BC) became a wholly-owned subsidiary of the Company (the &#8220;Reverse Acquisition&#8221;). As a result of the shareholders of DelMar (BC) having a controlling interest in the Company subsequent to the Reverse Acquisition, for accounting purposes the transaction is a capital transaction with DelMar (BC) being the accounting acquirer even though the legal acquirer is the Company.</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 12pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">DelMar Pharmaceuticals, Inc. is the parent company of DelMar (BC), a British Columbia, Canada corporation, and Callco and Exchangeco which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition.</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 12pt; margin: 0px 0px 13pt 21.55pt;"><font style="font-family: 'times new roman', times, serif; background-color: white;">The address of the Company&#8217;s administrative offices is Suite 720 - 999 West Broadway, Vancouver, British Columbia, V5Z 1K5 and the Company&#8217;s clinical operations are located at 3485 Edison Way, Suite R, Menlo Park, California, 94025.</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 12pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">References to the Company refer to the Company and its wholly-owned subsidiaries, DelMar (BC), Callco and Exchangeco.</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-weight: bold; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt; text-indent: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Liquidity risk</font></p>
<p style="color: #000000; font-family: 'times
 new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"><font style="font-family: 'times new roman', times, serif;">For the nine-month period ended March 31, 2016, the Company reported a loss of $5,408,479 and an accumulated deficit of $24,028,040 at that date. As at March 31, 2016, the Company had cash and cash equivalents on hand of $937,355. The Company does not have the prospect of achieving revenues in the near future and the Company will require additional funding to maintain its research and development projects and for general operations. There is a great degree of uncertainty with respect to the expenses the Company will incur in executing its business plan. In addition, the Company has not begun to commercialize or generate revenues from its product candidate.</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"><font style="font-family: 'times new roman', times, serif;">Consequently, management is pursuing various financing alternatives to fund the Company&#8217;s operations so it can continue as a going concern (note 9) in the medium to longer term. Subsequent to March 31, 2016, the Company completed a convertible preferred share private placement for gross proceeds of $6.1 million. We believe, based on our current estimates, that we will be able to fund our operations beyond the next twelve months.</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;">There is no assurance that our cost estimates will prove to be accurate or that unforeseen events, problems or delays will not occur that would require us to seek additional debt and/or equity funding. The ability of the Company to meet its obligations and continue the research and development of its product candidate is dependent on its ability to continue to raise adequate financing. There can be no assurance that such financing will be available to the Company in the amount required at any time or for any period or, if available, that it can be obtained on terms satisfactory to the Company. The Company may tailor its drug candidate development program based on the amount of funding the Company raises.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6003-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=SL51803626-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6826214496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Financial Statements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Restatement of Previously Issued Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock', window );">Restatement of previously issued financial statements</a></td>
<td class="text"><table style="font: bold 10pt/13pt 'times new roman', times, serif; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 6pt; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; text-align: justify;"><td style="width: 15pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">2</font></td><td style="width: 5pt;"></td><td style="text-align: justify;"><font style="font-family: 'times new roman', times, serif;">Restatement of previously issued financial statements</font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"><font style="font-family: 'times new roman', times, serif; font-weight: normal; background-color: white;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"><font style="font-family: 'times new roman', times, serif; font-weight: normal; background-color: white;">In our 2015 Annual Report on Form 10-K/A, we restated our previously issued consolidated financial statements and the related disclosures for the fiscal years ended June 30, 2015 and June 30, 2014 and for each of the quarters ended March 31, 2013, June 30, 2013, September 30, 2013, December 31, 2013, March 31, 2014, September 30, 2014, December 31, 2014, and March 31, 2015 (the "Restated Periods").</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"><font style="font-family: 'times new roman', times, serif; background-color: white;">The restatement is the result of our corrections for the effect of financial statement errors attributable to the incorrect accounting for certain warrants issued for placement agent services issued on March 6, 2013 (the &#8220;2013 Placement Agent Warrants&#8221;). The 2013 Placement Agent Warrants were improperly accounted for as equity instruments at the time they were issued. During the preparation of our financial statements for the first quarter of fiscal 2016, we discovered that the 2013 Placement Agent Warrants represented a derivative liability and should not have been recognized as equity. The exercise price of the 2013 Placement Agent Warrants is subject to adjustment in certain circumstances. The public equity financing that we completed in August 2015 resulted in the exercise price of the 2013 Placement Agent Warrants being reduced. Accordingly, we have classified the 2013 Placement Agent Warrants as a derivative liability on the Consolidated Balance Sheets at June 30, 2015 and June 30, 2014 as well as recognized the gain/loss from the revaluation of the derivative liability in the Consolidated Statement of Operations and Comprehensive Loss of the years ended June 30, 2015 and June 30, 2014. We have also reflected the cumulative impact of the fair value adjustments from March 6, 2013 to June 30, 2014 in the accumulated deficit.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="background-color: white;">The aggregate impacts of correcting the errors relating to the 2013 Placement Agent Warrants, as of, and for the three and nine months ended March 31, 2015 were as follows:</font></p><table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10">Three Months Ended March 31, 2015</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">As previously reported&#160;<br />$</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">Restatement adjustment&#160;<br />$</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">As restated&#160;<br />$</font></td><td
 style="font-weight: bold;
 padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: right;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: right;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: right;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 944.203125px; text-align: left; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Change in fair value of derivative liability</font></td><td style="width: 16px; font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 137px; font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">343,569</font></td><td style="width: 15px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">437,583</font></td><td style="width: 15px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">781,152</font></td><td style="width: 15px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Loss for the period</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">1,649,136</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">437,583</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">2,086,719</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Basic and diluted loss per share</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.04</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.01</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.05</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font
 style="font-family: 'times new roman', times, serif;">&#160;</font></td><td
 style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><div>&#160;</div><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"></p><table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; text-align: center;" colspan="10">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10">Nine Months Ended March 31, 2015</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">As previously reported&#160;<br />$</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">Restatement adjustment&#160;<br />$</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">As restated&#160;<br />$</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: right;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: right;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: right;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 944.203125px; text-align: left; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Change in fair value of derivative liability</font></td><td style="width: 16px; font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 137px; font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">276,963</font></td><td style="width: 15px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times,
 serif;">174,831</font></td><td style="width: 15px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times,
 serif;">&#160;</font></td><td style="width: 15px; font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">451,794</font></td><td style="width: 15px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Loss for the period</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">4,048,256</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">174,831</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">4,223,087</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Basic and diluted loss per share</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.11</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.00</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.11</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font
 style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: bold; text-align: right; padding-bottom:
 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10"><font style="font-family: 'times new roman', times, serif;">As At March 31, 2015</font></td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">As previously reported</font></p><p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">$&#160;</font></p></td><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">Restatement adjustment</font></p><p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">$&#160;</font></p></td><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">As restated</font></p><p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">$&#160;</font></p></td><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Derivative liability</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">1,487,137</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">1,956,471</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">3,443,608</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;
 background-color: white;"><td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Additional paid-in capital</font></td><td style="font-weight: normal;"><font style="font-family: 'times new
 roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">17,455,279</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(136,800</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">17,318,479</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Warrants</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">6,138,426</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(6,048,994</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">89,432</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Accumulated deficit</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(22,715,848</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">4,229,323</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif; font-weight: normal;">(18,486,525</font></td><td style="font-weight: normal; text-align: left;">)<font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"><font style="font-family: 'times new roman', times, serif;">We assessed the impact of these errors on our previously issued
 financial statements and concluded that the combined impact of these errors was material to our financial statements. Consequently, we have restated the prior period financial statements identified above. All amounts in our consolidated financial statements in this Quarterly Report on Form 10-Q affected by the restatement
 adjustments reflect such amounts as restated.</font></p><div>&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 6.G.2.b(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26874127&amp;loc=d3e31034-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=6368906&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 1.N.Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26874127&amp;loc=d3e30840-122693<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6759122768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant accounting policies</a></td>
<td class="text"><table style="font: bold 10pt/normal 'times new roman', times, serif; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 6pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; text-align: justify;"><td style="width: 15pt; text-align: left;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">3</font></td><td style="width: 5pt;"></td><td style="text-align: justify;"><font style="font-family: 'times new roman', times, serif;">Significant accounting policies</font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;"><b>Basis of presentation</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">The consolidated condensed interim financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles (&#8220;U.S. GAAP&#8221;) and are presented in United States dollars. The Company&#8217;s functional currency is the United States dollar.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">The accompanying consolidated condensed interim financial statements include the accounts of the Company and its wholly-owned subsidiaries, DelMar BC, Callco, and Exchangeco. All intercompany balances and transactions have been eliminated.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">The principal accounting policies applied in the preparation of these financial statements are set out below and have been consistently applied to all periods presented.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;"><b>Unaudited interim financial data</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">The accompanying unaudited March 31, 2016 consolidated condensed interim balance sheet, the consolidated condensed interim statements of loss and comprehensive loss for the three and nine months ended March 31, 2016 and 2015, and consolidated condensed cash flows for the nine months ended March 31, 2016 and 2015, and the related interim information contained within the notes to the consolidated condensed interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. These consolidated condensed interim financial statements should be read in conjunction with the audited financial statements of the Company as at June 30, 2015 filed in our amended Form 10-K/A filed with the Securities and Exchange Commission on November 16, 2015. In the opinion of management, the unaudited consolidated condensed interim financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position at March 31, 2016 and results of its operations for the three and nine months ended March 31, 2016 and 2015, and its cash flows for the nine months ended March 31, 2016 and 2015. The results for three and nine months ended March 31, 2016 are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2016 or for any other future annual or interim period.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;"><b>Use of estimates</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant:
 normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"><font style="font-family: 'times new roman', times, serif;">The preparation of consolidated condensed interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end or during the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liability and the valuation of equity instruments issued for services. There have been no changes to the methodology used in determining these estimates from the period ended June 30, 2015.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><b>Intangible assets</b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><i>Website development costs</i></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"><font style="font-family: 'times new roman', times, serif;">Website development costs are stated at cost less accumulated amortization. The Company capitalizes website development costs associated with graphics design and development of the website application and infrastructure. Costs related to planning, content input, and website operations are expensed as incurred. The Company amortizes website development costs on a straight-line basis over three years. The website costs consist of $16,762 in cash costs and $29,543 in non-cash consideration in the form of the issuance of warrants. The Company recognized $3,858 and $6,430 respectively, in amortization during the three and nine months ended March 31, 2016. There was no amortization in either the three or nine months ended March 31, 2015.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 16pt; margin: 0px;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;"><b>Loss per share</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 0.3in;"><font style="font-family: 'times new roman', times, serif;">Loss per share is calculated based on the weighted average number of common shares outstanding. For the three and nine month periods ended March 31, 2016 and 2015 diluted loss per share does not differ from basic loss per share since the effect of the Company&#8217;s warrants and stock options are anti-dilutive. At March 31, 2016, potential common shares of 18,388,945 (March 31, 2015 &#8211; 13,472,870) relating to warrants and 3,465,000 (March 31, 2015 &#8211; 3,595,000) relating to stock options were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 0.3in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.3in;"><font style="font-family: 'times new roman', times, serif;"><b>Recent accounting pronouncements</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.3in;"><font style="font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times
 new roman', times, serif;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.3in;"><font style="font-family: 'times new roman', times, serif;"><i>Accounting Standards Update (&#8220;ASU&#8221;) 2014-15 - Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern</i></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 0.3in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 21.55pt;"><font style="font-family: 'times new roman', times, serif;">The objective of the guidance is to require management to explicitly assess an entity's ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management will assess if there is substantial doubt about an entity's ability to continue as a going concern within one year after the issuance date of an entity&#8217;s financial statements. The new standard defines substantial doubt and provides examples of indicators thereof. The definition of substantial doubt incorporates a likelihood threshold of "probable" similar to the current use of that term in U.S. GAAP for loss contingencies. The new standard will be effective for all entities in the first annual period ending after March 15, 2016 (March 31, 2016 for calendar year-end entities). Earlier application is permitted. The Company is currently assessing this standard for its impact on future reporting periods.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6746079808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Valent Technologies, LLC<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ValentTechnologiesLlcAbstract', window );"><strong>Valent Technologies, LLC [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ValentTechnologiesLlcTextBlock', window );">Valent Technologies, LLC</a></td>
<td class="text"><div><table style="font: bold 10pt/normal 'times new roman', times, serif; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 6pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 15pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">4</font></td><td style="width: 5pt;"></td><td style="text-align: justify;"><font style="font-family: 'times new roman', times, serif;">Valent Technologies, LLC</font></td></tr></table><p style="font: bold 10pt/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0pt; margin-bottom: 0pt; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 0px 21.55pt; color: #000000; text-transform: none; text-indent: 0in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-weight: normal;">On September 30, 2014, the Company entered into an exchange agreement (the &#8220;Valent Exchange Agreement&#8221;) with Valent Technologies, LLC (&#8220;Valent&#8221;), an entity owned by the Company&#8217;s Chief Scientific Officer and director, and DelMar (BC). Pursuant to the Valent Exchange Agreement, Valent exchanged its loan payable in the outstanding amount of $278,530 (including aggregate accrued interest to March 31, 2015 of $28,530), issued to Valent by DelMar (BC), for 278,530 shares of the Company&#8217;s Series A Preferred Stock. The shares of Series A Preferred Stock have a stated value of $1.00 per share (the &#8220;Stated Value&#8221;) and are not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3% of the Stated Value per year, payable quarterly in arrears.</font></p><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 0px 21.55pt; color: #000000; text-transform: none; text-indent: 0in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-weight: normal;"><br /></font></p><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 0px 21.55pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">For the three and nine months ended March 31, 2016, the Company recorded $2,089 and $6,267 respectively related to the dividend payable to Valent. The dividends have been recorded as a direct increase in accumulated deficit. For the nine months ended March 31, 2015 the Company accrued $2,091 in interest expense on the loan payable to the date of the conversion on September 30, 2014 and $4,178 related to the dividend for the period from October 1, 2014 to March 31, 2015.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ValentTechnologiesLlcAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ValentTechnologiesLlcAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ValentTechnologiesLlcTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Valent Technologies LLC loan agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ValentTechnologiesLlcTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6592347584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related party transactions</a></td>
<td class="text"><div><table style="font: bold 10pt/13pt 'times new roman', times, serif; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 6pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 15pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">5</font></td><td style="width: 5pt;"></td><td style="text-align: justify;"><font style="font-family: 'times new roman', times, serif;">Related party transactions</font></td></tr></table><p style="font: 13.33px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><i>During the nine months ended March 31, 2016</i></font></p><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">Pursuant to consulting agreements with the Company&#8217;s officers, the Company recognized a total of $360,000 (2015 - $385,000) in compensation expense for the nine months ended March 31, 2016.</font></p><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">At March 31, 2016 there is an aggregate amount of $29,018 (June 30, 2015 - $90,820) owed to the Company&#8217;s officers and directors for fees and expenses. The Company pays related party payables incurred for fees and expenses under normal commercial terms.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">The Company paid $127,583 in directors&#8217; fees (2015 - $77,667) during the nine months ended March 31, 2016.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.3in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">The Company recorded $6,267 in dividends related to the Series A Preferred Stock issued to Valent (note 4).</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><i>&#160;</i></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><i>During the nine months ended March 31, 2015</i></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><i>&#160;</i></font></p><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">Effective September 30, 2014, the Company entered into and closed an agreement with Valent to exchange its loan with Valent for 278,530 shares of preferred stock of the Company (note 4).</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 21.55pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">The Company accrued $2,091 in interest expense on the loan payable to Valent to the date of the conversion on September 30, 2014 and $4,178 related to the dividend on the Series A Preferred Stock for the period from October 1, 2014 to March 31, 2015 (note 4).</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6758460400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative liability</a></td>
<td class="text"><table style="font: bold 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0pt;"></td><td style="width: 21.55pt;"><font style="font-family: 'times new roman', times, serif;">6</font></td><td><font style="font-family: 'times new roman', times, serif;">Derivative liability</font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 12pt; margin: 0px 0px 13pt 21.55pt;"><font style="font-family: 'times new roman', times, serif;">The Company has issued common stock purchase warrants. Based on the terms of certain of these warrants the Company determined that the warrants were a derivative liability which is recognized at fair value at the date of the transaction and re-measured at fair value each reporting period with the changes in fair value recorded in the consolidated condensed statement of loss and comprehensive loss.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt;"><font style="font-family: 'times new roman', times, serif;"><i>Investor Warrants</i></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt;"><font style="font-family: 'times new roman', times, serif;"><i>&#160;</i></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"><font style="font-family: 'times new roman', times, serif;">In connection with the Reverse Acquisition (note 1), during the quarter ended March 31, 2013 the Company issued units consisting of one share of common stock and one five-year warrant (the &#8220;Investor Warrants&#8221;) to purchase one share of common stock at an exercise price of $0.80. The exercise price of the Investor Warrants is subject to adjustment in the event that the Company issues common stock at a price lower than the exercise price, subject to certain exceptions. As a result of the financing completed by the Company during the three months ended September 30, 2015 (note 7) the exercise price of the Investor Warrants was reduced from $0.80 to $0.786. As a result of the price being reduced, the Company has recognized a loss of $8,098 on the revaluation of the warrants</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;"><u>Investor Warrant exercises</u></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">During the nine months ended March 31, 2016, 515,500 Investor Warrants were exercised at an exercise price of $0.786 per share. The Company received proceeds of $405,183 from these exercises. The warrants that have been exercised were revalued at their exercise date and then the reclassification to equity was recorded resulting in $247,440 of the derivative liability being reclassified to equity.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">During the nine months ended March 31, 2015 the Company concluded a tender offer whereby the holders of the Investor Warrants had the opportunity to exercise their warrants at an exercise price of $0.65. Under the tender offer, a total of 762,227 warrants were exercised for net proceeds of $470,676 after payment by the Company of a 5% warrant agent fee of $24,772. In addition, during the nine months ended March 31, 2015, 1,223,847 warrants were exercised at an exercise price of $0.65 per warrant. The Company received proceeds of $795,501 from these exercises.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;
 font-stretch:
 normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">As a result of all of the Investor Warrant exercises during the nine months ended March 31, 2015, the Company received net proceeds of $1,266,177 from the exercise of 1,986,074 warrants. The Investor Warrants that have been exercised were revalued at their exercise date and then the reclassification to equity was recorded resulting in $391,422 of the derivative liability being reclassified to equity.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;"><u>Investor Warrant exchanges</u></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">On December 31, 2014, the Company issued 414,889 shares of common stock in exchange for 1,244,666 Investor Warrants. The Investor Warrants that have been exchanged were revalued at their exchange date and then a reclassification to equity was recorded. The reclassification to equity upon the exchange was $305,112. The Company recognized a loss of $92,843 at the time of the exchange.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">On January 8, 2015, the Company filed a tender offer statement with the Securities and Exchange Commission, and on January 23, 2015, the Company filed an amendment thereto. The tender offer provided the holders of the Investor Warrants with the opportunity to receive one&#160;share of common stock for every three Investor Warrants tendered. On February 9, 2015 the Company&#8217;s tender offer expired. A total of 1,591,875 Investor Warrants were exchanged for 530,625 shares of common stock. The Investor Warrants that have been exchanged were revalued at their exchange date and then a reclassification to equity was recorded. The reclassification to equity upon the exchange was $423,723. The Company recognized a loss of $156,219 at the time of the exchange</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"><font style="font-family: 'times new roman', times, serif;"><u>Investor Warrant amendments</u></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt; background-color: white;"><font style="font-family: 'times new roman', times, serif;">On March 29, 2016, the Company entered into amendments (the &#8220;Investor Warrant Amendments&#8221;) with the holders of certain Investor Warrants. Pursuant to the Investor Warrant Amendments, 250,000 Investor Warrants were amended to extend the expiration date to March 31, 2019 and remove the provision requiring an adjustment of the exercise price in the event the Company sells common stock at a purchase price lower than the current warrant exercise price. As a result of the Investor Warrant Amendments, the Company has recognized a loss of $7,000 and has reclassified $65,750 from the derivative liability to equity resulting in an increase to equity of $58,750. The Investor Warrants were revalued to the date of the amendment and were then reclassified to equity.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"><font style="font-family: 'times new roman', times, serif;"><i>2013 Placement Agent Warrants</i></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"><font style="font-family: 'times new roman', times, serif;">Also in connection with the Reverse Acquisition (note 1), on March 6, 2013 the Company issued 5,250,000 warrants (the &#8220;2013 Placement Agent Warrants&#8221;) that are exercisable at $0.80 per share until March 6, 2018 but can be exercised on a cashless basis. The exercise price of the 2013 Placement Agent Warrants is subject to adjustment in the event that the Company sells common stock at a price lower than the exercise price, subject to certain exceptions. As a result of the financing completed by the Company during the quarter ended September 30, 2015 (note 7) the exercise price of the 2013 Placement Agent Warrants was reduced from $0.80 to $0.786. As a result of the price being reduced, the Company has recognized a loss of $13,467.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing:
 0px;
 -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt; background-color: white;"><font style="font-family: 'times new roman', times, serif;">On December 30, 2015, the Company entered into amendments (the &#8220;2013 Placement Agent Warrant Amendments&#8221;) with the holders of the 2013 Placement Agent Warrants. Pursuant to the 2013 Placement Agent Warrant Amendments, 5,050,000 2013 Placement Agent Warrants were amended to extend the expiration date to June 30, 2019 and remove the provision requiring an adjustment of the exercise price in the event the Company sells common stock at a purchase price lower than the current warrant exercise price. As a result of the 2013 Placement Agent Warrant Amendments, the Company has recognized a loss of $242,400 and has reclassified $2,277,550 from the derivative liability to equity resulting in an increase to equity of $2,035,150. The 2013 Placement Agent Warrants were revalued to the date of the amendment and were then reclassified to equity.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;"><i>Dividend Warrants</i></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">In connection with the Reverse Acquisition (note 1), effective January 24, 2013, the Company effected a warrant dividend (the &#8220;Warrant Dividend&#8221;) pursuant to which the Company issued one five-year warrant to purchase one share of common stock at an exercise price of $1.25 for each outstanding share of common stock (the &#8220;Dividend Warrants&#8221;). Pursuant to the Warrant Dividend, the Company issued an aggregate of 3,250,007 Dividend Warrants.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">On October 31, 2014, the Company and all of its Dividend Warrant holders entered into amendments to the Dividend Warrants such that the Company&#8217;s redemption rights and certain provisions of the Dividend Warrant agreements relating to potential cash settlement of the Dividend Warrants were removed. The Dividend Warrants were revalued to the date of the amendment on October 31, 2014 which resulted in a reclassification to equity of $975,278.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;"><i>2015 Agent Warrants</i></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">As part of the Company&#8217;s financing completed during the quarter ended September 30, 2015 (note 7), the Company issued 93,908 warrants to certain placement agents (&#8220;2015 Agent Warrants&#8221;). The 2015 Agent Warrants are exercisable at a per share price equal to $0.75 during the five-year period commencing six months from the effective date of the Public Offering, which period shall not extend further than five years from the effective date of the Public Offering. Therefore, all 2015 Agent Warrants expire on July 15, 2020.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;"><i>Warrants issued for services</i></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">In a prior period, the Company issued 300,000 warrants for services. The warrants were issued on September 12, 2013 and are exercisable on a cashless basis at an exercise price of $1.76 for five years.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new
 roman',
 times, serif;">The Company&#8217;s derivative liability is summarized as follows:</font></p><table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">March 31,&#160;<br />2016&#160;<br />$</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">June 30,&#160;<br />2015&#160;<br />$</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="padding: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center;" colspan="2"><font style="font-family: 'times new roman', times, serif;">(as restated)</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1155px; font-weight: bold; text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Opening balance</font></td><td style="width: 16px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">2,364,381</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">5,111,007</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Issuance of 2015 Agent Warrants</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">29,594</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Change in fair value of warrants</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">943,050</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">(627,433</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;
 text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman',
 times, serif;">Change in fair value due to change in warrant terms</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">270,965</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">(23,658</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Reclassification to equity upon amendment of warrants</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">(2,343,300</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">(975,278</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Reclassification to equity upon exchange of warrants</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">(728,835</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Reclassification to equity upon exercise of warrants</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(247,440</font></td><td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(391,422</font></td><td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: bold; text-align: left; padding: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Closing balance</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">1,017,250</font></td><td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman',
 times, serif;">2,364,381</font></td><td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times,
 serif;">&#160;</font></td></tr></table><div>&#160;</div><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41620-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579240-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624177-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80784-113994<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41641-113959<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579245-113959<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624258-113959<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80748-113994<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5708775-113959<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5708773-113959<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5580258-113959<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624181-113959<br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41638-113959<br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6758327648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' equity</a></td>
<td class="text"><table style="font: bold 10pt/normal 'times new roman', times, serif; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 6pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 15pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">7</font></td>
<td style="width: 5pt;"></td>
<td style="text-align: justify;"><font style="font-family: 'times new roman', times, serif;">Stockholders&#8217; equity</font></td>
</tr>
</table>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;"><b>Preferred stock</b></font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 0.3in;"><font style="font-family: 'times new roman', times, serif;"><i>Authorized</i></font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 0.3in;"><font style="font-family: 'times new roman', times, serif;"><i>&#160;</i></font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 0.6in;"><font style="font-family: 'times new roman', times, serif;">5,000,000 preferred shares, $0.001 par value</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 0.6in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px; text-indent: 20pt;"><font style="font-family: 'times new roman', times, serif;"><i>Issued and outstanding</i></font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;"><i>&#160;</i></font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px; text-indent: 40pt;"><font style="font-family: 'times new roman', times, serif;">Special voting shares &#8211; at March 31, 2016 &#8211; 1 (June 30, 2015 &#8211; 1)</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px; text-indent: 40pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px; text-indent: 40pt;"><font style="font-family: 'times new roman', times, serif;">Series A shares &#8211; at March 31, 2016 &#8211; 278,530 (June 30, 2015 &#8211; 278,530)</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px
 0px 0px 21.55pt;"><font style="font-family: 'times new roman', times, serif;">Effective September 30, 2014 pursuant to the Company&#8217;s Valent Exchange Agreement (note 4), the Company filed the Series A Certificate of Designation with the Secretary of State of Nevada. Pursuant to the Series A Certificate of Designation, the Company designated 278,530 shares of preferred stock as Series A Preferred Stock. The shares of Series A Preferred Stock have a stated value of $1.00 per share (the &#8220;Stated Value&#8221;) and are not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3% of the Stated Value per year, payable quarterly in arrears. Upon any liquidation of the Company, the holder of the Series A Preferred Stock will be entitled to be paid, out of any assets of the Company available for distribution to stockholders, the Stated Value of the shares of Series A Preferred Stock held by such holder, plus any accrued but unpaid dividends thereon, prior to any payments being made with respect to the common stock.</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 21.55pt;"></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;"><b>Common stock</b></font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt;"><font style="font-family: 'times new roman', times, serif;"><i>Authorized</i></font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt;"><font style="font-family: 'times new roman', times, serif;"><i>&#160;</i></font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-indent: 0.3in;"><font style="font-family: 'times new roman', times, serif;">200,000,000 common shares, $0.001 par value</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-indent: 0.3in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 21.55pt;"><font style="font-family: 'times new roman', times, serif;"><i>Issued and outstanding</i></font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 21.55pt;"><font style="font-family: 'times new roman', times, serif;"><i>&#160;</i></font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 0.3in; text-indent: 0.3in;"><font style="font-family: 'times new roman', times, serif;">March 31, 2016 &#8211; 44,309,098 (June 30, 2015 &#8211; 39,455,931)</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 21.55pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 21.55pt;"><font style="font-family: 'times new roman', times, serif;">The issued and outstanding common shares at March 31, 2016 include 4,056,042 shares of common stock on an as-exchanged basis with respect to the shares of Exchangeco that can be exchanged for shares of common stock of the Company.</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal;
 widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 0px 21.55pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="padding: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">
<p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 10.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">Shares of common stock</font></p>
<p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 10.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">outstanding</font></p>
</td>
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">Common stock</font></td>
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">Additional paid-in capital</font></td>
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">
<p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 10.5pt; font-family: 'times new roman', times, serif; margin: 0px 0.1in 0px 0px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 10.5pt; font-family: 'times new roman', times, serif; margin: 0px 0.1in 0px 0px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 10.5pt; font-family: 'times new roman', times, serif; margin: 0px 0.1in 0px 0px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 10.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">Warrants</font></p>
</td>
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-weight: bold; text-align: right; padding: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: center;"><font style="font-family: 'times new roman', times, serif;">$</font></td>
<td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: center;"><font style="font-family: 'times new roman', times, serif;">$</font></td>
<td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left;"><font
 style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: center;"><font style="font-family: 'times new roman', times, serif;">$</font></td>
<td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 790px; font-weight: bold; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">June 30, 2015 &#8211; as previously reported</font></td>
<td style="width: 16px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 16px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 137px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">39,455,931</font></td>
<td style="width: 16px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 16px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 136px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">39,456</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 15px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 136px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">17,500,008</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 15px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 136px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">6,138,426</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Restatement adjustments</font></td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td>
<td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td>
<td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(136,800</font></td>
<td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(6,048,994</font></td>
<td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-weight: bold; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">June 30, 2015 &#8211; as restated</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">39,455,931</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">39,456</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">17,363,208</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman',
 times, serif;">89,432</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Issuance of shares and warrants &#8211; net of issue costs (i)</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">4,277,667</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">4,278</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">1,198,453</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">671,189</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Reclassification of warrants (ii)</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">2,343,300</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Exercise of warrants for cash (iii)</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">515,500</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">515</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman',
 times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">652,108</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Warrants issued for services (iv)</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">429,932</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Shares issued for services (v)</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">60,000</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">60</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">80,340</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Stock-based compensation</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">138,711</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Reclassification of stock option liability</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times
 new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">29,747</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-weight: bold; padding: 0px 0px 4pt; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">March 31, 2016</font></td>
<td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"><font style="font-family: 'times new roman', times, serif;">44,309,098</font></td>
<td style="padding-bottom: 4pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"><font style="font-family: 'times new roman', times, serif;">44,309</font></td>
<td style="padding-bottom: 4pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"><font style="font-family: 'times new roman', times, serif;">21,805,867</font></td>
<td style="padding-bottom: 4pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"><font style="font-family: 'times new roman', times, serif;">1,190,553</font></td>
<td style="padding-bottom: 4pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
</table>
<div>&#160;</div>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start;
 text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">(i) On July 15, 2015 the Company&#8217;s Registration Statement on Form S-1 relating to a public offering by the Company of common stock and common stock purchase warrants (the &#8220;Public Offering&#8221;) was declared effective by the Securities and Exchange Commission. Pursuant to the Offering, the Company issued 4,277,667 shares of common stock at $0.60 per share and 4,277,667 warrants (the &#8220;2015 Public Offering Warrants&#8221;) to purchase shares of common stock at $0.001 per warrant for total gross proceeds of $2,566,660. The 2015 Public Offering Warrants are exercisable at $0.75 per share for a period of five years until they expire on July 31, 2020.</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;">The Company engaged certain placement agents for the sale of a portion of the shares and 2015 Public Offering Warrants. Under the Company&#8217;s engagement agreements with these placement agents, the Company agreed to pay up to a 7% cash commission and issue warrants to purchase shares of common stock (the &#8220;2015 Agent Warrants&#8221;) up to the number of shares of our common stock equal to 5% of the aggregate number of shares sold in the Offering by such placement agents. Pursuant to the placement agent agreements the Company paid a total cash commission of $80,575 and issued 93,908 2015 Agent Warrants (note 6). The 2015 Agent Warrants are exercisable at a per share price equal to $0.75 during the five-year period commencing six months from the effective date of the Public Offering, which period shall not extend further than five years from the effective date of the 2015 Public Offering. Therefore, all 2015 Agent Warrants expire on July 15, 2020.</p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">In addition to the cash commission of $80,575 the Company also incurred additional cash issue and closing costs of $582,511 (including costs deferred at June 30, 2015 of $550,119) resulting in net cash proceeds of $1,903,514. The 2015 Agent Warrants have been recognized as non-cash issue costs of $29,594.</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">(ii) Upon the amendment of the Investor Warrants and the 2013 Placement Agent Warrants, the Company reclassified the related derivative liability to equity (note 6).</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">(iii) During the nine months ended March 31, 2016, 515,500 Investor Warrants were exercised for proceeds of $405,183 (note 6).</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;">(iv) During the nine months ended March 31, 2016, the Company issued 1,060,000 warrants for services. All warrants have an exercise price of $0.75. Of these warrants, 60,000 expire on July 31, 2020, 500,000 expire March 1, 2020, and 500,000 expire February 1, 2021.</p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">(v) During the nine months ended March 31, 2016, the Company issued 60,000 shares of common stock for services.</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.25in; text-indent: 0.05in;"><font style="font-family: 'times new roman', times,
 serif;"><b>Stock Options</b></font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.25in; text-indent: 0.05in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.25in; text-indent: 0.05in;"><font style="font-family: 'times new roman', times, serif;">The following table sets forth the stock options outstanding:&#160;</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.25in; text-indent: 0.05in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: center;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">
<p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;"><b>Number of</b></font></p>
<p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;"><b>stock</b></font></p>
<p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;"><b>options</b></font></p>
<p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;"><b>outstanding</b></font></p>
</td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">
<p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;"><b>Weighted</b></font></p>
<p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;"><b>average</b></font></p>
<p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;"><b>exercise</b></font></p>
<p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;"><b>price</b></font></p>
<p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;"><b>$</b></font></p>
</td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right; padding: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="width: 15px; font-weight: bold; text-align: left;"><font style="font-family: 'times new
 roman', times, serif;">&#160;</font></td>
<td style="width: 1110px; font-weight: bold; text-align: left; padding: 0px; text-indent: 0px; vertical-align: top;"><font style="font-family: 'times new roman', times, serif;"><b>June 30, 2015</b></font></td>
<td style="width: 15px; font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 15px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 142px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">3,595,000</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 15px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 16px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 145px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.94</font></td>
<td style="width: 16px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left; padding: 0px; text-indent: 0px; vertical-align: top;"><font style="font-family: 'times new roman', times, serif;">Granted</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">390,000</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">1.01</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left; padding: 0px; text-indent: 0px; vertical-align: top;"><font style="font-family: 'times new roman', times, serif;">Forfeited</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">(470,000</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">1.08</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding: 0px; text-align: left; text-indent: 0px; vertical-align: top;"><font style="font-family: 'times new roman', times, serif;">Cancelled</font></td>
<td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(50,000</font></td>
<td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">1.05</font></td>
<td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding: 0px; font-weight: bold; text-align: left; text-indent: 0px; vertical-align: top;"><font style="font-family: 'times new roman', times, serif;"><b>March 31, 2016</b></font></td>
<td style="padding-bottom: 4pt; font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"><font style="font-family: 'times new roman', times, serif;">3,465,000</font></td>
<td style="padding-bottom: 4pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;
 text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.92</font></td>
<td style="padding-bottom: 4pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
</table>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.3in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.3in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.3in;"><font style="font-family: 'times new roman', times, serif;">The following table summarizes stock options currently outstanding and exercisable at March 31, 2016:</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Weighted average exercise price&#160;<br />$</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Number&#160;<br />outstanding at&#160;<br />March 31,&#160;<br />2016</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Weighted&#160;<br />average&#160;<br />remaining&#160;<br />contractual&#160;<br />life&#160;<br />(years)</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Number&#160;<br />exercisable&#160;<br />at&#160;<br />March 31,&#160;<br />2016</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Weighted average&#160;<br />exercise&#160;<br />price&#160;<br />$</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-weight: bold; text-align: left;">&#160;</td>
<td style="font-weight: bold; text-align: right;">&#160;</td>
<td style="font-weight: bold; text-align: left;">&#160;</td>
<td style="font-weight: bold;">&#160;</td>
<td style="font-weight: bold; text-align: left;">&#160;</td>
<td style="font-weight: bold; text-align: right;">&#160;</td>
<td style="font-weight: bold; text-align: left;">&#160;</td>
<td style="font-weight: bold;">&#160;</td>
<td style="font-weight: bold; text-align: left;">&#160;</td>
<td style="font-weight: bold; text-align: right;">&#160;</td>
<td style="font-weight: bold; text-align: left;">&#160;</td>
<td style="font-weight: bold;">&#160;</td>
<td style="font-weight: bold; text-align: left;">&#160;</td>
<td style="font-weight: bold; text-align: right;">&#160;</td>
<td style="font-weight: bold; text-align: left;">&#160;</td>
<td style="font-weight: bold;">&#160;</td>
<td style="font-weight: bold; text-align: left;">&#160;</td>
<td style="font-weight: bold; text-align: right;">&#160;</td>
<td style="font-weight: bold; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 283px; text-align: right;">0.39</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 267px; text-align: right;">775,000</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 267px; text-align: right;">5.88</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 266px; text-align: right;">775,000</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 266px; text-align: right;">0.39</td>
<td style="width: 15px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.74</td>
<td style="text-align:
 left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">180,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">8.84</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">180,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.74</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.80</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">120,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">9.00</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">120,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.80</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.94</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">180,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">9.75</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">15,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.94</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.00</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">140,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">4.92</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">140,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.00</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.05</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,770,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">7.37</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,696,796</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.05</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.12</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">120,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">9.77</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">9,333</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.12</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.54</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">60,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">7.00</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">60,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.54</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">2.30</td>
<td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">120,000</td>
<td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">7.17</td>
<td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">120,000</td>
<td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">2.30</td>
<td style="padding-bottom: 1.5pt; text-align:
 left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">0.92</td>
<td style="padding-bottom: 4pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">3,465,000</td>
<td style="padding-bottom: 4pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">&#160;</td>
<td style="padding-bottom: 4pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">3,116,129</td>
<td style="padding-bottom: 4pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">0.91</td>
<td style="padding-bottom: 4pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
</table>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">Included in the number of stock options outstanding are 775,000 stock options granted at an exercise price of CDN $0.50. The exercise prices shown in the above table have been converted to $0.39 using the period ending closing exchange rate.</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;">Certain stock options have been granted to non-employees and will be revalued at each reporting date until they have fully vested. The stock options have been re-valued using a Black-Scholes pricing model using the following assumptions:</font></p>
<table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="font-weight: bold; text-align: right; padding: 0px 0px 1.5pt; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">
<p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">March 31,</font></p>
<p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">2016</font></p>
</td>
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-weight: bold; text-align: right; padding: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr
 style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 1279px; text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Dividend rate</font></td>
<td style="width: 15px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 194px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0</font></td>
<td style="width: 16px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">%</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Volatility</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">84.8% to 118</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">%</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Risk-free rate</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">1.00</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">%</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Term - years</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.5 to 3.0</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
</table>
<div>&#160;</div>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt;"></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;">The Company has recognized the following amounts as stock option expense for the periods noted:&#160; &#160;&#160;</p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"></p>
<table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="font-size: 18pt; font-weight: bold; text-align: right; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">
<p style="margin-top: 0px; text-align: center; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">Three months ended</font></p>
<p style="margin-top: 0px; text-align: center; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">March 31,</font></p>
</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">
<p style="margin-top: 0px; text-align: center; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">Nine months ended</font></p>
<p style="margin-top: 0px; text-align: center; margin-bottom: 0px;"></p>
<p style="margin-top: 0px; text-align: center; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">March 31,</font></p>
</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-size: 18pt; font-weight: bold; text-align: right; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">
<p style="margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times,
 serif;">2016</font></p>
<p style="margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">$</font></p>
</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">
<p style="margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">2015</font></p>
<p style="margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">$</font></p>
</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">2016&#160;<br />$</font></td>
<td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">
<p style="margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">2015</font></p>
<p style="margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">$</font></p>
</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-weight: bold; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: right;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: right;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: right;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: right;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 761.203125px; text-align: left; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Research and development</font></td>
<td style="width: 16px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 16px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 137px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">20,165</font></td>
<td style="width: 16px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 16px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 136px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">26,853</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 15px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 136px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">36,395</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 15px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 136px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">39,909</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">General and administrative</font></td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">3,678</font></td>
<td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td
 style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">35,995</font></td>
<td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">102,316</font></td>
<td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">102,262</font></td>
<td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 4pt; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"><font style="font-family: 'times new roman', times, serif;">23,843</font></td>
<td style="padding-bottom: 4pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"><font style="font-family: 'times new roman', times, serif;">62,848</font></td>
<td style="padding-bottom: 4pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"><font style="font-family: 'times new roman', times, serif;">138,711</font></td>
<td style="padding-bottom: 4pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"><font style="font-family: 'times new roman', times, serif;">142,171</font></td>
<td style="padding-bottom: 4pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font
 style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
</table>
<div>&#160;</div>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;">All of the total stock option expense of $138,711 for the nine months ended March 31, 2016 has been recognized as additional paid in capital. Of the stock option expense of $142,171 for the nine months ended March 31, 2015 $142,447 has been recognized as additional paid in capital and $276 has been recognized as a reduction of the stock option liability. The aggregate intrinsic value of stock options outstanding at March 31, 2016 was $396,538 (March 31, 2015 - $345,131) and the aggregate intrinsic value of stock options exercisable at March 31, 2016 was $396,538 (March 31, 2015 - $333,139). As of March 31, 2016 there was $93,016 in unrecognized compensation expense that will be recognized over the next three years. No stock options granted under the plan have been exercised to March 31, 2016. Upon the exercise of stock options new shares will be issued.</p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;">A summary of status of the Company&#8217;s unvested stock options under the plan is presented below:</p>
<table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="font-size: 18pt; font-weight: bold; text-align: right; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-size: 18pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">
<p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">Number of</font></p>
<p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">Options</font></p>
</td>
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">
<p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">Weighted</font></p>
<p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">average</font></p>
<p style="font-weight: bold;
 font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">exercise</font></p>
<p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">price</font></p>
<p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">$</font></p>
</td>
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">
<p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">Weighted</font></p>
<p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">average</font></p>
<p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">grant date</font></p>
<p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">fair value</font></p>
<p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">$</font></p>
</td>
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-weight: bold; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 866px; font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;"><b>Unvested at June 30, 2015</b></font></td>
<td style="width: 16px; font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 16px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 167px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">722,361</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 15px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 167px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.95</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 15px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 167px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.41</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;"><font style="font-family:
 'times new roman', times, serif;">Granted</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">390,000</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">1.01</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.73</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">Vested</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">(481,634</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.91</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.64</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">Forfeited</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">(260,370</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.92</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.24</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">Cancelled</font></td>
<td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(21,486</font></td>
<td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">1.05</font></td>
<td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.57</font></td>
<td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times,
 serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;"><b>Unvested at March 31, 2016</b></font></td>
<td style="padding-bottom: 4pt; font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"><font style="font-family: 'times new roman', times, serif;">348,871</font></td>
<td style="padding-bottom: 4pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"><font style="font-family: 'times new roman', times, serif;">1.02</font></td>
<td style="padding-bottom: 4pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="padding-bottom: 4pt; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">0.55</font></td>
<td style="padding-bottom: 4pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
</table>
<div>&#160;</div>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><font style="font-family: 'times new roman', times, serif;"><b>Warrants</b></font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;">Certain of the Company&#8217;s warrants have been recognized as a derivative liability (note 6). The following table&#160;summarizes all of the Company&#8217;s outstanding warrants as of March 31, 2016:</p>
<table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="font-weight: bold; text-indent: 0px; padding-top: 0px; padding-right: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-left: 0px;"><font style="font-family: 'times new roman', times, serif;">Description</font></td>
<td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;"><b>Number</b></font></td>
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times,
 serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 1337px; font-weight: bold; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Balance &#8211; June 30, 2015</font></td>
<td style="width: 16px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="width: 136px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">13,472,870</font></td>
<td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">2015 Public Offering Warrants (i)</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">4,277,667</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">2015 Agent Warrants (ii)</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">93,908</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Warrants issued for services (iii)</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">1,060,000</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; padding: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Warrants exercised for cash (iv)</font></td>
<td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(515,500</font></td>
<td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-weight: bold; padding: 0px 0px 4pt; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Balance - March 31, 2016</font></td>
<td style="font-weight: bold; padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-weight: bold; text-align: right;"><font style="font-family: 'times new roman', times, serif;">18,388,945</font></td>
<td style="padding-bottom: 4pt; font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td>
</tr>
</table>
<div>&#160;</div>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 13pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.6in;"></td>
<td style="width: 0.3in;"><font style="font-family: 'times new roman', times, serif;">i)</font></td>
<td><font style="font-family: 'times new roman', times, serif;">Issued as part of the Company&#8217;s financing completed in August 2015. Warrants are exercisable at $0.75 until July 31, 2020.</font></td>
</tr>
</table>
<table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 13pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align:
 top;">
<td style="width: 0.6in;"></td>
<td style="width: 0.3in;"><font style="font-family: 'times new roman', times, serif;">ii)</font></td>
<td><font style="font-family: 'times new roman', times, serif;">Issued as part of the Company&#8217;s financing completed in August 2015. The 2015 Agent Warrants are exercisable at a price of $0.75 during the period commencing January 15, 2016 until their expiry on July 15, 2020.</font></td>
</tr>
</table>
<table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 13pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.6in;"></td>
<td style="width: 0.3in;"><font style="font-family: 'times new roman', times, serif;">iii)</font></td>
<td><font style="font-family: 'times new roman', times, serif;">Warrants have an exercise price of $0.75. Of the total, 60,000 vest in tranches of 20,000 warrants each on November 30, 2015, March 31, 2016, and January 31, 2016 and are exercisable commencing January 1, 2016 until they expire on July 31, 2020. In addition, 500,000 of the warrants vest in tranches of 150,000 on March 1, 2015, and 50,000 on each of March 31, 2016, January 31, 2016, February 29, 2016, March 31, 2016, April 30, 2016, May 31, 2016, and June 30, 2016 until they expire on March 1, 2020. Also, 500,000 of the warrants vest in tranches of 83,333 on each of February 29, 2016, March 31, 2016, April 30, 2016, May 31, 2016, June 30, 2016 and July 31, 2016 until they expire on February 1, 2021.</font></td>
</tr>
</table>
<table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 13pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.6in;"></td>
<td style="width: 0.3in;"><font style="font-family: 'times new roman', times, serif;">iv)</font></td>
<td><font style="font-family: 'times new roman', times, serif;">515,500 Investor Warrants were exercised for cash at $0.786 per share for proceeds of $405,183.</font></td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6826362608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial instruments</a></td>
<td class="text"><div><table style="font: bold 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 13pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.3in;"><font style="font-family: 'times new roman', times, serif;">8</font></td><td><font style="font-family: 'times new roman', times, serif;">Financial instruments</font></td></tr></table><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">The Company has financial instruments that are measured at fair value. To determine the fair value, we use the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:</font></p><table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.3in;"></td><td style="width: 0.3in;"><font style="font-family: 'times new roman', times, serif;">&#183;</font></td><td><font style="font-family: 'times new roman', times, serif;">Level one&#160;- inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities;</font></td></tr></table><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.3in;"></td><td style="width: 0.3in;"><font style="font-family: 'times new roman', times, serif;">&#183;</font></td><td><font style="font-family: 'times new roman', times, serif;">Level two&#160;- inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals;&#160;and</font></td></tr></table><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.3in;"></td><td style="width: 0.3in;"><font style="font-family: 'times new roman', times, serif;">&#183;</font></td><td><font style="font-family: 'times new roman', times, serif;">Level three&#160;- unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.</font></td></tr></table><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.</font></p><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">The Company&#8217;s financial instruments consist of cash and cash equivalents, other receivables, accounts payable, related party payables and derivative liability. The carrying values of cash and cash equivalents, other receivables, accounts payable and related party payables approximate their fair values due to the immediate or short-term maturity of these financial instruments.</font></p><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><u>Derivative liability</u></font></p><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">The Company
 accounts for certain warrants under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company&#8217;s own stock, on the understanding that in compliance with applicable securities laws, the warrants require the issuance of securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. The Company classifies these warrants on its balance sheet as a derivative liability which is fair valued at each reporting period subsequent to the initial issuance. The Company has used a simulated probability valuation model to value the warrants. Determining the appropriate fair-value model and calculating the fair value of warrants requires considerable judgment. Any change in the estimates (specifically probabilities) used may cause the value to be higher or lower than that reported. The estimated volatility of the Company&#8217;s common stock at the date of issuance, and at each subsequent reporting period, is based on the historical volatility of similar life sciences companies. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining life of the warrants at the valuation date. The expected life of the warrants is assumed to be equivalent to their remaining contractual term.</font></p><table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 13pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.3in;"></td><td style="width: 0.3in;"><font style="font-family: 'times new roman', times, serif;">a)</font></td><td><font style="font-family: 'times new roman', times, serif;">Fair value of derivative liability</font></td></tr></table><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 20pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">The derivative is not traded in an active market and the fair value is determined using valuation techniques. The Company uses judgment to select a variety of methods to make assumptions that are based on specific management plans and market conditions at the end of each reporting period. The Company uses a fair value estimate to determine the fair value of the derivative liability. The carrying value of the derivative liability would be higher or lower as management estimates around specific probabilities change. The estimates may be significantly different from those recorded in the consolidated financial statements because of the use of judgment and the inherent uncertainty in estimating the fair value of these instruments that are not quoted in an active market. All changes in the fair value are recorded in the consolidated statement of operations and comprehensive loss each reporting period. This is considered to be a Level 2 financial </font></p><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">The Company has the following liabilities under the fair value hierarchy:</font></p><table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 18pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10"><font style="font-family: 'times new roman', times, serif;">March 31, 2016</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; font-size: 18pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="width: 915.4px; text-align: left; padding-left: 0.6in; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">Liability</font></td><td style="width: 16px; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 137px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">Level 1</font></td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new
 roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">Level 2</font></td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">Level 3</font></td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="text-align: right; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -0.3in; padding-bottom: 1.5pt; padding-left: 0.9in;"><font style="font-family: 'times new roman', times, serif;">Derivative liability</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">1,017,250</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><br style="font: 13.33px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; clear: both; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;" /><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 18pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="11"><font style="font-family: 'times new roman', times, serif;">June 30, 2015</font></td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; font-size: 18pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; font-weight: bold;" colspan="11"><font style="font-family: 'times new roman',
 times, serif;">(as restated)</font></td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; font-size: 18pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="width: 915.4px; text-align: left; padding-left: 0.6in; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">Liability</font></td><td style="width: 16px; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 137px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">Level 1</font></td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">Level 2</font></td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">Level 3</font></td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="text-align: right; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -0.3in; padding-bottom: 1.5pt; padding-left: 0.9in;"><font style="font-family: 'times new roman', times, serif;">Derivative liability</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">2,364,381</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font
 style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6758475760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text"><table style="font: bold 10pt/normal 'times new roman', times, serif; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 6pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 15pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">9</font></td>
<td style="width: 5pt;"></td>
<td style="text-align: justify;"><font style="font-family: 'times new roman', times, serif;">Subsequent events</font></td>
</tr>
</table>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"><font style="font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"><b>Series B Preferred Share Issuance</b></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"><b>&#160;</b></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"><b></b>On April 29, 2016, May 4, 2016, and May 12, 2016 the Company entered into Securities Purchase Agreements (the &#8220;Purchase Agreements&#8221;), pursuant to which it issued an aggregate of 764,363 shares of Series B Preferred Stock at a purchase price of at $8.00 per share for total gross proceeds of $6.1 million. Each share of Series B Preferred Stock is convertible into ten shares of common stock equating to a conversion price of $0.80 (the &#8220;Conversion Price&#8221;) and will automatically convert to common stock at the earlier of 24 hours following regulatory approval of VAL-083 with a minimum closing bid price of $2 or five years from the final closing dates. The holders of the Series B Preferred Stocks are entitled to an annual cumulative, in arrears dividend at the rate of 9% payable quarterly. The 9% dividend shall accrue quarterly commencing on the date of issue and be payable quarterly on June 30, September 30, December 31, and March 31&#160;of each year commencing on June 30, 2016. Dividends shall be payable solely by delivery of shares of common stock (the &#8220;PIK Shares&#8221;), in an amount for each holder equal to the aggregate dividend payable to such holder with respect to the shares of Series B Preferred Stock held by such holder divided by the Conversion Price. The Series B Preferred Shares do not contain any repricing features.</p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;">&#160;</p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 14px; margin: 2pt 0px 2pt 21.55pt;">In addition, the Company and the holders entered into a royalty agreement, pursuant to which the Company will pay the holders of the Series B preferred shares, in aggregate, a low, single-digit royalty based on their pro rata ownership of the Series B preferred shares on products sold directly by the Company or sold pursuant to a licensing or partnering arrangement (the &#8220;Royalty Agreement&#8221;).</p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 14px; margin: 2pt 0px 2pt 21.55pt;">&#160;</p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: left;">Upon conversion of a holder&#8217;s shares to common stock, such holder shall no longer receive ongoing royalty payments under the Royalty Agreement but will be entitled to receive any residual royalty payments that have vested. Rights to the royalties shall vest during the first three years following the applicable closing date, in equal thirds to holders of the Series B Preferred Stock on each of the three vesting dates, upon which vesting dates such royalty amounts shall become &#8220;Vested Royalties&#8221;.</p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height:
 normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt;">&#160;</p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: left;">The Company engaged certain placement agents for the sale of a portion of the Series B Preferred Stock. Under the Company&#8217;s engagement agreements with these placement agents, the Company agreed to pay up to an 8% cash commission and issue warrants to purchase shares of common stock (the &#8220;2016 Agent Warrants&#8221;) up to the number of shares of our common stock equal to 8% of the aggregate number of shares underlying the Series B Preferred Stock sold in the offering by such placement agents. Pursuant to the placement agent agreements the Company paid a total cash commission of approximately $283,000 and issued 356,050 2016 Agent Warrants. The 2016 Agent Warrants are exercisable at a per share price equal to $1.00 during the five-year period commencing six months from May 12, 2016 which period shall not extend further than five years from the closing dates. Therefore, all 2016 Agent Warrants expire on May 12, 2021.</p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.3in; text-indent: 0.5in;">&#160;</p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.3in; text-align: left;">In addition to the cash commission the Company also incurred additional cash issue and closing costs of approximately $340,000 (including costs deferred at March 31, 2016 of $60,647) resulting in net cash proceeds of approximately $5.5 million.</p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.3in;">&#160;</p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"><b>Investor Warrant Amendments</b></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"><b>&#160;</b></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;">Subsequent to March 31, 2016, the Company amended an additional 1,970,238 Investor Warrants (note 6). As a result of the amendments, the Company has reclassified a portion of its derivative liability to equity resulting in an increase in equity of approximately $500,000.</p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;">&#160;</p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;"><b>Stock Options</b></p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify; text-indent: 0.5in;">&#160;</p>
<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 21.55pt; text-align: justify;">Subsequent to March 31, 2016, 320,000 stock options were granted and 270,000 stock options were forfeited.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6762437920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>Basis of presentation</b></font></p><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">The consolidated condensed interim financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles (&#8220;U.S. GAAP&#8221;) and are presented in United States dollars. The Company&#8217;s functional currency is the United States dollar.</font></p><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">The accompanying consolidated condensed interim financial statements include the accounts of the Company and its wholly-owned subsidiaries, DelMar BC, Callco, and Exchangeco. All intercompany balances and transactions have been eliminated.</font></p><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">The principal accounting policies applied in the preparation of these financial statements are set out below and have been consistently applied to all periods presented.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_UnauditedInterimFinancialDataPolicyTextBlock', window );">Unaudited interim financial data</a></td>
<td class="text"><div><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>Unaudited interim financial data</b></font></p><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">The accompanying unaudited March 31, 2016 consolidated condensed interim balance sheet, the consolidated condensed interim statements of loss and comprehensive loss for the three and nine months ended March 31, 2016 and 2015, and consolidated condensed cash flows for the nine months ended March 31, 2016 and 2015, and the related interim information contained within the notes to the consolidated condensed interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. These consolidated condensed interim financial statements should be read in conjunction with the audited financial statements of the Company as at June 30, 2015 filed in our amended Form 10-K/A filed with the Securities and Exchange Commission on November 16, 2015. In the opinion of management, the unaudited consolidated condensed interim financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position at March 31, 2016 and results of its operations for the three and nine months ended March 31, 2016 and 2015, and its cash flows for the nine months ended March 31, 2016 and 2015. The results for three and nine months ended March 31, 2016 are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2016 or for any other future annual or interim period.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>Use of estimates</b></font></p><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 21.55pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">The preparation of consolidated condensed interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end or during the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liability and the valuation of equity instruments issued for services. There have been no changes to the methodology used in determining these estimates from the period ended June 30, 2015.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible assets</a></td>
<td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><b>Intangible assets</b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 0.3in;"><i>Website development costs</i></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px 0px 13pt 21.55pt;"><font style="font-family: 'times new roman', times, serif;">Website development costs are stated at cost less accumulated amortization. The Company capitalizes website development costs associated with graphics design and development of the website application and infrastructure. Costs related to planning, content input, and website operations are expensed as incurred. The Company amortizes website development costs on a straight-line basis over three years. The website costs consist of $16,762 in cash costs and $29,543 in non-cash consideration in the form of the issuance of warrants. The Company recognized $3,858 and $6,430 respectively, in amortization during the three and nine months ended March 31, 2016. There was no amortization in either the three or nine months ended March 31, 2015.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text"><div><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>Loss per share</b></font></p><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 0px 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">Loss per share is calculated based on the weighted average number of common shares outstanding. For the three and nine month periods ended March 31, 2016 and 2015 diluted loss per share does not differ from basic loss per share since the effect of the Company&#8217;s warrants and stock options are anti-dilutive. At March 31, 2016, potential common shares of 18,388,945 (March 31, 2015 &#8211; 13,472,870) relating to warrants and 3,465,000 (March 31, 2015 &#8211; 3,595,000) relating to stock options were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>Recent accounting pronouncements</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><i>Accounting Standards Update (&#8220;ASU&#8221;) 2014-15 - Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern</i></font></p><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 0px 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 0px 21.55pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">The objective of the guidance is to require management to explicitly assess an entity's ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management will assess if there is substantial doubt about an entity's ability to continue as a going concern within one year after the issuance date of an entity&#8217;s financial statements. The new standard defines substantial doubt and provides examples of indicators thereof. The definition of substantial doubt incorporates a likelihood threshold of "probable" similar to the current use of that term in U.S. GAAP for loss contingencies. The new standard will be effective for all entities in the first annual period ending after March 15, 2016 (March 31, 2016 for calendar year-end entities). Earlier application is permitted. The Company is currently assessing this standard for its impact on future reporting periods.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_UnauditedInterimFinancialDataPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of unaudited interim financial data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_UnauditedInterimFinancialDataPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6746706656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Financial Statements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Restatement of Previously Issued Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of aggregate impacts of correcting the errors relating to the Placement Agent Warrants</a></td>
<td class="text"><div>&#160;</div><table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;" colspan="10">Three Months Ended March 31, 2015<font style="font-family: 'times new roman', times, serif;"></font></td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;" colspan="2"><font style="font-family: 'times new roman', times, serif;">As previously reported&#160;<br />$</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;" colspan="2"><font style="font-family: 'times new roman', times, serif;">Restatement adjustment&#160;<br />$</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;" colspan="2"><font style="font-family: 'times new roman', times, serif;">As restated&#160;<br />$</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: right;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: right;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: right;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 944.203px; text-align: left; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Change in fair value of derivative liability</font></td><td style="width: 16px; font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 137px; font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">343,569</font></td><td style="width: 15px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">437,583</font></td><td style="width: 15px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">781,152</font></td><td style="width: 15px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Loss for the period</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">1,649,136</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">437,583</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family:
 'times new roman', times, serif;">&#160;</font></td><td
 style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">2,086,719</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Basic and diluted loss per share</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.04</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.01</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.05</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><div>&#160;</div><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"></p><table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; text-align: center;" colspan="10">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;" colspan="10">Nine Months Ended March 31, 2015</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;" colspan="2"><font style="font-family: 'times new roman', times, serif;">As previously reported&#160;<br />$</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;" colspan="2"><font style="font-family: 'times new roman', times, serif;">Restatement adjustment&#160;<br />$</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;" colspan="2"><font style="font-family: 'times new roman', times, serif;">As restated&#160;<br />$</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr
 style="vertical-align: bottom;"><td style="font-weight: bold; text-align: right;"><font style="font-family: 'times new roman', times,
 serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: right;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: right;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: right;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 944.203px; text-align: left; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Change in fair value of derivative liability</font></td><td style="width: 16px; font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 137px; font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">276,963</font></td><td style="width: 15px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">174,831</font></td><td style="width: 15px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">451,794</font></td><td style="width: 15px; font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Loss for the period</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">4,048,256</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">174,831</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">4,223,087</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Basic and diluted loss per share</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.11</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.00</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.11</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align:
 left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times,
 serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;" colspan="10"><font style="font-family: 'times new roman', times, serif;">As At March 31, 2015</font></td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: right; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;"><p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">As previously reported</font></p><p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">$&#160;</font></p></td><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;"><p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">Restatement adjustment</font></p><p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">$&#160;</font></p></td><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-width: 1.5pt; border-bottom-style: solid; border-bottom-color: black;"><p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">As restated</font></p><p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">$&#160;</font></p></td><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: right;"><font style="font-family: 'times new
 roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times
 new
 roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Derivative liability</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">1,487,137</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">1,956,471</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">3,443,608</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Additional paid-in capital</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">17,455,279</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(136,800</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">17,318,479</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Warrants</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">6,138,426</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(6,048,994</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">89,432</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Accumulated deficit</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(22,715,848</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times,
 serif;">4,229,323</font></td><td style="font-weight: normal; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align:
 left;"><font
 style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: normal; text-align: right;"><font style="font-family: 'times new roman', times, serif; font-weight: normal;">(18,486,525</font></td><td style="font-weight: normal; text-align: left;">)<font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22663-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6587056512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of derivative liabilities</a></td>
<td class="text"><div><table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">March 31,&#160;<br />2016&#160;<br />$</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">June 30,&#160;<br />2015&#160;<br />$</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="padding: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; font-weight: bold;" colspan="2"><font style="font-family: 'times new roman', times, serif;">(as restated)</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px; width: 1155px; text-align: left; text-indent: 0px; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">Opening balance</font></td><td style="width: 16px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">2,364,381</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">5,111,007</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px; text-align: left; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Issuance of 2015 Agent Warrants</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">29,594</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px; text-align: left; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Change in fair value of warrants</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">943,050</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">(627,433</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px; text-align: left; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Change in fair value due to change in warrant
 terms</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">270,965</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">(23,658</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px; text-align: left; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Reclassification to equity upon amendment of warrants</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">(2,343,300</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">(975,278</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px; text-align: left; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Reclassification to equity upon exchange of warrants</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">(728,835</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px; text-align: left; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Reclassification to equity upon exercise of warrants</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">(247,440</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">(391,422</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px; text-align: left; text-indent: 0px; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">Closing balance</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">1,017,250</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">2,364,381</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;"></font></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41641-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41678-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41638-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5580258-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579245-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579240-113959<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41620-113959<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6759884608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock', window );">Schedule of common stock issued and outstanding</a></td>
<td class="text"><div><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 0px 21.55pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><p style="font: bold 10pt/10.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Shares of common stock</font></p><p style="font: bold 10pt/10.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">outstanding</font></p></td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">Common stock</font></td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">Additional paid-in capital</font></td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><p style="font: bold 10pt/10.5pt 'times new roman', times, serif; margin: 0px 0.1in 0px 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: bold 10pt/10.5pt 'times new roman', times, serif; margin: 0px 0.1in 0px 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: bold 10pt/10.5pt 'times new roman', times, serif; margin: 0px 0.1in 0px 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: bold 10pt/10.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Warrants</font></p></td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="padding: 0px; text-align: right; text-indent: 0px; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="text-align: left; font-weight: bold;"><font
 style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px; width: 790px; text-indent: 0px; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">June 30, 2015 &#8211; as previously reported</font></td><td style="width: 16px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 137px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">39,455,931</font></td><td style="width: 16px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">39,456</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">17,500,008</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">6,138,426</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px; text-align: left; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Restatement adjustments</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">(136,800</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">(6,048,994</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px; text-indent: 0px; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">June 30, 2015 &#8211; as restated</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">39,455,931</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">39,456</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">17,363,208</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">89,432</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times,
 serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px; text-align: left; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Issuance of shares and warrants &#8211; net of issue costs (i)</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">4,277,667</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">4,278</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">1,198,453</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">671,189</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px; text-align: left; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Reclassification of warrants (ii)</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">2,343,300</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px; text-align: left; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Exercise of warrants for cash (iii)</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">515,500</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">515</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">652,108</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font
 style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px; text-align: left; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Warrants issued for services (iv)</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">429,932</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px; text-align: left; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Shares issued for services (v)</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">60,000</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">60</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">80,340</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px; text-align: left; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Stock-based compensation</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">138,711</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px; text-align: left; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Reclassification of stock option liability</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times,
 serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">29,747</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px 0px 4pt; text-indent: 0px; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">March 31, 2016</font></td><td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">44,309,098</font></td><td style="text-align: left; padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">44,309</font></td><td style="text-align: left; padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">21,805,867</font></td><td style="text-align: left; padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">1,190,553</font></td><td style="text-align: left; padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock options outstanding under the plan</a></td>
<td class="text"><div><br class="apple-interchange-newline" /><table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Number of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>stock</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>options</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>outstanding</b></font></p></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Weighted</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>average</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>exercise</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>price</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>$</b></font></p></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 15px; text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 1110px; text-align: left; text-indent: 0px; font-weight: bold; vertical-align: top;"><font style="font-family: 'times new roman', times, serif;"><b>June 30, 2015</b></font></td><td style="width: 15px; text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 142px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">3,595,000</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 145px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.94</font></td><td style="width: 16px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; vertical-align: top;"><font style="font-family: 'times new roman', times, serif;">Granted</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">390,000</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font
 style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">1.01</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; vertical-align: top;"><font style="font-family: 'times new roman', times, serif;">Forfeited</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">(470,000</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">1.08</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; vertical-align: top;"><font style="font-family: 'times new roman', times, serif;">Cancelled</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">(50,000</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">1.05</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-weight: bold; vertical-align: top;"><font style="font-family: 'times new roman', times, serif;"><b>March 31, 2016</b></font></td><td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">3,465,000</font></td><td style="text-align: left; padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">0.92</font></td><td style="text-align: left; padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Schedule of stock options currently outstanding and exercisable</a></td>
<td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"></p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Weighted average exercise price&#160;<br />$</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Number&#160;<br />outstanding at&#160;<br />March 31,&#160;<br />2016</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Weighted&#160;<br />average&#160;<br />remaining&#160;<br />contractual&#160;<br />life&#160;<br />(years)</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Number&#160;<br />exercisable&#160;<br />at&#160;<br />March 31,&#160;<br />2016</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td>
<td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Weighted average&#160;<br />exercise&#160;<br />price&#160;<br />$</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-weight: bold; text-align: left;">&#160;</td>
<td style="font-weight: bold; text-align: right;">&#160;</td>
<td style="font-weight: bold; text-align: left;">&#160;</td>
<td style="font-weight: bold;">&#160;</td>
<td style="font-weight: bold; text-align: left;">&#160;</td>
<td style="font-weight: bold; text-align: right;">&#160;</td>
<td style="font-weight: bold; text-align: left;">&#160;</td>
<td style="font-weight: bold;">&#160;</td>
<td style="font-weight: bold; text-align: left;">&#160;</td>
<td style="font-weight: bold; text-align: right;">&#160;</td>
<td style="font-weight: bold; text-align: left;">&#160;</td>
<td style="font-weight: bold;">&#160;</td>
<td style="font-weight: bold; text-align: left;">&#160;</td>
<td style="font-weight: bold; text-align: right;">&#160;</td>
<td style="font-weight: bold; text-align: left;">&#160;</td>
<td style="font-weight: bold;">&#160;</td>
<td style="font-weight: bold; text-align: left;">&#160;</td>
<td style="font-weight: bold; text-align: right;">&#160;</td>
<td style="font-weight: bold; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 283px; text-align: right;">0.39</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 267px; text-align: right;">775,000</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 267px; text-align: right;">5.88</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 266px; text-align: right;">775,000</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 266px; text-align: right;">0.39</td>
<td style="width: 15px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.74</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">180,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">8.84</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">180,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.74</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.80</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">120,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">9.00</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">120,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.80</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.94</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">180,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">9.75</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">15,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.94</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.00</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">140,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td
 style="text-align: left;">&#160;</td>
<td style="text-align: right;">4.92</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">140,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.00</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.05</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,770,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">7.37</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,696,796</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.05</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.12</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">120,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">9.77</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">9,333</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.12</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.54</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">60,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">7.00</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">60,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.54</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">2.30</td>
<td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">120,000</td>
<td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">7.17</td>
<td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">120,000</td>
<td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">2.30</td>
<td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">0.92</td>
<td style="padding-bottom: 4pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">3,465,000</td>
<td style="padding-bottom: 4pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">&#160;</td>
<td style="padding-bottom: 4pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">3,116,129</td>
<td style="padding-bottom: 4pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">0.91</td>
<td style="padding-bottom: 4pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align:
 left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
</table>
<div>&#160;</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of stock options valuation assumptions using a Black-Scholes pricing model</a></td>
<td class="text"><div>&#160;</div><table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: right; padding: 0px 0px 1.5pt; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">March 31,</font></p><p style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: 11.5pt; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; text-align: center;"><font style="font-family: 'times new roman', times, serif;">2016</font></p></td><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: right; padding: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1279px; text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Dividend rate</font></td><td style="width: 15px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 194px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0</font></td><td style="width: 16px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">%</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Volatility</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">84.8% to 118</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">%</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Risk-free rate</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">1.00</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">%</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Term - years</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.5 to 3.0</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><div>&#160;</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><div><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;&#160;&#160;</font></p><p style="font: 13px/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: right; padding-bottom: 1.5pt; font-size: 18pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"><p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">Three months ended March 31,</font></p></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"><p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">Nine months ended</font></p><p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">March 31,</font></p></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="text-align: right; padding-bottom: 1.5pt; font-size: 18pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">2016</font></p><p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">$</font></p></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">2015</font></p><p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">$</font></p></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">2016&#160;<br />$</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">2015</font></p><p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><font style="font-family: 'times new roman', times, serif;">$</font></p></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="text-align: right; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td
 style="width:
 761px; text-align: left; text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">Research and development</font></td><td style="width: 16px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 137px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">20,165</font></td><td style="width: 16px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">26,853</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">36,395</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">39,909</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -0.3in; padding-bottom: 1.5pt; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">General and administrative</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">3,678</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">35,995</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">102,316</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">102,262</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: -0.3in; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: -0.3in; padding-bottom: 4pt; padding-left: 0.3in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td
 style="text-align: left;
 padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">23,843</font></td><td style="text-align: left; padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">62,848</font></td><td style="text-align: left; padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">138,711</font></td><td style="text-align: left; padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">142,171</font></td><td style="text-align: left; padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of unvested stock options</a></td>
<td class="text"><div><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px 0px 13pt 0.3in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: right; padding-bottom: 1.5pt; font-size: 18pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 18pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Number of</font></p><p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Options</font></p></td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Weighted</font></p><p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">average</font></p><p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">exercise</font></p><p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">price</font></p><p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">$</font></p></td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Weighted</font></p><p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">average</font></p><p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">grant date</font></p><p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">fair value</font></p><p style="font: bold 10pt/11.5pt 'times new roman', times, serif; text-align: center; margin-top: 0px; margin-bottom: 0px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">$</font></p></td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="text-align: right; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times,
 serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 866px; text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;"><b>Unvested at June 30, 2015</b></font></td><td style="width: 16px; text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 167px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">722,361</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 167px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.95</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 167px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.41</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">Granted</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">390,000</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">1.01</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.73</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">Vested</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">(481,634</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.91</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.64</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">Forfeited</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">(260,370</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.92</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">0.24</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">Cancelled</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td
 style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">(21,486</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">1.05</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">0.57</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; font-weight: bold; vertical-align: bottom;"><font style="font-family: 'times new roman', times, serif;"><b>Unvested at March 31, 2016</b></font></td><td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">348,871</font></td><td style="text-align: left; padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">1.02</font></td><td style="text-align: left; padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; padding-bottom: 4pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif;">0.55</font></td><td style="text-align: left; padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><br style="font: 13.33px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; clear: both; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;" /><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ScheduleOfOutstandingWarrantsTableTextBlock', window );">Schedule of outstanding warrants</a></td>
<td class="text"><table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-indent: 0px; padding-top: 0px; padding-right: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-left: 0px;"><font style="font-family: 'times new roman', times, serif;">Description</font></td><td style="font-weight: bold; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;"><b>Number</b></font></td><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1337px; font-weight: bold; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Balance &#8211; June 30, 2015</font></td><td style="width: 16px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; text-align: right;"><font style="font-family: 'times new roman', times, serif;">13,472,870</font></td><td style="width: 15px; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">2015 Public Offering Warrants (i)</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">4,277,667</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">2015 Agent Warrants (ii)</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">93,908</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">Warrants issued for services (iii)</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">1,060,000</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Warrants exercised for cash (iv)</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(515,500</font></td><td style="padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0px; padding: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-weight: bold; padding: 0px 0px 4pt; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Balance - March 31, 2016</font></td><td style="font-weight: bold; padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-weight: bold; text-align: right;"><font style="font-family: 'times new roman', times, serif;">18,388,945</font></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><div>&#160;</div><p style="color: #000000;
 font-family: 'times new roman', times, serif; font-size: 10pt;
 font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 13pt; margin: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 13pt; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.6in;"></td><td style="width: 0.3in;"><font style="font-family: 'times new roman', times, serif;">i)</font></td><td><font style="font-family: 'times new roman', times, serif;">Issued as part of the Company&#8217;s financing completed in August 2015. Warrants are exercisable at $0.75 until July 31, 2020.</font></td></tr></table><table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 13pt; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.6in;"></td><td style="width: 0.3in;"><font style="font-family: 'times new roman', times, serif;">ii)</font></td><td><font style="font-family: 'times new roman', times, serif;">Issued as part of the Company&#8217;s financing completed in August 2015. The 2015 Agent Warrants are exercisable at a price of $0.75 during the period commencing January 15, 2016 until their expiry on July 15, 2020.</font></td></tr></table><table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 13pt; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.6in;"></td><td style="width: 0.3in;"><font style="font-family: 'times new roman', times, serif;">iii)</font></td><td><font style="font-family: 'times new roman', times, serif;">Warrants have an exercise price of $0.75. Of the total, 60,000 vest in tranches of 20,000 warrants each on November 30, 2015, March 31, 2016, and January 31, 2016 and are exercisable commencing January 1, 2016 until they expire on July 31, 2020. In addition, 500,000 of the warrants vest in tranches of 150,000 on March 1, 2015, and 50,000 on each of March 31, 2016, January 31, 2016, February 29, 2016, March 31, 2016, April 30, 2016, May 31, 2016, and June 30, 2016 until they expire on March 1, 2020. Also, 500,000 of the warrants vest in tranches of 83,333 on each of February 29, 2016, March 31, 2016, April 30, 2016, May 31, 2016, June 30, 2016 and July 31, 2016 until they expire on February 1, 2021.</font></td></tr></table><table style="font: 10pt/13pt 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 13pt; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.6in;"></td><td style="width: 0.3in;"><font style="font-family: 'times new roman', times, serif;">iv)</font></td><td><font style="font-family: 'times new roman', times, serif;">515,500 Investor Warrants were exercised for cash at $0.786 per share for proceeds of $405,183.</font></td></tr></table><div>&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ScheduleOfOutstandingWarrantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ScheduleOfOutstandingWarrantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number of fully vested share options (or share units) and share options expected to vest at the date of the latest statement of financial position, weighted-average exercise price (or conversion ratio), aggregate intrinsic value (except for nonpublic entities), and weighted-average remaining contractual term for both options (or share units) currently outstanding and options (or share units) exercisable (or convertible).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6826361808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of derivative liabilities under the fair value hierarchy</a></td>
<td class="text"><div><table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 18pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10"><font style="font-family: 'times new roman', times, serif;">March 31, 2016</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; font-size: 18pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="width: 915.4px; text-align: left; padding-left: 0.6in; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">Liability</font></td><td style="width: 16px; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 137px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">Level 1</font></td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">Level 2</font></td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">Level 3</font></td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="text-align: right; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -0.3in; padding-bottom: 1.5pt; padding-left: 0.9in;"><font style="font-family: 'times new roman', times, serif;">Derivative liability</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td
 style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">1,017,250</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><br style="font: 13.33px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; clear: both; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;" /><p style="font: 10pt/13pt 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><table align="right" style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 18pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="11"><font style="font-family: 'times new roman', times, serif;">June 30, 2015</font></td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; font-size: 18pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; font-weight: bold;" colspan="11"><font style="font-family: 'times new roman', times, serif;">(as restated)</font></td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; font-size: 18pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="width: 915.4px; text-align: left; padding-left: 0.6in; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">Liability</font></td><td style="width: 16px; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 137px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">Level 1</font></td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">Level 2</font></td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 136px; text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">Level 3</font></td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="text-align: right; font-weight:
 bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-weight: bold;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -0.3in; padding-bottom: 1.5pt; padding-left: 0.9in;"><font style="font-family: 'times new roman', times, serif;">Derivative liability</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">2,364,381</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif;">&#8211;</font></td><td style="text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6762707024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Liquidity Risk (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_NatureOfOperationsAndLiquidityRiskTextualAbstract', window );"><strong>Nature of Operations and Liquidity Risk (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents on hand</a></td>
<td class="nump">$ 3,006,598<span></span>
</td>
<td class="nump">$ 937,355<span></span>
</td>
<td class="nump">$ 3,006,598<span></span>
</td>
<td class="nump">$ 1,754,433<span></span>
</td>
<td class="nump">$ 4,759,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">18,486,525<span></span>
</td>
<td class="nump">24,028,040<span></span>
</td>
<td class="nump">18,486,525<span></span>
</td>
<td class="nump">$ 18,613,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,086,719)<span></span>
</td>
<td class="nump">5,408,479<span></span>
</td>
<td class="nump">$ 4,223,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_NatureOfOperationsAndLiquidityRiskTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_NatureOfOperationsAndLiquidityRiskTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6836555440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Financial Statements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative liability</a></td>
<td class="nump">$ 781,152<span></span>
</td>
<td class="nump">$ 943,050<span></span>
</td>
<td class="nump">$ 451,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period</a></td>
<td class="nump">$ 2,086,719<span></span>
</td>
<td class="num">(5,408,479)<span></span>
</td>
<td class="num">$ (4,223,087)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per share</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="nump">$ 3,443,608<span></span>
</td>
<td class="nump">1,017,250<span></span>
</td>
<td class="nump">$ 3,443,608<span></span>
</td>
<td class="nump">$ 2,364,381<span></span>
</td>
<td class="nump">$ 5,111,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">17,318,479<span></span>
</td>
<td class="nump">21,805,867<span></span>
</td>
<td class="nump">17,318,479<span></span>
</td>
<td class="nump">17,363,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">89,432<span></span>
</td>
<td class="nump">1,190,553<span></span>
</td>
<td class="nump">89,432<span></span>
</td>
<td class="nump">89,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(18,486,525)<span></span>
</td>
<td class="num">$ (24,028,040)<span></span>
</td>
<td class="num">(18,486,525)<span></span>
</td>
<td class="num">$ (18,613,294)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">As previously reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative liability</a></td>
<td class="nump">343,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period</a></td>
<td class="nump">$ 1,649,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,048,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per share</a></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="nump">$ 1,487,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,487,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">17,455,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,455,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">6,138,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,138,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(22,715,848)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,715,848)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_RestatementAdjustmentMember', window );">Restatement adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative liability</a></td>
<td class="nump">437,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period</a></td>
<td class="nump">$ 437,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="nump">$ 1,956,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,956,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="num">(136,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(136,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="num">(6,048,994)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,048,994)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 4,229,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,229,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6835786096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_SignificantAccountingPoliciesTextualAbstract', window );"><strong>Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForSoftware', window );">Website cost in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 3,858<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,430<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_SignificantAccountingPoliciesTextualAbstract', window );"><strong>Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,388,945<span></span>
</td>
<td class="nump">13,472,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForSoftware', window );">Website cost in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_SignificantAccountingPoliciesTextualAbstract', window );"><strong>Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,465,000<span></span>
</td>
<td class="nump">3,595,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_SignificantAccountingPoliciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_SignificantAccountingPoliciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6762470720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Valent Technologies LLC (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_AgreementsLineItems', window );"><strong>Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_AgreementsLineItems', window );"><strong>Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, rate of dividend</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=dmpi_ValentTechnologiesLlcMember', window );">Valent Technologies, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_AgreementsLineItems', window );"><strong>Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loan payable</a></td>
<td class="nump">$ 278,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Aggregate accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">278,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividend payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=dmpi_ValentTechnologiesLlcMember', window );">Valent Technologies, LLC [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_AgreementsLineItems', window );"><strong>Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">278,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, rate of dividend</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_AgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_AgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=dmpi_ValentTechnologiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=dmpi_ValentTechnologiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6762553488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_RelatedPartyTransactionsTextualsAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Aggregate amount owing to officers and directors for fees and expenses</a></td>
<td class="nump">$ 29,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock', window );">Series A preferred stock dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,267<span></span>
</td>
<td class="nump">4,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=dmpi_ValentTechnologiesLlcMember', window );">Valent Technologies, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_RelatedPartyTransactionsTextualsAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dmpi_OfficerAndDirectorMember', window );">Officer and Director [Member] | Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_RelatedPartyTransactionsTextualsAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Cash compensation to officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
<td class="nump">385,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Aggregate amount owing to officers and directors for fees and expenses</a></td>
<td class="nump">$ 29,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Director fees recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,583<span></span>
</td>
<td class="nump">$ 77,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_RelatedPartyTransactionsTextualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_RelatedPartyTransactionsTextualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=dmpi_ValentTechnologiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=dmpi_ValentTechnologiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dmpi_OfficerAndDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dmpi_OfficerAndDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_AgreementsAxis=dmpi_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_AgreementsAxis=dmpi_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6836164784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ScheduleOfDerivativeLiabilitiesRollForward', window );"><strong>Schedule of derivative liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Opening balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,364,381<span></span>
</td>
<td class="nump">$ 5,111,007<span></span>
</td>
<td class="nump">$ 5,111,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_IssuanceOfAgentWarrants', window );">Issuance of 2015 Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of warrants</a></td>
<td class="nump">$ 276,584<span></span>
</td>
<td class="num">$ (781,152)<span></span>
</td>
<td class="num">(943,050)<span></span>
</td>
<td class="num">(451,794)<span></span>
</td>
<td class="num">$ (627,433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms', window );">Change in fair value due to change in warrant terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,965<span></span>
</td>
<td class="num">(23,658)<span></span>
</td>
<td class="num">(23,658)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants', window );">Reclassification to equity upon amendment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,343,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(975,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponExchangeOfInvestorWarrants', window );">Reclassification to equity upon exchange of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(728,835)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants', window );">Reclassification to equity upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (247,440)<span></span>
</td>
<td class="num">(1,120,257)<span></span>
</td>
<td class="num">(391,422)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Closing balance</a></td>
<td class="nump">$ 1,017,250<span></span>
</td>
<td class="nump">$ 3,443,608<span></span>
</td>
<td class="nump">$ 1,017,250<span></span>
</td>
<td class="nump">$ 3,443,608<span></span>
</td>
<td class="nump">$ 2,364,381<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of derivative liability due to change in warrant termsChange in fair value of derivative liability due to change in warrant terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ChangeInFairValueOfDerivativeLiabilityDueToChangeInWarrantTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_IssuanceOfAgentWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of agent warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_IssuanceOfAgentWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of derivative liability to equity upon the amendment of Dividend Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ReclassificationOfDerivativeLiabilityToEquityUponExchangeOfInvestorWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of derivative liability to equity upon the exchange of Investor Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ReclassificationOfDerivativeLiabilityToEquityUponExchangeOfInvestorWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of derivative liability upon the exercise of investor warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ScheduleOfDerivativeLiabilitiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents roll forward of derivatives liabilities from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ScheduleOfDerivativeLiabilitiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6840450896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 29, 2016</div></th>
<th class="th"><div>Feb. 09, 2015</div></th>
<th class="th"><div>Sep. 12, 2013</div></th>
<th class="th"><div>Mar. 06, 2013</div></th>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Jan. 24, 2013</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from the exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 405,183<span></span>
</td>
<td class="nump">$ 1,404,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants', window );">Common stock shares issued on exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,986,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants', window );">Reclassification of derivative liability upon the exercise or exchange of Investor Warrants (note 6)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,440<span></span>
</td>
<td class="nump">$ 1,120,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 391,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants', window );">Reclassification of derivative liability upon the amendment of warrants (note 6)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,343,300<span></span>
</td>
<td class="nump">$ 975,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dmpi_TwoThousandFifteenAgentWarrantMember', window );">2015 Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ClassOfWarrantOrRightExercised', window );">Number of warrants of exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 15,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dmpi_TwoThousandThirteenPlacementAgentWarrantsMember', window );">2013 Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings', window );">Recognized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ClassOfWarrantOrRightIssued', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dmpi_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember', window );">2013 Placement Agent Warrant Amendments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings', window );">Recognized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 242,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants', window );">Common stock shares issued on exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Derivaitve liability increase to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,035,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants', window );">Reclassification of derivative liability upon the amendment of warrants (note 6)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,277,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | 2013 Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | 2013 Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dmpi_InvestorWarrantsMember', window );">Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ReverseAcquisitionDescription', window );">Reverse acquisition description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company issued units consisting of one share of common stock and one five-year warrant (the "Investor Warrants") to purchase one share of common stock at an exercise price of $0.80.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.786<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings', window );">Recognized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ClassOfWarrantOrRightExercised', window );">Number of warrants of exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515,500<span></span>
</td>
<td class="nump">762,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_WarrantsAgentFee', window );">Agent fee of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_PercentageOfWarrantAgentFee', window );">Percentage of agent fee of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_GrossProceedsFromExerciseOfWarrants', window );">Gross proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 795,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from the exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 405,183<span></span>
</td>
<td class="nump">$ 470,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants', window );">Common stock shares issued on exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,223,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dmpi_InvestorWarrantsMember', window );">Investor Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dmpi_InvestorWarrantsMember', window );">Investor Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dmpi_InvestorWarrantExercisesMember', window );">Investor Warrant Exercises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from the exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,266,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dmpi_WarrantsIssuedForServicesMember', window );">Warrants Issued for Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_TermOfWarrants', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ClassOfWarrantOrRightIssued', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dmpi_InvestorWarrantsExchangeMember', window );">Investor Warrants Exchange [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings', window );">Recognized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants', window );">Common stock shares issued on exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,591,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ClassOfWarrantOrRightIssued', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,244,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants', window );">Reclassification of derivative liability upon the exercise or exchange of Investor Warrants (note 6)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 423,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ReclassificationOfDerivativeLiabilityUponTheExchangeOfInvestorWarrants', window );">Reclassification of derivative liability upon the exchange of Investor Warrants (note 6)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 305,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dmpi_InvestorWarrantAmendmentsMember', window );">Investor Warrant Amendments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings', window );">Recognized loss</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="text">Mar. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Derivaitve liability increase to equity</a></td>
<td class="nump">$ 58,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ClassOfWarrantOrRightIssued', window );">Number of warrants issued</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants', window );">Reclassification of derivative liability upon the amendment of warrants (note 6)</a></td>
<td class="nump">$ 65,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dmpi_DividendWarrantsMember', window );">Dividend Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ClassOfWarrantOrRightIssued', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants', window );">Reclassification of derivative liability upon the amendment of warrants (note 6)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 975,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of each class of warrants or rights issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_GrossProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_GrossProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued on the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_PercentageOfWarrantAgentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of warrant agent fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_PercentageOfWarrantAgentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of derivative liability upon the amendment of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ReclassificationOfDerivativeLiabilityUponTheAmendmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ReclassificationOfDerivativeLiabilityUponTheExchangeOfInvestorWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of derivative liability upon the exchange of Investor Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ReclassificationOfDerivativeLiabilityUponTheExchangeOfInvestorWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of derivative liability upon the exercise of investor warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ReclassificationOfDerivativeLiabilityUponTheExerciseOfInvestorWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ReverseAcquisitionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse acquisition description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ReverseAcquisitionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_TermOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the term of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_TermOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_WarrantsAgentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agent fee of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_WarrantsAgentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentWarrantsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of warrants held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentWarrantsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dmpi_TwoThousandFifteenAgentWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dmpi_TwoThousandFifteenAgentWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dmpi_TwoThousandThirteenPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dmpi_TwoThousandThirteenPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dmpi_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dmpi_TwoThousandThirteenPlacementAgentWarrantsAmendmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dmpi_InvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dmpi_InvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dmpi_InvestorWarrantExercisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dmpi_InvestorWarrantExercisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dmpi_WarrantsIssuedForServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dmpi_WarrantsIssuedForServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dmpi_InvestorWarrantsExchangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dmpi_InvestorWarrantsExchangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dmpi_InvestorWarrantAmendmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dmpi_InvestorWarrantAmendmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dmpi_DividendWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dmpi_DividendWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6838494112">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems', window );"><strong>Schedule Of Common Stock Issued And Outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (821,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised', window );">Exercise of warrants for cash, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">515,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Warrants issued for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 400,389<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">142,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions', window );">Reclassification of stock option liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,747<span></span>
</td>
<td class="nump">$ 38,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(687,603)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems', window );"><strong>Schedule Of Common Stock Issued And Outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 39,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,455,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockIssuedDuringPeriodSharesAndWarrantsValue', window );">Issuance of shares and warrants - net of issue costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 4,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares', window );">Issuance of shares and warrants - net of issue costs, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">4,277,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockIssuedDuringPeriodValueReclassificationOfWarrants', window );">Reclassification of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockIssuedDuringPeriodValueStockWarrantExercised', window );">Exercise of warrants for cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised', window );">Exercise of warrants for cash, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">515,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Warrants issued for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions', window );">Reclassification of stock option liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 44,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,309,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock [Member] | As previously reported [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems', window );"><strong>Schedule Of Common Stock Issued And Outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 39,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,455,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 39,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,455,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock [Member] | Restatement adjustment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems', window );"><strong>Schedule Of Common Stock Issued And Outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 39,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,455,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional paid-in capital [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems', window );"><strong>Schedule Of Common Stock Issued And Outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 17,500,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockIssuedDuringPeriodSharesAndWarrantsValue', window );">Issuance of shares and warrants - net of issue costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,198,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockIssuedDuringPeriodValueReclassificationOfWarrants', window );">Reclassification of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">2,343,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockIssuedDuringPeriodValueStockWarrantExercised', window );">Exercise of warrants for cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 652,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Warrants issued for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">$ 80,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">138,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions', window );">Reclassification of stock option liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,805,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional paid-in capital [Member] | As previously reported [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems', window );"><strong>Schedule Of Common Stock Issued And Outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,500,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional paid-in capital [Member] | Restatement adjustment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems', window );"><strong>Schedule Of Common Stock Issued And Outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(136,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,363,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems', window );"><strong>Schedule Of Common Stock Issued And Outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,138,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockIssuedDuringPeriodSharesAndWarrantsValue', window );">Issuance of shares and warrants - net of issue costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 671,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockIssuedDuringPeriodValueReclassificationOfWarrants', window );">Reclassification of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockIssuedDuringPeriodValueStockWarrantExercised', window );">Exercise of warrants for cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Warrants issued for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">$ 429,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,190,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member] | As previously reported [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems', window );"><strong>Schedule Of Common Stock Issued And Outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,138,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member] | Restatement adjustment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems', window );"><strong>Schedule Of Common Stock Issued And Outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,048,994)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 89,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">515,500 Investor Warrants were exercised for cash at $0.786 per share for proceeds of $405,183.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">On July 15, 2015 the Company's Registration Statement on Form S-1 relating to a public offering by the Company of common stock and common stock purchase warrants (the "Offering") was declared effective by the Securities and Exchange Commission. Pursuant to the Offering, the Company issued 4,277,667 shares of common stock at $0.60 per share and 4,277,667 warrants (the "2015 Offering Warrants") to purchase shares of common stock at $0.001 per warrant for total gross proceeds of $2,566,660. The 2015 Offering Warrants are exercisable at $0.75 per share for a period of five years until they expire on July 31, 2020. The Company engaged certain placement agents for the sale of a portion of the shares and 2015 Offering Warrants. Under the Company's engagement agreements with these placement agents, the Company agreed to pay up to a 7% cash commission and issue warrants to purchase shares of common stock (the "2015 Agent Warrants") up to the number of shares of our common stock equal to 5% of the aggregate number of shares sold in the Offering by such placement agents. Pursuant to the placement agent agreements the Company paid a total cash commission of $80,575 and issued 93,908 2015 Agent Warrants (note 6). The 2015 Agent Warrants are exercisable at a per share price equal to $0.75 during the five-year period commencing six months from the effective date of the Offering, which period shall not extend further than five years from the effective date of the 2015 Offering. Therefore, all 2015 Agent Warrants expire on July 15, 2020. In addition to the cash commission of $80,575 the Company also incurred additional cash issue and closing costs of $582,511 (including costs deferred at June 30, 2015 of $550,119) resulting in net cash proceeds of $1,903,514. The 2015 Agent Warrants have been recognized as non-cash issue costs of $29,594.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Upon the amendment of the Investor Warrants and the 2013 Placement Agent Warrants, the Company reclassified the related derivative liability to equity (note 6).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">During the period ended March 31, 2016, 515,500 Investor Warrants were exercised for proceeds of $405,183 (note 6).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">During the period ended March 31, 2016, the Company issued 1,060,000 warrants for services. All warrants have an exercise price of $0.75. Of these warrants, 60,000 expire on July 31, 2020, 500,000 expire March 1, 2020, and 500,000 expire February 1, 2021.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">During the period ended March 31, 2016, the Company issued 60,000 shares of common stock for services.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of stock option liability upon the forfeiture of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ReclassificationOfStockOptionLiabilityUponTheForfeitureOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ScheduleOfCommonStockIssuedAndOutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares and warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_StockIssuedDuringPeriodSharesAndWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares and warrants value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_StockIssuedDuringPeriodSharesAndWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of sharewarrants (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_StockIssuedDuringPeriodValueReclassificationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the reclassification of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_StockIssuedDuringPeriodValueReclassificationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_StockIssuedDuringPeriodValueStockWarrantExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_StockIssuedDuringPeriodValueStockWarrantExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment for noncash service expenses paid for by granting of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentOfWarrantsGrantedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66904339&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6824791296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 1)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>CAD / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of stock options outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">390,000<span></span>
</td>
<td class="nump">390,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross', window );">Cancelled</a></td>
<td class="num">(21,486)<span></span>
</td>
<td class="num">(21,486)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted | (per share)</a></td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="nump">CAD 0.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of stock options outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance</a></td>
<td class="nump">3,595,000<span></span>
</td>
<td class="nump">3,595,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">390,000<span></span>
</td>
<td class="nump">390,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(470,000)<span></span>
</td>
<td class="num">(470,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross', window );">Cancelled</a></td>
<td class="num">(50,000)<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance</a></td>
<td class="nump">3,465,000<span></span>
</td>
<td class="nump">3,465,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Beginning balance | $ / shares</a></td>
<td class="nump">$ 0.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted | $ / shares</a></td>
<td class="nump">1.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited | $ / shares</a></td>
<td class="nump">1.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Cancelled | $ / shares</a></td>
<td class="nump">1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending balance | $ / shares</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) cancelled during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which cancelled can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6762424768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_ZeroPointThreeNineMember', window );">0.39 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options outstanding</a></td>
<td class="nump">775,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">5 years 10 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of stock options exercisable</a></td>
<td class="nump">775,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_ZeroPointSevenFourMember', window );">0.74 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 0.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options outstanding</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">8 years 10 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of stock options exercisable</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 0.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_ZeroPointEightZeroMember', window );">0.80 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options outstanding</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of stock options exercisable</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_ZeroPointNineFourMember', window );">0.94 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 0.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options outstanding</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">9 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of stock options exercisable</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 0.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_OnePointZeroZeroMember', window );">1.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options outstanding</a></td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">4 years 11 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of stock options exercisable</a></td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_OnepointzerofiveMember', window );">1.05 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options outstanding</a></td>
<td class="nump">1,770,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">7 years 4 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of stock options exercisable</a></td>
<td class="nump">1,696,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_OnePointOneTwoMember', window );">1.12 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options outstanding</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">9 years 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of stock options exercisable</a></td>
<td class="nump">9,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_OnePointFiveFourMember', window );">1.54 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 1.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options outstanding</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of stock options exercisable</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 1.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_TwoPointThreeZeroMember', window );">2.30 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options outstanding</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">7 years 2 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of stock options exercisable</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_ZeroPointNineTwoMember', window );">0.92 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options outstanding</a></td>
<td class="nump">3,465,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of stock options exercisable</a></td>
<td class="nump">3,116,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options outstanding</a></td>
<td class="nump">3,465,000<span></span>
</td>
<td class="nump">3,595,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_ZeroPointThreeNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_ZeroPointThreeNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_ZeroPointSevenFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_ZeroPointSevenFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_ZeroPointEightZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_ZeroPointEightZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_ZeroPointNineFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_ZeroPointNineFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_OnePointZeroZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_OnePointZeroZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_OnepointzerofiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_OnepointzerofiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_OnePointOneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_OnePointOneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_OnePointFiveFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_OnePointFiveFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_TwoPointThreeZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_TwoPointThreeZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_ZeroPointNineTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmpi_ZeroPointNineTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6825748096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 3) - Stock options [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">84.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term - years</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">118.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term - years</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6762741536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 4) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 23,843<span></span>
</td>
<td class="nump">$ 62,848<span></span>
</td>
<td class="nump">$ 138,711<span></span>
</td>
<td class="nump">$ 142,171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">20,165<span></span>
</td>
<td class="nump">26,853<span></span>
</td>
<td class="nump">36,395<span></span>
</td>
<td class="nump">39,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,678<span></span>
</td>
<td class="nump">$ 35,995<span></span>
</td>
<td class="nump">$ 102,316<span></span>
</td>
<td class="nump">$ 102,262<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6835556368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 5)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of options unvested, Beginning balance | shares</a></td>
<td class="nump">722,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of unvested options granted | shares</a></td>
<td class="nump">390,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of options, Vested | shares</a></td>
<td class="num">(481,634)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of options, Forfeited | shares</a></td>
<td class="num">(260,370)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross', window );">Number of options, Cancelled | shares</a></td>
<td class="num">(21,486)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of options unvested, Ending balance | shares</a></td>
<td class="nump">348,871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice', window );">Weighted average exercise price unvested, Beginning balance</a></td>
<td class="nump">$ 0.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice', window );">Weighted average exercise price unvested, Granted</a></td>
<td class="nump">1.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice', window );">Weighted average exercise price unvested, Vested</a></td>
<td class="nump">0.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice', window );">Weighted average excercise price unvested, Forfeited</a></td>
<td class="nump">0.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsCancelledWeightedAverageExercisePrice', window );">Weighted average exercise price unvested, Cancelled</a></td>
<td class="nump">1.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice', window );">Weighted average exercise price unvested, Ending balance</a></td>
<td class="nump">1.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, unvested, Beginning balance</a></td>
<td class="nump">0.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, unvested, Granted</a></td>
<td class="nump">0.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, unvested, Vested</a></td>
<td class="nump">0.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, unvested,Forfeited</a></td>
<td class="nump">0.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, unvested, Cancelled</a></td>
<td class="nump">0.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, unvested, Ending balance</a></td>
<td class="nump">$ 0.55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) cancelled during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options cancelled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsCancelledWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average price cancelled stock options during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsCancelledWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average price forfeited stock options during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average price granted stock options during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average price unvested stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average price vested stock options during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6614709312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 6)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Mar. 31, 2016 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_NumberOfWarrantsRollForward', window );"><strong>Number of Warrants [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Beginning Balance</a></td>
<td class="nump">13,472,870<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_NumberOfOfferingWarrants', window );">2015 Public Offering Warrants</a></td>
<td class="nump">4,277,667<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_NumberOfWarrantsIssuedToAgents', window );">2015 Agent Warrants</a></td>
<td class="nump">93,908<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_NumberOfWarrantsIssuedForServices', window );">Warrants issued for services</a></td>
<td class="nump">1,060,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised', window );">Warrants exercised for cash</a></td>
<td class="num">(515,500)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Ending Balance</a></td>
<td class="nump">18,388,945<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Issued as part of the Company's financing completed in August 2015. Warrants are exercisable at $0.75 until July 31, 2020.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Issued as part of the Company's financing completed in August 2015. The 2015 Agent Warrants are exercisable at a price of $0.75 during the period commencing January 15, 2016 until their expiry on July 15, 2020.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Warrants have an exercise price of $0.75. Of the total, 60,000 vest in tranches of 20,000 warrants each on November 30, 2015, March 31, 2016, and January 31, 2016 and are exercisable commencing January 1, 2016 until they expire on July 31, 2020. In addition, 500,000 of the warrants vest in tranches of 150,000 on March 1, 2015, and 50,000 on each of March 31, 2016, January 31, 2016, February 29, 2016, March 31, 2016, April 30, 2016, May 31, 2016, and June 30, 2016 until they expire on March 1, 2020. Also, 500,000 of the warrants vest in tranches of 83,333 on each of February 29, 2016, March 31, 2016, April 30, 2016, May 31, 2016, June 30, 2016 and July 31, 2016 until they expire on February 1, 2021.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">515,500 Investor Warrants were exercised for cash at $0.786 per share for proceeds of $405,183.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_NumberOfOfferingWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of offering warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_NumberOfOfferingWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_NumberOfWarrantsIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued for services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_NumberOfWarrantsIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_NumberOfWarrantsIssuedToAgents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued to agents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_NumberOfWarrantsIssuedToAgents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_NumberOfWarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_NumberOfWarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of sharewarrants (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6825160272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details Textual) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_PreferredStockSpecialVotingSharesIssued', window );">Preferred stock special voting shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,309,098<span></span>
</td>
<td class="nump">39,455,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockIssuedAndOutstandingOnExchangedBasis', window );">Stock issued and outstanding on exchanged basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,056,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,530<span></span>
</td>
<td class="nump">278,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,530<span></span>
</td>
<td class="nump">278,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, rate of dividend</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_AgreementsAxis=dmpi_ExchangeAgreementMember', window );">Exchange Agreement | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_PreferredStockSpecialVotingSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of special voting preferred stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_PreferredStockSpecialVotingSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_StockIssuedAndOutstandingOnExchangedBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issued and outstanding of common stock on an as-exchanged basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_StockIssuedAndOutstandingOnExchangedBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_StockholdersEquityNoteLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_StockholdersEquityNoteLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_AgreementsAxis=dmpi_ExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_AgreementsAxis=dmpi_ExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6838753200">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details Textual 1)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 15, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>CAD / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of unvested options granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockOptionExpense', window );">Stock Option Expense | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option recognized as additional paid in capital | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised', window );">Exercise of warrants for cash, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price | (per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="nump">CAD 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockOptionLiabilityNoncurrent', window );">Stock option liability | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,698<span></span>
</td>
<td class="nump">CAD 149,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of stock options outstanding | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396,538<span></span>
</td>
<td class="nump">396,538<span></span>
</td>
<td class="nump">345,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of stock options exercisable | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396,538<span></span>
</td>
<td class="nump">396,538<span></span>
</td>
<td class="nump">$ 333,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,016<span></span>
</td>
<td class="nump">CAD 93,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants', window );">Common stock shares issued on exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,986,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">CAD 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_NumberOfWarrantsIssuedToAgents', window );">Number of warrants issued to agents</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDerivativeIssuanceCosts', window );">Issuance of cash | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 582,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds from exercise of warrants | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,903,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Warrants vest in tranches</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred costs | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,647<span></span>
</td>
<td class="nump">CAD 60,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_NumberOfWarrantsIssuedForServices', window );">Number of warrants issued for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,060,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_ReductionInStockOptionLiability', window );">Reduction in stock option liability | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">November 30, 2015 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Warrants vest in tranches</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">March 31, [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Warrants vest in tranches</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">January 31, 2016 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Warrants vest in tranches</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=dmpi_ShareBasedCompensationAwardTrancheFourMember', window );">March 1, 2015 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Warrants vest in tranches</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=dmpi_ShareBasedCompensationAwardTrancheFiveMember', window );">February 29, 2016 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Warrants vest in tranches</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=dmpi_ShareBasedCompensationAwardTrancheSixMember', window );">March 31, 2016 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Warrants vest in tranches</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=dmpi_ShareBasedCompensationAwardTrancheSevenMember', window );">April 30, 2016 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Warrants vest in tranches</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=dmpi_ShareBasedCompensationAwardTrancheEightMember', window );">May 31, 2016 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Warrants vest in tranches</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=dmpi_ShareBasedCompensationAwardTrancheNineMember', window );">June 30, 2016 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Warrants vest in tranches</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=dmpi_ShareBasedCompensationAwardTrancheTenMember', window );">July 31, 2016 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Warrants vest in tranches</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option recognized as additional paid in capital | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised', window );">Exercise of warrants for cash, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants', window );">Common stock shares issued on exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,277,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares', window );">Issuance of shares and warrants - net of issue costs, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,277,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds from exercise of warrants | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,566,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option recognized as additional paid in capital | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExercisePrice', window );">Investment Warrants, Exercise Price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="nump">CAD 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds from exercise of warrants | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 405,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Warrants vest in tranches</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | March 31, [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Warrants vest in tranches</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | January 31, 2016 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Warrants vest in tranches</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | February 29, 2016 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Warrants vest in tranches</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | March 31, 2016 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Warrants vest in tranches</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | April 30, 2016 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Warrants vest in tranches</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | May 31, 2016 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Warrants vest in tranches</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | June 30, 2016 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Warrants vest in tranches</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dmpi_InvestorWarrantExercisesMember', window );">Investor Warrant Exercises [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dmpi_TwoZeroOneFiveAgentWarrantsMember', window );">2015 Agent Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="nump">CAD 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_CashCommission', window );">Total cash commission | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_NoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued', window );">Issuance of noncash finance | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 15,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dmpi_TwoZeroOneFiveOfferingWarrantsMember', window );">2015 offering warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants', window );">Common stock shares issued on exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,277,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExercisePrice', window );">Investment Warrants, Exercise Price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Sale of stock description</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">The Company agreed to pay up to a 7% cash commission and issue warrants to purchase shares of common stock (the "2015 Agent Warrants") up to the number of shares of our common stock equal to 5% of the aggregate number of shares sold in the Offering by such placement agents.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Jul. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">515,500 Investor Warrants were exercised for cash at $0.786 per share for proceeds of $405,183.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Issued as part of the Company's financing completed in August 2015. The 2015 Agent Warrants are exercisable at a price of $0.75 during the period commencing January 15, 2016 until their expiry on July 15, 2020.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Warrants have an exercise price of $0.75. Of the total, 60,000 vest in tranches of 20,000 warrants each on November 30, 2015, March 31, 2016, and January 31, 2016 and are exercisable commencing January 1, 2016 until they expire on July 31, 2020. In addition, 500,000 of the warrants vest in tranches of 150,000 on March 1, 2015, and 50,000 on each of March 31, 2016, January 31, 2016, February 29, 2016, March 31, 2016, April 30, 2016, May 31, 2016, and June 30, 2016 until they expire on March 1, 2020. Also, 500,000 of the warrants vest in tranches of 83,333 on each of February 29, 2016, March 31, 2016, April 30, 2016, May 31, 2016, June 30, 2016 and July 31, 2016 until they expire on February 1, 2021.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">During the period ended March 31, 2016, 515,500 Investor Warrants were exercised for proceeds of $405,183 (note 6).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">On July 15, 2015 the Company's Registration Statement on Form S-1 relating to a public offering by the Company of common stock and common stock purchase warrants (the "Offering") was declared effective by the Securities and Exchange Commission. Pursuant to the Offering, the Company issued 4,277,667 shares of common stock at $0.60 per share and 4,277,667 warrants (the "2015 Offering Warrants") to purchase shares of common stock at $0.001 per warrant for total gross proceeds of $2,566,660. The 2015 Offering Warrants are exercisable at $0.75 per share for a period of five years until they expire on July 31, 2020. The Company engaged certain placement agents for the sale of a portion of the shares and 2015 Offering Warrants. Under the Company's engagement agreements with these placement agents, the Company agreed to pay up to a 7% cash commission and issue warrants to purchase shares of common stock (the "2015 Agent Warrants") up to the number of shares of our common stock equal to 5% of the aggregate number of shares sold in the Offering by such placement agents. Pursuant to the placement agent agreements the Company paid a total cash commission of $80,575 and issued 93,908 2015 Agent Warrants (note 6). The 2015 Agent Warrants are exercisable at a per share price equal to $0.75 during the five-year period commencing six months from the effective date of the Offering, which period shall not extend further than five years from the effective date of the 2015 Offering. Therefore, all 2015 Agent Warrants expire on July 15, 2020. In addition to the cash commission of $80,575 the Company also incurred additional cash issue and closing costs of $582,511 (including costs deferred at June 30, 2015 of $550,119) resulting in net cash proceeds of $1,903,514. The 2015 Agent Warrants have been recognized as non-cash issue costs of $29,594.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">During the period ended March 31, 2016, the Company issued 60,000 shares of common stock for services.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_CashCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the commission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_CashCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_NoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of warrants issued as [noncash or part noncash] consideration for a business or asset acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_NoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued on the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_NumberOfCommonStockIssuedUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_NumberOfWarrantsIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued for services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_NumberOfWarrantsIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_NumberOfWarrantsIssuedToAgents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued to agents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_NumberOfWarrantsIssuedToAgents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_ReductionInStockOptionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in stock option liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_ReductionInStockOptionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares and warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_StockIssuedDuringPeriodSharesAndWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of sharewarrants (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_StockIssuedDuringPeriodSharesStockWarrantExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_StockOptionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock option expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_StockOptionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_StockOptionLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represent stock option outstanding as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_StockOptionLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_StockholdersEquityNoteLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_StockholdersEquityNoteLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentWarrantsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price of the warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentWarrantsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentWarrantsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of warrants held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentWarrantsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66904339&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDerivativeIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of a derivative security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDerivativeIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4582445-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569655-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=dmpi_ShareBasedCompensationAwardTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=dmpi_ShareBasedCompensationAwardTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=dmpi_ShareBasedCompensationAwardTrancheFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=dmpi_ShareBasedCompensationAwardTrancheFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=dmpi_ShareBasedCompensationAwardTrancheSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=dmpi_ShareBasedCompensationAwardTrancheSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=dmpi_ShareBasedCompensationAwardTrancheSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=dmpi_ShareBasedCompensationAwardTrancheSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=dmpi_ShareBasedCompensationAwardTrancheEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=dmpi_ShareBasedCompensationAwardTrancheEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=dmpi_ShareBasedCompensationAwardTrancheNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=dmpi_ShareBasedCompensationAwardTrancheNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=dmpi_ShareBasedCompensationAwardTrancheTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=dmpi_ShareBasedCompensationAwardTrancheTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dmpi_InvestorWarrantExercisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dmpi_InvestorWarrantExercisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dmpi_TwoZeroOneFiveAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dmpi_TwoZeroOneFiveAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dmpi_TwoZeroOneFiveOfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dmpi_TwoZeroOneFiveOfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6631590960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">$ 1,017,250<span></span>
</td>
<td class="nump">$ 2,364,381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13495-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6825545376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May. 12, 2016</div></th>
<th class="th"><div>May. 12, 2016</div></th>
<th class="th"><div>Apr. 10, 2016</div></th>
<th class="th"><div>Jul. 15, 2015</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_EngagementAgreementPrivatePlacementDescription', window );">Engagement agreement private placement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company engaged certain placement agents for the sale of a portion of the Series B Preferred Stock. Under the Company's engagement agreements with these placement agents, the Company agreed to pay up to an 8% cash commission and issue warrants to purchase shares of common stock (the "2016 Agent Warrants") up to the number of shares of our common stock equal to 8% of the aggregate number of shares underlying the Series B Preferred Stock sold in the offering by such placement agents.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_CommissionPaidInLeiuOfIssuanceOfWarrants', window );">Cash commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net cash proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExercisePrice', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event [Member] | Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Warrant issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_CommissionPaidInLeiuOfIssuanceOfWarrants', window );">Cash commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 283,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExercisePrice', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 12,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event [Member] | Investor Warrant Amendments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Warrant issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,970,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmpi_DerivativeLiabilityEquityIssuanceReclassified', window );">Derivative liability, equity issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event [Member] | Series B preferred stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="nump">764,363<span></span>
</td>
<td class="nump">764,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds from preferred stock</a></td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price of Series B Preferred Share</a></td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, rate of dividend</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockDescription', window );">Series B Preferred Share conversion terms</a></td>
<td class="text">Each share of Series B Preferred Stock is convertible into ten shares of common stock equating to a conversion price of $0.80 (the "Conversion Price") and will automatically convert to common stock at the earlier of 24 hours following regulatory approval of VAL-083 with a minimum closing bid price of $2 or five years from the final closing dates.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_CommissionPaidInLeiuOfIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission Paid In Leiu Of Issuance Of Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_CommissionPaidInLeiuOfIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_DerivativeLiabilityEquityIssuanceReclassified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative liability equity issuance reclassified.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_DerivativeLiabilityEquityIssuanceReclassified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmpi_EngagementAgreementPrivatePlacementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Engagement agreement private placement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmpi_EngagementAgreementPrivatePlacementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmpi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentWarrantsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price of the warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentWarrantsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentWarrantsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of warrants held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentWarrantsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=dmpi_InvestorWarrantAmendmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=dmpi_InvestorWarrantAmendmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>52
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M P04    " #M@*Q(2'4%[L4    K @  "P   %]R96QS+RYR96QSK9++;L)
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M!+"SO^*$E,Q^)#C=MV3X"U!+ P04    " #M@*Q(9(?"OI<#  #X#   #P
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MO9U,4PU.XT_8T2^RU'9CA]T8<X[WOMAKI]KFM",?^_7WOP!02P,$%     @
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M]>5G%3NKR*8!J1>0&OOB$= 8168!5@&3U3)>HFE,YL5D)LARI ZK6$T#%E[
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MK)J"YRDL&YPQ4S:JQ_*22.AAQ-E"QW8C)2J9FK%\752(HWB5$.)X8+26$!U
M'ACW_P8&1-0>IN:@:(:_ $2[!.10\4GD/C%CE'$JL75+Y@J#:.8HPK@B\CR9
M6.5K9M )2 HBS F+8H:>N(4".9],F18SIM#.)$:R9,YJ*>R<$8J[*+!'IJR+
M&5#.N.00,5<XI>8HBGLID >JE'\Q P(*U FP9!"E4=+.V1MQ2P6R0I6R,6;
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MG"NJZ^!5XGN-/B5O'4:/RC37NBW@W(".XL/U&+R=Q>4_4$L#!!0    ( .V
MK$AQ1_NV[0,  !D0   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULC9A+
M<Z,X$,>_"N5[@IX(I1Q7C8&IW<-63<UAYTQL^5'#PP,XGOWV*^B&Q!Y9YA)
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M?B)0AP@GC#F3 %@"F"1$26<2 $LE1JV%=B<+N RYB% =L\?J(J>Z"$*//>H
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M5R_EVZ[_T1R_530&/33XW.RZ\6_V_-;U33V%S+*Z_!4^M_OQ\QC^DPL*XP.
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M-&"==%$^DU""DYA2;2*/0Z27V^LZ\M(442Z75MC(&A>3T#/:%P4)^8U\V8E
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MZ:9@9R]TA8G$XXQ9$<RIWVR1T5OT+-"S[^F;:_HF.MS,#O/O!?)K@3P*Y+/
M]M:($7-<,+LO3=C%GBK0;;@ZAE0X]C9NZ5I=;^=#%L[D$UX6 V_A#]>MZ TY
MH74G&PZ@0;3@VB=W6THZ]W[61$)C??C#Q3I>J9A8')8'LK[2\@-02P,$%
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M"9T+X9V/3;I2*7$XGA[(^DKK_U!+ P04    " #M@*Q(,,G@"*,!  "Q P
M&    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;(U3RV[;,!#\%8(?$.KAI(4A
M"XA3%.VA0)!#>Z:EE42$Y*HD9:5_7SXDQ2Z,MA=Q=S4S.\M'-:-YM0. (V]*
M:GN@@W/CGC';#*"XO<,1M/_3H5'<^=3TS(X&>!M)2K(BRQZ8XD+3NHJU9U-7
M.#DI-#P;8B>EN/EU!(GS@>9T+;R(?G"AP.J*;;Q6*-!6H"8&N@-]S/?'74!$
MP'<!L[V(2?!^0GP-R=?V0+-@ 20T+BAPOYSA":0,0K[QST7SO64@7L:K^N<X
MK7=_XA:>4/X0K1N\V8R2%CH^2?>"\Q=81K@/@@U*&[^DF:Q#M5(H4?PMK4+'
M=4Y_RH>%=IM0+(1B(WS,HO'4*-K\Q!VO*X,SL2,/9Y?O/=P$$:],O#?KQXZ:
M)@Y>5^<Z+_**G8/0%281CPMF0S"O?K-%06_1BT@O_DTOK^EE<E@N#O]#8'<M
ML$L"N[^-F##'%5/^T81=[*D"T\>K8TF#DW9I2[?J=CL?BW@F[_"Z&GD/W[CI
MA;;DA,Z?;#R #M&!;Y_=W5,R^/>S)1(Z%\(//C;I2J7$X;@^D.V5UK\!4$L#
M!!0    ( .V K$@E> ,MI@$  +$#   9    >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;(53RV[;,!#\%8(?$,JRG 2&+"!.4;2' D$.[9F65A(1DJN2E)7^
M??F0%#LPD(NXNYJ9G>6CG-"\V1[ D7<EM3W0WKEASYBM>U#<WN$ VO]IT2CN
M?&HZ9@<#O(DD)5F>9?=,<:%I5<;:BZE*')T4&EX,L:-2W/P[@L3I0#=T*;R*
MKG>AP*J2K;Q&*-!6H"8&V@-]VNR/14!$P&\!D[V(2?!^0GP+R<_F0+-@ 234
M+BAPOYSA&:0,0K[QWUGSHV4@7L:+^O<XK7=_XA:>4?X1C>N]V8R2!EH^2O>*
MTP^81]@%P1JEC5]2C]:A6BB4*/Z>5J'C.J4_V\>9=IN0SX1\)3QFT7AJ%&U^
MXXY7I<&)V(&'L]OL/=P$$:],O#?KQXZ:)@Y>E>=JDQ<E.P>A*TPB'F?,BF!>
M_6:+G-ZBYY&>?TW?7M.WR>%V=KC[6J"X%BB20#$+W-\:,6&."^;A4Q-VL:<*
M3!>OCB4UCMJE+5VKZ^U\RN.9?,"K<N =_.*F$]J2$SI_LO$ 6D0'OGUVMZ.D
M]^]G322T+H0//C;I2J7$X; \D/655O\!4$L#!!0    ( .V K$@.H%5QIP$
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MG3_9>  MH@/?/KNYI:3W[V=-)+0NA-]];-*52HG#87D@ZRNM_@-02P,$%
M  @ [8"L2(WMGM/M 0  J04  !D   !X;"]W;W)K<VAE971S+W-H965T,34N
M>&ULC93;;J,P%$5_Q>(#RCT)$4%J.JHZ#R-5?9AY=LCAHMJ8L4WH_/WX!DTJ
M%/H27]A[KW,(=CXR_BX: (D^*.G$P6ND[/>^+\H&*!8/K(=./:D8IUBJ):]]
MT7/ 9V.BQ(^"8.-3W'9>D9N]5U[D;)"D[>"5(S%0BOF_(Q V'KS0FS;>VKJ1
M>L,O<G_VG5L*G6A9ASA4!^\QW!\SK3""WRV,XFJ.=.TGQM[UXN?YX 6Z!"!0
M2IV U7"!)R!$!RGP7Y?YB=3&Z_F4_FRZ5=6?L( G1OZT9]FH8@,/G:'" Y%O
M;'P!UT*J TM&A/E%Y2 DHY/%0Q1_V+'MS#C:)TGL;,N&R!FBV; +3.$69,K\
M@24N<LY&)'JL_[MPK^1<AZADI&H3JFV3R4WC17XIPB3*_8L.NM%8X]%I9H6O
MTA<1D;=DCXP]6K?'M_;85AA;>KA;#TAN Q(;D+@6XZ46K>8X:9)U2+H(25U
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M0H\+"H4RTXV>"_=FN87B[? $C_\#^7]02P,$%     @ [8"L2/Q.]S*F 0
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M971S+W-H965T,C N>&ULC55-;^(P$/TK4>[;./Z( PJ1VE"T>UBIZF%[=L%
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M[PB@Y^V2&+N=M<"(_"( AC7Y'1SR!3:7DW=A!E+'T"*(AK]+^^T7&2WR)2G
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M]C>AYY&<W]_Y!PAX:Z;Y* ,A8^J*(".X&ZQH4BK!8$H  8?]BJ:D"FR+:6\
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M*>++=-&CF:*76)4AMO0B"6R!-,VT9H MO2C#$M%,:PXTR8NP)FD::!U8!39
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MXUL[O&_G0\+Y0]^<PYGG[>!U\R]02P,$%     @ [8"L2(NA\1H( @  N08
M !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&ULC55;;YLP%/XK%C^@QEQR
M$T%J.DW;PZ2J#]NSDYP$5!LSVX3NW\\7H$EE);P$VWRW<U".BU[(=U4!:/3!
M6:.V4:5UN\%8'2K@5#V)%AKSYB0DI]ILY1FK5@(].A)G.(GC!>:T;J*R<&>O
MLBQ$IUG=P*M$JN.<RG\[8*+?1B0:#][J<Z7M 2X+//&.-8=&U:)!$D[;Z)EL
M=B2U$(?X74.OKM;(AM\+\6XW/X_;*+89@,%!6PEJ'A=X <:LDG'^.XA^>EKB
M]7I4_^[*-?'W5,&+8'_JHZY,VCA"1SC1CNDWT?^ H8;<"AX$4^X7'3JE!1\I
M$>+TPS_KQCU[_V:Y'FAA0C(0DHG@?; W<C&_44W+0HH>J9;:CT<V!BZMB%%&
M)ILR93M-Z0HOBTN9INL"7ZS0#<83=QY#)@0VZD&+) K1$T=/'M/36WKJ$Z8^
M(5D]%LAN!3(OD'F!+ Z5Z#&[$3.CR#QHD@\"R1V3$9,^-ED$31:#0/988!GL
MY7)^+U?!!*LA07ZGS!&S>&RR#IJL!X'E'9,1,Z,2$@==W+&56,^0(,%V$C*_
MGR0)ITAF='0$Y?$,GS3LD\YHZ@C*O_X-\-5HX2#/;H(J=!!=H_UDF4ZG*?V<
MN-'T"2^+EI[A%Y7GNE%H+[09<&X.G8308/SCISQ"E;E'I@V#D[;+I5E+/UG]
M1HMVO"BFVZK\#U!+ P04    " #M@*Q(GC&BOFL"   S"   &0   'AL+W=O
M<FMS:&5E=',O<VAE970S,2YX;6R-5EV3FC 4_2L,/V A 0(XR,R*=MJ'SNSL
M0_L<-0JS0&@2U^V_;[[$CT;TQ9#+.>?>>Q(2BR-E'[PF1'A?7=OSN5\+,<R"
M@&]JTF'^0@?2RS<[RCHLY)3M SXP@K>:U+4!#$,4=+CI_;+0L3=6%O0@VJ8G
M;\SCAZ[#[.^"M/0X]X%_"KPW^UJH0% 6P<C;-AWI>4-[CY'=W'\%LQ4(%40C
M?C7DR"^>/57\FM(/-?FQG?NAJH&T9".4!);#)ZE(VRHEF?F/%3WG5,3+YY/Z
M-]VN+'^-.:EH^[O9BEI6&_K>ENSPH17O]/B=V!X2);BA+=>_WN; !>U.%-_K
M\)<9FUZ/1_,FS2W-38"6 $?"F,=-B"PA.A/B24)L"?&S&1)+2&XR!*9W[=P2
M"UP6C!X]/F"UG\!,PID2D<J>M(O+E=":3*]%67R640*+X%,)76&@QBP,!D7W
M(4L# 2,BD 4XJX"^*P/4](D:*H- \40-#T56_XG<+3.Z+C,R9D7&+) ]%HBO
M!6(C$%NW;ZSL-28U7A@,C+)X E49%()9G-U'+0T*1%D*P'W8RL)B"-(GEC!Q
MMI;8UIXP%SG-1<^;FSHK2*?,1<9<@X$A0,E]5&51*)O26MI\*,HGM%86E>=A
M_KBQS-E89AM+'@OD3FOSYZT%H;,$'7ZT<T\@E$[LR6J4RMV^V:UK82"$$4 3
M>_>,@PC>]!=<G(@=87M]%W%O0P^],-_X&!WONU>H3M2;^ +,*N"(+]7]J$_@
MLWQ9#'A/?F*V;WKNK:F0Y[@^;G>4"B)+#E^DU;6\P<=)2W9"/:9J#<R=9B:"
M#J<K>OR?4/X#4$L#!!0    ( .V K$B@/JQ8T0(  #T+   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;(V646^;,!" _PKBO0$;L*$B2&VG:7N85/5A
M>Z:)DZ "SK#3=/]^QCYH,MV(\Q# N;OO'/B2*\]R>%,'(73PT;6]6H<'K8_W
M4:0V!]'5:B6/HC>?[.30U=I<#OM('0=1;VU2UT8TCEG4U4T?5J5=>QZJ4IYT
MV_3B>0C4J>OJX<^C:.5Y'9)P6GAI]@<]+D15&<UYVZ83O6ID'PQBMPX?R/TC
M3<80&_&S$6=U<1Z,S;]*^39>?-^NPWCL0;1BH\<2M3F\BR?1MF,E0_X-13^9
M8^+E^53]J]VN:?^U5N))MK^:K3Z8;N,PV(I=?6KUBSQ_$["';"RXD:VR[\'F
MI+3LII0PZ.H/=VQZ>SR[3U@.:7@"A00Z)R2Q;=R!;)M?:EU7Y2#/@3K6X\TC
M]R9\&(N8RH'I39EMVYJ#W7A5OE=)QLKH?2QT%>,2'UT,F2,B4QU%T!!+IPX1
M>Q1(K@LDKL<$>N2W"Z37!5)7((4"^?4F>QO#7)<NAE.:,(]&,Y23 :=8X$!,
M$9O7;0Y#.<S58/$"Q\7<I3EA27H;Q%$0!Q!9 +F8.\KBA'OL*$=!.8#H B@'
M$$ES=IM3H)P".,D"!V+2/.<>3P*)T6?6+H\DC^^>$+17 FZR#&NV #==4+PJ
M,@\0Q4%@*&,8B$R_ BZ*K'Q$)@E. I497R0ETYY\2+CR!)QGJ/,S*9U(U(.$
M2T_ :(9:/Y.RZ=OSN4^X]@2\YZCW,XE-))\]<?SI!?&]!,"-)J T1Y6>F\WA
M!J0^)-QI L)R5.J95 #I(NS_?V0Q2J(@-4^72! 5KWS<I[C[%-SGJ/LS:9*?
M^I!P^2G(SQ?EAZAXY?,G3''Y*<C/4?GA]XQ.[F?_>A)=C#>=&/9VBE/!1IYZ
M[::;>76>%!^H'8\^PZOR6._%CWK8-[T*7J4V0Y:=A792:F$:,. P.)A9=KYH
MQ4Z/I]R<#VZZ<Q=:'J=A=9Z8J[]02P,$%     @ [8"L2')4>N"7 @  "0D
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M/.&DFF769.2D2B#4K[)T9>2DFB=D6+/,P,RZ!3P:9UFW\@3=TJI4I8$H%Z-
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M^;P@N)-Z6J@YMX>574@VG<[>\P>@_@M02P,$%     @ [8"L2.;X[!V) P
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MX)<.A'' .P?!5<.*#C%V"X.0.T*HG5IBE#47@>8BH!AT] SSU#/B=I  #1*
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M1NM:-4[(7?,ZNU/)^G23J4W=7H;-=6E>\<U-K??]+Q:GGTVF_P%02P,$%
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MBNOT-LMSG!16&[[?79^G*/BW?7BUW^TV1*V2\@%6K(T_'AI9YV3!GD],$1]
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MZ>' Z&K_AAW@RIL%=#?9[#5ZXI^"2\L"2W.\U0U;?B"80PY_!"UN6(5!--X
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M1PODS_LOI:3;HN&7H=B;KRD0\:,VG:C!V8&#OL65LILUS*\X"QZ.C:\SVW7
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MZ9*>NB.X^R +-45Q([0U^53G+0EZ#LJHAI^]%0I%!<*,'V4ELPN23N^56-T
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M8X&J4Z;$7V]') .C%47A5<?H;+[P0L9/AX/%L"L&W@=C5]P[F88_$E%1&.D
MI?)7):?; /ND?+=0<'MDSVB5T4AW,H<TD(MO(NM-1'W# .GY$AQNX5$]17R
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M5 LS:"0;F(YUX)M]F $AO8O*SCFPU4#4+V<0+IZ$=&>[34I51TO7Z3&ZLA:
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M@HJQWY'E1+9=>'>IK<:HZ)XU(0J29PY5OLM*YMIM.-?,C+/LYK4VI.'"U.B
ME:3R,(X[3_@<]-V0D2V\-^ VQ99; K%O])W:/!S]EX[^;]O=WS/:/Q>+7R'<
M?_8EP_T7?<+]Z7IL'A3.M2*.G190_,/2 BPC"M"MT]%BK(O;J?H-F)8X'8H
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M;M/H,VY@_4U5U=_]?U!+ 0(4 Q0    ( .V K$B)6B0\O $  "88   3
M          "  0    !;0V]N=&5N=%]4>7!E<UTN>&UL4$L! A0#%     @
M[8"L2$AU!>[%    *P(   L              ( ![0$  %]R96QS+RYR96QS
M4$L! A0#%     @ [8"L2,3+)$.4 0  /!<  !H              ( !VP(
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ [8"L2+.N
M&!JH @  G0H  !               ( !IP0  &1O8U!R;W!S+V%P<"YX;6Q0
M2P$"% ,4    " #M@*Q(*X)[I3X!  !I P  $0              @ %]!P
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #M@*Q(F5R<(Q &  "<)P
M$P              @ 'J"   >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( .V K$B+;8(G>P(  %@.   -              "  2L/  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ [8"L2&2'PKZ7 P  ^ P   \
M ( !T1$  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( .V K$B=X5*'4 (
M /0'   8              "  945  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " #M@*Q(JL;"Z:X#   9$   &               @ $;
M&   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ [8"L2(<G
M-N\H @  EP<  !@              ( !_QL  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( .V K$AQ1_NV[0,  !D0   8
M  "  5T>  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #M
M@*Q(X)6?2,P$  "*%@  &               @ & (@  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ [8"L2&N.<42E 0  L0,  !@
M         ( !@B<  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( .V K$BCDIXWI $  +$#   8              "  5TI  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #M@*Q(%+SO[*8!  "Q P
M&               @ $W*P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ [8"L2##)X BC 0  L0,  !@              ( !$RT  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( .V K$@E> ,MI@$
M +$#   9              "  >PN  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ [8"L2 Z@57&G 0  L ,  !D              ( !
MR3   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #M@*Q(
M"YQO/J0!  "Q P  &0              @ &G,@  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( .V K$C:+4!WHP$  +$#   9
M      "  8(T  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ [8"L2.SGC ^F 0  L0,  !D              ( !7#8  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #M@*Q(C>V>T^T!  "I!0
M&0              @ $Y.   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( .V K$BQB>)9I $  +$#   9              "  5TZ  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ [8"L2#"83(ZE
M 0  L0,  !D              ( !.#P  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " #M@*Q(P!\YP_4!   3!@  &0
M@ $4/@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( .V
MK$C\3O<RI@$  +$#   9              "  4!   !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ [8"L2)*FB;)R @  YP<  !D
M         ( !'4(  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " #M@*Q(I=AZ720$  "@$P  &0              @ '&1   >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( .V K$B!7"F#;P(  &D(
M   9              "  2%)  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ [8"L2"0P4H.] @  -@P  !D              ( !QTL
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #M@*Q(.UEW
M$\D"   $"P  &0              @ &[3@  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( .V K$BD9$<,^ (   $+   9
M  "  ;M1  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M[8"L2(A5\&*\!0  8R$  !D              ( !ZE0  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " #M@*Q(7X)IC2$&  #D)   &0
M            @ '=6@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( .V K$B@7&_IT (  &X+   9              "  35A  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ [8"L2/C5%%N2!
MA!T  !D              ( !/&0  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " #M@*Q(BZ'Q&@@"  "Y!@  &0              @ $%
M:0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( .V K$B>
M,:*^:P(  #,(   9              "  41K  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ [8"L2* ^K%C1 @  /0L  !D
M     ( !YFT  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .V K$CF^.P=B0,  $(1   9              "
M ?"   !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ [8"L
M2!&"9?LD10  A30! !0              ( !L(0  'AL+W-H87)E9%-T<FEN
<9W,N>&UL4$L%!@     N "X = P   ;*      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.4.0.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>142</ContextCount>
  <ElementCount>198</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>54</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Condensed Interim Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/ConsolidatedCondensedInterimBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Condensed Interim Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Condensed Interim Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/Consolidatedcondensedinterimbalancesheetsunauditedparenthetical</Role>
      <ShortName>Consolidated Condensed Interim Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Condensed Interim Statement of Loss and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/ConsolidatedcondensedinterimstatementoflossandcomprehensivelossUnaudited</Role>
      <ShortName>Consolidated Condensed Interim Statement of Loss and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Condensed Interim Statement of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/ConsolidatedCondensedInterimStatementOfCashFlowsUnaudited</Role>
      <ShortName>Consolidated Condensed Interim Statement of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Disclosure - Nature of Operations and Liquidity Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/NatureOfOperationsAndLiquidityRisk</Role>
      <ShortName>Nature of Operations and Liquidity Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Disclosure - Restatement of Previously Issued Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/Restatementofpreviouslyissuedfinancialstatements</Role>
      <ShortName>Restatement of Previously Issued Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Valent Technologies, LLC</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/ValentTechnologiesLlc</Role>
      <ShortName>Valent Technologies, LLC</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Derivative Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/DerivativeLiability</Role>
      <ShortName>Derivative Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/Stockholdersequity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Financial instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/Financialinstruments</Role>
      <ShortName>Financial instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Restatement of Previously Issued Financial Statements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/Restatementofpreviouslyissuedfinancialstatementstables</Role>
      <ShortName>Restatement of Previously Issued Financial Statements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/Restatementofpreviouslyissuedfinancialstatements</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Derivative Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/DerivativeliabilityTables</Role>
      <ShortName>Derivative Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/DerivativeLiability</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/Stockholdersequitytables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/Stockholdersequity</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Financial instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/Financialinstrumentstables</Role>
      <ShortName>Financial instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/Financialinstruments</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - Nature of Operations and Liquidity Risk (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/NatureOfOperationsAndLiquidityRiskDetailsTextual</Role>
      <ShortName>Nature of Operations and Liquidity Risk (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/NatureOfOperationsAndLiquidityRisk</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - Restatement of Previously Issued Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails</Role>
      <ShortName>Restatement of Previously Issued Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/Restatementofpreviouslyissuedfinancialstatementstables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/Significantaccountingpoliciesdetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/SignificantAccountingPoliciesPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - Valent Technologies LLC (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/ValentTechnologiesLlcDetails</Role>
      <ShortName>Valent Technologies LLC (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/ValentTechnologiesLlc</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/RelatedPartyTransactions</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/DerivativeLiabilityDetails</Role>
      <ShortName>Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/DerivativeliabilityTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - Derivative Liability (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/DerivativeLiabilityDetailsTextual</Role>
      <ShortName>Derivative Liability (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/DerivativeliabilityTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/Stockholdersequitydetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/Stockholdersequitytables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Stockholders' Equity (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/Stockholdersequitydetails1</Role>
      <ShortName>Stockholders' Equity (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/Stockholdersequitytables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Stockholders' Equity (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/Stockholdersequitydetails2</Role>
      <ShortName>Stockholders' Equity (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/Stockholdersequitytables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Stockholders' Equity (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/Stockholdersequitydetails3</Role>
      <ShortName>Stockholders' Equity (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/Stockholdersequitytables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - Stockholders' Equity (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/Stockholdersequitydetails4</Role>
      <ShortName>Stockholders' Equity (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/Stockholdersequitytables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>032 - Disclosure - Stockholders' Equity (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/Stockholdersequitydetails5</Role>
      <ShortName>Stockholders' Equity (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/Stockholdersequitytables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>033 - Disclosure - Stockholders' Equity (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/Stockholdersequitydetails6</Role>
      <ShortName>Stockholders' Equity (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/Stockholdersequitytables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>034 - Disclosure - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/StockholdersEquityDetailsTextual</Role>
      <ShortName>Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/Stockholdersequitytables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>035 - Disclosure - Stockholders' Equity (Details Textual 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/StockholdersEquityDetailsTextual1</Role>
      <ShortName>Stockholders' Equity (Details Textual 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/Stockholdersequitytables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>036 - Disclosure - Financial instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/Financialinstrumentsdetails</Role>
      <ShortName>Financial instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/Financialinstrumentstables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="dmpi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>037 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delmarpharma.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.delmarpharma.com/role/SubsequentEvents</ParentRole>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>dmpi-20160331.xml</File>
    <File>dmpi-20160331.xsd</File>
    <File>dmpi-20160331_cal.xml</File>
    <File>dmpi-20160331_def.xml</File>
    <File>dmpi-20160331_lab.xml</File>
    <File>dmpi-20160331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>58
<FILENAME>0001013762-16-001577-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001013762-16-001577-xbrl.zip
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MT'1=.5O>[6I>7<IJ?RA)Q^%:?>M6M:\J^97(4<9^WTE.'DKZL#_8M1=)P60
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MVY)&^DC3->%M[[JW_-HUB*'I%=_ [K"W^BO>2N@OODE?Q)X&Q(Q\7+]-89T
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MQS&6B\YHG'D)">DT [38=[F0IU3J\8654S(T6#I'(><L,B<4!BAD^%1"!9T
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M"YR[DOI'U*.$2A5ZP:9 G/]HV5SZ9&)V)E=S[\56 GX)%"\J4BNBDV3V;>I
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MX],*%_.IGC]VZ-XUX&*EZY+]P-2B >!H/Z'><;1SM+>'V9U"^W.P$\6AM/(
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M6LHKCJ/CX6@DCJ11)WEUV#25=47!#VA*_D)<XAL.M20-:V:[=A#Z1FC?5\X
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MLSA%-D8<[TK#: UC 32 >(. 2/],'E,*3C$(\"8OIH&-4IC!CX/M !F-$@#
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M:%B3Q)K<'5/EV421-7TJ;5KB4'H!^S<BC7\<23<A'IQ15RK;AF=VNOR:)>W
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M^M:.0RU=!UQ]8>7U5PVC#GS2LKLCR+(12I<0U30;#/A2ML:!M$F9VQ7Q #)
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MJR(5Z7BLNV^R(5RDEETD[J)):;=!=L8VI[X1_/SDV 2C24_"/1)*,5#S*.1
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M%7!5DB:M:ZK\,2"/EN-AN6+ES[B.!98=Q99;?8'K+'8\^<6:6$'XX[-E2IW
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MF)F\<^Y!T_.$5J/XU><#[QY7KK\FY!,)GAR;[#C"<.$!]*_;Q4=B^P^>\Q\
M!>CAPW5A%'9Y5+ 9LDJ. %1]%34-'A5"UGB7,M(=[^_2YBR%#DX']DTJ:/>(
MH'79KOJK86#Q%9+Z6^.#FN*DA<ME3$ZK"SKFZG6,Q+&AR]UQRLW4UV)(>\KU
M#+0BP#S 5T'CBJA=MTWAQ]LG215'!8W.&-KR(9>X8WJ$^Y:A1$ =YU*34YM!
M2@#O\ D)K:+B'XY7%M F:W[/,%^8"IUX,"=6M^=A.S3N;,>>TW)>P/SA,LS$
M<. 3VK)#6RK&@0MM$=JRS>\>U:6%):%$@/(PK<%SBW?XA.T5MK=O:6Q_0\.-
M>G$#2#,BM6_@!TLP;@ 1G!LJ(()S0P5$<*ZGM.:\_3IS).'S9*PVR&R^3L[M
M4P\'+WF5'.:WE=)&0D(CR98WE^;DB;C^"M,MFK%J>Q;@V:7E++F\QP*EUTTI
M;,.CE]5QA4\_.#IQ(#]<ILOK=>,,6Y"?L3PU]0N@DRBWZ$5^]+&LSPZT/US2
M2<A//_(SDV?*;'!TZBG)>],;W(AW=>@D_D(\$E@N]1&M^:/C.6$46)'SU+ J
MCH/"WSHJ=UG.W_L6CU_D='D\.;9^B8=:<B'?0KYKY=N49TV](R'@0L ')^"J
MHLEZ5?:3D' AX1<CX=I8&["$=UR$?<9(=5-!ZU^L+[(0=6@$>9Y8"S$08B#$
M0(B!$(/V?:%F39=V16F-CF.TIVYXC/-O=VK&TL-/E01LOZ\_!YIP[#;H7+AI
MNCPU&AX3[]\$]2!H',G\873B5R8N6=['&LA[:R<30MZ%O/,M[ZH^E2>J*@1>
M"/PS$7A#D]7)< 7^R-HBL>466VX1>1%B(,1 B($0 R$&',1ARUUBZQK"MMRV
MM;HW[!^^]T1'TM''W]B1\^1$Z\YGP[D7W_!5] \5_4/YJH"MR]#A& 4^FUT<
M2^+N&[+T3X7S-J#9L9[@"Y-%A3YDOX4\M@M,M>EJB0]_Q(_W))#\Q38;=C7E
MOA#,DZ;W-7BWK8["P D#)PS<F=7\GY1^S1H07Q3B%GBBUD-%/>&%XTW8<//G
MA_@J@%W\L\/ZX.9V8@$7"[A8P(>CX&(!?V9X/P06W#ZOG =YX:@O+">0GBPW
M?GZH7^PZ?L%M:[=9P UHW #",8V$: G1$J+%$VBM H+%0!=))2%<';D?A[4K
M2#:HTW%U ]0.$8<GW.,??R:Y)9(52;_&'I%T19:RH0SW&0GV<JV^E6O?+!3=
M71O3I=ONP!--D_5QPRQWK@DEVG/V(D#*2#1W%=)SO/08P[,]9VOMVA)6OV#T
ML2K:S%_6KTC^[JR+LB(KBC(,:O1/^XN4 76D'%O.* 3@$@1 &4V.[= QI 5V
M7S_"#O#ZBV[:AT!;H5P=*=<+8ZK*8]WHEQP_"M[W8EAG8F7E&.LS","X9\6_
MS*WK>S]8$$<LK5QCW?W2JHT569_TO'L52VM/2^NQK=6%\E^& &C/86GM8=/Z
MQO*P]OOHQ96'T07%!K%<@+.;6A==%\ O<B\T53:F? Z@V>-2",$6@ET;SA>#
MPX1X7ZIX*R-S,F#Q/D>DY1FW!Q/;+2$&0@R$& @Q$&+01PBFNE$[1:Q<';^O
M+/)$NK@5=0._6X&]E'25%@ZPC>]]1J(6O*D=J'*R>Q#M_ >UGS@7;KHQE:<#
M;N<_8('G #C>I5,=*:T-$!:B*6QQ9>M=OA%61F9KX<P^AZV4NY7?!\57OY)4
M?:3KJV^->U"WW9S;=HD54"]T>52G[KW=I5^FF+?2K/RBNI/7=:YOTE0>V]'/
M'U=.X;;;. HCRT/A_Z<58)U/V%DC^@MJKLXX.H2.ZA4[RFVBI.8O;W64?A.P
M&XOT:#/4OSFKMKTBRK<DM .']C-NMBA4$(J#4X#]C.3MW*(QQ&F;+7Y/D++@
M".L(?F@@9"@<:Z,;5Y4Y:56?11Q7Q'$YB..F)DC7)UGWOX:K:ZOJ\+/E8O*=
MQ.@QU51P,[?;O>QEDVB>4@^4OM7]IMV"6ETV)IH\;9J9SA&MSE8(<B:%0IV1
M[N)[U[&EV\4"?O >I'1+)+UP1/)^'\N.(6N3B3P>'YO(,R25..CT\(Q*<?,
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M-IN.E8DQ0-RZ6:E43=.GQH0#>J1JH%4[L+#KV?Z^/N94@*:Q4="2'+!!DN.
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MU@- _X#%3%M/"'T7X/7H92D=I/NU%,;V4EJYEDTE!YZ  C,JK#S[69FYZF^
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MK]P*+G'LH;QA*[5LQ::MV+85&;=>I>;_L]V^LQ.F2$347<035S2%"4E+)!X
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M>2+JA'J \1H'E]3V%UAV[!,WP.S$^5_( [7B/G;%4TM>YB(;G0?=26N#+&S
MIU2,)L3Q&8[^OZ15@4G>QQV4^C -3)AO8^SP"^8O<OU7/<4$*&#J:ZW1@RZ?
MM3][V"L@8NQ.Y_@6!X$7'Y807Z]\1"?H258)COK.-GK D.C0'N)<G1:06N#<
M_GGI4X'M_!$SFW#!Q*5:Q/,9T'TV9; /@ZL+UA.AYT3=9$W60$N][&I0\A2#
M%(/+Q20ZC)83J^=L)7M]Z&AG\<1SZO. "]S^C))_L',2;WQ0B8HJRZ\OM-?I
M0><!3^4 JRH-<N8LIX -E9M-/GBB=S8AR@E&D*(+@H^#Y/?O%G6EEP#&UP6F
M^SO.4(#4";0G"&4W-<,PRYO6G="3YV9#>6Z9R@OJD[E9G4"&('?2,@QQ\SGA
M>-\4,$17T#5GV-;>:U*-N9N:.7!/9@RK[]-25%PN>.8F.\'Q7&@R.[S#EYVF
MV$]X<8=9T_R:2!6&G>,O$*'?W17\BE!<3M/!4G/ZT=@5G1\S,=#/",.VB/0U
M/U2+&.F$DT<"\Q\5//]X<,A"7K#LT\KQD+7Q3)$(-C\I,HAT>1]QZ,D9,VNF
MUGWJA S"4G7".7X&<.#9T5[%G/&>Q39Z'BMFV!O?\T1&]H"8 P9$S4KF0,W6
MATYFXE<@N:^4Z$/JV6IE8NI'2:5,MG/+$V?DGC@87&7<K-D?DLCLS=.ZRVUM
MK?:!QG*KM0=!E8!!#X%2$Y-ET$8LFJ!!F!*ZXZN&LG=C&JA&28-0E3M3,GH:
M>UU9T%Q,Z<3:V/UT28-0E1\*&I@J 8,P3!_\Z=P/Y1]JN2!N@#'-!PP:HG;B
M9N*;S@F3+9YXR%8BA="H#FH[S3ZBKAF):]@PB(D;+/^6)SZQ133"U7FC,\QM
M1I91!;F@IE:N7>S_+.N@IS+X2M_#C=D-F<W3QW0^MVD2-&>/6=J39+>ZP!AX
M<F=%/7AS-!$<R\-ZN2U< +1:J7@(B?&SC,2^6W\34ISG=VADK]"A76QMI'O@
MPNM03F5C]]1?B!:JU[=1\!@E-#4,=-9<<QQ^@X@Z]W)('XJ%0G/F$+GQ#_1'
MN2#?Y(0[LR9S;=MPK91!W:?;1IQ-+36T,-B#"2=;B=0F#KD3,!MTY==B715-
M?&W6&@/T'FH597/6<G.M/0ME0R:J(FWSH]H&73X%TEZO#^ML;2%%/ZS 1:)H
MT)19T73E-7WV Z;(50WTN$,H;*JLM$CIM.2E0K?'E$0]>T5.:I5-&BNR^@^(
MRPV&BR6F/#JX*%L\4W(?GC*1"7I2*Q7RW5V\\?)4.L/SY(:O"+A*5O+\?*,*
M^L0A[XKQ#RRC4?&LO<=,Y+))UYDP8N,NW&ZXXD("K0Q_-\[_BYD_\0D-IG.&
M\;6(0K3%MFH1@];2TD;>XGM,+_Q0WU%3+6(BCG/9@>2W:AR:B(DX9'^I=T=9
MPB 48XI5$V5;05]4"9B%82F;^(]HGBMR4P@#*& 6!D6S^'_Z4.V%8K&![;\0
M](*#H4K ( R"V>PI  Z&2@F#4!1F':@O50D8A&'E4#!_TN>S6HC"M9%*Q;ZT
M[U*]0:LBSX7_>W"^=G"ZP67SC8#^*'/&Y^6Y594&Y0 ; ?WEV;MSFQI_-);C
M<YO/2W3+2G\TKM.D_CFY;EGIC\!UR[43-9N>H0"G%ZY\RU6Q%I4;Q'WR/C]9
M.H<#MEHI<^*JI)ECU\4L=_830**+&+2,6:8[6M2>^FH##82F2M!X3/"]0"UD
M#4*F_]V$:S_ VHOL.BD3WUHG.P[2TU]:HELI85*F"](.OFAODC1GGJO< Y#=
MKN:(YQ6I>)/:I&/0V/K _*^X^F@*7&Q0]]/.F[0[[6#P88?I@UJF'E,L5QH;
M-YDWR1J+K!P@-("K$C<(7T6D*X,X>0K6GL,+R]W4^H47>IG13:U7>&_)XPIP
M<UK]0BM?TJZ"-Z_7*\3J=>X*B MZO4(,;C?HIM8KO-.5>O34S/Z<+5J=/\IV
M:^E2J?#;[6#;V#YG>76KW*=+.">%$UCE@C[LQI/7KHMFIS>'C5E\TUWZ=^7D
M'2'$B6^=*F;K^71^/3M]H.H&.Z&Z1.220G<F%C;]-TCV >XYG:%9?%8RSOTG
MZN0"3@]1P@<1NRJVR[F?YS!+.GHGB#B7] J3<.QF5Y$ BXWM57HPM0%G4[*+
M+V5=V7[LPNCOJ&=F]Q]&?^WD_<\__1]02P,$%     @ [8"L2( 7O1-""
MBV,  !4   !D;7!I+3(P,38P,S,Q7V-A;"YX;6S=75]3VS@0?^],OX,O?3TG
M!.[:PI1V H%.9J!A^-/K6T>Q-T176\I)-B3]]+=RG)+$MBR3D,@=9B"876EW
M?RMI=R69#Y\F8> \@)"4L^-&N[G7<(!YW*?L_KAQ=WONOF]\^OCZU8<_7/?;
MR?6%T^5>' *+G$ND&5+PG4<:C9RSG^Z93R,NG*^SMIQV\VUSK[GGX,?;42RD
M3Z9_.I=DZK3W_W3V]]IOG7;[Z&#_:/^=<W7IN*[J)*#LQX!(<% H)H\;HR@:
M'[5:CX^/S<E !$TN[EO[>WL'K3EA8T9Y-)%TB?KQ8$[;;GV[O+CQ1A 2ES(9
M$>8]<:EF\OC:AX>'K>2O2"KID4SX+[A'HL1,I7(YA13J-W=.YJI';GO?/6@W
M)])O*!L('L U#)VD^Z-H.H;CAJ3A.%!B)\]& H;'#3\<4U?9<>]@QOWFE#/)
M ^J3"'S\[ .3X/=8!(*&)R10FM^, ")YQTB,8('?<%1O=]>])95\"$(BQB,B
M0M+T>-A21*UGM-Y2^G@D\.(@,=P%2K^D%TPBP);\N6:JHY<1)?$N[BWU'B@\
MN5@V:]IY MJ0R$&"7"S=>T+&+67N%@21G#]) '#WVBF ;]+'WSM28O>GL1 X
M5.8=!&0 0=+M]WRZUI:E/"5RU&&^^G'V7TP?2(!2R$YT2H28X@3PE00Q:*0W
MXU_U@HY85I (;]X'?LRXP/+P22E:,@[#I#47X0WG_$/!0YV!Y_WRY^CA<.&#
MP#D2I\A8HI!\K 0@0<-Y!'H_BO!/%2#,CE_UY/LMF8!$8?K1",0U>(#B# +0
M^)(1F[T@F&F=VGY_,[;?S/"Y$C FU#^;C-4$5#[8\^GM1:9$SQ22 YL@Z<(0
M4#Q<%:3)])M+;C\@^5JF>/QE$QXS=4H70)1KQQ8O,O4*'F9+P#8M?$X9ZG=!
M'Y((B+![BO/F3.HOH//]$D9K$2E3V&REV"9$%Y0,:$ CJEO%-<3;E;;C>3S&
M\.>*3-42C(LR/A$Q^)74J-+*#EVM6*?,1%#%+/9-$]T8;ODU!"IENB+"#$0-
M4RTPTREM]31A-C]8 D*1]5]Z8!0D4#<1]W[TQ[-ZPTR"Z1?./'W^5,)EIZ6-
M]+7/T;L@,+V+< 5?T$T+D2FGG3 9ZVV646T3JL2Y1CQ N:0JC413#3HYQ-N5
M%A/566*42%)6O<JCWJ$#%9LZ)Q_/JKF%F?4KCRB[OQD1D6?6#(G5MLPJ9-\\
M><K#D#,C7\Z06FW\8@7MFP$[OD]G,EP1BAGG*1G3B 0+HNNRH'+F6@!E8@2S
M\M,VH?N'"$%4(9_YUTH"V8\CM0&H]C8UH&G9:@&77O$4J+_M >H:(D(9^&=$
M,!118F8=AW&2MG5A2#VJBPD-F&L!FHD14NC>V@/=@I3)W@U."6,!(V 2P]P>
M\W@(%URJREQ_>$LF^HI1I99J 6IE\Z0(O[,'X85<!>>32@E!*:L=^9I6+4U5
MPSCHKIN.>92&X7%KY;C'Q]>OGKXV=+;%FQ_YH+,C'[BTH1DP@^;#  <3KG/>
MXC!3S]8^\;)6G]LX![.6@%O>%>R/01"5>J5;RKIZ9Y9VVWN8UR !1YXZ(=(%
M9;FQ,FLJCC8PT?'M=)>Y$(!L4*+5?;,G8C8#UV=@J%R@-FC\D#(J(Y'4W,H!
M*^.L!V2E^MMXE.8+9WRNX"PL*H>KF&>[ =)G#-M5$-=G3P7>'D.S)^=D56QW
M)3"VU\6^QDWL,)@HA2CCB,9VV4+M\DF8TQ%A]RC(.:$BJ3KUA]G"_#39.IR3
MIOGT+8@P;ZG:< =UP'C3-BV?D]P-NL#9Q$NDZ _GE9)R5'-X:@A4GN;VU5S/
MN<">V6S7V)O>HJ"2>$JJN28G,$0:?4&A2BMU@/)9UK&O*IN<TP=I$$"O4M8)
MI(R6Y577"C/<9I&8*934IPS06*2N(R)+VMI74,VI$!H43W5<.P3)0)E5F'+R
MG/+PT-UIF>T96FJ\=[U"VPM='[N95Y/Z0W5+YCS@CYN_1:;O9!>7R?02K7O5
M!YWD:0N@,\0>._Z_L8R2]*@_1!]1G?90@L+XM$H36\_I%V73Y?%+=#LILCP7
MCLRP7E;9QO+8DTX81W9"+B+Z,S&-]AA#$4^MT=*8PL8:V4I(V86!;EL\C[K6
M:.6J;^,=M#LF@ 3T)_AY%3#=3%C&66O\2LU2GJJZ&[A?^T+EO_6+?C6$=C,&
M-3N/M";L+U#\JRM@1M5 34:\B5'8DS)6KVGH#Y.S!KC^WH!XH%[N]%C&45\H
M=&8P.PFTJ^#QR64^J^_@ZR&LV$ M$:UJI!3@]S8!G)R%/R%2I<*ABK/*4H,"
MAEH#6&2$%+!#FP!#73&L4N'P[&>/_2J@I8>TM3E"*?.:>V[9'HK>]%$X[YNW
ML,,2H#D,R_-_!?/8=Z<X*_WRFT(J>=X*:ZVP-#>(?9>,LC*;W'2O!*U1@[\)
MX&;&*R];[& S<%65G-OSE6#/X_]-4,XUC6']8LLE>!7M7 G^0'WP3Z9WR=[&
M+\4['B;I90.Z0B.[W ^NK.K22EPI;+3\V/_S35%EK&STR-:+NGN//8!<U]WS
M&K'F34]7("CW5U'3G8VJW)9]_JR!M<([HXI,9U^X76 &U(TP;TWOSFMDS=0/
MN_  ?'F.>"[4N51NK1*<LN*K*;M]?JD!9&G),3:0?:Z(T6VZ,':ITIWY<OFE
M%"C_[ &H=_&6W))_3FNUA'TM\UFXWBYZ<.JN9Q,0'M5?Z=*RU1M8K4'L.VB]
MX(@PB.:34/):4;/QFN&J-WPZ<UB8WN6_M[IR,%BIF5V>LWR&NCDGM(QS(\O3
MO!<T1VYH;5B[_ W-D3N%&,[F^@OQO_YA!#[^'U!+ P04    " #M@*Q(\>GH
M7M\C  "T;@( %0   &1M<&DM,C Q-C S,S%?9&5F+GAM;.U=6W/;1I9^WZK]
M#UK/Z\BR2#F3N"8[1>OB495LLB3%F=T7% 0T*4Q @&F M)1?/]T  0)DWP!T
MHP\<OB2RU-TXYWQ]/=>__^-E&9YL$$Z"./KYS?G;=V].4.3%?A M?G[SR^/-
MZ8]O_O&___U??_^?T]-_?;R_.[F*O?421>G)9])F'B#_Y%N0/I]<_W%Z[0=I
MC$^^YF.=G+_]X>V[M^].R(^/SVN<^.[K7T\^NZ\GYZ._GHS>G?]P<G[^83SZ
M,/K;R>SSR>DI_4@81+\]N0DZ(41%R<]OGM-T]>'L[-NW;V]?GG#X-L:+L]&[
M=^.SHN&;O.6'ER2HM?XV+MJ>G_WK\]V#]XR6[FD0):D;>;M>=!A6O_.??OKI
M+/LK:9H$'Y*L_UWLN6DF)BE=)]P6]%^G1;-3^JO3\]'I^/SM2^*7=)$V?EI^
MICK ^[/\CV^HN%SLX3A$]VA^LOWQE_O;PVY!E)[YP?)LV^;,#4/R)4K#A_1U
MA7Y^DP3+58B*WSUC-.>R6'R?4OZ>TOP7.MI9!VK(SRBB,^;41W-W':8::3L<
M6Q.E\=(-(C.$YD-WHC,;XG2)ED\(ZR2R-FX7"I\),=A;/Z'3DG&-=+)&[T)M
M%*<3K4MF.V!&4T&0;'!_N0I.Z;;Y;IQO%G^YC*,D#@/?39'OQ9%/.$5DVTX1
M#I9/;D@WNN09H3191^Z:[,W(7[F8[-S/* T\E_"S+P!*N(_"I8M7SRY>NF^]
M>'F62:#KISIR>H_(OITB>NQ,YS.,-D&\3L+7VR19(_\FB,CW S=\*-HD5RAU
M@S!IPF';3W3D["%81.04]=PH=3TO7D<I.7=71-1>@!*_.1M*XW6D^:L;$@D\
M(N\YBL-X00:^"[T6(A>.TWG&A'2NSER<OCYB-TI<CY[<[6:&>*B.E%Z1-;0A
MUXH-N@O<IR ,TM?MR(_H)5TW6Z?RP;K.US3V?GN.0Y]<\M#O:S)^FTG*'<04
M=>=:R#LW1M]("WTC8_2-M= W-D;?A1;Z+G32=YV-W'XI2\<R3&OK)<,>K".U
MY0E,GW X>X"V.1Y%PW25Y_J)SB8RXO6FY1V$-T1&&7G !%% 3YX[0D:-0")C
M1.YD?D$B':R'2UWV8(^]&BDA?2+'F'DOSN[$<S=YRB[&Z^1TX;JK,RK$,Q2F
M2?&;3*RG[\ZW;^*_;'_ME'<OPC^Z)3\FQ5="]PF%V;<=?F/G72Y'&Q0_ND^[
M"22B-FOHG.\C/L%UFLG#I!AM^T9I].B?XWBI(*[BD[&$V),8DW7_\QO28YT0
M2N(5I9GN=OF[YP.97"F9H]=AUHTL*+2@/^S^'L9DYOW\AJQ(9 ^DR]!-DND\
MV\HF+X'2[-KOXXQ,0"=X+0N@+.&1P,C@@8MHW^!4:;NJZ5P8J!PV=L8FX."I
M@018L&3,AH7)Q/>#AW-5U<,9PZ6N2#0&3,D-&( >R.&-DLF,#(DP1GY&[N>:
M(I"UG_%[.1=&H&)I* ]A8B\&SGXFY $,0'7Z9BZ>XFPR^E_=<(UF"#^06YKH
MKJ V@//>(FQ-;A/*[!0(G@.#,*,OF:S3YQ@'?^PNX5+H]CLZ/PP2,@8;!50C
MD%#E*MV&,.6=G+\-&**2A0*>,4AXINN4&FFI_;DA1I6>SH\#!JK.1X'610>T
M#K45]#?['U\AJAGY&E.3@62I-.GN_ 0<BX;,%("\M[Y\+N/E,HZ:GD*"7L[Y
M.^!8*3)18/0#)(Q:7/84>COG1M1%9C$3,5-@]S=(V"E>'3@]G',C>J$^UM6.
M@0*7']FXG-45U&94UFVM]#U/G&N,8WP9D^,D-Q5/(G^&@QB3:1[$_L3_]SI)
M,_HJ_*AHM3N-:T,![CTC?QVBZ5R5\@KA4J5YY\$M*-J[(LA3?NB0Q;#U^&TD
M^_&U\H]MP\B?+*G?C,0$8.)S$*P'6B82>Y(:$AD8U5Z%@YL8[W$KU98K]+9M
MSC %('NZJ GDSX0^$.,)P&D T!#CH<@E;.XNJ?=H%6/RX)%;8R1=K9ID%%<E
M[YHBY0P,@)7YNN-9BIV@EU633"?8Q$S!,<S\$F'DAE0'](GP<Q<GR33:><2*
M;G.2GE9-,X:>#'*6X0#[!:6WD1<O$253 &.MG55CC2'0]AF$8VF[=G$41(ND
MT.1]=)/ (UQ?!>$Z%>K,)#VMFG(,P2AG&8Z-[C"D($#)ESCRUACGCW\>L)*>
M5NU"AH"5LZS#G*?KP>('^:=G;N#?1I?N*DC=L*(!%KY79)WMVI(,X:O&-AP+
MX:\NQB[ADK!_'RR>4T7KNJB;77N3(5QE#,.Q)]Y3BT:$_.((F7C>>KG.(M3(
M&SCP M&.+.]LUU)E"%TUMB5VQU[L6TKAFWV?$X0(GUY,R*GV@,A)EAUJUR]>
MN"8,WA 0R?:W6J=9:H3I?/]NHV+7TO4)JR:NCDRHF[MT?,B"Z4LCR%(KF"81
M#=LBUE$('U_9 T@,8P:_"LH^IFN*<2Z:1J4(1LG*IO*+NT1RBXFDJVUCF6$$
MFTR;FE#^'-@#,94!G03PS&77RU48OR*4O:&G&1526PNWCUT#F<(2Y&@%!?R
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MJ,5D@[E0ZTUB;,\:J[15JS  YQ[=-64N% ,J2\AL7)A,@%DJG?$ HB;6! Q
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MQNLHE=SY3'S.3 !]_U=%0[*!L\PK+-S$>(]=Z9U&H;>A0'[EZZ<I!'G[NXI
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M-5F::5X?BZZ1S;=D%6[@7-6KQ$E5'H>-;?M!"H7,QH7)!)AUTQD/('HG3<#
M4S4](!R@9#(C0R*,R1.-DBM53@AZ6?6O9"\&SH8FY $,0'7Z9BZ>XFPR^ID!
M>89P]J@68*4V@!4WS7;OML:,P3F>ZB3OI_E2!G&_HQ572IW@,1B"XS7&(O4V
M2=:- <L[V?$GU(_6CALXKE,L.BMI;QKB5>EIQ[E./VA[+!E,#KSW]17R C?\
M&J?DRY(EU*2['>>R#OK&!GSI2 RLZ18?+Y=QU/3,$O2RDUBXVW*2L*,C5[!V
MM%I<%Q5ZV\D[K T]$5LZ$@H;6G/2*P>GAYT4Q)K7VHX5'>F$#2&D=M,0=;.3
MC%@S5GO\P$DO7#][JQ%59 OP4)2Z"_6'-+N[G52^.N^)?+YVSVC]M\7LT_DB
MGT1^909-H\(ZX']T$[[14WD .YEMNUJH53DK,8+L0G%^]*$X^E ,Q+]]JU'^
MU:6>4.D4W]/TCQ+#'[?/H'PQ5+@!HR5G$JEJ<&+ULNVD+I1Z Z#@.:@;@ J(
MD5 W9CUXF'S$\6\(;S^?B-U+6&VM.I)+)CSCI.*P &9M7"$<;#)OZ-LH(><=
M/0=IP++DP!%U&Z2SB80A. :]':%%ZGR:^$VZFXFZV?9!D<E>AAB3(X K3"-@
M0,X?$\CU< ;=1AN4D,;;;;DL^2,^C<2]K'JAR-8"XV"2<M.C^'.=0D/I5SM9
M3?FE0_A[S!@L%OWX+2O7.HT0+6XX69 5JW89DW:TFEZK!0@J#!DL"%W__'0^
M)QQ$BS98L/O:S2+5&0\^4W"</TH?S?R:24/,XD@0+*/4SY#C1U_.VCR6X'A7
M[5$HO8DQVYMR VGNN,T5.!LH+C=@+LRZ\ %R1]8-%#R/[HH]5NK'?=#6;L5O
M_FK@:,]8Y(,!8GM62D&HM;-;T[LI  >DP]',?"57>G)AD9S]E5:&_&0,G_1[
M#,"YC6T)DYX7M7:F_%^4S_%]<0J%OJ,9S)[35NI 3N=VXH=W!G.R:62)P<B&
MZ3TC\JZ21UFICV*WA/CA>N \2YHQ-" XR6M9 YSE*';+;^N#L\80G+N! N'D
M<SH6:&4<NX6I-6):9\F@3DY.RTV\QF+=7),Q[)9HEB'4BAT=]\'VZ 0;B1FA
MR1AVRQ/K0J?&CL'P*SDI#\%+5W#*(9R1S1S?FK"I<:,C^*H]-&B#^'7SF@_B
MC&QJ=73!4^='1[Q5:X"NJ:=15X J@S@CFUH?30#M\:,CE*HU0%\"P?NJ\1C.
MR&:>34WPU-G1$4;5&IW'[KO;XVXOL)DV4Q,V-6[@!$RU3@J:5S!-/F6VXMMH
MAG 0^Y]PG!BIPL#_FC,:7CB6(3$8=&)YV!6MY>?"Y;1T1D,,QSI@ 8X]?>+_
M>YVD6=*]QWCB^T%.Q\P-_-OHTET%J1NR"]?<TPHO29"2FQ;>!![*)] ]\N)%
M#DP6+2U8P*8_[8R&E^>F#YF8?.3O@@^OUM0!**<B#_3-_KCGL<A-Z-%\)&<\
MG$0Y'5C4H03HZ;CG5CMA'CV_(OH@0/YD@["[0 73,TPF<Y=K@#XJG/'PLOKT
M+!Z3>I#=27H7N$]9S<@O<>2M,<[#/V57"$8O9SRP?$!R=N DENEZ,ZW$KM]&
M*=D@D\"3W2F,?=,9#R\%D5%AP$E]T[JNXK0HI9AM8M1QILZFD0*8TH\ZX^&E
M2S(K#3@Y?*Z7JS!^1<4=F[W R'Y, T3((4DY)/=X<F>O_OTR3E(BU_]#Z?9V
M+LZ+9NR;SGAXF9Z,"@..)LT8F_DM[B;&E8>A:)OKEQ!G/+Q\5OU+R&1B)6:,
MO#CUIJ"+,QZ./E6%%UFZI!YW"":E7]94(M/Y R(/ B)NE%RZ88C\CZ]%(-:V
M8>-T-.HC.^/A:&@ULEQ.#0..304EE?B%?$[^LJ):Y?P)7I+/36?5<!AG/!SU
M:5O^2M3ZUH5.(K^@(_]%*SWHP2C.Q?>D V6R5T)F7P%J/G/NQ? 4CHILE3#J
M2E>=(._M(MX09NE-BX(XWOY,X1M7X,M_NPWC7U8"QV4J9[6.SL5P=(KJ')5X
MV=<K,D_K&L&[3;XXHD5OG%;C.1?#TP>V9K0$'X"RSPU14;$')1X.,D*F<^H9
MD[@>_8=(:R?O[5P,4/VFQE8)HP$OKDLW>:9;?Y D; @8K9R+X2B@..27(NVB
M,Y)<^XLEF5^3'N,LV8GTEL_NY5P,1\.BR,[.E\;ZYK35;),]MI);BQ#L1AZB
M*A[1LUO:U[D8CC*E$5,E@/:U*C,<>PCYR0WAOZ!3^+!6Z^A<#$\G(N>HQ,V$
MRB../++9W@01^6[@AE.<$[_+5'<91TE OI_I3^N[ W=K[#*H<S$T=4A7;DM\
M[6<':&W)WF<YF:;/"#\^N]'6\O@U4\L7[BTF/ L:DN"\'XX*QX9LREEI7_]S
MM2V$D9UDEUP_)%%SY_WP-#P\/DID[%<@$ZH5\]_?Q'AKLA,G>VLRD/-^.*J?
M]AR6.!N(I6-?]\58J75TW@]'8:/.48F%+LV,%C7J*LCO%%=NVE"/6NWIO!^.
M)J8!2R5D!K0P]\A?9^J>VXCE*<I;/))NSON!Z6D4^"E1X"AN>JE\5-[-@]T-
MR,]K'ZG7/-)S8MZX <Z,-),D02DUO17B"FA::3=9DQ-_&MU38S@])4@#\L#
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MCA.A/Y'^K]FIR=Y^3A@2@98R4S"FU$V,YRA(UU3/;#!I,O]K=HJPVYM2'!$
M*H-5<<^L912_1QX*-C0Q0>/B+/)Q[%1N[S -FC*GI4 6YTUTF.CA=9N)>_L"
M(%31 ))@'O"SZ3<:Q$[Y]):OH\:<R8IC,3)DG-'/TG+8Y!__ 5!+ P04
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MRB2DP(V9%&;/4]:'/0Y.R*!/?(A]AV]>36 'F5<KF9D_%KP?&M<Y-4\TJG
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M>]C'5/0PL8.M_-?V3[/^@?-L3G"=O<,.(E>%*N,U'38P5M4.LWZGT4H.1T#
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M=MET-JZ=4Y<&?!K$(N3F@.8"88XYKFAX$'',@?,0)KVHJZ'A2>!AI,?BZ,-
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M:.UB__)Y3:\O?/8*VP.IYQJN3!X$OO*Y3PR]*&9Z'B6I8+F*F@,I !NRDX.
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MX!O28E03(=-[[0"S',Y]% 174?S#C5GK3',$8'>/=I1FO9NUH _C:=59C2E
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M<?W)B0PSP!'?O3#,?!J(+$Z#;'#DLVE2+$"1/Z;2 %:F1=1E.%N8E G0E0<
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M3S\9Z )T)W="U*+,7SH<7YMR5@BV%37W3B^HT*NF6NKOU<'QP$FN];HYW4S
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M6*64.1]H]E--S'*UCL['7JD,U4'M6 KO9FK$>K#&^8WLPDTUS0?5GL['7ND
M-5#M^&U5]H=[Y&\R%>5UR/+?YRU;23?G8__T@PJ0=BSL0&%XLHJ%NY<5WE]
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MK\@O_PM02P$"% ,4    " #M@*Q(/;8@: 2_  !:E0P $0
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M+3(P,38P,S,Q7VQA8BYX;6Q02P$"% ,4    " #M@*Q(*\CQGH<X   R%00
M%0              @ '_7 $ 9&UP:2TR,#$V,#,S,5]P<F4N>&UL4$L%!@
0   &  8 B@$  +F5 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
